HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

ABSTRACT

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis B virus (HBV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection and/or HBV-associated disorder, e.g., chronic hepatitis B infection.

RELATED APPLICATIONS

This application is a 35 § U.S.C. 111(a) continuation application of U.S. application Ser. No. 15/591,532 filed May 10, 2017, issued as U.S. Pat. No. 10,513,703 on Dec. 24, 2019, which is a continuation application that claims the benefit of priority to PCT/US2015/059916, filed on Nov. 10, 2015, which claims priority to U.S. Provisional Application, 62/077,799, filed on Nov. 10, 2014, and U.S. Provisional Application, 62/137,464, filed on Mar. 24, 2015. The entire contents of each of the foregoing patent applications are incorporated herein by reference.

This application also claims priority to U.S. Provisional Application, 62/077,672, filed on Nov. 10, 2014, the entire contents of which are hereby incorporated herein by reference.

This application is related to International Patent Application, PCT/US2015/059958, entitled “Hepatitis D Viris (HDV) iRNA Compositions and Methods of Use Thereof,” filed on Nov. 10, 2015, the entire contents of which are incorporated herein by reference.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 4, 2019, is named SequenceListing_930385_408C2.txt, and is 386,156 bytes in size.

BACKGROUND OF THE INVENTION

Worldwide more than 400 million people are chronically infected with HBV and are, thus, at increased risk of developing serious liver disease, such as chronic hepatitis, cirrhosis, liver failure and hepatocellular carcinoma (HCC) resulting in an estimated 600,000 deaths each year.

The natural evolution of chronic HBV infection includes four consecutive phases: (1) early ‘immunotolerant’ phase, high levels of virus replication and minimal liver inflammation; (2) immune reactive phase, significant hepatic inflammation and elevated serum aminotransferases; with some patients progressing to (3) ‘non-replicative’ phase, seroconversion to anti-HBe; undetectable or low level of viremia (below 2000 IU/ml by PCR-based assays); resolution of hepatic inflammation; and (4) HBeAg-negative chronic hepatitis B, due to the emergence of specific viral mutations, which prevent the production of HBeAg but do not hamper virus replication. This form of chronic hepatitis B (CHB) is characterized by fluctuating serum HBV DNA and serum aminostransferases (ALT and AST) levels, and progressive liver disease. It is important to note that CHB may present either as HBeAg-positive or HBeAg-negative CHB. Longitudinal studies of patients with CHB indicate that the 5-year cumulative incidence of developing cirrhosis ranges from 8 to 20%. The 5-year cumulative incidence of hepatic decompensation is approximately 20%. The worldwide incidence of HCC has increased and presently constitutes the fifth most common cancer. The annual incidence of HBV-related HCC is high, ranging from 2-5% when cirrhosis is established.

The primary goal of treatment for HBV is to permanently suppress HBV replication and improve liver disease. Clinically important short-term goals are to achieve HBeAg-seroconversion, normalization of serum ALT and AST, resolution of liver inflammation and to prevent hepatic decompensation. The ultimate goal of treatment is to achieve durable response to prevent development of cirrhosis, liver cancer and prolong survival. HBV infection cannot be eradicated completely due to persistence of a particular form of viral covalently closed circular DNA (ccc HBV DNA) in the nuclei of infected hepatocytes. However, treatment-induced clearance of serum HBsAg is a marker of termination of chronic HBV infection and has been associated with the best long-term outcome.

The current standard methods of treatment for HBV include interferon or thymosin al-based immunotherapies and the suppression of viral production by inhibition of the HBV polymerase. HBV polymerase inhibitors are effective in reducing viral production but have little to no effect in rapidly reducing HBsAg or can slowly reduce HBsAg with long term treatment in a limited number of patients (as is the case with tenofovir disoproxil fumarate). Interferon based immunotherapy can achieve a reduction of both viral production and early removal of HBsAg from the blood but only in a small percentage of treated subjects. The generally accepted role of HBsAg in the blood is to sequester anti-HBsAg antibodies and allow infectious viral particles to escape immune detection which is likely one of the reasons why HBV infection remains a chronic condition. In addition HBsAg, HBeAg and HBcAg all have immuno-inhibitory properties and the persistence of these viral proteins in the blood of patients following the administration of any of the currently available treatments for HBV is likely having a significant impact in preventing patients from achieving immunological control of their HBV infection.

Although the three primary HBV proteins (HBsAg, HBeAg and HBcAg) all have immunoinhibitory properties, HBsAg comprises the overwhelming majority of HBV protein in the circulation of HBV infected subjects. Additionally, while the removal (via seroconversion) of HBeAg or reductions in serum viremia are not correlated with the development of sustained control of HBV infection off treatment, the removal of serum HBsAg from the blood (and seroconversion) in HBV infection is a well-recognized prognostic indicator of antiviral response on treatment which will lead to control of HBV infection off treatment (although this only occurs in a small fraction of patients receiving immunotherapy). Thus, while reduction of all three major HBV proteins (HBsAg, HBeAg and HBcAg) may result in the optimal removal of inhibitory effect, the removal of HBsAg alone is likely sufficient in and of itself to remove the bulk of the viral inhibition of immune function in subjects with HBV infection.

Therefore, in the absence of any current treatment regimen which can restore immunological control of HBV in a large proportion of patients, there is a need for an effective treatment against HBV infection which can inhibit viral replication as well as restore immunological control in the majority of patients. Accordingly, there is a need in the art for alternative therapies and combination therapies for subjects infected with HBV and/or having an HBV-associated disease.

SUMMARY OF THE INVENTION

The present invention provides iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a Hepatitis B virus (HBV) gene. The HBV gene may be within a cell, e.g., a cell within a subject, such as a human.

The present invention also provides methods and therapies for treating a subject having a disorder that would benefit from inhibiting or reducing the expression of an HBV gene, e.g., an HBV infection and/or an HBV-associated disease, such as chronic Hepatitis B infection (CHB), cirrhosis, liver failure, and hepatocellular carcinoma (HCC), using iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of an HBV gene for inhibiting the expression of an HBV gene.

The RNAi agents of the invention have been designed to target regions in the HBV genome that are conserved across all 8 serotypes of HBV. In addition, the RNAi agents of the invention have been designed to inhibit all steps of the HBV life cycle, e.g., replication, assembly, secretion of virus, and secretion of sub-viral antigens, by inhibiting expression of more than one HBV gene. In particular, since transcription of the HBV genome results in polycistronic, overlapping RNAs, an RNAi agent of the invention targeting a single HBV gene results in significant inhibition of expression of most or all HBV transcripts. For example, because the HBV genome is transcribed into a single mRNA, an RNAi agent of the invention targeting the S gene will result in inhibition of not only S gene expression but also the expression of the “downstream” reverse transcriptase gene. Furthermore, the RNAi agents of the invention have been designed to inhibit HBV viral replication by targeting HBV structural genes, and the HBV X gene thereby permitting a subject's immune system to detect and respond to the presence of HBsAg to produce anti-HBV antibodies to clear an HBV infection. Without intending to be limited by theory, it is believed that a combination or sub-combination of the foregoing properties and the specific target sites and/or the specific modifications in these RNAi agents confer to the RNAi agents of the invention improved efficacy, stability, safety, potency, and durability.

Accordingly, in one aspect, the present invention provides double stranded RNAi agents for inhibiting expression of hepatitis B virus (HBV) in a cell. The double stranded RNAi agents include a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO: 1, and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:2, wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

In one embodiment, the one or more of the 3 nucleotide differences in the nucleotide sequence of the antisense strand is a nucleotide mismatch in the antisense strand.

In another embodiment, the one or more of the 3 nucleotide differences in the nucleotide sequence of the antisense strand is a nucleotide mismatch in the sense strand.

In one embodiment, all of the nucleotides of said sense strand and all of the nucleotides of said antisense strand are modified nucleotides.

In one embodiment, the sense strand and the antisense strand comprise a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the sequences listed in any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26.

In one embodiment, the at least one of said modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.

In one embodiment, the at least one strand comprises a 3′ overhang of at least 1 nucleotide. In another embodiment, the at least one strand comprises a 3′ overhang of at least 2 nucleotides.

In one embodiment, the double-stranded region is 15-30 nucleotide pairs in length. In another embodiment, the double-stranded region is 17-23 nucleotide pairs in length. In yet another embodiment, the double-stranded region is 17-25 nucleotide pairs in length. In one embodiment, the e double-stranded region is 23-27 nucleotide pairs in length. In another embodiment, the double-stranded region is 19-21 nucleotide pairs in length. In yet another embodiment, the double-stranded region is 21-23 nucleotide pairs in length.

In one embodiment, each strand has 15-30 nucleotides. In another embodiment, each strand has 19-30 nucleotides.

In one embodiment, the ligand is

In one embodiment, the RNAi agent is conjugated to the ligand at the 3′ end of the sense strand, as shown in the following structure:

wherein X is O or S.

In one embodiment, the RNAi agent is selected from the group of RNAi agents listed in any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26.

In one aspect, the present invention provides double stranded RNAi agents for inhibiting expression of hepatitis B virus (HBV) in a cell. The double stranded RNAi agents include a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-UCGUGGUGGACUUCUCUCA-3′ (SEQ ID NO:5), and said antisense strand comprises 5′-UGAGAGAAGUCCACCACGAUU-3′ (SEQ ID NO:6), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

The present invention also provides RNAi agents comprising sense and antisense nucleotide sequences which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over their entire length to the foregoing sense and antisense nucleotide sequences.

In another aspect, the present invention provides double stranded RNAi agents for inhibiting expression of hepatitis B virus (HBV) in a cell. The double stranded RNAi agents include a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-GUGCACUUCGCUUCACCUCUA-3′ (SEQ ID NO:7), and said antisense strand comprises 5′-UAGAGGUGAAGCGAAGUGCACUU-3′ (SEQ ID NO:8), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker. The present invention also provides RNAi agents comprising sense and antisense nucleotide sequences which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over their entire length to the foregoing sense and antisense nucleotide sequences.

In another aspect, the present invention provides double stranded RNAi agents for inhibiting expression of hepatitis B virus (HBV) in a cell. The double stranded RNAi agents include a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-CGUGGUGGACUUCUCUCAAUU-3′ (SEQ ID NO:9), and said antisense strand comprises 5′-AAUUGAGAGAAGUCCACCAGCAG-3′ (SEQ ID NO:10), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker. The present invention also provides RNAi agents comprising sense and antisense nucleotide sequences which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over their entire length to the foregoing sense and antisense nucleotide sequences.

In another aspect, the present invention provides double stranded RNAi agents for inhibiting expression of hepatitis B virus (HBV) in a cell. The double stranded RNAi agents include a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand comprises 5′-CGUGGUGGUCUUCUCUAAAUU-3′ (SEQ ID NO:37), and the antisense strand comprises 5′-AAUUGAGAGAAGUCCACCAGCUU-3′ (SEQ ID NO:38),

wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker. The present invention also provides RNAi agents comprising sense and antisense nucleotide sequences which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over their entire length to the foregoing sense and antisense nucleotide sequences.

In another aspect, the present invention provides double stranded RNAi agents for inhibiting expression of hepatitis B virus (HBV) in a cell. The double stranded RNAi agents include a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-GGUGGACUUCUCUCAAUUUUA-3′ (SEQ ID NO: 11), and said antisense strand comprises 5′-UAAAAUUGAGAGAAGUCCACCAC-3′ (SEQ ID NO: 12), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker. The present invention also provides RNAi agents comprising sense and antisense nucleotide sequences which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over their entire length to the foregoing sense and antisense nucleotide sequences.

In another aspect, the present invention provides double stranded RNAi agents for inhibiting expression of hepatitis B virus (HBV) in a cell. The double stranded RNAi agents include a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-GUGUGCACUUCGCUUCACA-3′ (SEQ ID NO:39), and said antisense strand comprises 5′-UGUGAAGCGAAGUGCACACUU-3′ (SEQ ID NO:40), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker. The present invention also provides RNAi agents comprising sense and antisense nucleotide sequences which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over their entire length to the foregoing sense and antisense nucleotide sequences.

In one embodiment, all of the nucleotides of said sense strand and all of the nucleotides of said antisense strand comprise a modification.

In one embodiment, at least one of said modified nucleotides is selected from the group consisting of a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.

In one embodiment, the 5′-phosphate mimic is a 5′-vinyl phosphate (5′-VP).

In one embodiment, the sense strand comprises 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO: 13) and the antisense strand comprises 5′-usGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 14), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In another embodiment, the sense strand comprises 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO:15) and the antisense strand comprises 5′-PusGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 16), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In one embodiment, the sense strand comprises 5′-gsusgcacUfuCfGfCfuucaccucua-3′ (SEQ ID NO:17) and the antisense strand comprises 5′-usAfsgagGfugaagcgAfaGfugcacsusu-3′ (SEQ ID NO:18), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In another embodiment, the sense strand comprises 5′-gsusgcacUfuCfGfCfuucaccucua-3′ (SEQ ID NO:19) and the antisense strand comprises 5′-PusAfsgagGfugaagcgAfaGfugcacsusu-3′ (SEQ ID NO:20), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In one embodiment, the sense strand comprises 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:21) and the antisense strand comprises 5′-asAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:22), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In another embodiment, the sense strand comprises 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:23) and the antisense strand comprises 5′-PasAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:24), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In another embodiment, the sense strand comprises 5′-csgsuggudGgucdTucucuaaauu-3′ (SEQ ID NO:35) and the antisense strand comprises 5′-asdAsuugagagdAagudCcaccagcsusu-3′ (SEQ ID NO:36), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; dA, dC, dG, and dT are deoxyribose A, C, G, and T; and s is a phosphorothioate linkage.

In one embodiment, the sense strand comprises 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:25) and the antisense strand comprises 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:26), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In another embodiment, the sense strand comprises 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:27) and the antisense strand comprises 5′-PusAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:28), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In another embodiment, the sense strand comprises 5′-gsusguGfcAfCfUfucgcuucaca-3′ (SEQ ID NO:41) and the antisense strand comprises 5′-usGfsugaAfgCfGfaaguGfcAfcacsusu-3′ (SEQ ID NO:42), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In one embodiment, the ligand is

In one embodiment, the RNAi agent is conjugated to the ligand at the 3′ end of the sense strand, as shown in the following structure:

wherein X is O or S.

In one embodiment, the P is a 5′-phosphate mimic. In one embodiment, the 5′-phosphate mimic is a 5′-vinyl phosphate (5′-VP).

In another aspect, the present invention provides compositions comprising two or more double stranded RNAi agents for inhibiting expression of hepatitis B virus (HBV) in a cell, wherein each double stranded RNAi agent independently comprises a sense strand and an antisense strand forming a double-stranded region, wherein each of said sense strands independently comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO: 1, and each of said antisense strands independently comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:2, wherein substantially all of the nucleotides of each of said sense strands and substantially all of the nucleotides of each of said antisense strands are independently modified nucleotides, wherein each of said sense strands are independently conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

In one embodiment, the one or more of the 3 nucleotide differences in the nucleotide sequence of the antisense strand is a nucleotide mismatch in the antisense strand. In another embodiment, the one or more of the 3 nucleotide differences in the nucleotide sequence of the antisense strand is a nucleotide mismatch in the sense strand.

In one embodiment, all of the nucleotides of said sense strand and all of the nucleotides of said antisense strand are modified nucleotides.

In one embodiment, the sense strand and said antisense strand comprise a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the sequences listed in any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26.

In one embodiment, the at least one of said modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.

In another aspect, the present invention provides compositions for inhibiting expression of hepatitis B virus (HBV) in a cell, the composition comprising (a) a first double-stranded RNAi agent comprising a first sense strand and a first antisense strand forming a double-stranded region, wherein substantially all of the nucleotides of said first sense strand and substantially all of the nucleotides of the first antisense strand are modified nucleotides, wherein said first sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; and (b) a second double-stranded RNAi agent comprising a second sense strand and a second antisense strand forming a double-stranded region, wherein substantially all of the nucleotides of said second sense strand and substantially all of the nucleotides of said second antisense strand are modified nucleotides, wherein said second sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; wherein the first and second sense strands each independently comprise a sequence selected from the group consisting of 5′-UCGUGGUGGACUUCUCUCA-3′ (SEQ ID NO:5), 5′-GUGCACUUCGCUUCACCUCUA-3′ (SEQ ID NO:7), 5′-CGUGGUGGACUUCUCUCAAUU-3′ (SEQ ID NO:9), 5′-CGUGGUGGUCUUCUCUAAAUU-3′ (SEQ ID NO:37), 5′-GGUGGACUUCUCUCAAUUUUA-3′ (SEQ ID NO:11), and 5′-GUGUGCACUUCGCUUCACA-3′ (SEQ ID NO:39) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequences), and wherein the first and second antisense strands each independently comprise a sequence selected from the group consisting of 5′-UGAGAGAAGUCCACCACGAUU-3′ (SEQ ID NO:6), 5′-UAGAGGUGAAGCGAAGUGCACUU-3′ (SEQ ID NO:8), 5′-AAUUGAGAGAAGUCCACCAGCAG-3′ (SEQ ID NO: 10), 5′-AAUUGAGAGAAGUCCACCAGCUU-3′ (SEQ ID NO:38), 5′-UAAAAUUGAGAGAAGUCCACCAC-3′ (SEQ ID NO:12), and 5′-UGUGAAGCGAAGUGCACACUU-3′ (SEQ ID NO:40) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequences).

In one embodiment, the first and second sense strand and/or all of the nucleotides of the first and second antisense strand comprise a modification.

In one embodiment, the at least one of said modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.

In one embodiment, the first and second RNAi agents are selected from the group consisting of: 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO:13) 5′-usGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 14); 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO: 15) 5′-PusGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 16); 5′-gsusgcacUfuCfGfCfuucaccucua-3′ (SEQ ID NO:17) 5′-usAfsgagGfugaagcgAfaGfugcacsusu-3′ (SEQ ID NO: 18); 5′-gsusgcacUfuCfGfCfuucaccucua-3′ (SEQ ID NO:19) 5′-PusAfsgagGfugaagcgAfaGfugcacsusu-3′ (SEQ ID NO:20); 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:21) 5′-asAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:22); 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:23) 5′-PasAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:24); 5′-csgsuggudGgucdTucucuaaauu-3′ (SEQ ID NO:35) 5′-asdAsuugagagdAagudCcaccagcsusu-3′ (SEQ ID NO:36); 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:25) 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:26); 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:27) 5′-PusAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:28); and 5′-gsusguGfcAfCfUfucgcuucaca-3′ (SEQ ID NO:41) 5′-usGfsugaAfgCfGfaaguGfcAfcacsusu-3′ (SEQ ID NO:42), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; dA, dC, dG, and dT are deoxyribose A, C, G, and T; s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In one embodiment, the first and second RNAi agents are 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO: 15) 5′-PusGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 16); 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:21) 5′-asAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:22), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In another embodiment, the first and second RNAi agents are 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:25) 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:26); and 5′-gsusguGfcAfCfUfucgcuucaca-3′ (SEQ ID NO:41) 5′-usGfsugaAfgCfGfaaguGfcAfcacsusu-3′ (SEQ ID NO:42), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In one aspect, the present invention provides a double stranded RNAi agent comprising the RNAi agents listed in any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26.

The present invention also provides vectors and cells comprising the double stranded RNAi agent of the invention.

In another aspect, the present invention provides pharmaceutical compositions comprising the double stranded RNAi agents of the invention, or the compositions of the invention, or the vectors of the invention.

In one embodiment, the double stranded RNAi agent is administered in an unbuffered solution. In one embodiment, the unbuffered solution is saline or water.

In another embodiment, the double stranded RNAi agent is administered with a buffer solution. In one embodiment, the buffer solution comprises acetate, citrate, prolamine, carbonate, or phosphate or any combination thereof. In another embodiment, the buffer solution is phosphate buffered saline (PBS).

In one aspect, the present invention provides methods of inhibiting Hepatitis B virus (HBV) gene expression in a cell. The methods include contacting the cell with the double stranded RNAi agent of the invention, or the composition of the invention, or the vector of the invention, or the pharmaceutical composition of the invention; and maintaining the cell produced for a time sufficient to obtain degradation of the mRNA transcript of an HBV gene, thereby inhibiting expression of the HBV gene in the cell.

In one embodiment, the HBV gene is selected from the group consisting of C, X, P, S, and a combination thereof.

In one aspect, the present invention provides methods of inhibiting replication of a Hepatitis B virus (HBV) in a cell. The methods include contacting the cell with the double stranded RNAi agent of the invention, or the composition of the invention, or the vector of the invention, or the pharmaceutical composition of the invention; and maintaining the cell produced for a time sufficient to obtain degradation of the mRNA transcript of an HBV gene, thereby inhibiting replication of the HBV in the cell.

In one embodiment, the cell is within a subject. In one embodiment, the subject is a human.

In one embodiment, the subject suffers from an HBV-associated disease.

In one embodiment, HBV gene expression is inhibited by at least about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98% or about 100%.

In one embodiment, replication of HBV in the cell is inhibited by at least about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98% or about 100%.

In one aspect, the present invention provides methods of reducing the level of Hepatitis B virus (HBV) DNA in a subject infected with HBV. The methods include administering to the subject a therapeutically effective amount of the double stranded RNAi agent of the invention, or the composition of the invention, or the vector of the invention, or the pharmaceutical composition of the invention, thereby reducing the level of HBV ccc DNA in the subject.

In another aspect, the present invention provides methods of reducing the level of a Hepatitis B virus (HBV) antigen in a subject infected with HBV. The methods include administering to the subject a therapeutically effective amount of the double stranded RNAi agent of the invention, or the composition of the invention, or the vector of the invention, or the pharmaceutical composition of the invention, thereby reducing the level of the HBV antigen in the subject.

In one embodiment, the HBV antigen is HBsAg. In another embodiment, the HBV antigen is HBeAg.

In another aspect, the present invention provides methods of reducing the viral load of Hepatitis B virus (HBV) in a subject infected with HBV. The methods include administering to the subject a therapeutically effective amount of the double stranded RNAi agent of the invention, or the composition of the invention, or the vector of the invention, or the pharmaceutical composition of the invention, thereby reducing the viral load of HBV in the subject.

In yet another aspect, the present invention provides methods of reducing the level of alanine aminotransferase (ALT) in a subject infected with HBV. The methods include administering to the subject a therapeutically effective amount of the double stranded RNAi agent of the invention, or the composition of the invention, or the vector of the invention, or the pharmaceutical composition of the invention, thereby reducing the level of ALT in the subject.

In another aspect, the present invention provides methods of reducing the level of aspartate aminotransferase (AST) in a subject infected with HBV. The methods include administering to the subject a therapeutically effective amount of the double stranded RNAi agent of the invention, or the composition of the invention, or the vector of the invention, or the pharmaceutical composition of the invention, thereby reducing the level of AST in the subject.

In another aspect, the present invention provides methods of increasing the level of anti-Hepatitis B virus (HBV) antibodies in a subject infected with HBV. The methods include administering to the subject a therapeutically effective amount of the double stranded RNAi agent of the invention, or the composition of the invention, or the vector of the invention, or the pharmaceutical composition of the invention, thereby increasing the level of anti-HBV antibodies in the subject.

In one aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV) infection. The methods include administering to the subject a therapeutically effective amount of the double stranded RNAi agent of the invention, or the composition of the invention, or the vector of the invention, or the pharmaceutical composition of the invention, thereby treating said subject.

In another aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV)-associated disorder. The methods include administering to the subject a therapeutically effective amount of the double stranded RNAi agent of the invention, or the composition of the invention, or the vector of the invention, or the pharmaceutical composition of the invention, thereby treating said subject.

In one embodiment, the HBV-associated disorder is selected from the group consisting of hepatitis D virus infection, delta hepatitis, acute hepatitis B; acute fulminant hepatitis B; chronic hepatitis B; liver fibrosis; end-stage liver disease; hepatocellular carcinoma.

In one embodiment, the HBV-associated disorder is chronic hepatitis and the subject is HBeAg positive. In another embodiment, the HBV-associated disorder is chronic hepatitis and the subject is HBeAg negative.

In one aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV) infection. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-UCGUGGUGGACUUCUCUCA-3′ (SEQ ID NO:5) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), and said antisense strand comprises 5′-UGAGAGAAGUCCACCACGAUU-3′ (SEQ ID NO:6) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In another aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV)-associated disorder. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-UCGUGGUGGACUUCUCUCA-3′ (SEQ ID NO:5) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), and said antisense strand comprises 5′-UGAGAGAAGUCCACCACGAUU-3′ (SEQ ID NO:6) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In one aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV) infection. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-GUGCACUUCGCUUCACCUCUA-3′ (SEQ ID NO:7) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), and said antisense strand comprises 5′-UAGAGGUGAAGCGAAGUGCACUU-3′ (SEQ ID NO:8) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In another aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV)-associated disorder. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-GUGCACUUCGCUUCACCUCUA-3′ (SEQ ID NO:7) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), and said antisense strand comprises 5′-UAGAGGUGAAGCGAAGUGCACUU-3′ (SEQ ID NO:8) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In one aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV) infection. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-CGUGGUGGACUUCUCUCAAUU-3′ (SEQ ID NO:9) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), and said antisense strand comprises 5′-AAUUGAGAGAAGUCCACCAGCAG-3′ (SEQ ID NO:10) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In another aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV)-associated disorder. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-CGUGGUGGACUUCUCUCAAUU-3′ (SEQ ID NO:9) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), and said antisense strand comprises 5′-AAUUGAGAGAAGUCCACCAGCAG-3′ (SEQ ID NO:10) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In one aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV) infection. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand comprises 5′-CGUGGUGGUCUUCUCUAAAUU-3′ (SEQ ID NO:37), (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), and the antisense strand comprises 5′-AAUUGAGAGAAGUCCACCAGCUU-3′ (SEQ ID NO:38) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In another aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV)-associated disorder. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein the double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand comprises 5′-CGUGGUGGUCUUCUCUAAAUU-3′ (SEQ ID NO:37) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), and the antisense strand comprises 5′-AAUUGAGAGAAGUCCACCAGCUU-3′ (SEQ ID NO:38) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In one aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV) infection. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-GGUGGACUUCUCUCAAUUUUA-3′ (SEQ ID NO: 11) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), and said antisense strand comprises 5′-UAAAAUUGAGAGAAGUCCACCAC-3′ (SEQ ID NO:12) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In another aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV)-associated disorder. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-GGUGGACUUCUCUCAAUUUUA-3′ (SEQ ID NO: 11) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), and said antisense strand comprises 5′-UAAAAUUGAGAGAAGUCCACCAC-3′ (SEQ ID NO:12) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In one aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV) infection. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-GUGUGCACUUCGCUUCACA-3′ (SEQ ID NO:39) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), and said antisense strand comprises 5′-UGUGAAGCGAAGUGCACACUU-3′ (SEQ ID NO:40) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In another aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV)-associated disorder. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein said sense strand comprises 5′-GUGUGCACUUCGCUUCACA-3′ (SEQ ID NO:39) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), and said antisense strand comprises 5′-UGUGAAGCGAAGUGCACACUU-3′ (SEQ ID NO:40) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequence), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In one embodiment, all of the nucleotides of said sense strand and all of the nucleotides of said antisense strand comprise a modification.

In one embodiment, the at least one of said modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.

In one embodiment, the 5′-phosphate mimic is a 5′-vinyl phosphate (5′-VP).

In one embodiment, the sense strand comprises 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO: 13) and the antisense strand comprises 5′-usGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 14), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In another embodiment, the sense strand comprises 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO:15) and the antisense strand comprises 5′-PusGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 16), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In one embodiment, the sense strand comprises 5′-gsusgcacUfuCfGfCfuucaccucua-3′ (SEQ ID NO:17) and the antisense strand comprises 5′-usAfsgagGfugaagcgAfaGfugcacsusu-3′ (SEQ ID NO:18), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In another embodiment, the sense strand comprises 5′-gsusgcacUfuCfGfCfuucaccucua-3′ (SEQ ID NO:19) and the antisense strand comprises 5′-PusAfsgagGfugaagcgAfaGfugcacsusu-3′ (SEQ ID NO:20), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In one embodiment, the sense strand comprises 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:21) and the antisense strand comprises 5′-asAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:22), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In another embodiment, the sense strand comprises 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:23) and the antisense strand comprises 5′-PasAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:24), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In another embodiment, the sense strand comprises 5′-csgsuggudGgucdTucucuaaauu-3′ (SEQ ID NO:35) and the antisense strand comprises 5′-asdAsuugagagdAagudCcaccagcsusu-3′ (SEQ ID NO:36), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; dA, dC, dG, and dT are deoxyribose A, C, G, and T; and s is a phosphorothioate linkage.

In one embodiment, the sense strand comprises 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:25) and the antisense strand comprises 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:26), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In another embodiment, the sense strand comprises 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:27) and the antisense strand comprises 5′-PusAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:28), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In another embodiment, the sense strand comprises 5′-gsusguGfcAfCfUfucgcuucaca-3′ (SEQ ID NO:41) and the antisense strand comprises 5′-usGfsugaAfgCfGfaaguGfcAfcacsusu-3′ (SEQ ID NO:42), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In one embodiment, the ligand is

In one embodiment, the RNAi agent is conjugated to the ligand at the 3′ end of the sense strand, as shown in the following structure:

wherein X is O or S.

In one embodiment, the HBV-associated disorder is selected from the group consisting of hepatitis D virus infection, delta hepatitis, acute hepatitis B; acute fulminant hepatitis B; chronic hepatitis B; liver fibrosis; end-stage liver disease; hepatocellular carcinoma.

In one embodiment, the HBV-associated disorder is chronic hepatitis and the subject is HBeAg positive. In another embodiment, the HBV-associated disorder is chronic hepatitis and the subject is HBeAg negative.

In one aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV) infection. The methods include administering to the subject a therapeutically effective amount of a composition for inhibiting expression of hepatitis B virus (HBV) in a cell. The composition includes: (a) a first double-stranded RNAi agent comprising a first sense strand and a first antisense strand forming a double-stranded region,

wherein substantially all of the nucleotides of said first sense strand and substantially all of the nucleotides of said first antisense strand are modified nucleotides, wherein said first sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; and (b) a second double-stranded RNAi agent comprising a second sense strand and a second antisense strand forming a double-stranded region, wherein substantially all of the nucleotides of said second sense strand and substantially all of the nucleotides of said second antisense strand are modified nucleotides, wherein said second sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; wherein the first and second sense strands each independently comprise a sequence selected from the group consisting of 5′-UCGUGGUGGACUUCUCUCA-3′ (SEQ ID NO:5), 5′-GUGCACUUCGCUUCACCUCUA-3′ (SEQ ID NO:7), 5′-CGUGGUGGACUUCUCUCAAUU-3′ (SEQ ID NO:9), 5′-CGUGGUGGUCUUCUCUAAAUU-3′ (SEQ ID NO:37), 5′-GGUGGACUUCUCUCAAUUUUA-3′ (SEQ ID NO:11), and 5′-GUGUGCACUUCGCUUCACA-3′ (SEQ ID NO:39) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to any of the foregoing nucleotide sequences), and wherein the first and second antisense strands each independently comprise a sequence selected from the group consisting of 5′-UGAGAGAAGUCCACCACGAUU-3′ (SEQ ID NO:6); 5′-UAGAGGUGAAGCGAAGUGCACUU-3′ (SEQ ID NO:8); 5′-AAUUGAGAGAAGUCCACCAGCAG-3′ (SEQ ID NO: 10); 5′-AAUUGAGAGAAGUCCACCAGCUU-3′ (SEQ ID NO:38), 5′-UAAAAUUGAGAGAAGUCCACCAC-3′ (SEQ ID NO:12), and 5′-UGUGAAGCGAAGUGCACACUU-3′ (SEQ ID NO:40) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to any of the foregoing nucleotide sequences), thereby treating the subject.

In another aspect, the present invention provides methods of treating a subject having a Hepatitis B virus (HBV)-associated disorder. The methods include administering to the subject a therapeutically effective amount of a composition for inhibiting expression of hepatitis B virus (HBV) in a cell. The composition includes: (a) a first double-stranded RNAi agent comprising a first sense strand and a first antisense strand forming a double-stranded region, wherein substantially all of the nucleotides of said first sense strand and substantially all of the nucleotides of said first antisense strand are modified nucleotides, wherein said first sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; and (b) a second double-stranded RNAi agent comprising a second sense strand and a second antisense strand forming a double-stranded region, wherein substantially all of the nucleotides of said second sense strand and substantially all of the nucleotides of said second antisense strand are modified nucleotides, wherein said second sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; wherein the first and second sense strands each independently comprise a sequence selected from the group consisting of 5′-UCGUGGUGGACUUCUCUCA-3′ (SEQ ID NO:5), 5′-GUGCACUUCGCUUCACCUCUA-3′ (SEQ ID NO:7), 5′-CGUGGUGGACUUCUCUCAAUU-3′ (SEQ ID NO:9), 5′-CGUGGUGGUCUUCUCUAAAUU-3′ (SEQ ID NO:37), 5′-GGUGGACUUCUCUCAAUUUUA-3′ (SEQ ID NO:11), and 5′-GUGUGCACUUCGCUUCACA-3′ (SEQ ID NO:39) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to any of the foregoing nucleotide sequences), and wherein the first and second antisense strands each independently comprise a sequence selected from the group consisting of 5′-UGAGAGAAGUCCACCACGAUU-3′ (SEQ ID NO:6); 5′-UAGAGGUGAAGCGAAGUGCACUU-3′ (SEQ ID NO:8); 5′-AAUUGAGAGAAGUCCACCAGCAG-3′ (SEQ ID NO: 10); 5′-AAUUGAGAGAAGUCCACCAGCUU-3′ (SEQ ID NO:38), 5′-UAAAAUUGAGAGAAGUCCACCAC-3′ (SEQ ID NO:12), and 5′-UGUGAAGCGAAGUGCACACUU-3′ (SEQ ID NO:40) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to any of the foregoing nucleotide sequences), thereby treating the subject.

In one embodiment, all of the nucleotides of the first and second sense strand and all of the nucleotides of the first and second antisense strand comprise a modification.

In one embodiment, the at least one of said modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.

In one embodiment, the first and second RNAi agent are selected from the group consisting of: 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO: 13) 5′-usGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 14); 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO: 15) 5′-PusGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 16); 5′-gsusgcacUfuCfGfCfuucaccucua-3′ (SEQ ID NO:17) 5′-usAfsgagGfugaagcgAfaGfugcacsusu-3′ (SEQ ID NO: 18); 5′-gsusgcacUfuCfGfCfuucaccucua-3′ (SEQ ID NO:19) 5′-PusAfsgagGfugaagcgAfaGfugcacsusu-3′ (SEQ ID NO:20); 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:21) 5′-asAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:22); 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:23) 5′-PasAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:24); 5′-csgsuggudGgucdTucucuaaauu-3′ (SEQ ID NO:35) 5′-asdAsuugagagdAagudCcaccagcsusu-3′ (SEQ ID NO:36); 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:25) 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:26); 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:27) 5′-PusAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:28); and 5′-gsusguGfcAfCfUfucgcuucaca-3′ (SEQ ID NO:41) 5′-usGfsugaAfgCfGfaaguGfcAfcacsusu-3′ (SEQ ID NO:42), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; dA, dC, dG, and dT are deoxyribose A, C, G, and T; s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In one embodiment, the first and second RNAi agents are 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO: 15) 5′-PusGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 16); and 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:21) 5′-asAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:22), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In another embodiment, the first and second RNAi agents are 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:25) 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:26); and 5′-gsusguGfcAfCfUfucgcuucaca-3′ (SEQ ID NO:41) 5′-usGfsugaAfgCfGfaaguGfcAfcacsusu-3′ (SEQ ID NO:42), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In one embodiment, the ligand is

In one embodiment, the RNAi agent is conjugated to the ligand at the 3′ end of the sense strand, as shown in the following structure:

wherein X is O or S.

In one embodiment, the subject is a human.

In one embodiment, the HBV-associated disorder is selected from the group consisting of hepatitis D virus infection, delta hepatitis, acute hepatitis B; acute fulminant hepatitis B; chronic hepatitis B; liver fibrosis; end-stage liver disease; hepatocellular carcinoma.

In one embodiment, the HBV-associated disorder is chronic hepatitis and the subject is HBeAg positive. In another embodiment, the HBV-associated disorder is chronic hepatitis and the subject is HBeAg negative.

In one embodiment, the double stranded RNAi agent is administered at a dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 50 mg/kg.

In one embodiment, the double stranded RNAi agent is administered at a dose of about 10 mg/kg to about 30 mg/kg. In another embodiment, the double stranded RNAi agent is administered at a dose of about 3 mg/kg. In one embodiment, the double stranded RNAi agent is administered at a dose of about 10 mg/kg.

In one embodiment, the double stranded RNAi agent is administered at a dose of about 0.5 mg/kg twice per week.

In one embodiment, the double stranded RNAi agent is administered at a fixed dose of about 50 mg to 200 mg.

In one embodiment, the double stranded RNAi agent is administered subcutaneously.

In another embodiment, the double stranded RNAi agent is administered intravenously.

In one embodiment, the RNAi agent is administered in two or more doses.

In one embodiment, the RNAi agent is administered at intervals selected from the group consisting of once every about 12 hours, once every about 24 hours, once every about 48 hours, once every about 72 hours, and once every about 96 hours.

In one embodiment, the RNAi agent is administered twice per week. In another embodiment, the RNAi agent is administered every other week.

In one embodiment, the methods of the invention further include administering to the subject an additional therapeutic agent.

In one embodiment, the additional therapeutic agent is selected from the group consisting of an antiviral agent, a reverse transcriptase inhibitor, an immune stimulator, a therapeutic vaccine, a viral entry inhibitor, an oligonucleotide that inhibits the secretion or release of HbsAg, a capsid inhibitor, a cccDNA inhibitor, and a combination of any of the foregoing.

In another embodiment, the methods of the invention further include administering administering to the subject a reverse transcriptase inhibitor. In yet another embodiment, the methods of the invention further include administering to the subject a reverse transcriptase inhibitor and an immune stimulator.

In one embodiment, the reverse transcriptase inhibitor is selected from the group consisting of Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide, Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, and AGX-1009.

In some embodiments, the methods of the invention further comprise treatment of hepatitis D virus (HDV) in the subject. Methods of treatment can include any methods of treatment known in the art. In certain embodiments, HDV is treated in the subject using one of more of the iRNA agents targeting HBV as described herein.

In some embodiments, the methods of the invention further include methods to modulate, e.g., decrease, the expression of PD-L1. Compositions and methods to reduce the expression of PD-L1 are provided, for example, in PCT publication no. WO2011/127180, the entire contents of which are hereby incorporated herein by reference.

In one embodiment, the immune stimulator is selected from the group consisting of pegylated interferon alfa 2a (PEG-IFN-α2a), Interferon alfa-2b, a recombinant human interleukin-7, and aToll-like receptor 7 (TLR7) agonist.

In a further aspect, the present invention provides a method of treating a subject having a Hepatitis B virus (HBV)-associated disorder, comprising administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein the double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:29, and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:30, wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides, wherein the sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In another aspect, the present invention also provides a method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of a composition for inhibiting expression of hepatitis B virus (HBV) in a cell, said composition comprising

(a) a first double-stranded RNAi agent comprising a first strand and a first antisense strand forming a double-stranded region, wherein substantially all of the nucleotides of the first sense strand and substantially all of the nucleotides of the first antisense strand are modified nucleotides, wherein said first sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; and

(b) a second double-stranded RNAi agent comprising a second sense strand and a second antisense strand forming a double-stranded region, wherein substantially all of the nucleotides of the second sense strand and substantially all of the nucleotides of the second antisense strand are modified nucleotides, wherein the second sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; wherein the first sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO: 1, and said first antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:2, wherein the sense second strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:29, and the second antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:30, thereby treating the subject.

In some embodiments, the first sense strand comprises a sequence selected from the group consisting of 5′-UCGUGGUGGACUUCUCUCA-3′ (SEQ ID NO:5), 5′-GUGCACUUCGCUUCACCUCUA-3′ (SEQ ID NO:7), 5′-CGUGGUGGACUUCUCUCAAUU-3′ (SEQ ID NO:9), 5′-CGUGGUGGUCUUCUCUAAAUU-3′ (SEQ ID NO:37) 5′-GGUGGACUUCUCUCAAUUUUA-3′ (SEQ ID NO:11), and 5′-GUGUGCACUUCGCUUCACA-3′ (SEQ ID NO:39), (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequences), and the second antisense strand comprises a sequence selected from the group consisting of 5′-UGAGAGAAGUCCACCACGAUU-3′ (SEQ ID NO:6); 5′-UAGAGGUGAAGCGAAGUGCACUU-3′ (SEQ ID NO:8); 5′-AAUUGAGAGAAGUCCACCAGCAG-3′ (SEQ ID NO: 10); 5′-AAUUGAGAGAAGUCCACCAGCUU-3′ (SEQ ID NO:38); 5′-UAAAAUUGAGAGAAGUCCACCAC-3′ (SEQ ID NO: 12); and 5′-UGUGAAGCGAAGUGCACACUU-3′ (SEQ ID NO:40) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the foregoing nucleotide sequences).

In some aspects, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification.

In certain embodiments, at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.

In some embodiments, the ligand is

In a specific embodiment, the RNAi agent is conjugated to the ligand at the 3′ end of the sense strand, as shown in the following structure:

wherein X is O or S.

In certain embodiments, the double stranded RNAi agents and compositions provided herein are used for treatment of an HDV infection and/or an HDV-associated disorder.

Accordingly, the present invention provides methods of inhibiting replication of a Hepatitis D virus (HDV) in a cell. The methods include (a) contacting the cell with a double stranded RNAi agent, composition, vector, or the pharmaceutical composition provided herein; and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of an HBV gene, thereby inhibiting replication of the HDV in the cell.

In certain embodiments, the cell is within a subject. In certain embodiments, the subject is a human.

The invention further provides methods of reducing the level of a Hepatitis D virus (HDV) antigen in a subject infected with HDV. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, composition, vector, or the pharmaceutical composition provided herein, thereby reducing the level of the HDV antigen, e.g., S-HDAg or L-HDAg, in the subject.

The invention also provides methods of reducing the viral load of Hepatitis D virus (HDV) in a subject infected with HDV. The methods include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, composition, vector, or pharmaceutical composition provided herein, thereby reducing the viral load of HDV in the subject.

The invention also provides methods of treating a subject having a Hepatitis D virus (HDV) infection, comprising administering to the subject a therapeutically effective amount of a double stranded RNAi agent, composition, vector, or pharmaceutical composition provided herein, thereby treating the subject.

In certain embodiments, the double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region. Sense strand and antisense strands can be selected from the following RNAi agents wherein, the sense strand comprises 5′-UCGUGGUGGACUUCUCUCA-3′ (SEQ ID NO:5), and the antisense strand comprises 5′-UGAGAGAAGUCCACCACGAUU-3′ (SEQ ID NO:6); the sense strand comprises 5′-GUGCACUUCGCUUCACCUCUA-3′ (SEQ ID NO:7), and the antisense strand comprises 5′-UAGAGGUGAAGCGAAGUGCACUU-3′ (SEQ ID NO:8); the sense strand comprises 5′-CGUGGUGGACUUCUCUCAAUU-3′ (SEQ ID NO:9), and the antisense strand comprises 5′-AAUUGAGAGAAGUCCACCAGCAG-3′ (SEQ ID NO:10); the sense strand comprises 5′-CGUGGUGGUCUUCUCUAAAUU-3′ (SEQ ID NO:37), and the antisense strand comprises 5′-AAUUGAGAGAAGUCCACCAGCUU-3′ (SEQ ID NO:38); the sense strand comprises 5′-GGUGGACUUCUCUCAAUUUUA-3′ (SEQ ID NO:11), and the antisense strand comprises 5′-UAAAAUUGAGAGAAGUCCACCAC-3′ (SEQ ID NO:12); or the sense strand comprises 5′-GUGUGCACUUCGCUUCACA-3′ (SEQ ID NO:39), and the antisense strand comprises 5′-UGUGAAGCGAAGUGCACACUU-3′ (SEQ ID NO:40), wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides, wherein the sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker, thereby treating the subject.

In certain embodiments, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification. In certain embodiments, at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic. In certain embodiments, the 5′-phosphate mimic is a 5′-vinyl phosphate (5′-VP).

In certain embodiments, the sense strand comprises 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO:13) and the antisense strand comprises 5′-usGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 14), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In certain embodiments, the sense strand comprises 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO:15) and the antisense strand comprises 5′-PusGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 16), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In certain embodiments, the sense strand comprises 5′-gsusgcacUfuCfGfCfuucaccucua-3′ (SEQ ID NO:17) and the antisense strand comprises 5′-usAfsgagGfugaagcgAfaGfugcacsusu-3′ (SEQ ID NO:18), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In certain embodiments, the sense strand comprises 5′-gsusgcacUfuCfGfCfuucaccucua-3′ (SEQ ID NO:19) and the antisense strand comprises 5′-PusAfsgagGfugaagcgAfaGfugcacsusu-3′ (SEQ ID NO:20), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In certain embodiments, sense strand comprises 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:21) and the antisense strand comprises 5′-AfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:22), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In certain embodiments, the sense strand comprises 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:23) and the antisense strand comprises 5′-PasAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:24), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In certain embodiments, the sense strand comprises 5′-csgsuggudGgucdTucucuaaauu-3′ (SEQ ID NO:35) and the antisense strand comprises 5′-asdAsuugagagdAagudCcaccagcsusu-3′ (SEQ ID NO:36), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; dA, dC, dG, and dT are deoxyribose A, C, G, and T; and s is a phosphorothioate linkage.

In certain embodiments, the sense strand comprises 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:25) and the antisense strand comprises 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:26), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In certain embodiments, the sense strand comprises 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:27) and the antisense strand comprises 5′-PusAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:28), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In certain embodiments, sense strand comprises 5′-gsusguGfcAfCfUfucgcuucaca-3′ (SEQ ID NO:41) and the antisense strand comprises 5′-usGfsugaAfgCfGfaaguGfcAfcacsusu-3′ (SEQ ID NO:42), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; and s is a phosphorothioate linkage.

In certain embodiments, the ligand is

In certain embodiments, the RNAi agent is conjugated to the ligand at the 3′ end of the sense strand, as shown in the following structure:

wherein X is O or S.

The invention provides methods of treating a subject having a Hepatitis D virus (HDV) infection. The methods include administering to the subject a therapeutically effective amount of a composition for inhibiting expression of hepatitis B virus (HBV) in a cell, the composition comprising (a) a first double-stranded RNAi agent comprising a first sense strand and a first antisense strand forming a double-stranded region, wherein substantially all of the nucleotides of the first sense strand and substantially all of the nucleotides of the first antisense strand are modified nucleotides, wherein the first sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; and (b) a second double-stranded RNAi agent comprising a second sense strand and a second antisense strand forming a double-stranded region, wherein substantially all of the nucleotides of the second sense strand and substantially all of the nucleotides of the second antisense strand are modified nucleotides, wherein the second sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; wherein the first and second sense strands each independently comprise a sequence selected from the group consisting of 5′-UCGUGGUGGACUUCUCUCA-3′ (SEQ ID NO:5), 5′-GUGCACUUCGCUUCACCUCUA-3′ (SEQ ID NO:7), 5′-CGUGGUGGACUUCUCUCAAUU-3′ (SEQ ID NO:9), 5′-CGUGGUGGUCUUCUCUAAAUU-3′ (SEQ ID NO:37), 5′-GGUGGACUUCUCUCAAUUUUA-3′ (SEQ ID NO:11), and 5′-GUGUGCACUUCGCUUCACA-3′ (SEQ ID NO:39), and wherein the first and second antisense strands each independently comprise a sequence selected from the group consisting of 5′-UGAGAGAAGUCCACCACGAUU-3′ (SEQ ID NO:6); 5′-UAGAGGUGAAGCGAAGUGCACUU-3′ (SEQ ID NO:8); 5′-AAUUGAGAGAAGUCCACCAGCAG-3′ (SEQ ID NO: 10); 5′-AAUUGAGAGAAGUCCACCAGCUU-3′ (SEQ ID NO:38), 5′-UAAAAUUGAGAGAAGUCCACCAC-3′ (SEQ ID NO:12), and 5′-UGUGAAGCGAAGUGCACACUU-3′ (SEQ ID NO:40), thereby treating the subject.

In certain embodiments, all of the nucleotides of the first and second sense strand and all of the nucleotides of the first and second antisense strand comprise a modification. In certain embodiments, at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.

In certain embodiments, the first and second RNAi agent are selected from the group: 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO: 13) 5′-usGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 14); 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO:15) 5′-PusGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 16); 5′-gsusgcacUfuCfGfCfuucaccucua-3′ (SEQ ID NO:17) 5′-usAfsgagGfugaagcgAfaGfugcacsusu-3′ (SEQ ID NO: 18); 5′-gsusgcacUfuCfGfCfuucaccucua-3′ (SEQ ID NO:19) 5′-PusAfsgagGfugaagcgAfaGfugcacsusu-3′ (SEQ ID NO:20); 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:21) 5′-asAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:22); 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:23) 5′-PasAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:24); 5′-csgsuggudGgucdTucucuaaauu-3′ (SEQ ID NO:35) 5′-asdAsuugagagdAagudCcaccagcsusu-3′ (SEQ ID NO:36); 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:25) 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:26); 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:27) 5′-PusAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:28); and 5′-gsusguGfcAfCfUfucgcuucaca-3′ (SEQ ID NO:41) 5′-usGfsugaAfgCfGfaaguGfcAfcacsusu-3′ (SEQ ID NO:42), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; dA, dC, dG, and dT are deoxyribose A, C, G, and T; s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In certain embodiments, the first and second RNAi agents are 5′-uscsguGfgUfGfGfacuucucuca-3′ (SEQ ID NO: 15) 5′-PusGfsagaGfaAfGfuccaCfcAfcgasusu-3′ (SEQ ID NO: 16); and 5′-csgsugguGfgAfCfUfucucUfCfaauu-3′ (SEQ ID NO:21) 5′-asAfsuugAfgAfgAfaguCfcAfccagcsasg-3′ (SEQ ID NO:22), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In certain embodiments, the first and second RNAi agents are 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:25) 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:26); and 5′-gsusguGfcAfCfUfucgcuucaca-3′ (SEQ ID NO:41) 5′-usGfsugaAfgCfGfaaguGfcAfcacsusu-3′ (SEQ ID NO:42), wherein A, C, G, and U are ribose A, C, G or U; a, g, c and u are 2′-O-methyl (2′-OMe) A, U, C, or G; Af, Cf, Gf or Uf are 2′-fluoro A, G, C or U; s is a phosphorothioate linkage; and P is a 5′-phosphate or 5′phosphate mimic.

In certain embodiments, the ligand is

In certain embodiments, the RNAi agent is conjugated to the ligand at the 3′ end of the sense strand, as shown in the following structure:

wherein X is O or S.

In certain embodiments, the subject is a human.

In certain embodiments, the double stranded RNAi agent is administered at a dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 50 mg/kg. In certain embodiments, the double stranded RNAi agent is administered at a dose of about 10 mg/kg to about 30 mg/kg. In certain embodiments, the double stranded RNAi agent is administered at a dose of about 3 mg/kg. In certain embodiments, the double stranded RNAi agent is administered at a dose of about 10 mg/kg. In certain embodiments, the double stranded RNAi agent is administered at a dose of about 0.5 mg/kg twice per week. In certain embodiments, the double stranded RNAi agent is administered at a fixed dose of about 50 mg to 200 mg.

In certain embodiments, the double stranded RNAi agent is administered subcutaneously.

In certain embodiments, the double stranded RNAi agent is administered intravenously.

In certain embodiments, the RNAi agent is administered in two or more doses. In certain embodiments, the RNAi agent is administered at intervals selected from the group consisting of once every about 12 hours, once every about 24 hours, once every about 48 hours, once every about 72 hours, and once every about 96 hours. In certain embodiments, the RNAi agent is administered twice per week. In certain embodiments, the RNAi agent is administered every other week. In certain embodiments, the RNAi agent is administered once per month. In certain embodiments, the RNAi agent is administered once every other month. In certain embodiments, the RNAi agent is administered once every three months.

In certain embodiments, the RNAi agent is administered to the subject with an additional therapeutic agent. Additional therapeutic agents include, for example, an antiviral agent, a reverse transcriptase inhibitor, an immune stimulator, a therapeutic vaccine, a viral entry inhibitor, an oligonucleotide that inhibits the secretion or release of HbsAg, a capsid inhibitor, a covalently closed circular (ccc) HBV DNA inhibitor, and a combination of any of the foregoing.

In certain embodiments, the additional agent is a reverse transcriptase inhibitor. In certain embodiments, the additional agent is a reverse transcriptase inhibitor and an immune stimulator. Exemplary reverse transcriptase inhibitors include Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide, Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, and AGX-1009. Exemplary immune stimulators include pegylated interferon alfa 2a (PEG-IFN-α2a), Interferon alfa-2b, a recombinant human interleukin-7, and a Toll-like receptor 7 (TLR7) agonist.

The invention further provides methods of treating a subject having a Hepatitis D virus (HDV) infection, comprising administering to the subject a therapeutically effective amount of a composition for inhibiting expression of hepatitis B virus (HBV) in a cell, the composition comprising (a) a first double-stranded RNAi agent comprising a first strand and a first antisense strand forming a double-stranded region, wherein substantially all of the nucleotides of the first sense strand and substantially all of the nucleotides of the first antisense strand are modified nucleotides, wherein the first sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; and (b) a second double-stranded RNAi agent comprising a second sense strand and a second antisense strand forming a double-stranded region, wherein substantially all of the nucleotides of the second sense strand and substantially all of the nucleotides of the second antisense strand are modified nucleotides, wherein the second sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; wherein the first sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO: 1, and the first antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:2, wherein the sense second strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:29, and the second antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:30, thereby treating the subject.

In certain embodiments, the first sense strand comprises a sequence selected from the group consisting of

5′-UCGUGGUGGACUUCUCUCA-3′ (SEQ ID NO:5), 5′-GUGCACUUCGCUUCACCUCUA-3′ (SEQ ID NO:7), 5′-CGUGGUGGACUUCUCUCAAUU-3′ (SEQ ID NO:9), 5′-CGUGGUGGUCUUCUCUAAAUU-3′ (SEQ ID NO:37), 5′-GGUGGACUUCUCUCAAUUUUA-3′ (SEQ ID NO:11), and 5′-GUGUGCACUUCGCUUCACA-3′ (SEQ ID NO:39), and

the second antisense strand comprises a sequence selected from the group consisting of

5′-UGAGAGAAGUCCACCACGAUU-3′ (SEQ ID NO:6); 5′-UAGAGGUGAAGCGAAGUGCACUU-3′ (SEQ ID NO:8); 5′-AAUUGAGAGAAGUCCACCAGCAG-3′ (SEQ ID NO: 10); 5′-AAUUGAGAGAAGUCCACCAGCUU-3′ (SEQ ID NO:38), 5′-UAAAAUUGAGAGAAGUCCACCAC-3′ (SEQ ID NO:12), and 5′-UGUGAAGCGAAGUGCACACUU-3′ (SEQ ID NO:40).

In certain embodiments, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification. In certain embodiments, the additional agent is at least one of the modified nucleotides is selected from the group consisting of a dexoy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.

In certain embodiments, the ligand is

In certain embodiments, the RNAi agent is conjugated to the ligand at the 3′ end of the sense strand, as shown in the following structure:

wherein X is O or S.

The present invention is further illustrated by the following detailed description and drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 schematically depicts the structure of the approximately 3.2 kb double-stranded HBV genome. Replication of the HBV genome occurs through an RNA intermediate and produces 4 overlapping viral transcripts (an about 3.5 kb transcript, an about 2.4 kb transcript, an about 2.1 kb transcript, and an about 0.7 kb transcript) encoding seven viral proteins (pre-S1, pre-S2, S, P, X, pre-C and C) translated across three reading frames.

FIG. 2 is a graph depicting the log decrease of HBsAg serum levels normalized to pre-dose HBsAg serum levels following administration of a single 3 mg/kg dose of the indicated iRNA agents.

FIG. 3 is a graph depicting the log decrease of HBsAg serum levels normalized to pre-dose HBsAg serum levels following administration of a single 3 mg/kg dose of the indicated iRNA agents.

FIG. 4 is a graph depicting the percent of pre-dose HBsAg remaining at days 5 and 10 following administration of a single 3 mg/kg dose of the indicated iRNA agents. FIG. 4 also depicts the percent of HBsAG remaining at day 10 post-dose relative to the percent of HBsAG remaining at day 10 post-dose in an animal administered 3 mg/kg of a control dsRNA targeting mouse/rat transtherytin (mrTTR).

FIG. 5 is a graph depicting the log decrease of HBsAg serum levels normalized to pre-dose HBsAg serum levels following administration of a single 3 mg/kg dose of AD-65403.

FIG. 6A is a graph depicting the decrease of HBsAg serum levels normalized to pre-dose HBsAg serum levels on a standard linear scale following administration of a single subcutaneous 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 9 mg/kg dose of AD-66810.

FIG. 6B is a graph depicting the decrease of HBsAg serum levels normalized to pre-dose HBsAg serum levels on a log₁₀ scale following administration of a single subcutaneous 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 9 mg/kg dose of AD-66810.

FIG. 7 is a graph depicting the decrease of HBsAg plasma levels normalized to pre-dose HBsAg plasma levels on a log₁₀ scale following administration of three weekly subcutaneous 3 mg/kg doses of AD-66810.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a Hepatitis B virus (HBV) gene. The gene may be within a cell, e.g., a cell within a subject, such as a human. The use of these iRNAs enables the targeted degradation of mRNAs of the correponding gene (HBV gene) in mammals.

The RNAi agents of the invention have been designed to target regions in the HBV genome that are conserved across all 8 serotypes of HBV. In addition, the RNAi agents of the invention have been designed to inhibit all steps of the HBV life cycle, e.g., replication, assembly, secretion of virus, and secretion of sub-viral antigens, by inhibiting expression of more than one HBV gene. In particular, since transcription of the HBV genome results in polycistronic, overlapping RNAs, an RNAi agent of the invention targeting a single HBV gene results in significant inhibition of expression of most or all HBV transcripts. For example, because the HBV genome is transcribed into a single mRNA, an RNAi agent of the invention targeting the S gene will result in inhibition of not only S gene expression but also the expression of the “downstream” polymerase gene. Furthermore, the RNAi agents of the invention have been designed to inhibit HBV viral replication by targeting HBV structural genes, and the HBV X gene thereby permiting a subject's immune sytem to detect and respond to the presence of HBsAg to produce anti-HBV antibodies to clear an HBV infection. Without intending to be limited by theory, it is believed that a combination or sub-combination of the foregoing properties and the specific target sites and/or the specific modifications in these RNAi agents confer to the RNAi agents of the invention improved efficacy, stability, safety, potency, and durability.

Using in vitro and in vivo assays, the present inventors have demonstrated that iRNAs targeting an HBV gene can potently mediate RNAi, resulting in significant inhibition of expression of more than one HBVgene. The present inventors have also demonstrated that the RNAi agents of the invention are exceptionally stable in the cytoplasm and lysosme. Thus, methods and compositions including these iRNAs are useful for treating a subject having an HBV infection and/or an HBV-associated disease, such as chronic hepatitis B (CHB).

Accordingly, the present invention also provides methods for treating a subject having a disorder that would benefit from inhibiting or reducing the expression of an HBV gene, e.g., an HBV-associated disease, such as chronic Hepatitis B virus infection (CHB), using iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of an HBV gene.

Very low dosages of the iRNAs of the invention, in particular, can specifically and efficiently mediate RNA interference (RNAi), resulting in significant inhibition of expression of the corresponding gene (HBV gene).

The iRNAs of the invention include an RNA strand (the antisense strand) having a region which is about 30 nucleotides or less in length, e.g., 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length, which region is substantially complementary to at least part of an mRNA transcript of an HBV gene.

The following detailed description discloses how to make and use compositions containing iRNAs to inhibit the expression of an HBV gene as well as compositions, uses, and methods for treating subjects having diseases and disorders that would benefit from inhibition and/or reduction of the expression of an HBV gene.

I. Definitions

In order that the present invention may be more readily understood, certain terms are first defined. In addition, it should be noted that whenever a value or range of values of a parameter are recited, it is intended that values and ranges intermediate to the recited values are also intended to be part of this invention.

The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element, e.g., a plurality of elements.

The term “including” is used herein to mean, and is used interchangeably with, the phrase “including but not limited to”.

The term “or” is used herein to mean, and is used interchangeably with, the term “and/or,” unless context clearly indicates otherwise.

As used herein, “Hepatitis B virus,” used interchangeably with the term “HBV” refers to the well-known noncytopathic, liver-tropic DNA virus belonging to the Hepadnaviridae family.

The HBV genome is partially double-stranded, circular DNA with overlapping reading frames (see, e.g., FIG. 1).

There are four known genes encoded by the HBC genome, called C, X, P, and S. The core protein is coded for by gene C (HBcAg). Hepatitis B antigen (HBeAg) is produced by proteolytic processing of the pre-core (pre-C) protein. The DNA polymerase is encoded by gene P. Gene S is the gene that codes for the surface antigen (HBsAg). The HBsAg gene is one long open reading frame but contains three in frame “start” (ATG) codons that divide the gene into three sections, pre-S1, pre-S2, and S. Because of the multiple start codons, polypeptides of three different sizes called large, middle, and small (pre-S1+pre-S2+S, pre-S2+S, or S) are produced. The function of the non-structural protein coded for by gene X is not fully understood but it is associated with the development of liver cancer and encodes a decoy protein which permits HBsAg in the blood to sequester anti-HBsAg antibodies and allow infectious viral particles to escape immune detection.

The proteins encoded by the HBV genome include: envelope proteins—i) small, Hepatitis B surface antigen (HBsAg); ii) middle—preS2 plus HBsAg; iii) large—preS1 plus preS2 plus HBsAg; nucleocapsid protein, hepatitis B core antigen (HBcAg). Hepatitis B e antigen (HBeAg) is a non-structural protein produced during the HBV replication which shares 90% amino acids with the nucleocapsid HBcAg; and the X protein is a nonstructural protein (HBx) which functions in the cytoplasm to activate various signaling pathways, many of which are controlled by modulation of cytosolic calcium and in the nucleus to regulate transcription through a direct interaction with different transcription factors and, in some cases, enhance their binding to specific transcription elements.

HBV is one of the few DNA viruses that utilize reverse transcriptase in the replication process which involves multiple stages including entry, uncoating and transport of the virus genome to the nucleus. Initially, replication of the HBV genome involves the generation of an RNA intermediate that is then reverse transcribed to produce the DNA viral genome.

Upon infection of a cell with HBV, the viral genomic relaxed circular DNA (rcDNA) is transported into the cell nucleus and converted into episomal covalently closed circular DNA (cccDNA), which serves as the transcription template for the viral mRNAs. After transcription and nuclear export, cytoplasmic viral pregenomic RNA (pgRNA) is assembled with HBV polymerase and capsid proteins to form the nucleocapsid, inside which polymerase-catalyzed reverse transcription yields minus-strand DNA, which is subsequently copied into plus-strand DNA to form the progeny rcDNA genome. The mature nucleocapsids are then either packaged with viral envelope proteins to egress as virion particles or shuttled to the nucleus to amplify the cccDNA reservoir through the intracellular cccDNA amplification pathway. cccDNA is an essential component of the HBV replication cycle and is responsible for the establishment of infection and viral persistence.

HBV infection results in the production of two different particles: 1) the HBV virus itself (or Dane particle) which includes a viral capsid assembled from the HBcAg and is covered by the HBsAg and is capable of reinfecting cells and 2) subviral particles (or SVPs) which are high density lipoprotein-like particles comprised of lipids, cholesterol, cholesterol esters and the small and medium forms of the hepatitis B surface antigen HBsAg which are non-infectious. For each viral particle produced, 1,000-10,000 SVPs are released into the blood. As such SVPs (and the HBsAg protein they carry) represent the overwhelming majority of viral protein in the blood. HBV infected cells also secrete a soluble proteolytic product of the pre-core protein called the HBV e-antigen (HBeAg).

Eight genotypes of HBV, designated A to H, have been determined, each having a distinct geographical distribution. The virus is non-cytopathic, with virus-specific cellular immunity being the main determinant for the outcome of exposure to HBV—acute infection with resolution of liver diseases with 6 months, or chronic HBV infection that is frequently associated with progressive liver injury.

The term “HBV” includes any of the eight genotypes of HBV (A to H). The amino acid and complete coding sequence of the reference sequence of the HBV genome may be found in for example, GenBank Accession Nos. GI:21326584 (SEQ ID NO: 1) and GI:3582357 (SEQ ID NO:3).

Additional examples of HBV mRNA sequences are readily available using publicly available databases, e.g., GenBank, UniProt, and OMIM.

The term “HBV,” as used herein, also refers to naturally occurring DNA sequence variations of the HBV genome.

As used herein, “Hepatitis D virus,” used interchangeably with the term “HDV” refers to the well-known noncytopathic, liver-tropic DNA virus belonging to the Hepadnaviridae family. See, e.g., Ciancio and Rizzetto, Nat. Rev. 11:68-71, 2014; Le Gal et al., Emerg. Infect. Dis. 12:1447-1450, 2006; and Abbas and afzal, World J. Hep., 5:666-675, 2013, all of which are incorporated by reference. Unless otherwise indicated, HDV refers to all clades and variants of HDV.

HDV produces one protein, namely HDAg. It comes in two forms; a 27 kDa large-HDAg (also referred to herein as 1HD, L-HDAg, and large HDV antigen), and a small-HDAg of 24 kDa (also referred to herein as sHD, S-HDAg, and small HDV antigen). The N-terminals of the two forms are identical, they differ by 19 amino acids in the C-terminal of the large HDAg. Both isoforms are produced from the same reading frame which contains an UAG stop codon at codon 196, which normally produces only the small-HDAg. However, editing by cellular enzyme adenosine deaminase-1 changes the stop codon to UCG, allowing the large-HDAg to be produced. Despite having 90% identical sequences, these two proteins play diverging roles during the course of an infection. HDAg-S is produced in the early stages of an infection and enters the nucleus and supports viral replication. HDAg-L, in contrast, is produced during the later stages of an infection, acts as an inhibitor of viral replication, and is required for assembly of viral particles.

Additional examples of HDV mRNA sequences are readily available using publicly available databases, e.g., GenBank, UniProt, and OMIM.

The term “HDV,” as used herein, also refers to naturally occurring DNA sequence variations of the HDV genome.

As used herein, “target sequence” refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an HBV gene, including mRNA that is a product of RNA processing of a primary transcription product. In one embodiment, the target portion of the sequence will be at least long enough to serve as a substrate for iRNA-directed cleavage at or near that portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an HBV gene.

The target sequence may be from about 9-36 nucleotides in length, e.g., about 15-30 nucleotides in length. For example, the target sequence can be from about 15-30 nucleotides, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.

As used herein, the term “strand comprising a sequence” refers to an oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.

“G,” “C,” “A,” “T” and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine and uracil as a base, respectively. However, it will be understood that the term “ribonucleotide” or “nucleotide” can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety (see, e.g., Table 2). The skilled person is well aware that guanine, cytosine, adenine, and uracil can be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base can base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of dsRNA featured in the invention by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the invention.

The terms “iRNA”, “RNAi agent,” “iRNA agent,”, “RNA interference agent” as used interchangeably herein, refer to an agent that contains RNA as that term is defined herein, and which mediates the targeted cleavage of an RNA transcript via an RNA-induced silencing complex (RISC) pathway. iRNA directs the sequence-specific degradation of mRNA through a process known as RNA interference (RNAi). The iRNA modulates, e.g., inhibits, the expression of an HBV gene (e.g., one or more HBV genes) in a cell, e.g., a cell within a subject, such as a mammalian subject.

In one embodiment, an RNAi agent of the invention includes a single stranded RNA that interacts with a target RNA sequence, e.g., an HBV target mRNA sequence, to direct the cleavage of the target RNA. Without wishing to be bound by theory it is believed that long double stranded RNA introduced into cells is broken down into siRNA by a Type III endonuclease known as Dicer (Sharp et al. (2001) Genes Dev. 15:485). Dicer, a ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3′ overhangs (Bernstein, et al., (2001) Nature 409:363). The siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition (Nykanen, et al., (2001) Cell 107:309). Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleave the target to induce silencing (Elbashir, et al., (2001) Genes Dev. 15:188). Thus, in one aspect the invention relates to a single stranded siRNA (ssRNA) generated within a cell and which promotes the formation of a RISC complex to effect silencing of the target gene, i.e., an HBV gene. Accordingly, the term “siRNA” is also used herein to refer to an RNAi as described above.

In another embodiment, the RNAi agent may be a single-stranded siRNA that is introduced into a cell or organism to inhibit a target mRNA. Single-stranded RNAi agents bind to the RISC endonuclease, Argonaute 2, which then cleaves the target mRNA. The single-stranded siRNAs are generally 15-30 nucleotides and are chemically modified. The design and testing of single-stranded siRNAs are described in U.S. Pat. No. 8,101,348 and in Lima et al., (2012) Cell 150:883-894, the entire contents of each of which are hereby incorporated herein by reference. Any of the antisense nucleotide sequences described herein may be used as a single-stranded siRNA as described herein or as chemically modified by the methods described in Lima et al., (2012) Cell 150:883-894.

In another embodiment, an “iRNA” for use in the compositions, uses, and methods of the invention is a double-stranded RNA and is referred to herein as a “double stranded RNAi agent,” “double-stranded RNA (dsRNA) molecule,” “dsRNA agent,” or “dsRNA”. The term “dsRNA”, refers to a complex of ribonucleic acid molecules, having a duplex structure comprising two anti-parallel and substantially complementary nucleic acid strands, referred to as having “sense” and “antisense” orientations with respect to a target RNA, i.e., an HBV gene. In some embodiments of the invention, a double-stranded RNA (dsRNA) triggers the degradation of a target RNA, e.g., an mRNA, through a post-transcriptional gene-silencing mechanism referred to herein as RNA interference or RNAi.

In general, the majority of nucleotides of each strand of a dsRNA molecule are ribonucleotides, but as described in detail herein, each or both strands can also include one or more non-ribonucleotides, e.g., a deoxyribonucleotide and/or a modified nucleotide. In addition, as used in this specification, an “RNAi agent” may include ribonucleotides with chemical modifications; an RNAi agent may include substantial modifications at multiple nucleotides. As used herein, the term “modified nucleotide” refers to a nucleotide having, independently, a modified sugar moiety, a modified internucleotide linkage, and/or modified nucleobase. Thus, the term modified nucleotide encompasses substitutions, additions or removal of, e.g., a functional group or atom, to internucleoside linkages, sugar moieties, or nucleobases. The modifications suitable for use in the agents of the invention include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a siRNA type molecule, are encompassed by “RNAi agent” for the purposes of this specification and claims.

The duplex region may be of any length that permits specific degradation of a desired target RNA through a RISC pathway, and may range from about 9 to 36 base pairs in length, e.g., about 15-30 base pairs in length, for example, about 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 base pairs in length, such as about 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.

The two strands forming the duplex structure may be different portions of one larger RNA molecule, or they may be separate RNA molecules. Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′-end of the respective other strand forming the duplex structure, the connecting RNA chain is referred to as a “hairpin loop.” A hairpin loop can comprise at least one unpaired nucleotide. In some embodiments, the hairpin loop can comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 23 or more unpaired nucleotides.

Where the two substantially complementary strands of a dsRNA are comprised by separate RNA molecules, those molecules need not, but can be covalently connected. Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′-end of the respective other strand forming the duplex structure, the connecting structure is referred to as a “linker.” The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest strand of the dsRNA minus any overhangs that are present in the duplex. In addition to the duplex structure, an RNAi may comprise one or more nucleotide overhangs.

In one embodiment, an RNAi agent of the invention is a dsRNA, each strand of which comprises 24-30 nucleotides, that interacts with a target RNA sequence, e.g., an HBV target mRNA sequence, to direct the cleavage of the target RNA. Without wishing to be bound by theory, long double stranded RNA introduced into cells is broken down into siRNA by a Type III endonuclease known as Dicer (Sharp et al. (2001) Genes Dev. 15:485). Dicer, a ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3′ overhangs (Bernstein, et al., (2001) Nature 409:363). The siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition (Nykanen, et al., (2001) Cell 107:309). Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleave the target to induce silencing (Elbashir, et al., (2001) Genes Dev. 15:188).

As used herein, the term “nucleotide overhang” refers to at least one unpaired nucleotide that protrudes from the duplex structure of an iRNA, e.g., a dsRNA. For example, when a 3′-end of one strand of a dsRNA extends beyond the 5′-end of the other strand, or vice versa, there is a nucleotide overhang. A dsRNA can comprise an overhang of at least one nucleotide; alternatively the overhang can comprise at least two nucleotides, at least three nucleotides, at least four nucleotides, at least five nucleotides or more. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5′-end, 3′-end or both ends of either an antisense or sense strand of a dsRNA.

In one embodiment, the antisense strand of a dsRNA has a 1-10 nucleotide, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3′-end and/or the 5′-end. In one embodiment, the sense strand of a dsRNA has a 1-10 nucleotide, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3′-end and/or the 5′-end. In another embodiment, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.

“Blunt” or “blunt end” means that there are no unpaired nucleotides at that end of the double stranded RNAi agent, i.e., no nucleotide overhang. A “blunt ended” RNAi agent is a dsRNA that is double-stranded over its entire length, i.e., no nucleotide overhang at either end of the molecule. The RNAi agents of the invention include RNAi agents with nucleotide overhangs at one end (i.e., agents with one overhang and one blunt end) or with nucleotide overhangs at both ends.

The term “antisense strand” or “guide strand” refers to the strand of an iRNA, e.g., a dsRNA, which includes a region that is substantially complementary to a target sequence, e.g., a HBV mRNA. As used herein, the term “region of complementarity” refers to the region on the antisense strand that is substantially complementary to a sequence, for example a target sequence, e.g., an HBV nucleotide sequence, as defined herein. Where the region of complementarity is not fully complementary to the target sequence, the mismatches can be in the internal or terminal regions of the molecule. Generally, the most tolerated mismatches are in the terminal regions, e.g., within 5, 4, 3, 2, or 1 nucleotides of the 5′- and/or 3′-terminus of the iRNA. In one embodiment, a double-stranded RNAi agent of the invention includes a nucleotide mismatch in the antisense strand. In another embodiment, a double-stranded RNAi agent of the invention includes a nucleotide mismatch in the sense strand. In one embodiment, the nucleotide mismatch is, for example, within 5, 4, 3, 2, or 1 nucleotides from the 3′-terminus of the iRNA. In another embodiment, the nucleotide mismatch is, for example, in the 3′-terminal nucleotide of the iRNA.

The term “sense strand,” or “passenger strand” as used herein, refers to the strand of an iRNA that includes a region that is substantially complementary to a region of the antisense strand as that term is defined herein.

As used herein, the term “cleavage region” refers to a region that is located immediately adjacent to the cleavage site. The cleavage site is the site on the target at which cleavage occurs. In some embodiments, the cleavage region comprises three bases on either end of, and immediately adjacent to, the cleavage site. In some embodiments, the cleavage region comprises two bases on either end of, and immediately adjacent to, the cleavage site. In some embodiments, the cleavage site specifically occurs at the site bound by nucleotides 10 and 11 of the antisense strand, and the cleavage region comprises nucleotides 11, 12 and 13.

As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleotide sequence in relation to a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to hybridize and form a duplex structure under certain conditions with an oligonucleotide or polynucleotide comprising the second nucleotide sequence, as will be understood by the skilled person. Such conditions can, for example, be stringent conditions, where stringent conditions can include: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50° C. or 70° C. for 12-16 hours followed by washing (see, e.g., “Molecular Cloning: A Laboratory Manual, Sambrook, et al. (1989) Cold Spring Harbor Laboratory Press). Other conditions, such as physiologically relevant conditions as can be encountered inside an organism, can apply. The skilled person will be able to determine the set of conditions most appropriate for a test of complementarity of two sequences in accordance with the ultimate application of the hybridized nucleotides.

Complementary sequences within an iRNA, e.g., within a dsRNA as described herein, include base-pairing of the oligonucleotide or polynucleotide comprising a first nucleotide sequence to an oligonucleotide or polynucleotide comprising a second nucleotide sequence over the entire length of one or both nucleotide sequences. Such sequences can be referred to as “fully complementary” with respect to each other herein. However, where a first sequence is referred to as “substantially complementary” with respect to a second sequence herein, the two sequences can be fully complementary, or they can form one or more, but generally not more than 5, 4, 3 or 2 mismatched base pairs upon hybridization for a duplex up to 30 base pairs, while retaining the ability to hybridize under the conditions most relevant to their ultimate application, e.g., inhibition of gene expression via a RISC pathway. However, where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs shall not be regarded as mismatches with regard to the determination of complementarity. For example, a dsRNA comprising one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is fully complementary to the shorter oligonucleotide, can yet be referred to as “fully complementary” for the purposes described herein.

“Complementary” sequences, as used herein, can also include, or be formed entirely from, non-Watson-Crick base pairs and/or base pairs formed from non-natural and modified nucleotides, in so far as the above requirements with respect to their ability to hybridize are fulfilled. Such non-Watson-Crick base pairs include, but are not limited to, G:U Wobble or Hoogstein base pairing.

The terms “complementary,” “fully complementary” and “substantially complementary” herein can be used with respect to the base matching between the sense strand and the antisense strand of a dsRNA, or between the antisense strand of an iRNA agent and a target sequence, as will be understood from the context of their use.

As used herein, a polynucleotide that is “substantially complementary to at least part of” a messenger RNA (mRNA) refers to a polynucleotide that is substantially complementary to a contiguous portion of the mRNA of interest (e.g., an mRNA encoding an HBV gene). For example, a polynucleotide is complementary to at least a part of an HBV mRNA if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding an HBV gene.

Accordingly, in some embodiments, the antisense strand polynucleotides disclosed herein are fully complementary to the target HBV sequence. In other embodiments, the antisense strand polynucleotides disclosed herein are substantially complementary to the target HBV sequence and comprise a contiguous nucleotide sequence which is at least about 80% complementary over its entire length to the equivalent region of the nucleotide sequence of SEQ ID NO:1, or a fragment of SEQ ID NO: 1, such as about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about % 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In one embodiment, an RNAi agent of the invention includes a sense strand that is substantially complementary to an antisense polynucleotide which, in turn, is complementary to a target HBV sequence, and wherein the sense strand polynucleotide comprises a contiguous nucleotide sequence which is at least about 80% complementary over its entire length to the equivalent region of the nucleotide sequence of any one of SEQ ID NOs:6, 8, 10, 12, 38, and 40, or a fragment of any one of SEQ ID NOs:6, 8, 10, 12, 38, and 40, such as about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about % 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary. In another embodiment, an RNAi agent of the invention includes an antisense strand that is substantially complementary to the target HBV sequence and comprise a contiguous nucleotide sequence which is at least about 80% complementary over its entire length to the equivalent region of the nucleotide sequence of any one of SEQ ID NOs:5, 7, 9, 11, 37, and 39, or a fragment of any one of SEQ ID NOs:5, 7, 9, 11, 37, and 39, such as about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about % 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In some embodiments, the majority of nucleotides of each strand are ribonucleotides, but as described in detail herein, each or both strands can also include one or more non-ribonucleotides, e.g., a deoxyribonucleotide and/or a modified nucleotide. In addition, an “iRNA” may include ribonucleotides with chemical modifications. Such modifications may include all types of modifications disclosed herein or known in the art. Any such modifications, as used in an iRNA molecule, are encompassed by “iRNA” for the purposes of this specification and claims.

In one aspect of the invention, an agent for use in the methods and compositions of the invention is a single-stranded antisense nucleic acid molecule that inhibits a target mRNA via an antisense inhibition mechanism. The single-stranded antisense RNA molecule is complementary to a sequence within the target mRNA. The single-stranded antisense oligonucleotides can inhibit translation in a stoichiometric manner by base pairing to the mRNA and physically obstructing the translation machinery, see Dias, N. et al., (2002) Mol Cancer Ther 1:347-355. The single-stranded antisense RNA molecule may be about 15 to about 30 nucleotides in length and have a sequence that is complementary to a target sequence. For example, the single-stranded antisense RNA molecule may comprise a sequence that is at least about 15, 16, 17, 18, 19, 20, or more contiguous nucleotides from any one of the antisense sequences described herein.

As used herein, a “subject” is an animal, such as a mammal, including a primate (such as a human, a non-human primate, e.g., a monkey, and a chimpanzee), a non-primate (such as a cow, a pig, a camel, a llama, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, a mouse, a horse, and a whale), or a bird (e.g., a duck or a goose). In an embodiment, the subject is a human, such as a human being treated or assessed for a disease, disorder or condition that would benefit from reduction in HBV gene expression and/or replication; a human at risk for a disease, disorder or condition that would benefit from reduction in HBV gene expression and/or replication; a human having a disease, disorder or condition that would benefit from reduction in HBV gene expression and/or replication; and/or human being treated for a disease, disorder or condition that would benefit from reduction in HBV gene expression and/or replication, as described herein. In another embodiment, the subject has a hepatitis B virus (HBV) infection. In another embodiment, the subject has both a hepatitis B virus (HBV) infection and a hepatitis D virus (HDV) infection.

As used herein, the terms “treating” or “treatment” refer to a beneficial or desired result including, but not limited to, alleviation or amelioration of one or more symptoms associated with unwanted HBV gene expression and/or HBV replication, e.g., the presence of serum and/or liver HBV ccc DNA, the presence of serum and/or liver HBV antigen, e.g., HBsAg and/or HBeAg, elevated ALT, elevated AST, the absence or low level of anti-HBV antibodies, liver injury; cirrhosis; delta hepatitis, acute hepatitis B; acute fulminant hepatitis B; chronic hepatitis B; liver fibrosis; end-stage liver disease; hepatocellular carcinoma; serum sickness-like syndrome; anorexia; nausea; vomiting, low-grade fever; myalgia; fatigability; disordered gustatory acuity and smell sensations (aversion to food and cigarettes); and/or right upper quadrant and epigastric pain (intermittent, mild to moderate); hepatic encephalopathy; somnolence; disturbances in sleep pattern; mental confusion; coma; ascites; gastrointestinal bleeding; coagulopathy; jaundice; hepatomegaly (mildly enlarged, soft liver); splenomegaly; palmar erythema; spider nevi; muscle wasting; spider angiomas; vasculitis; variceal bleeding; peripheral edema; gynecomastia; testicular atrophy; abdominal collateral veins (caput medusa); high levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), within a range of 1000-2000 IU/mL, although values 100 times above the upper limit of normal (ULN) can be also be identified; ALT levels higher than AST levels; elevated gamma-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP) levels (e.g., not more than 3 times the ULN); slightly low albumin levels; elevated serum iron levels; leukopenia (i.e., granulocytopenia); lymphocytosis; increased erythrocyte sedimentation rate (ESR); shortened red blood cell survival; hemolysis; thrombocytopenia; a prolongation of the international normalized ratio (INR); the presence of serum and/or liverHBsAg, HBeAg, Hepatitis B core antibody (anti-HBc) immunoglobulin M (IgM); hepatitis B surface antibody (anti-HBs), hepatitis B e antibody (anti-HBe), and/or HBV DNA; elevation of the aminotransferases (<5 times the ULN); ALT levels higher than the AST levels; increased bilirubin levels, prolonged prothrombin time (PT); hyperglobulinemia; the presence of tissue-nonspecific antibodies, such as anti-smooth muscle antibodies (ASMAs) or antinuclear antibodies (ANAs) (10-20%); the presence of tissue-specific antibodies, such as antibodies against the thyroid gland (10-20%); elevated levels of rheumatoid factor (RF); hyperbilirubinemia, prolonged PT, low platelet and white blood cell counts, AST levels higher than ALT levels; elevated alkaline phosphatase (ALP) and GGT levels; lobular, with degenerative and regenerative hepatocellular changes, and accompanying inflammation; predominantly centrilobular necrosis whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival in the absence of treatment.

The term “lower” in the context of the level of HBV gene expression and/or HBV replication in a subject or a disease marker or symptom refers to a statistically significant decrease in such level. The decrease can be, for example, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or more and is preferably down to a level accepted as within the range of normal for an individual without such disorder. In certain embodiments, the expression of the target is normalized, i.e., decreased to a level accepted as within the range of normal for an individual without such disorder, e.g., the level of a disease marker, such as, ALT or AST, is decreased to a level accepted as within the range of normal for an individual without such disorder.

As used herein, “prevention” or “preventing,” when used in reference to a disease, disorder or condition thereof, that would benefit from a reduction in expression of an HBV gene and/or replication, refers to a reduction in the likelihood that a subject will develop a symptom associated with such a disease, disorder, or condition, e.g., a symptom of unwanted HBV infection, such as the presence of serum and/or liver HBV ccc DNA, the presence of serum HBV DNA, the presence of serum and/or liver HBV antigen, e.g., HBsAg and/or HBeAg, elevated ALT, elevated AST, the absence or low level of anti-HBV antibodies, a liver injury; cirrhosis; delta hepatitis, acute hepatitis B; acute fulminant hepatitis B; chronic hepatitis B; liver fibrosis; end-stage liver disease; hepatocellular carcinoma; serum sickness-like syndrome; anorexia; nausea; vomiting, low-grade fever; myalgia; fatigability; disordered gustatory acuity and smell sensations (aversion to food and cigarettes); and/or right upper quadrant and epigastric pain (intermittent, mild to moderate); hepatic encephalopathy; somnolence; disturbances in sleep pattern; mental confusion; coma; ascites; gastrointestinal bleeding; coagulopathy; jaundice; hepatomegaly (mildly enlarged, soft liver); splenomegaly; palmar erythema; spider nevi; muscle wasting; spider angiomas; vasculitis; variceal bleeding; peripheral edema; gynecomastia; testicular atrophy; abdominal collateral veins (caput medusa); high levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), within a range of 1000-2000 IU/mL, although values 100 times above the upper limit of normal (ULN) can be also be identified; ALT levels higher than AST levels; elevated gamma-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP) levels (e.g., not more than 3 times the ULN); slightly low albumin levels; elevated serum iron levels; leukopenia (i.e., granulocytopenia); lymphocytosis; increased erythrocyte sedimentation rate (ESR); shortened red blood cell survival; hemolysis; thrombocytopenia; a prolongation of the international normalized ratio (INR); the presence of serum and/or liverHBsAg, HBeAg, Hepatitis B core antibody (anti-HBc) immunoglobulin M (IgM); hepatitis B surface antibody (anti-HBs), hepatitis B e antibody (anti-HBe), and/or HBV DNA; elevation of the aminotransferases (<5 times the ULN); ALT levels higher than the AST levels; increased bilirubin levels, prolonged prothrombin time (PT); hyperglobulinemia; the presence of tissue-nonspecific antibodies, such as anti-smooth muscle antibodies (ASMAs) or antinuclear antibodies (ANAs) (10-20%); the presence of tissue-specific antibodies, such as antibodies against the thyroid gland (10-20%); elevated levels of rheumatoid factor (RF); hyperbilirubinemia, prolonged PT, low platelet and white blood cell counts, AST levels higher than ALT levels; elevated alkaline phosphatase (ALP) and GGT levels; lobular, with degenerative and regenerative hepatocellular changes, and accompanying inflammation; predominantly centrilobular necrosis, whether detectable or undetectable. The likelihood of developing, e.g., liver fibrosis, is reduced, for example, when an individual having one or more risk factors for liver fibrosis, e.g., chronic hepatitis B infection, either fails to develop liver fibrosis or develops liver fibrosis with less severity relative to a population having the same risk factors and not receiving treatment as described herein. The failure to develop a disease, disorder or condition, or the reduction in the development of a symptom associated with such a disease, disorder or condition (e.g., by at least about 10% on a clinically accepted scale for that disease or disorder), or the exhibition of delayed symptoms delayed (e.g., by days, weeks, months or years) is considered effective prevention.

As used herein, the term “Hepatitis B virus-associated disease” or “HBV-associated disease,” is a disease or disorder that is caused by, or associated with HBV infection and/or replication. The term “HBV-associated disease”includes a disease, disorder or condition that would benefit from reduction in HBV gene expression and/or replication. Non-limiting examples of HBV-associated diseases include, for example, hepatitis D virus infection, delta hepatitis, acute hepatitis B; acute fulminant hepatitis B; chronic hepatitis B; liver fibrosis; end-stage liver disease; hepatocellular carcinoma.

In one embodiment, an HBV-associated disease is hepatitis D virus infection. Hepatitis D virus or hepatitis delta virus (HDV) is a human pathogen. However, the virus is defective and depends on obligatory helper functions provided by hepatitis B virus (HBV) for transmission; indeed, HDV requires an associated or pre-existing HBV infection to become infectious and thrive, in particular, the viral envelope containing the surface antigen of hepatitis B. HDV can lead to severe acute and chronic forms of liver disease in association with HBV. Hepatitis D infection and/or delta hepatitis is highly endemic to several African countries, the Amazonian region, and the Middle East, while its prevalence is low in industrialized countries, except in the Mediterranean.

Transmission of HDV can occur either via simultaneous infection with HBV (coinfection) or superimposed on chronic hepatitis B or hepatitis B carrier state (superinfection). Both superinfection and coinfection with HDV results in more severe complications compared to infection with HBV alone. These complications include a greater likelihood of experiencing liver failure in acute infections and a rapid progression to liver cirrhosis, with an increased chance of developing liver cancer in chronic infections. In combination with hepatitis B virus, hepatitis D has the highest fatality rate of all the hepatitis infections, at 20%.

In one embodiment, an HBV-associated disease is acute hepatitis B. Acute hepatitis B includes inflammation of the liver that lasts less than six months. Typical symptoms of acute hepatitis B are fatigue, anorexia, nausea, and vomiting. Very high aminotransferase values (>1000 U/L) and hyperbilirubinemia are often observed. Severe cases of acute hepatitis B may progress rapidly to acute liver failure, marked by poor hepatic synthetic function. This is often defined as a prothrombin time (PT) of 16 seconds or an international normalized ratio (INR) of 1.5 in the absence of previous liver disease. Acute hepatitis B may evolve into chronic hepatitis B.

In one embodiment, an HBV-associated disease is chronic hepatitis. Chronic hepatitis B (CHB) includes inflammation of the liver that lasts more than six months. Subjects having chronic hepatitis B disease can be immune tolerant or have an inactive chronic infection without any evidence of active disease, and they are also asymptomatic. Patients with chronic active hepatitis, especially during the replicative state, may have symptoms similar to those of acute hepatitis. The persistence of HBV infection in CHB subjects is the result of ccc HBV DNA. In one embodiment, a subject having CHB is HBeAg positive. In another embodiment, a subject having CHB is HBeAg negative. Subjects having CHB have a level of serum HBV DNA of less than about 10⁵ and a persistent elevation in transaminases, for examples ALT, AST and gamma-glutamyl transferase. A subject having CHB may have a liver biopsy score of less than about 4 (e.g., a necroinflammatory score). In addition, a subject having CHB may have

In one embodiment, an HBV-associated disease is acute fulminant hepatitis B. A subject having acute fulminant hepatitis B has symptoms of acute hepatitis and the additional symptoms of confusion or coma (due to the liver's failure to detoxify chemicals) and bruising or bleeding (due to a lack of blood clotting factors).

Subjects having an HBV infection, e.g., CHB, may develop liver fibrosis. Accordingly, in one embodiment, an HBV-associated disease is liver fibrosis. Liver fibrosis, or cirrhosis, is defined histologically as a diffuse hepatic process characterized by fibrosis (excess fibrous connective tissue) and the conversion of normal liver architecture into structurally abnormal nodules.

Subjects having an HBV infection, e.g., CHB, may develop end-stage liver disease. Accordingly, in one embodiment, an HBV-associated disease is end-stage liver disease. For example, liver fibrosis may progress to a point where the body may no longer be able to compensate for, e.g., reduced liver function, as a result of liver fibrosis, and result in, e.g., mental and neurological symptoms and liver failure.

Subjects having an HBV infection, e.g., CHB, may develop hepatocellular carcinoma (HCC), also referred to as malignant hepatoma. Accordingly, in one embodiment, an HBV-associated disease is HCC. HCC commonly develops in subjects having CHB and may be fibrolamellar, pseudoglandular (adenoid), pleomorphic (giant cell) or clear cell.

An “HDV-associated disorder” or a Hepatitis D-virus-associated disorder” is a disease or disorder associated with expression of an HDV. Exemplary HDV-associated disorders include, hepatitis B virus infection, acute hepatits B, acute hepatitis D; acute fulminant hepatitis D; chronic hepatitis D; liver fibrosis; end-stage liver disease; and hepatocellular carcinoma.

“Therapeutically effective amount,” as used herein, is intended to include the amount of an RNAi agent that, when administered to a patient for treating a subject having an HBV infection and/or HBV-associated disease, is sufficient to effect treatment of the disease (e.g., by diminishing, ameliorating or maintaining the existing disease or one or more symptoms of disease). The “therapeutically effective amount” may vary depending on the RNAi agent, how the agent is administered, the disease and its severity and the history, age, weight, family history, genetic makeup, stage of pathological processes mediated by HBV gene expression, the types of preceding or concomitant treatments, if any, and other individual characteristics of the patient to be treated.

“Prophylactically effective amount,” as used herein, is intended to include the amount of an RNAi agent that, when administered to a subject who does not yet experience or display symptoms of an HBV infection and/or HBV-associated disease, but who may be predisposed, is sufficient to prevent or ameliorate the disease or one or more symptoms of the disease. Ameliorating the disease includes slowing the course of the disease or reducing the severity of later-developing disease. The “prophylactically effective amount” may vary depending on the RNAi agent, how the agent is administered, the degree of risk of disease, and the history, age, weight, family history, genetic makeup, the types of preceding or concomitant treatments, if any, and other individual characteristics of the patient to be treated.

A “therapeutically-effective amount” or “prophylacticaly effective amount” also includes an amount of an RNAi agent that produces some desired local or systemic effect at a reasonable benefit/risk ratio applicable to any treatment. RNAi agents employed in the methods of the present invention may be administered in a sufficient amount to produce a reasonable benefit/risk ratio applicable to such treatment.

The term “sample,” as used herein, includes a collection of similar fluids, cells, or tissues isolated from a subject, as well as fluids, cells, or tissues present within a subject. Examples of biological fluids include blood, serum and serosal fluids, plasma, cerebrospinal fluid, ocular fluids, lymph, urine, saliva, and the like. Tissue samples may include samples from tissues, organs or localized regions. For example, samples may be derived from particular organs, parts of organs, or fluids or cells within those organs. In certain embodiments, samples may be derived from the liver (e.g., whole liver or certain segments of liver or certain types of cells in the liver, such as, e.g., hepatocytes), the retina or parts of the retina (e.g., retinal pigment epithelium), the central nervous system or parts of the central nervous system (e.g., ventricles or choroid plexus), or the pancreas or certain cells or parts of the pancreas. In some embodiments, a “sample derived from a subject” refers tocerebrospinal fluid obtained from the subject. In preferred embodiments, a “sample derived from a subject” refers to blood or plasma drawn from the subject. In further embodiments, a “sample derived from a subject” refers to liver tissue (or subcomponents thereof) or retinal tissue (or subcomponents thereof) derived from the subject.

II. iRNAs of the Invention

The present invention provides iRNAs which inhibit the expression of one or more HBV genes. In one embodiment, the iRNA agent includes double-stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of an HBV gene in a cell, such as a cell within a subject, e.g., a mammal, such as a human having an HBV-associated disease, e.g., chronic hepatitis B. The dsRNA includes an antisense strand having a region of complementarity which is complementary to at least a part of an mRNA formed in the expression of an HBV gene. The region of complementarity is about 30 nucleotides or less in length (e.g., about 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, or 18 nucleotides or less in length). Upon contact with a cell expressing the HBV gene, the iRNA inhibits the expression of the HBV gene by at least about 10% as assayed by, for example, a PCR or branched DNA (bDNA)-based method, or by a protein-based method, such as by immunofluorescence analysis, using, for example, western blotting or flowcytometric techniques.

A dsRNA includes two RNA strands that are complementary and hybridize to form a duplex structure under conditions in which the dsRNA will be used. One strand of a dsRNA (the antisense strand) includes a region of complementarity that is substantially complementary, and generally fully complementary, to a target sequence. The target sequence can be derived from the sequence of an mRNA formed during the expression of an HBV gene. The other strand (the sense strand) includes a region that is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. As described elsewhere herein and as known in the art, the complementary sequences of a dsRNA can also be contained as self-complementary regions of a single nucleic acid molecule, as opposed to being on separate oligonucleotides.

Generally, the duplex structure is between 15 and 30 base pairs in length, e.g., between, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.

Similarly, the region of complementarity to the target sequence is between 15 and 30 nucleotides in length, e.g., between 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.

In some embodiments, the dsRNA is between about 15 and about 20 nucleotides in length, or between about 25 and about 30 nucleotides in length. In general, the dsRNA is long enough to serve as a substrate for the Dicer enzyme. For example, it is well-known in the art that dsRNAs longer than about 21-23 nucleotides in length may serve as substrates for Dicer. As the ordinarily skilled person will also recognize, the region of an RNA targeted for cleavage will most often be part of a larger RNA molecule, often an mRNA molecule. Where relevant, a “part” of an mRNA target is a contiguous sequence of an mRNA target of sufficient length to allow it to be a substrate for RNAi-directed cleavage (i.e., cleavage through a RISC pathway).

One of skill in the art will also recognize that the duplex region is a primary functional portion of a dsRNA, e.g., a duplex region of about 9 to 36 base pairs, e.g., about 10-36, 11-36, 12-36, 13-36, 14-36, 15-36, 9-35, 10-35, 11-35, 12-35, 13-35, 14-35, 15-35, 9-34, 10-34, 11-34, 12-34, 13-34, 14-34, 15-34, 9-33, 10-33, 11-33, 12-33, 13-33, 14-33, 15-33, 9-32, 10-32, 11-32, 12-32, 13-32, 14-32, 15-32, 9-31, 10-31, 11-31, 12-31, 13-32, 14-31, 15-31, 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs. Thus, in one embodiment, to the extent that it becomes processed to a functional duplex, of e.g., 15-30 base pairs, that targets a desired RNA for cleavage, an RNA molecule or complex of RNA molecules having a duplex region greater than 30 base pairs is a dsRNA. Thus, an ordinarily skilled artisan will recognize that in one embodiment, a miRNA is a dsRNA. In another embodiment, a dsRNA is not a naturally occurring miRNA. In another embodiment, an iRNA agent useful to target HBV gene expression is not generated in the target cell by cleavage of a larger dsRNA.

A dsRNA as described herein can further include one or more single-stranded nucleotide overhangs e.g., 1, 2, 3, or 4 nucleotides. dsRNAs having at least one nucleotide overhang can have unexpectedly superior inhibitory properties relative to their blunt-ended counterparts. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5′-end, 3′-end or both ends of either an antisense or sense strand of a dsRNA.

A dsRNA can be synthesized by standard methods known in the art as further discussed below, e.g., by use of an automated DNA synthesizer, such as are commercially available from, for example, Biosearch, Applied Biosystems, Inc.

iRNA compounds of the invention may be prepared using a two-step procedure. First, the individual strands of the double-stranded RNA molecule are prepared separately. Then, the component strands are annealed. The individual strands of the siRNA compound can be prepared using solution-phase or solid-phase organic synthesis or both. Organic synthesis offers the advantage that the oligonucleotide strands comprising unnatural or modified nucleotides can be easily prepared. Single-stranded oligonucleotides of the invention can be prepared using solution-phase or solid-phase organic synthesis or both.

In one aspect, a dsRNA of the invention includes at least two nucleotide sequences, a sense sequence and an anti-sense sequence. The sense strand is selected from the group of sequences provided in any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26, and the corresponding antisense strand of the sense strand is selected from the group of sequences of any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26. In this aspect, one of the two sequences is complementary to the other of the two sequences, with one of the sequences being substantially complementary to a sequence of an mRNA generated in the expression of an HBV gene. As such, in this aspect, a dsRNA will include two oligonucleotides, where one oligonucleotide is described as the sense strand in any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26, and the second oligonucleotide is described as the corresponding antisense strand of the sense strand in any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26. In one embodiment, the substantially complementary sequences of the dsRNA are contained on separate oligonucleotides. In another embodiment, the substantially complementary sequences of the dsRNA are contained on a single oligonucleotide.

It will be understood that, although some of the sequences in Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26 are described as modified and/or conjugated sequences, the RNA of the iRNA of the invention e.g., a dsRNA of the invention, may comprise any one of the sequences set forth in Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26 that is un-modified, un-conjugated, and/or modified and/or conjugated differently than described therein.

The skilled person is well aware that dsRNAs having a duplex structure of between about 20 and 23 base pairs, e.g., 21, base pairs have been hailed as particularly effective in inducing RNA interference (Elbashir et al., EMBO 2001, 20:6877-6888). However, others have found that shorter or longer RNA duplex structures can also be effective (Chu and Rana (2007) RNA 14:1714-1719; Kim et al. (2005) Nat Biotech 23:222-226). In the embodiments described above, by virtue of the nature of the oligonucleotide sequences provided in any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26, dsRNAs described herein can include at least one strand of a length of minimally 21 nucleotides. It can be reasonably expected that shorter duplexes having one of the sequences of any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26 minus only a few nucleotides on one or both ends can be similarly effective as compared to the dsRNAs described above. Hence, dsRNAs having a sequence of at least 15, 16, 17, 18, 19, 20, or more contiguous nucleotides derived from one of the sequences of any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26, and differing in their ability to inhibit the expression of a HBV gene by not more than about 5, 10, 15, 20, 25, or 30% inhibition from a dsRNA comprising the full sequence, are contemplated to be within the scope of the present invention.

In addition, the RNAs provided in any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26 identify a site(s) in a HBV transcript that is susceptible to RISC-mediated cleavage. As such, the present invention further features iRNAs that target within one of these sites. As used herein, an iRNA is said to target within a particular site of an RNA transcript if the iRNA promotes cleavage of the transcript anywhere within that particular site. Such an iRNA will generally include at least about 15 contiguous nucleotides from one of the sequences provided in any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26 coupled to additional nucleotide sequences taken from the region contiguous to the selected sequence in a HBV gene.

While a target sequence is generally about 15-30 nucleotides in length, there is wide variation in the suitability of particular sequences in this range for directing cleavage of any given target RNA. Various software packages and the guidelines set out herein provide guidance for the identification of optimal target sequences for any given gene target, but an empirical approach can also be taken in which a “window” or “mask” of a given size (as a non-limiting example, 21 nucleotides) is literally or figuratively (including, e.g., in silico) placed on the target RNA sequence to identify sequences in the size range that can serve as target sequences. By moving the sequence “window” progressively one nucleotide upstream or downstream of an initial target sequence location, the next potential target sequence can be identified, until the complete set of possible sequences is identified for any given target size selected. This process, coupled with systematic synthesis and testing of the identified sequences (using assays as described herein or as known in the art) to identify those sequences that perform optimally can identify those RNA sequences that, when targeted with an iRNA agent, mediate the best inhibition of target gene expression. Thus, while the sequences identified, for example, in any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26 represent effective target sequences, it is contemplated that further optimization of inhibition efficiency can be achieved by progressively “walking the window” one nucleotide upstream or downstream of the given sequences to identify sequences with equal or better inhibition characteristics.

Further, it is contemplated that for any sequence identified, e.g., in any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26, further optimization could be achieved by systematically either adding or removing nucleotides to generate longer or shorter sequences and testing those sequences generated by walking a window of the longer or shorter size up or down the target RNA from that point. Again, coupling this approach to generating new candidate targets with testing for effectiveness of iRNAs based on those target sequences in an inhibition assay as known in the art and/or as described herein can lead to further improvements in the efficiency of inhibition. Further still, such optimized sequences can be adjusted by, e.g., the introduction of modified nucleotides as described herein or as known in the art, addition or changes in overhang, or other modifications as known in the art and/or discussed herein to further optimize the molecule (e.g., increasing serum stability or circulating half-life, increasing thermal stability, enhancing transmembrane delivery, targeting to a particular location or cell type, increasing interaction with silencing pathway enzymes, increasing release from endosomes) as an expression inhibitor.

An iRNA as described herein can contain one or more mismatches to the target sequence. In one embodiment, an iRNA as described herein contains no more than 3 mismatches. If the antisense strand of the iRNA contains mismatches to a target sequence, it is preferable that the area of mismatch is not located in the center of the region of complementarity. If the antisense strand of the iRNA contains mismatches to the target sequence, it is preferable that the mismatch be restricted to be within the last 5 nucleotides from either the 5′- or 3′-end of the region of complementarity. For example, for a 23 nucleotide iRNA agent the strand which is complementary to a region of an HBV gene, generally does not contain any mismatch within the central 13 nucleotides. The methods described herein or methods known in the art can be used to determine whether an iRNA containing a mismatch to a target sequence is effective in inhibiting the expression of an HBV gene. Consideration of the efficacy of iRNAs with mismatches in inhibiting expression of an HBV gene is important, especially if the particular region of complementarity in an HBV gene is known to have polymorphic sequence variation within the population.

III. Modified iRNAs of the Invention

In one embodiment, the RNA of the iRNA of the invention e.g., a dsRNA, is un-modified, and does not comprise, e.g., chemical modifications and/or conjugations known in the art and described herein. In another embodiment, the RNA of an iRNA of the invention, e.g., a dsRNA, is chemically modified to enhance stability or other beneficial characteristics. In certain embodiments of the invention, substantially all of the nucleotides of an iRNA of the invention are modified. In other embodiments of the invention, all of the nucleotides of an iRNA of the invention are modified. iRNAs of the invention in which “substantially all of the nucleotides are modified” are largely but not wholly modified and can include not more than 5, 4, 3, 2, or 1 unmodified nucleotides.

The nucleic acids featured in the invention can be synthesized and/or modified by methods well established in the art, such as those described in “Current protocols in nucleic acid chemistry,” Beaucage, S. L. et al. (Edrs.), John Wiley & Sons, Inc., New York, N.Y., USA, which is hereby incorporated herein by reference. Modifications include, for example, end modifications, e.g., 5′-end modifications (phosphorylation, conjugation, inverted linkages) or 3′-end modifications (conjugation, DNA nucleotides, inverted linkages, etc.); base modifications, e.g., replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases; sugar modifications (e.g., at the 2′-position or 4′-position) or replacement of the sugar; and/or backbone modifications, including modification or replacement of the phosphodiester linkages. Specific examples of iRNA compounds useful in the embodiments described herein include, but are not limited to RNAs containing modified backbones or no natural internucleoside linkages. RNAs having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. In some embodiments, a modified iRNA will have a phosphorus atom in its intemucleoside backbone.

Modified RNA backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′-linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts and free acid forms are also included.

Representative U.S. patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170; 6,172,209; 6,239,265; 6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,534,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and U.S. Pat. RE39464, the entire contents of each of which are hereby incorporated herein by reference.

Modified RNA backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl intemucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl intemucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative U.S. patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and, 5,677,439, the entire contents of each of which are hereby incorporated herein by reference.

In other embodiments, suitable RNA mimetics are contemplated for use in iRNAs, in which both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an RNA mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of an RNA is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, the entire contents of each of which are hereby incorporated herein by reference. Additional PNA compounds suitable for use in the iRNAs of the invention are described in, for example, in Nielsen et al., Science, 1991, 254, 1497-1500.

Some embodiments featured in the invention include RNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular —CH₂—NH—CH₂—, —CH₂—N(CH₃)—O—CH₂—[known as a methylene (methylimino) or MMI backbone], —CH₂—O—N(CH₃)—CH₂—, —CH₂—N(CH₃)—N(CH₃)—CH₂—and —N(CH₃)—CH₂—CH₂—[wherein the native phosphodiester backbone is represented as —O—P—O—CH₂—] of the above-referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above-referenced U.S. Pat. No. 5,602,240. In some embodiments, the RNAs featured herein have morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.

Modified RNAs can also contain one or more substituted sugar moieties. The iRNAs, e.g., dsRNAs, featured herein can include one of the following at the 2′-position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Exemplary suitable modifications include O[(CH₂)_(n)O] _(m)CH₃, O(CH₂)._(n)OCH₃, O(CH₂)_(n)NH₂, O(CH₂) _(n)CH₃, O(CH₂)_(n)ONH₂, and O(CH₂)_(n)ON[(CH₂)_(n)CH₃)]2, where n and m are from 1 to about 10. In other embodiments, dsRNAs include one of the following at the 2′ position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an iRNA, or a group for improving the pharmacodynamic properties of an iRNA, and other substituents having similar properties. In some embodiments, the modification includes a 2′-methoxyethoxy (2′-O—CH₂CH₂OCH₃, also known as 2′-O-(2-methoxyethyl) or 2′-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78:486-504) i.e., an alkoxy-alkoxy group. Another exemplary modification is 2′-dimethylaminooxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2′-DMAOE, as described in examples herein below, and 2′-dimethylaminoethoxyethoxy (also known in the art as 2′-O-dimethylaminoethoxyethyl or 2′-DMAEOE), i.e., 2′-O—CH₂—O—CH₂—N(CH₂)₂.

Other modifications include 2′-methoxy (2′-OCH₃), 2′-aminopropoxy (2′-OCH₂CH₂CH₂NH₂) and 2′-fluoro (2′-F). Similar modifications can also be made at other positions on the RNA of an iRNA, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked dsRNAs and the 5′ position of 5′ terminal nucleotide. iRNAs can also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative U.S. patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application. The entire contents of each of the foregoing are hereby incorporated herein by reference.

An iRNA can also include nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as deoxy-thymine (dT), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl anal other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008; those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. L, ed. John Wiley & Sons, 1990, these disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y S., Chapter 15, dsRNA Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., Ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., dsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are exemplary base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications.

Representative U.S. patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. Nos. 3,687,808, 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,681,941; 5,750,692; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, the entire contents of each of which are hereby incorporated herein by reference.

The RNA of an iRNA can also be modified to include one or more bicyclic sugar moities. A “bicyclic sugar” is a furanosyl ring modified by the bridging of two atoms. A“bicyclic nucleoside” (“BNA”) is a nucleoside having a sugar moiety comprising a bridge connecting two carbon atoms of the sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the bridge connects the 4′-carbon and the 2′-carbon of the sugar ring. Thus, in some embodiments an agent of the invention may include one or more locked nucleic acids (LNA). A locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2′ and 4′ carbons. In other words, an LNA is a nucleotide comprising a bicyclic sugar moiety comprising a 4′-CH₂—O-2′ bridge. This structure effectively “locks” the ribose in the 3′-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, and to reduce off-target effects (Elmen, J. et al., (2005) Nucleic Acids Research 33(1):439-447; Mook, O R. et al., (2007) Mol Canc Ther 6(3):833-843; Grunweller, A. et al., (2003) Nucleic Acids Research 31(12):3185-3193). Examples of bicyclic nucleosides for use in the polynucleotides of the invention include without limitation nucleosides comprising a bridge between the 4′ and the 2′ ribosyl ring atoms. In certain embodiments, the antisense polynucleotide agents of the invention include one or more bicyclic nucleosides comprising a 4′ to 2′ bridge. Examples of such 4′ to 2′ bridged bicyclic nucleosides, include but are not limited to 4′-(CH₂)—O-2′ (LNA); 4′-(CH₂)—S-2′; 4′—(CH₂)₂—O-2′ (ENA); 4′-CH(CH₃)—O-2′ (also referred to as “constrained ethyl” or “cEt”) and 4′-CH(CH₂OCH₃)—O-2′ (and analogs thereof; see, e.g., U.S. Pat. No. 7,399,845); 4′-C(CH₃)(CH₃)—O-2′ (and analogs thereof, see e.g., U.S. Pat. No. 8,278,283); 4′-CH₂—N(OCH₃)-2′ (and analogs thereof; see e.g., U.S. Pat. No. 8,278,425); 4′-CH₂—O—N(CH₃)-2′ (see, e.g., U.S. Patent Publication No. 2004/0171570); 4′-CH₂—N(R)—O-2′, wherein R is H, C1-C12 alkyl, or a protecting group (see, e.g., U.S. Pat. No. 7,427,672); 4′-CH₂—C(H)(CH₃)-2′ (see, e.g., Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134); and 4′-CH₂—C(═CH₂)-2′ (and analogs thereof; see, e.g., U.S. Pat. No. 8,278,426). The entire contents of each of the foregoing are hereby incorporated herein by reference.

Additional representative U.S. Patents and US Patent Publications that teach the preparation of locked nucleic acid nucleotides include, but are not limited to, the following: U.S. Pat. Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 6,998,484; 7,053,207; 7,034,133; 7,084,125; 7,399,845; 7,427,672; 7,569,686; 7,741,457; 8,022,193; 8,030,467; 8,278,425; 8,278,426; 8,278,283; US 2008/0039618; and US 2009/0012281, the entire contents of each of which are hereby incorporated herein by reference.

Any of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example α-L-ribofuranose and β-D-ribofuranose (see WO 99/14226).

The RNA of an iRNA can also be modified to include one or more constrained ethyl nucleotides. As used herein, a “constrained ethyl nucleotide” or “cEt” is a locked nucleic acid comprising a bicyclic sugar moiety comprising a 4′-CH(CH₃)-0-2′ bridge. In one embodiment, a constrained ethyl nucleotide is in the S conformation referred to herein as “S-cEt.”

An iRNA of the invention may also include one or more “conformationally restricted nucleotides” (“CRN”). CRN are nucleotide analogs with a linker connecting the C2′ and C4′ carbons of ribose or the C3 and —C5′ carbons of ribose. CRN lock the ribose ring into a stable conformation and increase the hybridization affinity to mRNA. The linker is of sufficient length to place the oxygen in an optimal position for stability and affinity resulting in less ribose ring puckering.

Representative publications that teach the preparation of certain of the above noted CRN include, but are not limited to, US Patent Publication No. 2013/0190383; and PCT publication WO 2013/036868, the entire contents of each of which are hereby incorporated herein by reference.

One or more of the nucleotides of an iRNA of the invention may also include a hydroxymethyl substituted nucleotide. A “hydroxymethyl substituted nucleotide” is an acyclic 2′-3′-seco-nucleotide, also referred to as an “unlocked nucleic acid” (“UNA”) modification.

Representative U.S. publications that teach the preparation of UNA include, but are not limited to, U.S. Pat. No. 8,314,227; and US Patent Publication Nos. 2013/0096289; 2013/0011922; and 2011/0313020, the entire contents of each of which are hereby incorporated herein by reference.

Potentially stabilizing modifications to the ends of RNA molecules can include N-(acetylaminocaproyl)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(caproyl-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2′-O-deoxythymidine (ether), N-(aminocaproyl)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyl-uridine-3″-phosphate, inverted base dT (idT) and others. Disclosure of this modification can be found in PCT Publication No. WO 2011/005861.

Other modifications of the nucleotides of an iRNA of the invention include a 5′ phosphate or 5′ phosphate mimic, e.g., a 5′-terminal phosphate or phosphate mimic on the antisense strand of an RNAi agent. Suitable phosphate mimics are disclosed in, for example US Patent Publication No. 2012/0157511, the entire contents of which are incorporated herein by reference.

A. Modified iRNAs Comprising Motifs of the Invention

In certain aspects of the invention, the double-stranded RNAi agents of the invention include agents with chemical modifications as disclosed, for example, in WO 2013/075035, filed on Nov. 16, 2012, the entire contents of which are incorporated herein by reference. As shown herein and in PCT Publication No. WO 2013/075035, a superior result may be obtained by introducing one or more motifs of three identical modifications on three consecutive nucleotides into a sense strand and/or antisense strand of an RNAi agent, particularly at or near the cleavage site. In some embodiments, the sense strand and antisense strand of the RNAi agent may otherwise be completely modified. The introduction of these motifs interrupts the modification pattern, if present, of the sense and/or antisense strand. The RNAi agent may be optionally conjugated with a GalNAc derivative ligand, for instance on the sense strand. The resulting RNAi agents present superior gene silencing activity.

More specifically, it has been surprisingly discovered that when the sense strand and antisense strand of the double-stranded RNAi agent are completely modified to have one or more motifs of three identical modifications on three consecutive nucleotides at or near the cleavage site of at least one strand of an RNAi agent, the gene silencing activity of the RNAi agent was superiorly enhanced.

Accordingly, the invention provides double-stranded RNAi agents capable of inhibiting the expression of a target gene (i.e., HBV gene) in vivo. The RNAi agent comprises a sense strand and an antisense strand. Each strand of the RNAi agent may range from 12-30 nucleotides in length. For example, each strand may be between 14-30 nucleotides in length, 17-30 nucleotides in length, 25-30 nucleotides in length, 27-30 nucleotides in length, 17-23 nucleotides in length, 17-21 nucleotides in length, 17-19 nucleotides in length, 19-25 nucleotides in length, 19-23 nucleotides in length, 19-21 nucleotides in length, 21-25 nucleotides in length, or 21-23 nucleotides in length.

The sense strand and antisense strand typically form a duplex double stranded RNA (“dsRNA”), also referred to herein as an “RNAi agent.” The duplex region of an RNAi agent may be 12-30 nucleotide pairs in length. For example, the duplex region can be between 14-nucleotide pairs in length, 17-30 nucleotide pairs in length, 27-30 nucleotide pairs in length, 17-23 nucleotide pairs in length, 17-21 nucleotide pairs in length, 17-19 nucleotide pairs in length, 19-25 nucleotide pairs in length, 19-23 nucleotide pairs in length, 19-21 nucleotide pairs in length, 21-25 nucleotide pairs in length, or 21-23 nucleotide pairs in length. In another example, the duplex region is selected from 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, and 27 nucleotides in length.

In one embodiment, the RNAi agent may contain one or more overhang regions and/or capping groups at the 3′-end, 5′-end, or both ends of one or both strands. The overhang can be 1-6 nucleotides in length, for instance 2-6 nucleotides in length, 1-5 nucleotides in length, 2-5 nucleotides in length, 1-4 nucleotides in length, 2-4 nucleotides in length, 1-3 nucleotides in length, 2-3 nucleotides in length, or 1-2 nucleotides in length. The overhangs can be the result of one strand being longer than the other, or the result of two strands of the same length being staggered. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence. The first and second strands can also be joined, e.g., by additional bases to form a hairpin, or by other non-base linkers.

In one embodiment, the nucleotides in the overhang region of the RNAi agent can each independently be a modified or unmodified nucleotide including, but no limited to 2′-sugar modified, such as, 2-F, 2′-Omethyl, thymidine (T), 2′-O-methoxyethyl-5-methyluridine (Teo), 2′-O-methoxyethyladenosine (Aeo), 2′-O-methoxyethyl-5-methylcytidine (m5Ceo), and any combinations thereof. For example, TT can be an overhang sequence for either end on either strand. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence.

The 5′- or 3′-overhangs at the sense strand, antisense strand or both strands of the RNAi agent may be phosphorylated. In some embodiments, the overhang region(s) contains two nucleotides having a phosphorothioate between the two nucleotides, where the two nucleotides can be the same or different. In one embodiment, the overhang is present at the 3′-end of the sense strand, antisense strand, or both strands. In one embodiment, this 3′-overhang is present in the antisense strand. In one embodiment, this 3′-overhang is present in the sense strand.

The RNAi agent may contain only a single overhang, which can strengthen the interference activity of the RNAi, without affecting its overall stability. For example, the single-stranded overhang may be located at the 3′-terminal end of the sense strand or, alternatively, at the 3′-terminal end of the antisense strand. The RNAi may also have a blunt end, located at the 5′-end of the antisense strand (or the 3′-end of the sense strand) or vice versa. Generally, the antisense strand of the RNAi has a nucleotide overhang at the 3′-end, and the 5′-end is blunt. While not wishing to be bound by theory, the asymmetric blunt end at the 5′-end of the antisense strand and 3′-end overhang of the antisense strand favor the guide strand loading into RISC process.

In one embodiment, the RNAi agent is a double ended bluntmer of 19 nucleotides in length, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 7, 8, 9 from the 5′end. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5′end.

In another embodiment, the RNAi agent is a double ended bluntmer of 20 nucleotides in length, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 8, 9, 10 from the 5′end. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5′end.

In yet another embodiment, the RNAi agent is a double ended bluntmer of 21 nucleotides in length, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 9, 10, 11 from the 5′end. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5′end.

In one embodiment, the RNAi agent comprises a 21 nucleotide sense strand and a 23 nucleotide antisense strand, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 9, 10, 11 from the 5′end; the antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5′end, wherein one end of the RNAi agent is blunt, while the other end comprises a 2 nucleotide overhang. Preferably, the 2 nucleotide overhang is at the 3′-end of the antisense strand.

When the 2 nucleotide overhang is at the 3′-end of the antisense strand, there may be two phosphorothioate internucleotide linkages between the terminal three nucleotides, wherein two of the three nucleotides are the overhang nucleotides, and the third nucleotide is a paired nucleotide next to the overhang nucleotide. In one embodiment, the RNAi agent additionally has two phosphorothioate internucleotide linkages between the terminal three nucleotides at both the 5′-end of the sense strand and at the 5′-end of the antisense strand. In one embodiment, every nucleotide in the sense strand and the antisense strand of the RNAi agent, including the nucleotides that are part of the motifs are modified nucleotides. In one embodiment each residue is independently modified with a 2′-O-methyl or 3′-fluoro, e.g., in an alternating motif. Optionally, the RNAi agent further comprises a ligand (preferably GalNAc₃).

In one embodiment, the RNAi agent comprises a sense and an antisense strand, wherein the sense strand is 25-30 nucleotide residues in length, wherein starting from the 5′ terminal nucleotide (position 1) positions 1 to 23 of the first strand comprise at least 8 ribonucleotides; the antisense strand is 36-66 nucleotide residues in length and, starting from the 3′ terminal nucleotide, comprises at least 8 ribonucleotides in the positions paired with positions 1-23 of sense strand to form a duplex; wherein at least the 3′ terminal nucleotide of antisense strand is unpaired with sense strand, and up to 6 consecutive 3′ terminal nucleotides are unpaired with sense strand, thereby forming a 3′ single stranded overhang of 1-6 nucleotides; wherein the 5′ terminus of antisense strand comprises from 10-30 consecutive nucleotides which are unpaired with sense strand, thereby forming a 10-30 nucleotide single stranded 5′ overhang; wherein at least the sense strand 5′ terminal and 3′ terminal nucleotides are base paired with nucleotides of antisense strand when sense and antisense strands are aligned for maximum complementarity, thereby forming a substantially duplexed region between sense and antisense strands; and antisense strand is sufficiently complementary to a target RNA along at least 19 ribonucleotides of antisense strand length to reduce target gene expression when the double stranded nucleic acid is introduced into a mammalian cell; and wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides, where at least one of the motifs occurs at or near the cleavage site. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at or near the cleavage site.

In one embodiment, the RNAi agent comprises sense and antisense strands, wherein the RNAi agent comprises a first strand having a length which is at least 25 and at most 29 nucleotides and a second strand having a length which is at most 30 nucleotides with at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at position 11, 12, 13 from the 5′ end; wherein the 3′ end of the first strand and the 5′ end of the second strand form a blunt end and the second strand is 1-4 nucleotides longer at its 3′ end than the first strand, wherein the duplex region region which is at least 25 nucleotides in length, and the second strand is sufficiently complemenatary to a target mRNA along at least 19 nucleotide of the second strand length to reduce target gene expression when the RNAi agent is introduced into a mammalian cell, and wherein dicer cleavage of the RNAi agent preferentially results in an siRNA comprising the 3′ end of the second strand, thereby reducing expression of the target gene in the mammal. Optionally, the RNAi agent further comprises a ligand.

In one embodiment, the sense strand of the RNAi agent contains at least one motif of three identical modifications on three consecutive nucleotides, where one of the motifs occurs at the cleavage site in the sense strand.

In one embodiment, the antisense strand of the RNAi agent can also contain at least one motif of three identical modifications on three consecutive nucleotides, where one of the motifs occurs at or near the cleavage site in the antisense strand

For an RNAi agent having a duplex region of 17-23 nucleotide in length, the cleavage site of the antisense strand is typically around the 10, 11 and 12 positions from the 5′-end. Thus the motifs of three identical modifications may occur at the 9, 10, 11 positions; 10, 11, 12 positions; 11, 12, 13 positions; 12, 13, 14 positions; or 13, 14, 15 positions of the antisense strand, the count starting from the 1^(st) nucleotide from the 5′-end of the antisense strand, or, the count starting from the 1^(st) paired nucleotide within the duplex region from the 5′-end of the antisense strand. The cleavage site in the antisense strand may also change according to the length of the duplex region of the RNAi from the 5′-end.

The sense strand of the RNAi agent may contain at least one motif of three identical modifications on three consecutive nucleotides at the cleavage site of the strand; and the antisense strand may have at least one motif of three identical modifications on three consecutive nucleotides at or near the cleavage site of the strand. When the sense strand and the antisense strand form a dsRNA duplex, the sense strand and the antisense strand can be so aligned that one motif of the three nucleotides on the sense strand and one motif of the three nucleotides on the antisense strand have at least one nucleotide overlap, i.e., at least one of the three nucleotides of the motif in the sense strand forms a base pair with at least one of the three nucleotides of the motif in the antisense strand. Alternatively, at least two nucleotides may overlap, or all three nucleotides may overlap.

In one embodiment, the sense strand of the RNAi agent may contain more than one motif of three identical modifications on three consecutive nucleotides. The first motif may occur at or near the cleavage site of the strand and the other motifs may be a wing modification. The term “wing modification” herein refers to a motif occurring at another portion of the strand that is separated from the motif at or near the cleavage site of the same strand. The wing modification is either adjacent to the first motif or is separated by at least one or more nucleotides. When the motifs are immediately adjacent to each other then the chemistry of the motifs are distinct from each other and when the motifs are separated by one or more nucleotide than the chemistries can be the same or different. Two or more wing modifications may be present. For instance, when two wing modifications are present, each wing modification may occur at one end relative to the first motif which is at or near cleavage site or on either side of the lead motif.

Like the sense strand, the antisense strand of the RNAi agent may contain more than one motifs of three identical modifications on three consecutive nucleotides, with at least one of the motifs occurring at or near the cleavage site of the strand. This antisense strand may also contain one or more wing modifications in an alignment similar to the wing modifications that may be present on the sense strand.

In one embodiment, the wing modification on the sense strand or antisense strand of the RNAi agent typically does not include the first one or two terminal nucleotides at the 3′-end, 5′-end or both ends of the strand.

In another embodiment, the wing modification on the sense strand or antisense strand of the RNAi agent typically does not include the first one or two paired nucleotides within the duplex region at the 3′-end, 5′-end or both ends of the strand.

When the sense strand and the antisense strand of the RNAi agent each contain at least one wing modification, the wing modifications may fall on the same end of the duplex region, and have an overlap of one, two or three nucleotides.

When the sense strand and the antisense strand of the RNAi agent each contain at least two wing modifications, the sense strand and the antisense strand can be so aligned that two modifications each from one strand fall on one end of the duplex region, having an overlap of one, two or three nucleotides; two modifications each from one strand fall on the other end of the duplex region, having an overlap of one, two or three nucleotides; two modifications one strand fall on each side of the lead motif, having an overlap of one, two or three nucleotides in the duplex region.

In one embodiment, every nucleotide in the sense strand and antisense strand of the RNAi agent, including the nucleotides that are part of the motifs, may be modified. Each nucleotide may be modified with the same or different modification which can include one or more alteration of one or both of the non-linking phosphate oxygens and/or of one or more of the linking phosphate oxygens; alteration of a constituent of the ribose sugar, e.g., of the 2′ hydroxyl on the ribose sugar; wholesale replacement of the phosphate moiety with “dephospho” linkers; modification or replacement of a naturally occurring base; and replacement or modification of the ribose-phosphate backbone.

As nucleic acids are polymers of subunits, many of the modifications occur at a position which is repeated within a nucleic acid, e.g., a modification of a base, or a phosphate moiety, or a non-linking O of a phosphate moiety. In some cases the modification will occur at all of the subject positions in the nucleic acid but in many cases it will not. By way of example, a modification may only occur at a 3′ or 5′ terminal position, may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand. A modification may occur in a double strand region, a single strand region, or in both. A modification may occur only in the double strand region of a RNA or may only occur in a single strand region of a RNA. For example, a phosphorothioate modification at a non-linking O position may only occur at one or both termini, may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand, or may occur in double strand and single strand regions, particularly at termini. The 5′ end or ends can be phosphorylated.

It may be possible, e.g., to enhance stability, to include particular bases in overhangs, or to include modified nucleotides or nucleotide surrogates, in single strand overhangs, e.g., in a 5′ or 3′ overhang, or in both. For example, it can be desirable to include purine nucleotides in overhangs. In some embodiments all or some of the bases in a 3′ or 5′ overhang may be modified, e.g., with a modification described herein. Modifications can include, e.g., the use of modifications at the 2′ position of the ribose sugar with modifications that are known in the art, e.g., the use of deoxyribonucleotides, 2′-deoxy-2′-fluoro (2′-F) or 2′-O-methyl modified instead of the ribosugar of the nucleobase, and modifications in the phosphate group, e.g., phosphorothioate modifications. Overhangs need not be homologous with the target sequence.

In one embodiment, each residue of the sense strand and antisense strand is independently modified with LNA, CRN, cET, UNA, HNA, CeNA, 2′-methoxyethyl, 2′-O-methyl, 2′-O-allyl, 2′-C— allyl, 2′-deoxy, 2′-hydroxyl, or 2′-fluoro. The strands can contain more than one modification. In one embodiment, each residue of the sense strand and antisense strand is independently modified with 2′-O-methyl or 2′-fluoro.

At least two different modifications are typically present on the sense strand and antisense strand. Those two modifications may be the 2′-O-methyl or 2′-fluoro modifications, or others.

In one embodiment, the N_(a) and/or N_(b) comprise modifications of an alternating pattern. The term “alternating motif” as used herein refers to a motif having one or more modifications, each modification occurring on alternating nucleotides of one strand. The alternating nucleotide may refer to one per every other nucleotide or one per every three nucleotides, or a similar pattern. For example, if A, B and C each represent one type of modification to the nucleotide, the alternating motif can be “ABABABABABAB . . . ,” “AABBAABBAABB . . . ,” “AABAABAABAAB . . . ,” “AAABAAABAAAB . . . ,” “AAABBBAAABBB . . . ,” or “ABCABCABCABC . . . ,” etc.

The type of modifications contained in the alternating motif may be the same or different. For example, if A, B, C, D each represent one type of modification on the nucleotide, the alternating pattern, i.e., modifications on every other nucleotide, may be the same, but each of the sense strand or antisense strand can be selected from several possibilities of modifications within the alternating motif such as “ABABAB . . . ”, “ACACAC . . . ” “BDBDBD . . . ” or “CDCDCD . . . ,” etc.

In one embodiment, the RNAi agent of the invention comprises the modification pattern for the alternating motif on the sense strand relative to the modification pattern for the alternating motif on the antisense strand is shifted. The shift may be such that the modified group of nucleotides of the sense strand corresponds to a differently modified group of nucleotides of the antisense strand and vice versa. For example, the sense strand when paired with the antisense strand in the dsRNA duplex, the alternating motif in the sense strand may start with “ABABAB” from 5′-3′ of the strand and the alternating motif in the antisense strand may start with “BABABA” from 5′-3′ of the strand within the duplex region. As another example, the alternating motif in the sense strand may start with “AABBAABB” from 5′-3′ of the strand and the alternating motif in the antisenese strand may start with “BBAABBAA” from 5′-3′ of the strand within the duplex region, so that there is a complete or partial shift of the modification patterns between the sense strand and the antisense strand.

In one embodiment, the RNAi agent comprises the pattern of the alternating motif of 2′-O-methyl modification and 2′-F modification on the sense strand initially has a shift relative to the pattern of the alternating motif of 2′-O-methyl modification and 2′-F modification on the antisense strand initially, i.e., the 2′-O-methyl modified nucleotide on the sense strand base pairs with a 2′-F modified nucleotide on the antisense strand and vice versa. The 1 position of the sense strand may start with the 2′-F modification, and the 1 position of the antisense strand may start with the 2′-O-methyl modification.

The introduction of one or more motifs of three identical modifications on three consecutive nucleotides to the sense strand and/or antisense strand interrupts the initial modification pattern present in the sense strand and/or antisense strand. This interruption of the modification pattern of the sense and/or antisense strand by introducing one or more motifs of three identical modifications on three consecutive nucleotides to the sense and/or antisense strand surprisingly enhances the gene silencing activity to the target gene.

In one embodiment, when the motif of three identical modifications on three consecutive nucleotides is introduced to any of the strands, the modification of the nucleotide next to the motif is a different modification than the modification of the motif. For example, the portion of the sequence containing the motif is “ . . . N_(a)YYYN_(b) . . . ,” where “Y” represents the modification of the motif of three identical modifications on three consecutive nucleotide, and “N_(a)” and “N_(b)” represent a modification to the nucleotide next to the motif “YYY” that is different than the modification of Y, and where N_(a) and N_(b) can be the same or different modifications. Alternatively, N_(a) and/or N_(b) may be present or absent when there is a wing modification present.

The RNAi agent may further comprise at least one phosphorothioate or methylphosphonate internucleotide linkage. The phosphorothioate or methylphosphonate internucleotide linkage modification may occur on any nucleotide of the sense strand or antisense strand or both strands in any position of the strand. For instance, the internucleotide linkage modification may occur on every nucleotide on the sense strand and/or antisense strand; each internucleotide linkage modification may occur in an alternating pattern on the sense strand and/or antisense strand; or the sense strand or antisense strand may contain both internucleotide linkage modifications in an alternating pattern. The alternating pattern of the internucleotide linkage modification on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the internucleotide linkage modification on the sense strand may have a shift relative to the alternating pattern of the internucleotide linkage modification on the antisense strand. In one embodiment, a double-standard RNAi agent comprises 6-8 phosphorothioate internucleotide linkages. In one embodiment, the antisense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus and two phosphorothioate internucleotide linkages at the 3′-terminus, and the sense strand comprises at least two phosphorothioate internucleotide linkages at either the 5′-terminus or the 3′-terminus.

In one embodiment, the RNAi comprises a phosphorothioate or methylphosphonate internucleotide linkage modification in the overhang region. For example, the overhang region may contain two nucleotides having a phosphorothioate or methylphosphonate internucleotide linkage between the two nucleotides. Internucleotide linkage modifications also may be made to link the overhang nucleotides with the terminal paired nucleotides within the duplex region. For example, at least 2, 3, 4, or all the overhang nucleotides may be linked through phosphorothioate or methylphosphonate internucleotide linkage, and optionally, there may be additional phosphorothioate or methylphosphonate internucleotide linkages linking the overhang nucleotide with a paired nucleotide that is next to the overhang nucleotide. For instance, there may be at least two phosphorothioate internucleotide linkages between the terminal three nucleotides, in which two of the three nucleotides are overhang nucleotides, and the third is a paired nucleotide next to the overhang nucleotide. These terminal three nucleotides may be at the 3′-end of the antisense strand, the 3′-end of the sense strand, the 5′-end of the antisense strand, and/or the 5′end of the antisense strand.

In one embodiment, the 2 nucleotide overhang is at the 3′-end of the antisense strand, and there are two phosphorothioate internucleotide linkages between the terminal three nucleotides, wherein two of the three nucleotides are the overhang nucleotides, and the third nucleotide is a paired nucleotide next to the overhang nucleotide. Optionally, the RNAi agent may additionally have two phosphorothioate internucleotide linkages between the terminal three nucleotides at both the 5′-end of the sense strand and at the 5′-end of the antisense strand.

In one embodiment, the RNAi agent comprises mismatch(es) with the target, within the duplex, or combinations thereof. The mistmatch may occur in the overhang region or the duplex region. The base pair may be ranked on the basis of their propensity to promote dissociation or melting (e.g., on the free energy of association or dissociation of a particular pairing, the simplest approach is to examine the pairs on an individual pair basis, though next neighbor or similar analysis can also be used). In terms of promoting dissociation: A:U is preferred over G:C; G:U is preferred over G:C; and I:C is preferred over G:C (I=inosine). Mismatches, e.g., non-canonical or other than canonical pairings (as described elsewhere herein) are preferred over canonical (A:T, A:U, G:C) pairings; and pairings which include a universal base are preferred over canonical pairings.

In one embodiment, the RNAi agent comprises at least one of the first 1, 2, 3, 4, or 5 base pairs within the duplex regions from the 5′-end of the antisense strand independently selected from the group of: A:U, G:U, I:C, and mismatched pairs, e.g., non-canonical or other than canonical pairings or pairings which include a universal base, to promote the dissociation of the antisense strand at the 5′-end of the duplex.

In one embodiment, the nucleotide at the 1 position within the duplex region from the 5′-end in the antisense strand is selected from the group consisting of A, dA, dU, U, and dT. Alternatively, at least one of the first 1, 2 or 3 base pair within the duplex region from the 5′-end of the antisense strand is an AU base pair. For example, the first base pair within the duplex region from the 5′-end of the antisense strand is an AU base pair.

In another embodiment, the nucleotide at the 3′-end of the sense strand is deoxy-thymine (dT). In another embodiment, the nucleotide at the 3′-end of the antisense strand is deoxy-thymine (dT). In one embodiment, there is a short sequence of deoxy-thymine nucleotides, for example, two dT nucleotides on the 3′-end of the sense and/or antisense strand.

In one embodiment, the sense strand sequence may be represented by formula (I):

5′n_(p)-N_(a)-(XXX)_(i)-N_(b)-YYY-N_(b)-(ZZZ)_(j)-N_(a)-n_(q)3′  (I)

wherein:

i and j are each independently 0 or 1;

p and q are each independently 0-6;

each N_(a) independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_(b) independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

each n_(p) and n_(q) independently represent an overhang nucleotide;

wherein N_(b) and Y do not have the same modification; and

XXX, YYY and ZZZ each independently represent one motif of three identical modifications on three consecutive nucleotides. Preferably YYY is all 2′-F modified nucleotides.

In one embodiment, the N_(a) and/or N_(b) comprise modifications of alternating pattern.

In one embodiment, the YYY motif occurs at or near the cleavage site of the sense strand. For example, when the RNAi agent has a duplex region of 17-23 nucleotides in length, the YYY motif can occur at or the vicinity of the cleavage site (e.g.: can occur at positions 6, 7, 8, 7, 8, 9, 8, 9, 10, 9, 10, 11, 10, 11,12 or 11, 12, 13) of—the sense strand, the count starting from the 1^(st) nucleotide, from the 5′-end; or optionally, the count starting at the 1^(st) paired nucleotide within the duplex region, from the 5′-end.

In one embodiment, i is 1 and j is 0, or i is 0 and j is 1, or both i and j are 1. The sense strand can therefore be represented by the following formulas:

5′n_(p)-N_(a)-YYY-N_(b)-ZZZ-N_(a)-n_(q)3′  (Ib);

5′n_(p)-N_(a)-XXX-N_(b)-YYY-N_(a)-n_(q)3′  (Ic); or

5′n_(p)-N_(a)-XXX-N_(b)-YYY-N_(b)-ZZZ-N_(a)-n_(q)3′  (Id).

When the sense strand is represented by formula (Ib), N_(b) represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_(a) independently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the sense strand is represented as formula (Ic), N_(b) represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_(a) can independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the sense strand is represented as formula (Id), each N_(b) independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Preferably, N_(b) is 0, 1, 2, 3, 4, 5 or 6 Each N_(a) can independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Each of X, Y and Z may be the same or different from each other.

In other embodiments, i is 0 and j is 0, and the sense strand may be represented by the formula:

5′n_(p)-N_(a)-YYY-N_(a)-n_(q)3′  (Ia).

When the sense strand is represented by formula (Ia), each N_(a) independently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

In one embodiment, the antisense strand sequence of the RNAi may be represented by formula (II):

5′n_(q′)-N_(a)′-(Z′Z′Z′)_(k)-N_(b)′-Y′Y′Y′-N_(b)′-(X′X′X′)_(l)-N′_(a)-n_(p)′3′  (II)

wherein:

k and 1 are each independently 0 or 1;

p′ and q′ are each independently 0-6;

each N_(a)′ independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_(b)′ independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

each n_(p)′ and n_(q)′ independently represent an overhang nucleotide;

wherein N_(b)‘ and Y’ do not have the same modification; and

X′X′X′, Y′Y′Y′ and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides.

In one embodiment, the N_(a)′ and/or N_(b)′ comprise modifications of alternating pattern.

The Y′Y′Y′ motif occurs at or near the cleavage site of the antisense strand. For example, when the RNAi agent has a duplex region of 17-23 nucleotidein length, the Y′Y′Y′ motif can occur at positions 9, 10, 11; 10, 11, 12; 11, 12, 13; 12, 13, 14; or 13, 14, 15 of the antisense strand, with the count starting from the 1^(st) nucleotide, from the 5′-end; or optionally, the count starting at the 1^(st) paired nucleotide within the duplex region, from the 5′-end. Preferably, the Y′Y′Y′ motif occurs at positions 11, 12, 13.

In one embodiment, Y′Y′Y′ motif is all 2′-OMe modified nucleotides.

In one embodiment, k is 1 and 1 is 0, or k is 0 and 1 is 1, or both k and 1 are 1.

The antisense strand can therefore be represented by the following formulas:

5′n_(q′)-N_(a)′-Z′Z′Z′-N_(b)′-Y′Y′Y′-N_(a)′-n_(p′)3′  (IIb);

5′n_(q′)-N_(a)′-Y′Y′Y′-N_(b)′-X′X′X′-n_(p′)3′  (IIc); or

5′n_(q′)-N_(a)′-Z′Z′Z′-N_(b)′-Y′Y′Y′-N_(b)′-X′X′X′-N_(a)′-n_(p′)3′  (IId).

When the antisense strand is represented by formula (IIb), N_(b)′ represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_(a)′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the antisense strand is represented as formula (IIc), N_(b)′ represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_(a)′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the antisense strand is represented as formula (IId), each N_(b)′ independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_(a)′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Preferably, N_(b) is 0, 1, 2, 3, 4, 5 or 6.

In other embodiments, k is 0 and 1 is 0 and the antisense strand may be represented by the formula:

5′n_(p′)-N_(a′)-Y′Y′Y′-N_(a′)-n_(q′)3′  (Ia).

When the antisense strand is represented as formula (IIa), each N_(a)′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Each of X′, Y′ and Z′ may be the same or different from each other.

Each nucleotide of the sense strand and antisense strand may be independently modified with LNA, CRN, UNA, cEt, HNA, CeNA, 2′-methoxyethyl, 2′-O-methyl, 2′-O-allyl, 2′-C— allyl, 2′-hydroxyl, or 2′-fluoro. For example, each nucleotide of the sense strand and antisense strand is independently modified with 2′-O-methyl or 2′-fluoro. Each X, Y, Z, X′, Y′ and Z′, in particular, may represent a 2′-O-methyl modification or a 2′-fluoro modification.

In one embodiment, the sense strand of the RNAi agent may contain YYY motif occurring at 9, 10 and 11 positions of the strand when the duplex region is 21 nt, the count starting from the 1^(st) nucleotide from the 5′-end, or optionally, the count starting at the 1^(st) paired nucleotide within the duplex region, from the 5′-end; and Y represents 2′-F modification. The sense strand may additionally contain XXX motif or ZZZ motifs as wing modifications at the opposite end of the duplex region; and XXX and ZZZ each independently represents a 2′-OMe modification or 2′-F modification.

In one embodiment the antisense strand may contain Y′Y′Y′ motif occurring at positions 11, 12, 13 of the strand, the count starting from the 1^(st) nucleotide from the 5′-end, or optionally, the count starting at the 1^(st) paired nucleotide within the duplex region, from the 5′-end; and Y′ represents 2′-O-methyl modification. The antisense strand may additionally contain X′X′X′ motif or Z′Z′Z′ motifs as wing modifications at the opposite end of the duplex region; and X′X′X′ and Z′Z′Z′ each independently represents a 2′-OMe modification or 2′-F modification.

The sense strand represented by any one of the above formulas (Ia), (Ib), (Ic), and (Id) forms a duplex with a antisense strand being represented by any one of formulas (IIa), (IIb), (IIc), and (IId), respectively.

Accordingly, the RNAi agents for use in the methods of the invention may comprise a sense strand and an antisense strand, each strand having 14 to 30 nucleotides, the RNAi duplex represented by formula (III):

sense: 5′n_(p)-N_(a)-(XXX)_(i)-N_(b)-YYY-N_(b)-(ZZZ)_(j)-N_(a)-n_(q)3′

antisense: 3′n_(p)′-N_(a)′-(X′X′X′)_(k)-N_(b)′-Y′Y′Y′-N_(b)′-(Z′Z′Z′)_(l)-N_(a)′-n_(q)′5′  (III)

wherein:

i, j, k, and l are each independently 0 or 1;

p, p′, q, and q′ are each independently 0-6;

each N_(a) and N_(a)′ independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified 10 nucleotides;

each N_(b) and N_(b)′ independently represents an oligonucleotide sequence comprising 0-modified nucleotides;

wherein each n_(p)′, n_(p), n_(q)′, and n_(q), each of which may or may not be present, independently represents an overhang nucleotide; and

XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides.

In one embodiment, i is 0 and j is 0; or i is 1 and j is 0; or i is 0 and j is 1; or both i and j are 0; or both i and j are 1. In another embodiment, k is 0 and 1 is 0; or k is l and 1 is 0; k is 0 and l is 1; or both k and 1 are 0; or both k and 1 are 1.

Exemplary combinations of the sense strand and antisense strand forming a RNAi duplex include the formulas below:

5′n_(p)-N_(a)-YYY-N_(a)-n_(q)3′

3′n_(p)′-N_(a)′-Y′Y′Y′-N_(a)′n_(q)′5′  (IIIa)

5′n_(p)-N_(a)-YYY-N_(b)-ZZZ-N_(a)-n_(q)3′

3′n_(p)′-N_(a)′-Y′Y′Y′-N_(b)′-Z′Z′Z′-N_(a)′n_(q)′5′  (IIIb)

5′n_(p)-N_(a)-XXX-N_(b)-YYY-N_(a)-n_(q)3′

3′n_(p)′-N_(a)′-X′X′X′-N_(b)′-Y′Y′Y′-N_(a)′-n_(q)′5′  (IIIc)

5′n_(p)-N_(a)-XXX-N_(b)-YYY-N_(b)-ZZZ-N_(a)-n_(q)3′

3′n_(p)′-N_(a)′-X′X′X′-N_(b)′-Y′Y′Y′-N_(b)′-Z′Z′Z′-N_(a)-n_(q)′5′  (IIId)

When the RNAi agent is represented by formula (IIIa), each N_(a) independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the RNAi agent is represented by formula (IIIb), each N_(b) independently represents an oligonucleotide sequence comprising 1-10, 1-7, 1-5 or 1-4 modified nucleotides. Each N_(a) independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the RNAi agent is represented as formula (IIIc), each N_(b), N_(b)′ independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_(a) independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the RNAi agent is represented as formula (IIId), each N_(b), N_(b)′ independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_(a), N_(a)′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Each of N_(a), N_(a)′, N_(b) and N_(b) independently comprises modifications of alternating pattern.

Each of X, Y and Z in formulas (III), (IIIa), (IIIb), (IIIc), and (IIId) may be the same or different from each other.

When the RNAi agent is represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), at least one of the Y nucleotides may form a base pair with one of the Y′ nucleotides. Alternatively, at least two of the Y nucleotides form base pairs with the corresponding Y′ nucleotides; or all three of the Y nucleotides all form base pairs with the corresponding Y′ nucleotides.

When the RNAi agent is represented by formula (IIIb) or (IIId), at least one of the Z nucleotides may form a base pair with one of the Z′ nucleotides. Alternatively, at least two of the Z nucleotides form base pairs with the corresponding Z′ nucleotides; or all three of the Z nucleotides all form base pairs with the corresponding Z′ nucleotides.

When the RNAi agent is represented as formula (IIIc) or (IIId), at least one of the X nucleotides may form a base pair with one of the X′ nucleotides. Alternatively, at least two of the X nucleotides form base pairs with the corresponding X′ nucleotides; or all three of the X nucleotides all form base pairs with the corresponding X′ nucleotides.

In one embodiment, the modification on the Y nucleotide is different than the modification on the Y′ nucleotide, the modification on the Z nucleotide is different than the modification on the Z′ nucleotide, and/or the modification on the X nucleotide is different than the modification on the X′ nucleotide.

In one embodiment, when the RNAi agent is represented by formula (IIId), the N_(a) modifications are 2′-O-methyl or 2′-fluoro modifications. In another embodiment, when the RNAi agent is represented by formula (IIId), the N_(a) modifications are 2′-O-methyl or 2′-fluoro modifications and n_(p)′>0 and at least one n_(p)′ is linked to a neighboring nucleotide a via phosphorothioate linkage. In yet another embodiment, when the RNAi agent is represented by formula (IIId), the N_(a) modifications are 2′-O-methyl or 2′-fluoro modifications, n_(p)′>0 and at least one n_(p)′ is linked to a neighboring nucleotide via phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker (described below). In another embodiment, when the RNAi agent is represented by formula (IIId), the N_(a) modifications are 2′-O-methyl or 2′-fluoro modifications, n_(p)′>0 and at least one n_(p)′ is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

In one embodiment, when the RNAi agent is represented by formula (IIIa), the N_(a) modifications are 2′-O-methyl or 2′-fluoro modifications, n_(p)′>0 and at least one n_(p)′ is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

In one embodiment, the RNAi agent is a multimer containing at least two duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.

In one embodiment, the RNAi agent is a multimer containing three, four, five, six or more duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.

In one embodiment, two RNAi agents represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId) are linked to each other at the 5′ end, and one or both of the 3′ ends and are optionally conjugated to to a ligand. Each of the agents can target the same gene or two different genes; or each of the agents can target same gene at two different target sites.

Various publications describe multimeric RNAi agents that can be used in the methods of the invention. Such publications include WO2007/091269, U.S. Pat. No. 7,858,769, WO2010/141511, WO2007/117686, WO2009/014887 and WO2011/031520 the entire contents of each of which are hereby incorporated herein by reference.

As described in more detail below, the RNAi agent that contains conjugations of one or more carbohydrate moieties to a RNAi agent can optimize one or more properties of the RNAi agent. In many cases, the carbohydrate moiety will be attached to a modified subunit of the RNAi agent. For example, the ribose sugar of one or more ribonucleotide subunits of a dsRNA agent can be replaced with another moiety, e.g., a non-carbohydrate (preferably cyclic) carrier to which is attached a carbohydrate ligand. A ribonucleotide subunit in which the ribose sugar of the subunit has been so replaced is referred to herein as a ribose replacement modification subunit (RRMS). A cyclic carrier may be a carbocyclic ring system, i.e., all ring atoms are carbon atoms, or a heterocyclic ring system, i.e., one or more ring atoms may be a heteroatom, e.g., nitrogen, oxygen, sulfur. The cyclic carrier may be a monocyclic ring system, or may contain two or more rings, e.g. fused rings. The cyclic carrier may be a fully saturated ring system, or it may contain one or more double bonds.

The ligand may be attached to the polynucleotide via a carrier. The carriers include (i) at least one “backbone attachment point,” preferably two “backbone attachment points” and (ii) at least one “tethering attachment point.” A “backbone attachment point” as used herein refers to a functional group, e.g. a hydroxyl group, or generally, a bond available for, and that is suitable for incorporation of the carrier into the backbone, e.g., the phosphate, or modified phosphate, e.g., sulfur containing, backbone, of a ribonucleic acid. A “tethering attachment point” (TAP) in some embodiments refers to a constituent ring atom of the cyclic carrier, e.g., a carbon atom or a heteroatom (distinct from an atom which provides a backbone attachment point), that connects a selected moiety. The moiety can be, e.g., a carbohydrate, e.g. monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide and polysaccharide. Optionally, the selected moiety is connected by an intervening tether to the cyclic carrier. Thus, the cyclic carrier will often include a functional group, e.g., an amino group, or generally, provide a bond, that is suitable for incorporation or tethering of another chemical entity, e.g., a ligand to the constituent ring.

The RNAi agents may be conjugated to a ligand via a carrier, wherein the carrier can be cyclic group or acyclic group; preferably, the cyclic group is selected from pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolane, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl and and decalin; preferably, the acyclic group is selected from serinol backbone or diethanolamine backbone.

In certain specific embodiments, the RNAi agent for use in the methods of the invention is an agent selected from the group of agents listed in any one of Tables 3, 4, 6, 7, 12, 13, 22, 23, 25, and 26. These agents may further comprise a ligand.

IV. iRNAs Conjugated to Ligands

Another modification of the RNA of an iRNA of the invention involves chemically linking to the RNA one or more ligands, moieties or conjugates that enhance the activity, cellular distribution or cellular uptake of the iRNA. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acid. Sci. USA, 1989, 86: 6553-6556), cholic acid (Manoharan et al., Biorg. Med. Chem. Let., 1994, 4:1053-1060), a thioether, e.g., beryl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306-309; Manoharan et al., Biorg. Med. Chem. Let., 1993, 3:2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991, 10:1111-1118; Kabanov et al., FEBS Lett., 1990, 259:327-330; Svinarchuk et al., Biochimie, 1993, 75:49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654; Shea et al., Nucl. Acids Res., 1990, 18:3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923-937).

In one embodiment, a ligand alters the distribution, targeting or lifetime of an iRNA agent into which it is incorporated. In preferred embodiments a ligand provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand. Preferred ligands will not take part in duplex pairing in a duplexed nucleic acid.

Ligands can include a naturally occurring substance, such as a protein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, N-acetylgalactosamine, or hyaluronic acid); or a lipid. The ligand can also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid. Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolied) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacryllic acid), N-isopropylacrylamide polymers, or polyphosphazine. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.

Ligands can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid or protein, e.g., an antibody, that binds to a specified cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucoseamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, vitamin A, biotin, or an RGD peptide or RGD peptide mimetic.

Other examples of ligands include dyes, intercalating agents (e.g. acridines), cross-linkers (e.g. psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g. EDTA), lipophilic molecules, e.g., cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid,O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine) and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG]2, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g. biotin), transport/absorption facilitators (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or AP.

Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a hepatic cell. Ligands can also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucosamine multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF-B.

The ligand can be a substance, e.g., a drug, which can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cell's cytoskeleton, e.g., by disrupting the cell's microtubules, microfilaments, and/or intermediate filaments. The drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.

In some embodiments, a ligand attached to an iRNA as described herein acts as a pharmacokinetic modulator (PK modulator). PK modulators include lipophiles, bile acids, steroids, phospholipid analogues, peptides, protein binding agents, PEG, vitamins etc. Exemplary PK modulators include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglyceride, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin etc. Oligonucleotides that comprise a number of phosphorothioate linkages are also known to bind to serum protein, thus short oligonucleotides, e.g., oligonucleotides of about 5 bases, 10 bases, 15 bases or 20 bases, comprising multiple of phosphorothioate linkages in the backbone are also amenable to the present invention as ligands (e.g. as PK modulating ligands). In addition, aptamers that bind serum components (e.g. serum proteins) are also suitable for use as PK modulating ligands in the embodiments described herein.

Ligand-conjugated oligonucleotides of the invention may be synthesized by the use of an oligonucleotide that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the oligonucleotide (described below). This reactive oligonucleotide may be reacted directly with commercially-available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto.

The oligonucleotides used in the conjugates of the present invention may be conveniently and routinely made through the well-known technique of solid-phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is also known to use similar techniques to prepare other oligonucleotides, such as the phosphorothioates and alkylated derivatives.

In the ligand-conjugated oligonucleotides and ligand-molecule bearing sequence-specific linked nucleosides of the present invention, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligand-bearing building blocks.

When using nucleotide-conjugate precursors that already bear a linking moiety, the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then reacted with the linking moiety to form the ligand-conjugated oligonucleotide. In some embodiments, the oligonucleotides or linked nucleosides of the present invention are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to the standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used in oligonucleotide synthesis.

A. Lipid Conjugates

In one embodiment, the ligand or conjugate is a lipid or lipid-based molecule. Such a lipid or lipid-based molecule preferably binds a serum protein, e.g., human serum albumin (HSA). An HSA binding ligand allows for distribution of the conjugate to a target tissue, e.g., a non-kidney target tissue of the body. For example, the target tissue can be the liver, including parenchymal cells of the liver. Other molecules that can bind HSA can also be used as ligands. For example, naproxen or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, and/or (c) can be used to adjust binding to a serum protein, e.g., HSA.

A lipid based ligand can be used to inhibit, e.g., control the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly can be used to target the conjugate to the kidney.

In a preferred embodiment, the lipid based ligand binds HSA. Preferably, it binds HSA with a sufficient affinity such that the conjugate will be preferably distributed to a non-kidney tissue. However, it is preferred that the affinity not be so strong that the HSA-ligand binding cannot be reversed.

In another preferred embodiment, the lipid based ligand binds HSA weakly or not at all, such that the conjugate will be preferably distributed to the kidney. Other moieties that target to kidney cells can also be used in place of or in addition to the lipid based ligand.

In another aspect, the ligand is a moiety, e.g., a vitamin, which is taken up by a target cell, e.g., a proliferating cell. These are particularly useful for treating disorders characterized by unwanted cell proliferation, e.g., of the malignant or non-malignant type, e.g., cancer cells. Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include are B vitamin, e.g., folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by target cells such as liver cells. Also included are HSA and low density lipoprotein (LDL).

B. Cell Permeation Agents

In another aspect, the ligand is a cell-permeation agent, preferably a helical cell-permeation agent. Preferably, the agent is amphipathic. An exemplary agent is a peptide such as tat or antennopedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. The helical agent is preferably an alpha-helical agent, which preferably has a lipophilic and a lipophobic phase.

The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The attachment of peptide and peptidomimetics to iRNA agents can affect pharmacokinetic distribution of the iRNA, such as by enhancing cellular recognition and absorption. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.

A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (e.g., consisting primarily of Tyr, Trp or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS). An exemplary hydrophobic MTS-containing peptide is RFGF having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 43). An RFGF analogue (e.g., amino acid sequence AALLPVLLAAP (SEQ ID NO: 44) containing a hydrophobic MTS can also be a targeting moiety. The peptide moiety can be a “delivery” peptide, which can carry large polar molecules including peptides, oligonucleotides, and protein across cell membranes. For example, sequences from the HIV Tat protein (GRKKRRQRRRPPQ (SEQ ID NO: 45) and the Drosophila Antennapedia protein (RQIKIWFQNRRMKWKK (SEQ ID NO: 46) have been found to be capable of functioning as delivery peptides. A peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature, 354:82-84, 1991). Examples of a peptide or peptidomimetic tethered to a dsRNA agent via an incorporated monomer unit for cell targeting purposes is an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized.

An RGD peptide for use in the compositions and methods of the invention may be linear or cyclic, and may be modified, e.g., glycosylated or methylated, to facilitate targeting to a specific tissue(s). RGD-containing peptides and peptidiomimemtics may include D-amino acids, as well as synthetic RGD mimics. In addition to RGD, one can use other moieties that target the integrin ligand. Preferred conjugates of this ligand target PECAM-1 or VEGF.

A “cell permeation peptide” is capable of permeating a cell, e.g., a microbial cell, such as a bacterial or fungal cell, or a mammalian cell, such as a human cell. A microbial cell-permeating peptide can be, for example, an α-helical linear peptide (e.g., LL-37 or Ceropin P1), a disulfide bond-containing peptide (e.g., α-defensin, β-defensin or bactenecin), or a peptide containing only one or two dominating amino acids (e.g., PR-39 or indolicidin). A cell permeation peptide can also include a nuclear localization signal (NLS). For example, a cell permeation peptide can be a bipartite amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-1 gp41 and the NLS of SV40 large T antigen (Simeoni et al., Nucl. Acids Res. 31:2717-2724, 2003).

C. Carbohydrate Conjugates

In some embodiments of the compositions and methods of the invention, an iRNA oligonucleotide further comprises a carbohydrate. The carbohydrate conjugated iRNA are advantageous for the in vivo delivery of nucleic acids, as well as compositions suitable for in vivo therapeutic use, as described herein. As used herein, “carbohydrate” refers to a compound which is either a carbohydrate per se made up of one or more monosaccharide units having at least 6 carbon atoms (which can be linear, branched or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom; or a compound having as a part thereof a carbohydrate moiety made up of one or more monosaccharide units each having at least six carbon atoms (which can be linear, branched or cyclic), with an oxygen, nitrogen or sulfur atom bonded to each carbon atom. Representative carbohydrates include the sugars (mono-, di-, tri- and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides such as starches, glycogen, cellulose and polysaccharide gums. Specific monosaccharides include HBV and above (e.g., HBV, C6, C7, or C8) sugars; di- and trisaccharides include sugars having two or three monosaccharide units (e.g., HBV, C6, C7, or C8).

In one embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is a monosaccharide. In one embodiment, the monosaccharide is an N-acetylgalactosamine, such as

In another embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is selected from the group consisting of:

Another representative carbohydrate conjugate for use in the embodiments described herein includes, but is not limited to,

(formula XXIII), when one of X or Y is an oligonucleotide, the other is a hydrogen.

In some embodiments, the carbohydrate conjugate further comprises one or more additional ligands as described above, such as, but not limited to, a PK modulator and/or a cell permeation peptide.

Additional carbohydrate conjugates (and linkers) suitable for use in the present invention include those described in PCT Publication Nos. WO 2014/179620 and WO 2014/179627, the entire contents of each of which are incorporated herein by reference.

D. Linkers

In some embodiments, the conjugate or ligand described herein can be attached to an iRNA oligonucleotide with various linkers that can be cleavable or non-cleavable.

The term “linker” or “linking group” means an organic moiety that connects two parts of a compound, e.g., covalently attaches two parts of a compound. Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NR8, C(O), C(O)NH, SO, SO2, SO2NH or a chain of atoms, such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylhererocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylhereroaryl, which one or more methylenes can be interrupted or terminated by O, S, S(O), SO2, N(R8), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic; where R8 is hydrogen, acyl, aliphatic or substituted aliphatic. In one embodiment, the linker is between about 1-24 atoms, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18 atoms, 7-17, 8-17, 6-16, 7-16, or 8-16 atoms.

A cleavable linking group is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In a preferred embodiment, the cleavable linking group is cleaved at least about 10 times, 20, times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times or more, or at least about 100 times faster in a target cell or under a first reference condition (which can, e.g., be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, e.g., be selected to mimic or represent conditions found in the blood or serum).

Cleavable linking groups are susceptible to cleavage agents, e.g., pH, redox potential or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include: redox agents which are selected for particular substrates or which have no substrate specificity, including, e.g., oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction; esterases; endosomes or agents that can create an acidic environment, e.g., those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.

A cleavable linkage group, such as a disulfide bond can be susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5.0. Some linkers will have a cleavable linking group that is cleaved at a preferred pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.

A linker can include a cleavable linking group that is cleavable by a particular enzyme. The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted. For example, a liver-targeting ligand can be linked to a cationic lipid through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other cell-types rich in esterases include cells of the lung, renal cortex, and testis.

Linkers that contain peptide bonds can be used when targeting cell types rich in peptidases, such as liver cells and synoviocytes.

In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, e.g., blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It can be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In preferred embodiments, useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).

i. Redox Cleavable Linking Groups

In one embodiment, a cleavable linking group is a redox cleavable linking group that is cleaved upon reduction or oxidation. An example of reductively cleavable linking group is a disulphide linking group (—S—S—). To determine if a candidate cleavable linking group is a suitable “reductively cleavable linking group,” or for example is suitable for use with a particular iRNA moiety and particular targeting agent one can look to methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents know in the art, which mimic the rate of cleavage which would be observed in a cell, e.g., a target cell. The candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions. In one, candidate compounds are cleaved by at most about 10% in the blood. In other embodiments, useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood (or under in vitro conditions selected to mimic extracellular conditions). The rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.

ii. Phosphate-Based Cleavable Linking Groups

In another embodiment, a cleavable linker comprises a phosphate-based cleavable linking group. A phosphate-based cleavable linking group is cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells. Examples of phosphate-based linking groups are —O—P(O)(ORk)-O—, —O—P(S)(ORk)-O—, —O—P(S)(SRk)-O—, —S—P(O)(ORk)-O—, —O—P(O)(ORk)-S—, —S—P(O)(ORk)-S—, —O—P(S)(ORk)-S—, —S—P(S)(ORk)-O—, —O—P(O)(Rk)-O—, —O—P(S)(Rk)-O—, —S—P(O)(Rk)-O—, —S—P(S)(Rk)-O—, —S—P(O)(Rk)-S—, —O—P(S)(Rk)-S—. Preferred embodiments are —O—P(O)(OH)-O—, —O—P(S)(OH)-O—, —O—P(S)(SH)-O—, —S—P(O)(OH)-O—, —O—P(O)(OH)-S—, —S—P(O)(OH)-S—, —O—P(S)(OH)-S—, —S—P(S)(OH)-O—, —O—P(O)(H)-O—, —O—P(S)(H)-O—, —S—P(O)(H)-O, —S—P(S)(H)-O—, —S—P(O)(H)-S—, —O—P(S)(H)-S—. A preferred embodiment is —O—P(O)(OH)-O—. These candidates can be evaluated using methods analogous to those described above.

iii. Acid Cleavable Linking Groups

In another embodiment, a cleavable linker comprises an acid cleavable linking group. An acid cleavable linking group is a linking group that is cleaved under acidic conditions. In preferred embodiments acid cleavable linking groups are cleaved in an acidic environment with a pH of about 6.5 or lower (e.g., about 6.0, 5.75, 5.5, 5.25, 5.0, or lower), or by agents such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups. Examples of acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids. Acid cleavable groups can have the general formula-C═NN—, C(O)O, or —OC(O). A preferred embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.

iv. Ester-Based Linking Groups

In another embodiment, a cleavable linker comprises an ester-based cleavable linking group. An ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in cells. Examples of ester-based cleavable linking groups include but are not limited to esters of alkylene, alkenylene and alkynylene groups. Ester cleavable linking groups have the general formula —C(O)O—, or —OC(O)—. These candidates can be evaluated using methods analogous to those described above.

v. Peptide-Based Cleaving Groups

In yet another embodiment, a cleavable linker comprises a peptide-based cleavable linking group. A peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (e.g., dipeptides, tripeptides etc.) and polypeptides. Peptide-based cleavable groups do not include the amide group (—C(O)NH—). The amide group can be formed between any alkylene, alkenylene or alkynelene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide based cleavage group is generally limited to the peptide bond (i.e., the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula—NHCHRAC(O)NHCHRBC(O)—, where RA and RB are the R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.

In one embodiment, an iRNA of the invention is conjugated to a carbohydrate through a linker. Non-limiting examples of iRNA carbohydrate conjugates with linkers of the compositions and methods of the invention include, but are not limited to,

when one of X or Y is an oligonucleotide, the other is a hydrogen.

In certain embodiments of the compositions and methods of the invention, a ligand is one or more “GalNAc” (N-acetylgalactosamine) derivatives attached through a bivalent or trivalent branched linker.

In one embodiment, a dsRNA of the invention is conjugated to a bivalent or trivalent branched linker selected from the group of structures shown in any of formula (XXXII)-(XXXV):

wherein: q2A, q2B, q3A, q3B, q4A, q4B, q5A, q5B and q5C represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different; p^(2A), P^(2B), P^(3A), P^(3B), P^(4A), P^(4B), P^(5A), P^(5B), P^(5C), T^(2A), T^(2B), T^(3A), T^(3B), T^(4A), T^(4B), T^(4A), T^(5B), T^(5C) are each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), CH₂, CH₂NH or CH₂O; Q^(2A), Q^(2B), Q^(3A), Q^(3B), Q^(4A), Q^(4B), Q^(5A) Q^(5B) Q^(5C) are independently for each occurrence absent, alkylene, substituted alkylene wherin one or more methylenes can be interrupted or terminated by one or more of O, S, S(O), SO2, N(R^(N)), C(R′)═C(R″), C≡C or C(O); R^(2A), R^(2B), R^(3A), R^(3B), R^(4A), R^(4B), R^(5A), R^(5B), R⁵ are each independently for each occurrence absent NH, O, S, CH₂, C(O)O, C(O)NH, NHCH(R^(a))C(O), —C(O)—CH(R^(a))-NH—, CO, CH═N—O,

or heterocyclyl;

L^(2A), L^(2B), L^(3A), L^(3B), L^(4A), L^(4B), L^(5A), L^(5B) and L^(5C) represent the ligand; i.e. each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; and R^(a) is H or amino acid side chain. Trivalent conjugating GalNAc derivatives are particularly useful for use with RNAi agents for inhibiting the expression of a target gene, such as those of formula (XXXVI):

-   -   wherein L^(5A), L^(5B) and L^(5C) represent a monosaccharide,         such as GalNAc derivative.

Examples of suitable bivalent and trivalent branched linker groups conjugating GalNAc derivatives include, but are not limited to, the structures recited above as formulas II, VII, XI, X, and XIII.

Representative U.S. patents that teach the preparation of RNA conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941; 6,294,664; 6,320,017; 6,576,752; 6,783,931; 6,900,297; 7,037,646; 8,106,022, the entire contents of each of which are hereby incorporated herein by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications can be incorporated in a single compound or even at a single nucleoside within an iRNA. The present invention also includes iRNA compounds that are chimeric compounds.

“Chimeric” iRNA compounds or “chimeras,” in the context of this invention, are iRNA compounds, preferably dsRNAs, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of a dsRNA compound. These iRNAs typically contain at least one region wherein the RNA is modified so as to confer upon the iRNA increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the iRNA can serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of iRNA inhibition of gene expression. Consequently, comparable results can often be obtained with shorter iRNAs when chimeric dsRNAs are used, compared to phosphorothioate deoxy dsRNAs hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

In certain instances, the RNA of an iRNA can be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to iRNAs in order to enhance the activity, cellular distribution or cellular uptake of the iRNA, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Kubo, T. et al., Biochem. Biophys. Res. Comm., 2007, 365(1):54-61; Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86:6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4:1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N. Y. Acad. Sci., 1992, 660:306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3:2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10:111; Kabanov et al., FEBS Lett., 1990, 259:327; Svinarchuk et al., Biochimie, 1993, 75:49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651; Shea et al., Nucl. Acids Res., 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923). Representative United States patents that teach the preparation of such RNA conjugates have been listed above. Typical conjugation protocols involve the synthesis of an RNAs bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction can be performed either with the RNA still bound to the solid support or following cleavage of the RNA, in solution phase. Purification of the RNA conjugate by HPLC typically affords the pure conjugate.

V. Delivery of an iRNA of the Invention

The delivery of an iRNA of the invention to a cell e.g., a cell within a subject, such as a human subject (e.g., a subject in need thereof, such as a subject having a disease, disorder or condition associated with HBV infection) can be achieved in a number of different ways. For example, delivery may be performed by contacting a cell with an iRNA of the invention either in vitro or in vivo. In vivo delivery may also be performed directly by administering a composition comprising an iRNA, e.g., a dsRNA, to a subject. Alternatively, in vivo delivery may be performed indirectly by administering one or more vectors that encode and direct the expression of the iRNA. These alternatives are discussed further below.

In general, any method of delivering a nucleic acid molecule (in vitro or in vivo) can be adapted for use with an iRNA of the invention (see e.g., Akhtar S. and Julian R L. (1992) Trends Cell. Biol. 2(5):139-144 and WO94/02595, which are incorporated herein by reference in their entireties). For in vivo delivery, factors to consider in order to deliver an iRNA molecule include, for example, biological stability of the delivered molecule, prevention of non-specific effects, and accumulation of the delivered molecule in the target tissue. The non-specific effects of an iRNA can be minimized by local administration, for example, by direct injection or implantation into a tissue or topically administering the preparation. Local administration to a treatment site maximizes local concentration of the agent, limits the exposure of the agent to systemic tissues that can otherwise be harmed by the agent or that can degrade the agent, and permits a lower total dose of the iRNA molecule to be administered. Several studies have shown successful knockdown of gene products when an iRNA is administered locally. For example, intraocular delivery of a VEGF dsRNA by intravitreal injection in cynomolgus monkeys (Tolentino, M J., et al (2004) Retina 24:132-138) and subretinal injections in mice (Reich, S J., et al (2003) Mol. Vis. 9:210-216) were both shown to prevent neovascularization in an experimental model of age-related macular degeneration. In addition, direct intratumoral injection of a dsRNA in mice reduces tumor volume (Pille, J., et al (2005) Mol. Ther. 11:267-274) and can prolong survival of tumor-bearing mice (Kim, W J., et al (2006) Mol. Ther. 14:343-350; Li, S., et al (2007) Mol. Ther. 15:515-523). RNA interference has also shown success with local delivery to the CNS by direct injection (Dorn, G., et al. (2004) Nucleic Acids 32:e49; Tan, P H., et al (2005) Gene Ther. 12:59-66; Makimura, H., et al (2002) BMC Neurosci. 3:18; Shishkina, G T., et al (2004) Neuroscience 129:521-528; Thakker, E R., et al (2004) Proc. Natl. Acad. Sci. U.S.A. 101:17270-17275; Akaneya, Y., et al (2005) J. Neurophysiol. 93:594-602) and to the lungs by intranasal administration (Howard, K A., et al (2006) Mol. Ther. 14:476-484; Zhang, X., et al (2004) J. Biol. Chem. 279:10677-10684; Bitko, V., et al (2005) Nat. Med. 11:50-55). For administering an iRNA systemically for the treatment of a disease, the RNA can be modified or alternatively delivered using a drug delivery system; both methods act to prevent the rapid degradation of the dsRNA by endo- and exo-nucleases in vivo. Modification of the RNA or the pharmaceutical carrier can also permit targeting of the iRNA composition to the target tissue and avoid undesirable off-target effects. iRNA molecules can be modified by chemical conjugation to lipophilic groups such as cholesterol to enhance cellular uptake and prevent degradation. For example, an iRNA directed against ApoB conjugated to a lipophilic cholesterol moiety was injected systemically into mice and resulted in knockdown of apoB mRNA in both the liver and jejunum (Soutschek, J., et al (2004) Nature 432:173-178). Conjugation of an iRNA to an aptamer has been shown to inhibit tumor growth and mediate tumor regression in a mouse model of prostate cancer (McNamara, J O., et al (2006) Nat. Biotechnol. 24:1005-1015). In an alternative embodiment, the iRNA can be delivered using drug delivery systems such as a nanoparticle, a dendrimer, a polymer, liposomes, or a cationic delivery system. Positively charged cationic delivery systems facilitate binding of an iRNA molecule (negatively charged) and also enhance interactions at the negatively charged cell membrane to permit efficient uptake of an iRNA by the cell. Cationic lipids, dendrimers, or polymers can either be bound to an iRNA, or induced to form a vesicle or micelle (see e.g., Kim S H., et al (2008) Journal of Controlled Release 129(2): 107-116) that encases an iRNA. The formation of vesicles or micelles further prevents degradation of the iRNA when administered systemically. Methods for making and administering cationic-iRNA complexes are well within the abilities of one skilled in the art (see e.g., Sorensen, D R., et al (2003) J. Mol. Biol 327:761-766; Verma, U N., et al (2003) Clin. Cancer Res. 9:1291-1300; Arnold, A S et al (2007) J. Hypertens. 25:197-205, which are incorporated herein by reference in their entirety). Some non-limiting examples of drug delivery systems useful for systemic delivery of iRNAs include DOTAP (Sorensen, D R., et al (2003), supra; Verma, U N., et al (2003), supra), Oligofectamine, “solid nucleic acid lipid particles” (Zimmermann, T S., et al (2006) Nature 441:111-114), cardiolipin (Chien, P Y., et al (2005) Cancer Gene Ther. 12:321-328; Pal, A., et al (2005) Int J. Oncol. 26:1087-1091), polyethyleneimine (Bonnet M E., et al (2008) Pharm. Res. August 16 Epub ahead of print; Aigner, A. (2006) J. Biomed. Biotechnol. 71659), Arg-Gly-Asp (RGD) peptides (Liu, S. (2006) Mol. Pharm. 3:472-487), and polyamidoamines (Tomalia, D A., et al (2007) Biochem. Soc. Trans. 35:61-67; Yoo, H., et al (1999) Pharm. Res. 16:1799-1804). In some embodiments, an iRNA forms a complex with cyclodextrin for systemic administration. Methods for administration and pharmaceutical compositions of iRNAs and cyclodextrins can be found in U.S. Pat. No. 7,427,605, which is herein incorporated by reference in its entirety.

A. Vector Encoded iRNAs of the Invention

iRNA targeting the HBV gene can be expressed from transcription units inserted into DNA or RNA vectors (see, e.g., Couture, A, et al., TIG. (1996), 12:5-10; Skillern, A., et al., International PCT Publication No. WO 00/22113, Conrad, International PCT Publication No. WO 00/22114, and Conrad, U.S. Pat. No. 6,054,299). Expression can be transient (on the order of hours to weeks) or sustained (weeks to months or longer), depending upon the specific construct used and the target tissue or cell type. These transgenes can be introduced as a linear construct, a circular plasmid, or a viral vector, which can be an integrating or non-integrating vector. The transgene can also be constructed to permit it to be inherited as an extrachromosomal plasmid (Gassmann, et al., Proc. Natl. Acad. Sci. USA (1995) 92:1292).

The individual strand or strands of an iRNA can be transcribed from a promoter on an expression vector. Where two separate strands are to be expressed to generate, for example, a dsRNA, two separate expression vectors can be co-introduced (e.g., by transfection or infection) into a target cell. Alternatively each individual strand of a dsRNA can be transcribed by promoters both of which are located on the same expression plasmid. In one embodiment, a dsRNA is expressed as inverted repeat polynucleotides joined by a linker polynucleotide sequence such that the dsRNA has a stem and loop structure.

iRNA expression vectors are generally DNA plasmids or viral vectors. Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can be used to produce recombinant constructs for the expression of an iRNA as described herein. Eukaryotic cell expression vectors are well known in the art and are available from a number of commercial sources. Typically, such vectors are provided containing convenient restriction sites for insertion of the desired nucleic acid segment. Delivery of iRNA expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that allows for introduction into a desired target cell.

iRNA expression plasmids can be transfected into target cells as a complex with cationic lipid carriers (e.g., Oligofectamine) or non-cationic lipid-based carriers (e.g., Transit-TKO™). Multiple lipid transfections for iRNA-mediated knockdowns targeting different regions of a target RNA over a period of a week or more are also contemplated by the invention. Successful introduction of vectors into host cells can be monitored using various known methods. For example, transient transfection can be signaled with a reporter, such as a fluorescent marker, such as Green Fluorescent Protein (GFP). Stable transfection of cells ex vivo can be ensured using markers that provide the transfected cell with resistance to specific environmental factors (e.g., antibiotics and drugs), such as hygromycin B resistance.

Viral vector systems which can be utilized with the methods and compositions described herein include, but are not limited to, (a) adenovirus vectors; (b) retrovirus vectors, including but not limited to lentiviral vectors, moloney murine leukemia virus, etc.; (c) adeno-associated virus vectors; (d) herpes simplex virus vectors; (e) SV 40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; (i) pox virus vectors such as an orthopox, e.g., vaccinia virus vectors or avipox, e.g. canary pox or fowl pox; and (j) a helper-dependent or gutless adenovirus. Replication-defective viruses can also be advantageous. Different vectors will or will not become incorporated into the cells' genome. The constructs can include viral sequences for transfection, if desired. Alternatively, the construct can be incorporated into vectors capable of episomal replication, e.g. EPV and EBV vectors. Constructs for the recombinant expression of an iRNA will generally require regulatory elements, e.g., promoters, enhancers, etc., to ensure the expression of the iRNA in target cells. Other aspects to consider for vectors and constructs are further described below.

Vectors useful for the delivery of an iRNA will include regulatory elements (promoter, enhancer, etc.) sufficient for expression of the iRNA in the desired target cell or tissue. The regulatory elements can be chosen to provide either constitutive or regulated/inducible expression.

Expression of the iRNA can be precisely regulated, for example, by using an inducible regulatory sequence that is sensitive to certain physiological regulators, e.g., circulating glucose levels, or hormones (Docherty et al., 1994, FASEB J. 8:20-24). Such inducible expression systems, suitable for the control of dsRNA expression in cells or in mammals include, for example, regulation by ecdysone, by estrogen, progesterone, tetracycline, chemical inducers of dimerization, and isopropyl-beta-D1-thiogalactopyranoside (IPTG). A person skilled in the art would be able to choose the appropriate regulatory/promoter sequence based on the intended use of the iRNA transgene.

Viral vectors that contain nucleic acid sequences encoding an iRNA can be used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding an iRNA are cloned into one or more vectors, which facilitate delivery of the nucleic acid into a patient. More detail about retroviral vectors can be found, for example, in Boesen et al., Biotherapy 6:291-302 (1994), which describes the use of a retroviral vector to deliver the mdr1 gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994); Kiem et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr. Opin. in Genetics and Devel. 3:110-114 (1993). Lentiviral vectors contemplated for use include, for example, the HIV based vectors described in U.S. Pat. Nos. 6,143,520; 5,665,557; and 5,981,276, which are herein incorporated by reference.

Adenoviruses are also contemplated for use in delivery of iRNAs of the invention. Adenoviruses are especially attractive vehicles, e.g., for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, Current Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783 (1995). A suitable AV vector for expressing an iRNA featured in the invention, a method for constructing the recombinant AV vector, and a method for delivering the vector into target cells, are described in Xia H et al. (2002), Nat. Biotech. 20: 1006-1010.

Adeno-associated virus (AAV) vectors may also be used to delivery an iRNA of the invention (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Pat. No. 5,436,146). In one embodiment, the iRNA can be expressed as two separate, complementary single-stranded RNA molecules from a recombinant AAV vector having, for example, either the U6 or H1 RNA promoters, or the cytomegalovirus (CMV) promoter. Suitable AAV vectors for expressing the dsRNA featured in the invention, methods for constructing the recombinant AV vector, and methods for delivering the vectors into target cells are described in Samulski R et al. (1987), J. Virol. 61: 3096-3101; Fisher K J et al. (1996), J. Virol, 70: 520-532; Samulski R et al. (1989), J. Virol. 63: 3822-3826; U.S. Pat. Nos. 5,252,479; 5,139,941; International Patent Application No. WO 94/13788; and International Patent Application No. WO 93/24641, the entire disclosures of which are herein incorporated by reference.

Another viral vector suitable for delivery of an iRNA of the inevtion is a pox virus such as a vaccinia virus, for example an attenuated vaccinia such as Modified Virus Ankara (MVA) or NYVAC, an avipox such as fowl pox or canary pox.

The tropism of viral vectors can be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses, or by substituting different viral capsid proteins, as appropriate. For example, lentiviral vectors can be pseudotyped with surface proteins from vesicular stomatitis virus (VSV), rabies, Ebola, Mokola, and the like. AAV vectors can be made to target different cells by engineering the vectors to express different capsid protein serotypes; see, e.g., Rabinowitz J E et al. (2002), J Virol 76:791-801, the entire disclosure of which is herein incorporated by reference.

The pharmaceutical preparation of a vector can include the vector in an acceptable diluent, or can include a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

VI. Pharmaceutical Compositions of the Invention

The present invention also includes pharmaceutical compositions and formulations which include the iRNAs of the invention. In one embodiment, provided herein are pharmaceutical compositions containing an iRNA, as described herein, and a pharmaceutically acceptable carrier. The pharmaceutical compositions containing the iRNA are useful for treating a disease or disorder associated with the expression or activity of an HBV gene. Such pharmaceutical compositions are formulated based on the mode of delivery. One example is compositions that are formulated for systemic administration via parenteral delivery, e.g., by subcutaneous (SC) or intravenous (IV) delivery. Another example is compositions that are formulated for direct delivery into the brain parenchyma, e.g., by infusion into the brain, such as by continuous pump infusion. The pharmaceutical compositions of the invention may be administered in dosages sufficient to inhibit expression of an HBV gene.

In one embodiment, an iRNA agent of the invention is administered to a subject as a weight-based dose. A “weight-based dose” (e.g., a dose in mg/kg) is a dose of the iRNA agent that will change depending on the subject's weight. In another embodiment, an iRNA agent is administered to a subject as a fixed dose. A “fixed dose” (e.g., a dose in mg) means that one dose of an iRNA agent is used for all subjects regardless of any specific subject-related factors, such as weight. In one particular embodiment, a fixed dose of an iRNA agent of the invention is based on a predetermined weight or age.

In general, a suitable dose of an iRNA of the invention will be in the range of about 0.001 to about 200.0 milligrams per kilogram body weight of the recipient per day, generally in the range of about 1 to 50 mg per kilogram body weight per day. For example, the dsRNA can be administered at about 0.01 mg/kg, about 0.05 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 1.5 mg/kg, about 2 mg/kg, about 3 mg/kg, about 10 mg/kg, about 20 mg/kg, about 30 mg/kg, about 40 mg/kg, or about 50 mg/kg per single dose.

For example, the dsRNA may be administered at a dose of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or about 10 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.

In another embodiment, the dsRNA is administered at a dose of about 0.1 to about 50 mg/kg, about 0.25 to about 50 mg/kg, about 0.5 to about 50 mg/kg, about 0.75 to about 50 mg/kg, about 1 to about 50 mg/kg, about 1.5 to about 50 mg/kg, about 2 to about 50 mg/kg, about 2.5 to about 50 mg/kg, about 3 to about 50 mg/kg, about 3.5 to about 50 mg/kg, about 4 to about 50 mg/kg, about 4.5 to about 50 mg/kg, about 5 to about 50 mg/kg, about 7.5 to about 50 mg/kg, about 10 to about 50 mg/kg, about 15 to about 50 mg/kg, about 20 to about 50 mg/kg, about 20 to about 50 mg/kg, about 25 to about 50 mg/kg, about 25 to about 50 mg/kg, about 30 to about 50 mg/kg, about 35 to about 50 mg/kg, about 40 to about 50 mg/kg, about 45 to about 50 mg/kg, about 0.1 to about 45 mg/kg, about 0.25 to about 45 mg/kg, about 0.5 to about 45 mg/kg, about 0.75 to about 45 mg/kg, about 1 to about 45 mg/kg, about 1.5 to about 45 mg/kg, about 2 to about 45 mg/kg, about 2.5 to about 45 mg/kg, about 3 to about 45 mg/kg, about 3.5 to about 45 mg/kg, about 4 to about 45 mg/kg, about 4.5 to about 45 mg/kg, about 5 to about 45 mg/kg, about 7.5 to about 45 mg/kg, about 10 to about 45 mg/kg, about 15 to about 45 mg/kg, about 20 to about 45 mg/kg, about 20 to about 45 mg/kg, about 25 to about 45 mg/kg, about 25 to about 45 mg/kg, about 30 to about 45 mg/kg, about 35 to about 45 mg/kg, about 40 to about 45 mg/kg, about 0.1 to about 40 mg/kg, about 0.25 to about 40 mg/kg, about 0.5 to about 40 mg/kg, about 0.75 to about 40 mg/kg, about 1 to about 40 mg/kg, about 1.5 to about 40 mg/kg, about 2 to about 40 mg/kg, about 2.5 to about 40 mg/kg, about 3 to about 40 mg/kg, about 3.5 to about 40 mg/kg, about 4 to about 40 mg/kg, about 4.5 to about 40 mg/kg, about 5 to about 40 mg/kg, about 7.5 to about 40 mg/kg, about 10 to about 40 mg/kg, about 15 to about 40 mg/kg, about 20 to about 40 mg/kg, about 20 to about 40 mg/kg, about 25 to about 40 mg/kg, about 25 to about 40 mg/kg, about 30 to about 40 mg/kg, about 35 to about 40 mg/kg, about 0.1 to about 30 mg/kg, about 0.25 to about 30 mg/kg, about 0.5 to about 30 mg/kg, about 0.75 to about 30 mg/kg, about 1 to about 30 mg/kg, about 1.5 to about 30 mg/kg, about 2 to about 30 mg/kg, about 2.5 to about 30 mg/kg, about 3 to about 30 mg/kg, about 3.5 to about 30 mg/kg, about 4 to about 30 mg/kg, about 4.5 to about 30 mg/kg, about 5 to about 30 mg/kg, about 7.5 to about 30 mg/kg, about 10 to about 30 mg/kg, about 15 to about 30 mg/kg, about 20 to about 30 mg/kg, about 20 to about 30 mg/kg, about 25 to about 30 mg/kg, about 0.1 to about 20 mg/kg, about 0.25 to about 20 mg/kg, about 0.5 to about 20 mg/kg, about 0.75 to about 20 mg/kg, about 1 to about 20 mg/kg, about 1.5 to about 20 mg/kg, about 2 to about 20 mg/kg, about 2.5 to about 20 mg/kg, about 3 to about 20 mg/kg, about 3.5 to about 20 mg/kg, about 4 to about 20 mg/kg, about 4.5 to about 20 mg/kg, about 5 to about 20 mg/kg, about 7.5 to about 20 mg/kg, about 10 to about 20 mg/kg, or about 15 to about 20 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.

For example, the dsRNA may be administered at a dose of about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or about 10 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.

In another embodiment, the dsRNA is administered at a dose of about 0.5 to about 50 mg/kg, about 0.75 to about 50 mg/kg, about 1 to about 50 mg/kg, about 1.5 to about 50 mg/kg, about 2 to about 50 mg/kg, about 2.5 to about 50 mg/kg, about 3 to about 50 mg/kg, about 3.5 to about 50 mg/kg, about 4 to about 50 mg/kg, about 4.5 to about 50 mg/kg, about 5 to about 50 mg/kg, about 7.5 to about 50 mg/kg, about 10 to about 50 mg/kg, about 15 to about 50 mg/kg, about 20 to about 50 mg/kg, about 20 to about 50 mg/kg, about 25 to about 50 mg/kg, about 25 to about 50 mg/kg, about 30 to about 50 mg/kg, about 35 to about 50 mg/kg, about 40 to about 50 mg/kg, about 45 to about 50 mg/kg, about 0.5 to about 45 mg/kg, about 0.75 to about 45 mg/kg, about 1 to about 45 mg/kg, about 1.5 to about 45 mg/kg, about 2 to about 45 mg/kg, about 2.5 to about 45 mg/kg, about 3 to about 45 mg/kg, about 3.5 to about 45 mg/kg, about 4 to about 45 mg/kg, about 4.5 to about 45 mg/kg, about 5 to about 45 mg/kg, about 7.5 to about 45 mg/kg, about 10 to about 45 mg/kg, about 15 to about 45 mg/kg, about 20 to about 45 mg/kg, about 20 to about 45 mg/kg, about 25 to about 45 mg/kg, about 25 to about 45 mg/kg, about 30 to about 45 mg/kg, about 35 to about 45 mg/kg, about 40 to about 45 mg/kg, about 0.5 to about 40 mg/kg, about 0.75 to about 40 mg/kg, about 1 to about 40 mg/kg, about 1.5 to about 40 mg/kg, about 2 to about 40 mg/kg, about 2.5 to about 40 mg/kg, about 3 to about 40 mg/kg, about 3.5 to about 40 mg/kg, about 4 to about 40 mg/kg, about 4.5 to about 40 mg/kg, about 5 to about 40 mg/kg, about 7.5 to about 40 mg/kg, about 10 to about 40 mg/kg, about 15 to about 40 mg/kg, about 20 to about 40 mg/kg, about 20 to about 40 mg/kg, about 25 to about 40 mg/kg, about 25 to about 40 mg/kg, about 30 to about 40 mg/kg, about 35 to about 40 mg/kg, about 0.5 to about 30 mg/kg, about 0.75 to about 30 mg/kg, about 1 to about 30 mg/kg, about 1.5 to about 30 mg/kg, about 2 to about 30 mg/kg, about 2.5 to about 30 mg/kg, about 3 to about 30 mg/kg, about 3.5 to about 30 mg/kg, about 4 to about 30 mg/kg, about 4.5 to about 30 mg/kg, about 5 to about 30 mg/kg, about 7.5 to about 30 mg/kg, about 10 to about 30 mg/kg, about 15 to about 30 mg/kg, about 20 to about 30 mg/kg, about 20 to about 30 mg/kg, about 25 to about 30 mg/kg, about 0.5 to about 20 mg/kg, about 0.75 to about 20 mg/kg, about 1 to about 20 mg/kg, about 1.5 to about 20 mg/kg, about 2 to about 20 mg/kg, about 2.5 to about 20 mg/kg, about 3 to about 20 mg/kg, about 3.5 to about 20 mg/kg, about 4 to about 20 mg/kg, about 4.5 to about 20 mg/kg, about 5 to about 20 mg/kg, about 7.5 to about 20 mg/kg, about 10 to about 20 mg/kg, or about 15 to about 20 mg/kg. In one embodiment, the dsRNA is administered at a dose of about 10 mg/kg to about 30 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.

For example, subjects can be administered, e.g., subcutaneously or intravenously, a single therapeutic amount of iRNA, such as about 0.1, 0.125, 0.15, 0.175, 0.2, 0.225, 0.25, 0.275, 0.3, 0.325, 0.35, 0.375, 0.4, 0.425, 0.45, 0.475, 0.5, 0.525, 0.55, 0.575, 0.6, 0.625, 0.65, 0.675, 0.7, 0.725, 0.75, 0.775, 0.8, 0.825, 0.85, 0.875, 0.9, 0.925, 0.95, 0.975, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, 30, 31, 32, 33, 34, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or about 50 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.

In some embodiments, subjects are administered, e.g., subcutaneously or intravenously, multiple doses of a therapeutic amount of iRNA, such as a dose about 0.1, 0.125, 0.15, 0.175, 0.2, 0.225, 0.25, 0.275, 0.3, 0.325, 0.35, 0.375, 0.4, 0.425, 0.45, 0.475, 0.5, 0.525, 0.55, 0.575, 0.6, 0.625, 0.65, 0.675, 0.7, 0.725, 0.75, 0.775, 0.8, 0.825, 0.85, 0.875, 0.9, 0.925, 0.95, 0.975, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, 30, 31, 32, 33, 34, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or about 50 mg/kg. A multi-dose regimine may include administration of a therapeutic amount of iRNA daily, such as for two days, three days, four days, five days, six days, seven days, or longer.

In other embodiments, subjects are administered, e.g., subcutaneously or intravenously, a repeat dose of a therapeutic amount of iRNA, such as a dose about 0.1, 0.125, 0.15, 0.175, 0.2, 0.225, 0.25, 0.275, 0.3, 0.325, 0.35, 0.375, 0.4, 0.425, 0.45, 0.475, 0.5, 0.525, 0.55, 0.575, 0.6, 0.625, 0.65, 0.675, 0.7, 0.725, 0.75, 0.775, 0.8, 0.825, 0.85, 0.875, 0.9, 0.925, 0.95, 0.975, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, 30, 31, 32, 33, 34, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or about 50 mg/kg. A repeat-dose regimine may include administration of a therapeutic amount of iRNA on a regular basis, such as every other day, every third day, every fourth day, twice a week, once a week, every other week, or once a month.

In certain embodiments, for example, when a composition of the invention comprises a dsRNA as described herein and a lipid, subjects can be administered a therapeutic amount of iRNA, such as about 0.01 mg/kg to about 5 mg/kg, about 0.01 mg/kg to about 10 mg/kg, about 0.05 mg/kg to about 5 mg/kg, about 0.05 mg/kg to about 10 mg/kg, about 0.1 mg/kg to about 5 mg/kg, about 0.1 mg/kg to about 10 mg/kg, about 0.2 mg/kg to about 5 mg/kg, about 0.2 mg/kg to about 10 mg/kg, about 0.3 mg/kg to about 5 mg/kg, about 0.3 mg/kg to about 10 mg/kg, about 0.4 mg/kg to about 5 mg/kg, about 0.4 mg/kg to about 10 mg/kg, about 0.5 mg/kg to about 5 mg/kg, about 0.5 mg/kg to about 10 mg/kg, about 1 mg/kg to about 5 mg/kg, about 1 mg/kg to about 10 mg/kg, about 1.5 mg/kg to about 5 mg/kg, about 1.5 mg/kg to about 10 mg/kg, about 2 mg/kg to about about 2.5 mg/kg, about 2 mg/kg to about 10 mg/kg, about 3 mg/kg to about 5 mg/kg, about 3 mg/kg to about 10 mg/kg, about 3.5 mg/kg to about 5 mg/kg, about 4 mg/kg to about 5 mg/kg, about 4.5 mg/kg to about 5 mg/kg, about 4 mg/kg to about 10 mg/kg, about 4.5 mg/kg to about 10 mg/kg, about 5 mg/kg to about 10 mg/kg, about 5.5 mg/kg to about 10 mg/kg, about 6 mg/kg to about 10 mg/kg, about 6.5 mg/kg to about 10 mg/kg, about 7 mg/kg to about 10 mg/kg, about 7.5 mg/kg to about 10 mg/kg, about 8 mg/kg to about 10 mg/kg, about 8.5 mg/kg to about 10 mg/kg, about 9 mg/kg to about 10 mg/kg, or about 9.5 mg/kg to about 10 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention. For example, the dsRNA may be administered at a dose of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or about 10 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.

In certain embodiments of the invention, for example, when a double-stranded RNAi agent includes a modification (e.g., one or more motifs of three identical modifications on three consecutive nucleotides), including one such motif at or near the cleavage site of the agent, six phosphorothioate linkages, and a ligand, such an agent is administered at a dose of about 0.01 to about 0.5 mg/kg, about 0.01 to about 0.4 mg/kg, about 0.01 to about 0.3 mg/kg, about 0.01 to about 0.2 mg/kg, about 0.01 to about 0.1 mg/kg, about 0.01 mg/kg to about 0.09 mg/kg, about 0.01 mg/kg to about 0.08 mg/kg, about 0.01 mg/kg to about 0.07 mg/kg, about 0.01 mg/kg to about 0.06 mg/kg, about 0.01 mg/kg to about 0.05 mg/kg, about 0.02 to about 0.5 mg/kg, about 0.02 to about 0.4 mg/kg, about 0.02 to about 0.3 mg/kg, about 0.02 to about 0.2 mg/kg, about 0.02 to about 0.1 mg/kg, about 0.02 mg/kg to about 0.09 mg/kg, about 0.02 mg/kg to about 0.08 mg/kg, about 0.02 mg/kg to about 0.07 mg/kg, about 0.02 mg/kg to about 0.06 mg/kg, about 0.02 mg/kg to about 0.05 mg/kg, about 0.03 to about 0.5 mg/kg, about 0.03 to about 0.4 mg/kg, about 0.03 to about 0.3 mg/kg, about 0.03 to about 0.2 mg/kg, about 0.03 to about 0.1 mg/kg, about 0.03 mg/kg to about 0.09 mg/kg, about 0.03 mg/kg to about 0.08 mg/kg, about 0.03 mg/kg to about 0.07 mg/kg, about 0.03 mg/kg to about 0.06 mg/kg, about 0.03 mg/kg to about 0.05 mg/kg, about 0.04 to about 0.5 mg/kg, about 0.04 to about 0.4 mg/kg, about 0.04 to about 0.3 mg/kg, about 0.04 to about 0.2 mg/kg, about 0.04 to about 0.1 mg/kg, about 0.04 mg/kg to about 0.09 mg/kg, about 0.04 mg/kg to about 0.08 mg/kg, about 0.04 mg/kg to about 0.07 mg/kg, about 0.04 mg/kg to about 0.06 mg/kg, about 0.05 to about 0.5 mg/kg, about 0.05 to about 0.4 mg/kg, about 0.05 to about 0.3 mg/kg, about 0.05 to about 0.2 mg/kg, about 0.05 to about 0.1 mg/kg, about 0.05 mg/kg to about 0.09 mg/kg, about 0.05 mg/kg to about 0.08 mg/kg, or about 0.05 mg/kg to about 0.07 mg/kg. Values and ranges intermediate to the foregoing recited values are also intended to be part of this invention, e.g., the RNAi agent may be administered to the subject at a dose of about 0.015 mg/kg to about 0.45 mg/kg.

For example, the RNAi agent, e.g., RNAi agent in a pharmaceutical composition, may be administered at a dose of about 0.01 mg/kg, 0.0125 mg/kg, 0.015 mg/kg, 0.0175 mg/kg, 0.02 mg/kg, 0.0225 mg/kg, 0.025 mg/kg, 0.0275 mg/kg, 0.03 mg/kg, 0.0325 mg/kg, 0.035 mg/kg, 0.0375 mg/kg, 0.04 mg/kg, 0.0425 mg/kg, 0.045 mg/kg, 0.0475 mg/kg, 0.05 mg/kg, 0.0525 mg/kg, 0.055 mg/kg, 0.0575 mg/kg, 0.06 mg/kg, 0.0625 mg/kg, 0.065 mg/kg, 0.0675 mg/kg, 0.07 mg/kg, 0.0725 mg/kg, 0.075 mg/kg, 0.0775 mg/kg, 0.08 mg/kg, 0.0825 mg/kg, 0.085 mg/kg, 0.0875 mg/kg, 0.09 mg/kg, 0.0925 mg/kg, 0.095 mg/kg, 0.0975 mg/kg, 0.1 mg/kg, 0.125 mg/kg, 0.15 mg/kg, 0.175 mg/kg, 0.2 mg/kg, 0.225 mg/kg, 0.25 mg/kg, 0.275 mg/kg, 0.3 mg/kg, 0.325 mg/kg, 0.35 mg/kg, 0.375 mg/kg, 0.4 mg/kg, 0.425 mg/kg, 0.45 mg/kg, 0.475 mg/kg, or about 0.5 mg/kg. Values intermediate to the foregoing recited values are also intended to be part of this invention.

In some embodiments, the RNAi agent is administered as a fixed dose of between about 100 mg to about 900 mg, e.g., between about 100 mg to about 850 mg, between about 100 mg to about 800 mg, between about 100 mg to about 750 mg, between about 100 mg to about 700 mg, between about 100 mg to about 650 mg, between about 100 mg to about 600 mg, between about 100 mg to about 550 mg, between about 100 mg to about 500 mg, between about 200 mg to about 850 mg, between about 200 mg to about 800 mg, between about 200 mg to about 750 mg, between about 200 mg to about 700 mg, between about 200 mg to about 650 mg, between about 200 mg to about 600 mg, between about 200 mg to about 550 mg, between about 200 mg to about 500 mg, between about 300 mg to about 850 mg, between about 300 mg to about 800 mg, between about 300 mg to about 750 mg, between about 300 mg to about 700 mg, between about 300 mg to about 650 mg, between about 300 mg to about 600 mg, between about 300 mg to about 550 mg, between about 300 mg to about 500 mg, between about 400 mg to about 850 mg, between about 400 mg to about 800 mg, between about 400 mg to about 750 mg, between about 400 mg to about 700 mg, between about 400 mg to about 650 mg, between about 400 mg to about 600 mg, between about 400 mg to about 550 mg, or between about 400 mg to about 500 mg.

In some embodiments, the RNAi agent is administered as a fixed dose of about 100 mg, about 125 mg, about 150 mg, about 175 mg, 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, or about 900 mg.

The pharmaceutical composition can be administered by intravenous infusion over a period of time, such as over a 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21, 22, 23, 24, or about a 25 minute period. The administration may be repeated, for example, on a regular basis, such as weekly, biweekly (i.e., every two weeks) for one month, two months, three months, four months or longer. After an initial treatment regimen, the treatments can be administered on a less frequent basis. For example, after administration weekly or biweekly for three months, administration can be repeated once per month, for six months or a year or longer.

The pharmaceutical composition can be administered once daily, or the iRNA can be administered as two, three, or more sub-doses at appropriate intervals throughout the day or even using continuous infusion or delivery through a controlled release formulation. In that case, the iRNA contained in each sub-dose must be correspondingly smaller in order to achieve the total daily dosage. The dosage unit can also be compounded for delivery over several days, e.g., using a conventional sustained release formulation which provides sustained release of the iRNA over a several day period. Sustained release formulations are well known in the art and are particularly useful for delivery of agents at a particular site, such as could be used with the agents of the present invention. In this embodiment, the dosage unit contains a corresponding multiple of the daily dose.

In other embodiments, a single dose of the pharmaceutical compositions can be long lasting, such that subsequent doses are administered at not more than 3, 4, or 5 day intervals, or at not more than 1, 2, 3, or 4 week intervals. In some embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered once per week. In other embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered bi-monthly. In some embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered once per month, once every other month, or once quarterly (i.e., every three months).

The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a composition can include a single treatment or a series of treatments. Estimates of effective dosages and in vivo half-lives for the individual iRNAs encompassed by the invention can be made using conventional methodologies or on the basis of in vivo testing using an appropriate animal model, as described elsewhere herein.

The pharmaceutical compositions of the present invention can be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration can be topical (e.g., by a transdermal patch), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal, oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; subdermal, e.g., via an implanted device; or intracranial, e.g., by intraparenchymal, intrathecal or intraventricular, administration.

The iRNA can be delivered in a manner to target a particular tissue, such as the liver (e.g., the hepatocytes of the liver).

Pharmaceutical compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like can be necessary or desirable. Coated condoms, gloves and the like can also be useful. Suitable topical formulations include those in which the iRNAs featured in the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Suitable lipids and liposomes include neutral (e.g., dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearolyphosphatidyl choline) negative (e.g., dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g., dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). iRNAs featured in the invention can be encapsulated within liposomes or can form complexes thereto, in particular to cationic liposomes. Alternatively, iRNAs can be complexed to lipids, in particular to cationic lipids. Suitable fatty acids and esters include but are not limited to arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C₁₋₂₀ alkyl ester (e.g., isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof). Topical formulations are described in detail in U.S. Pat. No. 6,747,014, which is incorporated herein by reference.

A. iRNA Formulations Comprising Membranous Molecular Assemblies

An iRNA for use in the compositions and methods of the invention can be formulated for delivery in a membranous molecular assembly, e.g., a liposome or a micelle. As used herein, the term “liposome” refers to a vesicle composed of amphiphilic lipids arranged in at least one bilayer, e.g., one bilayer or a plurality of bilayers. Liposomes include unilamellar and multilamellar vesicles that have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the iRNA composition. The lipophilic material isolates the aqueous interior from an aqueous exterior, which typically does not include the iRNA composition, although in some examples, it may. Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomal bilayer fuses with bilayer of the cellular membranes. As the merging of the liposome and cell progresses, the internal aqueous contents that include the iRNA are delivered into the cell where the iRNA can specifically bind to a target RNA and can mediate iRNA. In some cases the liposomes are also specifically targeted, e.g., to direct the iRNA to particular cell types.

A liposome containing an iRNA agent can be prepared by a variety of methods. In one example, the lipid component of a liposome is dissolved in a detergent so that micelles are formed with the lipid component. For example, the lipid component can be an amphipathic cationic lipid or lipid conjugate. The detergent can have a high critical micelle concentration and may be nonionic. Exemplary detergents include cholate, CHAPS, octylglucoside, deoxycholate, and lauroyl sarcosine. The iRNA agent preparation is then added to the micelles that include the lipid component. The cationic groups on the lipid interact with the iRNA agent and condense around the iRNA agent to form a liposome. After condensation, the detergent is removed, e.g., by dialysis, to yield a liposomal preparation of iRNA agent.

If necessary a carrier compound that assists in condensation can be added during the condensation reaction, e.g., by controlled addition. For example, the carrier compound can be a polymer other than a nucleic acid (e.g., spermine or spermidine). pH can also adjusted to favor condensation.

Methods for producing stable polynucleotide delivery vehicles, which incorporate a polynucleotide/cationic lipid complex as structural components of the delivery vehicle, are further described in, e.g., WO 96/37194, the entire contents of which are incorporated herein by reference. Liposome formation can also include one or more aspects of exemplary methods described in Felgner, P. L. et al., Proc. Natl. Acad. Sci., USA 8:7413-7417, 1987; U.S. Pat. Nos. 4,897,355; 5,171,678; Bangham, et al. M. Mol. Biol. 23:238, 1965; Olson, et al. Biochim. Biophys. Acta 557:9, 1979; Szoka, et al. Proc. Natl. Acad. Sci. 75: 4194, 1978; Mayhew, et al. Biochim. Biophys. Acta 775:169, 1984; Kim, et al. Biochim. Biophys. Acta 728:339, 1983; and Fukunaga, et al. Endocrinol. 115:757, 1984. Commonly used techniques for preparing lipid aggregates of appropriate size for use as delivery vehicles include sonication and freeze-thaw plus extrusion (see, e.g., Mayer, et al. Biochim. Biophys. Acta 858:161, 1986). Microfluidization can be used when consistently small (50 to 200 nm) and relatively uniform aggregates are desired (Mayhew, et al. Biochim. Biophys. Acta 775:169, 1984). These methods are readily adapted to packaging iRNA agent preparations into liposomes.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged nucleic acid molecules to form a stable complex. The positively charged nucleic acid/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., Biochem. Biophys. Res. Commun., 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap nucleic acids rather than complex with it. Since both the nucleic acid and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some nucleic acid is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver nucleic acids encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., Journal of Controlled Release, 1992, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Examples of other methods to introduce liposomes into cells in vitro and in vivo include U.S. Pat. Nos. 5,283,185; 5,171,678; WO 94/00569; WO 93/24640; WO 91/16024; Felgner, J. Biol. Chem. 269:2550, 1994; Nabel, Proc. Natl. Acad. Sci. 90:11307, 1993; Nabel, Human Gene Ther. 3:649, 1992; Gershon, Biochem. 32:7143, 1993; and Strauss EMBO J. 11:417, 1992.

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporine A into different layers of the skin (Hu et al. S.T.P.Pharma. Sci., 1994, 4(6) 466).

Liposomes also include “sterically stabilized” liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside GM1, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., FEBS Letters, 1987, 223, 42; Wu et al., Cancer Research, 1993, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (Ann. N.Y. Acad. Sci., 1987, 507, 64) reported the ability of monosialoganglioside GM1, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (Proc. Natl. Acad. Sci. U.S.A., 1988, 85, 6949). U.S. Pat. No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside GM1 or a galactocerebroside sulfate ester. U.S. Pat. No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al).

In one embodiment, cationic liposomes are used. Cationic liposomes possess the advantage of being able to fuse to the cell membrane. Non-cationic liposomes, although not able to fuse as efficiently with the plasma membrane, are taken up by macrophages in vivo and can be used to deliver iRNA agents to macrophages.

Further advantages of liposomes include: liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated iRNA agents in their internal compartments from metabolism and degradation (Rosoff, in “Pharmaceutical Dosage Forms,” Lieberman, Rieger and Banker (Eds.), 1988, volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

A positively charged synthetic cationic lipid, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) can be used to form small liposomes that interact spontaneously with nucleic acid to form lipid-nucleic acid complexes which are capable of fusing with the negatively charged lipids of the cell membranes of tissue culture cells, resulting in delivery of iRNA agent (see, e.g., Felgner, P. L. et al., Proc. Natl. Acad. Sci., USA 8:7413-7417, 1987 and U.S. Pat. No. 4,897,355 for a description of DOTMA and its use with DNA).

A DOTMA analogue, 1,2-bis(oleoyloxy)-3-(trimethylammonia)propane (DOTAP) can be used in combination with a phospholipid to form DNA-complexing vesicles. Lipofectin™ Bethesda Research Laboratories, Gaithersburg, Md.) is an effective agent for the delivery of highly anionic nucleic acids into living tissue culture cells that comprise positively charged DOTMA liposomes which interact spontaneously with negatively charged polynucleotides to form complexes. When enough positively charged liposomes are used, the net charge on the resulting complexes is also positive. Positively charged complexes prepared in this way spontaneously attach to negatively charged cell surfaces, fuse with the plasma membrane, and efficiently deliver functional nucleic acids into, for example, tissue culture cells. Another commercially available cationic lipid, 1,2-bis(oleoyloxy)-3,3-(trimethylammonia)propane (“DOTAP”) (Boehringer Mannheim, Indianapolis, Ind.) differs from DOTMA in that the oleoyl moieties are linked by ester, rather than ether linkages.

Other reported cationic lipid compounds include those that have been conjugated to a variety of moieties including, for example, carboxyspermine which has been conjugated to one of two types of lipids and includes compounds such as 5-carboxyspermylglycine dioctaoleoylamide (“DOGS”) (Transfectam™, Promega, Madison, Wis.) and dipalmitoylphosphatidylethanolamine 5-carboxyspermyl-amide (“DPPES”) (see, e.g., U.S. Pat. No. 5,171,678).

Another cationic lipid conjugate includes derivatization of the lipid with cholesterol (“DC-Chol”) which has been formulated into liposomes in combination with DOPE (See, Gao, X. and Huang, L., Biochim. Biophys. Res. Commun. 179:280, 1991). Lipopolylysine, made by conjugating polylysine to DOPE, has been reported to be effective for transfection in the presence of serum (Zhou, X. et al., Biochim. Biophys. Acta 1065:8, 1991). For certain cell lines, these liposomes containing conjugated cationic lipids, are said to exhibit lower toxicity and provide more efficient transfection than the DOTMA-containing compositions. Other commercially available cationic lipid products include DMRIE and DMRIE-HP (Vical, La Jolla, Calif.) and Lipofectamine (DOSPA) (Life Technology, Inc., Gaithersburg, Md.). Other cationic lipids suitable for the delivery of oligonucleotides are described in WO 98/39359 and WO 96/37194.

Liposomal formulations are particularly suited for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer iRNA agent into the skin. In some implementations, liposomes are used for delivering iRNA agent to epidermal cells and also to enhance the penetration of iRNA agent into dermal tissues, e.g., into skin. For example, the liposomes can be applied topically. Topical delivery of drugs formulated as liposomes to the skin has been documented (see, e.g., Weiner et al., Journal of Drug Targeting, 1992, vol. 2, 405-410 and du Plessis et al., Antiviral Research, 18, 1992, 259-265; Mannino, R. J. and Fould-Fogerite, S., Biotechniques 6:682-690, 1988; Itani, T. et al. Gene 56:267-276. 1987; Nicolau, C. et al. Meth. Enz. 149:157-176, 1987; Straubinger, R. M. and Papahadjopoulos, D. Meth. Enz. 101:512-527, 1983; Wang, C. Y. and Huang, L., Proc. Natl. Acad. Sci. USA 84:7851-7855, 1987).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver a drug into the dermis of mouse skin. Such formulations with iRNA agent are useful for treating a dermatological disorder.

Liposomes that include iRNA can be made highly deformable. Such deformability can enable the liposomes to penetrate through pore that are smaller than the average radius of the liposome. For example, transfersomes are a type of deformable liposomes. Transferosomes can be made by adding surface edge activators, usually surfactants, to a standard liposomal composition. Transfersomes that include iRNA agent can be delivered, for example, subcutaneously by infection in order to deliver iRNA agent to keratinocytes in the skin. In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. In addition, due to the lipid properties, these transferosomes can be self-optimizing (adaptive to the shape of pores, e.g., in the skin), self-repairing, and can frequently reach their targets without fragmenting, and often self-loading.

Other formulations amenable to the present invention are described in, for example, PCT Publication No. WO 2008/042973, the entire contents of which are incorporated herein by reference.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes can be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g., they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the “head”) provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in “Pharmaceutical Dosage Forms”, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in “Pharmaceutical Dosage Forms”, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

The iRNA for use in the methods of the invention can also be provided as micellar formulations. “Micelles” are defined herein as a particular type of molecular assembly in which amphipathic molecules are arranged in a spherical structure such that all the hydrophobic portions of the molecules are directed inward, leaving the hydrophilic portions in contact with the surrounding aqueous phase. The converse arrangement exists if the environment is hydrophobic.

A mixed micellar formulation suitable for delivery through transdermal membranes may be prepared by mixing an aqueous solution of the siRNA composition, an alkali metal C₈ to C₂₂ alkyl sulphate, and a micelle forming compounds. Exemplary micelle forming compounds include lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof, chenodeoxycholate, deoxycholate, and mixtures thereof. The micelle forming compounds may be added at the same time or after addition of the alkali metal alkyl sulphate. Mixed micelles will form with substantially any kind of mixing of the ingredients but vigorous mixing in order to provide smaller size micelles.

In one method a first micellar composition is prepared which contains the siRNA composition and at least the alkali metal alkyl sulphate. The first micellar composition is then mixed with at least three micelle forming compounds to form a mixed micellar composition. In another method, the micellar composition is prepared by mixing the siRNA composition, the alkali metal alkyl sulphate and at least one of the micelle forming compounds, followed by addition of the remaining micelle forming compounds, with vigorous mixing.

Phenol and/or m-cresol may be added to the mixed micellar composition to stabilize the formulation and protect against bacterial growth. Alternatively, phenol and/or m-cresol may be added with the micelle forming ingredients. An isotonic agent such as glycerin may also be added after formation of the mixed micellar composition.

For delivery of the micellar formulation as a spray, the formulation can be put into an aerosol dispenser and the dispenser is charged with a propellant. The propellant, which is under pressure, is in liquid form in the dispenser. The ratios of the ingredients are adjusted so that the aqueous and propellant phases become one, i.e., there is one phase. If there are two phases, it is necessary to shake the dispenser prior to dispensing a portion of the contents, e.g., through a metered valve. The dispensed dose of pharmaceutical agent is propelled from the metered valve in a fine spray.

Propellants may include hydrogen-containing chlorofluorocarbons, hydrogen-containing fluorocarbons, dimethyl ether and diethyl ether. In certain embodiments, HFA 134a (1,1,1,2 tetrafluoroethane) may be used.

The specific concentrations of the essential ingredients can be determined by relatively straightforward experimentation. For absorption through the oral cavities, it is often desirable to increase, e.g., at least double or triple, the dosage for through injection or administration through the gastrointestinal tract.

B. Lipid Particles

iRNAs, e.g., dsRNAs of in the invention may be fully encapsulated in a lipid formulation, e.g., a LNP, or other nucleic acid-lipid particle.

As used herein, the term “LNP” refers to a stable nucleic acid-lipid particle. LNPs typically contain a cationic lipid, a non-cationic lipid, and a lipid that prevents aggregation of the particle (e.g., a PEG-lipid conjugate). LNPs are extremely useful for systemic applications, as they exhibit extended circulation lifetimes following intravenous (i.v.) injection and accumulate at distal sites (e.g., sites physically separated from the administration site). LNPs include “pSPLP,” which include an encapsulated condensing agent-nucleic acid complex as set forth in PCT Publication No. WO 00/03683. The particles of the present invention typically have a mean diameter of about 50 nm to about 150 nm, more typically about 60 nm to about 130 nm, more typically about 70 nm to about 110 nm, most typically about 70 nm to about 90 nm, and are substantially nontoxic. In addition, the nucleic acids when present in the nucleic acid-lipid particles of the present invention are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, e.g., U.S. Pat. Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410; 6,815,432; U.S. Publication No. 2010/0324120 and PCT Publication No. WO 96/40964.

In one embodiment, the lipid to drug ratio (mass/mass ratio) (e.g., lipid to dsRNA ratio) will be in the range of from about 1:1 to about 50:1, from about 1:1 to about 25:1, from about 3:1 to about 15:1, from about 4:1 to about 10:1, from about 5:1 to about 9:1, or about 6:1 to about 9:1. Ranges intermediate to the above recited ranges are also contemplated to be part of the invention.

The cationic lipid can be, for example, N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N—(I-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N—(I-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3-dioleyloxy)propylamine (DODMA), 1,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-Dilinoleyoxy-3-(dimethylamino)acetoxypropane (DLin-DAC), 1,2-Dilinoleyoxy-3-morpholinopropane (DLin-MA), 1,2-Dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-Dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-Linoleoyl-2-linoleyloxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-Dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.C1), 1,2-Dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.C1), 1,2-Dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), or 3-(N,N-Dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-Dioleylamino)-1,2-propanedio (DOAP), 1,2-Dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA) or analogs thereof, (3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z, 12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-amine (ALN100), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3), 1,1′-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediyl)didodecan-2-ol (Tech G1), or a mixture thereof. The cationic lipid can comprise from about 20 mol % to about 50 mol % or about 40 mol % of the total lipid present in the particle.

In another embodiment, the compound 2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane can be used to prepare lipid-siRNA nanoparticles. Synthesis of 2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane is described in U.S. provisional patent application No. 61/107,998 filed on Oct. 23, 2008, which is herein incorporated by reference.

In one embodiment, the lipid-siRNA particle includes 40% 2, 2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane: 10% DSPC: 40% Cholesterol: 10% PEG-C-DOMG (mole percent) with a particle size of 63.0±20 nm and a 0.027 siRNA/Lipid Ratio.

The ionizable/non-cationic lipid can be an anionic lipid or a neutral lipid including, but not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), di stearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), cholesterol, or a mixture thereof. The non-cationic lipid can be from about 5 mol % to about 90 mol %, about 10 mol %, or about 58 mol % if cholesterol is included, of the total lipid present in the particle.

The conjugated lipid that inhibits aggregation of particles can be, for example, a polyethyleneglycol (PEG)-lipid including, without limitation, a PEG-diacylglycerol (DAG), a PEG-dialkyloxypropyl (DAA), a PEG-phospholipid, a PEG-ceramide (Cer), or a mixture thereof. The PEG-DAA conjugate can be, for example, a PEG-dilauryloxypropyl (Ci₂), a PEG-dimyristyloxypropyl (Ci₄), a PEG-dipalmityloxypropyl (Ci₆), or a PEG-distearyloxypropyl (C]₈). The conjugated lipid that prevents aggregation of particles can be from 0 mol % to about 20 mol % or about 2 mol % of the total lipid present in the particle.

In some embodiments, the nucleic acid-lipid particle further includes cholesterol at, e.g., about 10 mol % to about 60 mol % or about 48 mol % of the total lipid present in the particle.

In one embodiment, the lipidoid ND98.4HCl (MW 1487) (see U.S. patent application Ser. No. 12/056,230, filed Mar. 26, 2008, which is incorporated herein by reference), Cholesterol (Sigma-Aldrich), and PEG-Ceramide C16 (Avanti Polar Lipids) can be used to prepare lipid-dsRNA nanoparticles (i.e., LNPO1 particles). Stock solutions of each in ethanol can be prepared as follows: ND98, 133 mg/ml; Cholesterol, 25 mg/ml, PEG-Ceramide C16, 100 mg/ml. The ND98, Cholesterol, and PEG-Ceramide C16 stock solutions can then be combined in a, e.g., 42:48:10 molar ratio. The combined lipid solution can be mixed with aqueous dsRNA (e.g., in sodium acetate pH 5) such that the final ethanol concentration is about 35-45% and the final sodium acetate concentration is about 100-300 mM. Lipid-dsRNA nanoparticles typically form spontaneously upon mixing. Depending on the desired particle size distribution, the resultant nanoparticle mixture can be extruded through a polycarbonate membrane (e.g., 100 nm cut-off) using, for example, a thermobarrel extruder, such as Lipex Extruder (Northern Lipids, Inc). In some cases, the extrusion step can be omitted. Ethanol removal and simultaneous buffer exchange can be accomplished by, for example, dialysis or tangential flow filtration. Buffer can be exchanged with, for example, phosphate buffered saline (PBS) at about pH 7, e.g., about pH 6.9, about pH 7.0, about pH 7.1, about pH 7.2, about pH 7.3, or about pH 7.4.

LNPO1 formulations are described, e.g., in International Application Publication No. WO 2008/042973, which is hereby incorporated by reference.

Additional exemplary lipid-dsRNA formulations are described in Table 1.

TABLE 1 cationic lipid/non-cationic lipid/cholesterol/ Ionizable/Cationic Lipid PEG-lipid conjugate Lipid:siRNA ratio SNALP-1 1,2-Dilinolenyloxy-N,N- DLinDMA/DPPC/Cholesterol/PEG-cDMA dimethylaminopropane (DLinDMA) (57.1/7.1/34.4/1.4) lipid:siRNA ~7:1 2-XTC 2,2-Dilinoleyl-4-dimethylaminoethyl- XTC/DPPC/Cholesterol/PEG-cDMA [1,3]-dioxolane (XTC) 57.1/7.1/34.4/1.4 lipid:siRNA ~7:1 LNP05 2,2-Dilinoleyl-4-dimethylaminoethyl- XTC/DSPC/Cholesterol/PEG-DMG [1,3]-dioxolane (XTC) 57.5/7.5/31.5/3.5 lipid:siRNA ~6:1 LNP06 2,2-Dilinoleyl-4-dimethylaminoethyl- XTC/DSPC/Cholesterol/PEG-DMG [1,3]-dioxolane (XTC) 57.5/7.5/31.5/3.5 lipid: siRNA ~11:1 LNP07 2,2-Dilinoleyl-4-dimethylaminoethyl- XTC/DSPC/Cholesterol/PEG-DMG [1,3]-dioxolane (XTC) 60/7.5/31/1.5, lipid:siRNA ~6:1 LNP08 2,2-Dilinoleyl-4-dimethylaminoethyl- XTC/DSPC/Cholesterol/PEG-DMG [1,3]-dioxolane (XTC) 60/7.5/31/1.5, lipid: siRNA ~11:1 LNP09 2,2-Dilinoleyl-4-dimethylaminoethyl- XTC/DSPC/Cholesterol/PEG-DMG [1,3]-dioxolane (XTC) 50/10/38.5/1.5 Lipid:siRNA 10:1 LNP10 (3aR,5s,6aS)-N,N-dimethyl-2,2- ALN100/DSPC/Cholesterol/PEG-DMG di((9Z,12Z)-octadeca-9,12- 50/10/38.5/1.5 dienyl)tetrahydro-3aH- Lipid:siRNA 10:1 cyclopenta[d] [1,3] dioxol-5-amine (ALN100) LNP11 (6Z,9Z,28Z,31Z)-heptatriaconta- MC-3/DSPC/Cholesterol/PEG-DMG 6,9,28,31-tetraen-19-yl 4- 50/10/38.5/1.5 (dimethylamino)butanoate (MC3) Lipid:siRNA 10:1 LNP12 1,1′-(2-(4-(2-((2-(bis(2- Tech G1/DSPC/Cholesterol/PEG-DMG hydroxydodecyl)amino)ethyl)(2- 50/10/38.5/1.5 hydroxydodecyl)amino)ethyl)piperazin- Lipid:siRNA 10:1 1-yl)ethylazanediyl)didodecan-2-ol (Tech G1) LNP13 XTC XTC/DSPC/Chol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA: 33:1 LNP14 MC3 MC3/DSPC/Chol/PEG-DMG 40/15/40/5 Lipid:siRNA: 11:1 LNP15 MC3 MC3/DSPC/Chol/PEG-DSG/GalNAc- PEG-DSG 50/10/35/4.5/0.5 Lipid:siRNA: 11:1 LNP16 MC3 MC3/DSPC/Chol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA: 7:1 LNP17 MC3 MC3/DSPC/Chol/PEG-DSG 50/10/38.5/1.5 Lipid:siRNA: 10:1 LNP18 MC3 MC3/DSPC/Chol/PEG-DMG 50/10/38.5/1.5 Lipid:siRNA: 12:1 LNP19 MC3 MC3/DSPC/Chol/PEG-DMG 50/10/35/5 Lipid:siRNA: 8:1 LNP20 MC3 MC3/DSPC/Chol/PEG-DPG 50/10/38.5/1.5 Lipid:siRNA: 10:1 LNP21 C12-200 C12-200/DSPC/Chol/PEG-DSG 50/10/38.5/1.5 Lipid:siRNA: 7:1 LNP22 XTC XTC/DSPC/Chol/PEG-DSG 50/10/38.5/1.5 Lipid:siRNA: 10:1 DSPC: distearoylphosphatidylcholine DPPC: dipalmitoylphosphatidylcholine PEG-DMG: PEG-didimyristoyl glycerol (C14-PEG, or PEG-C14) (PEG with avg mol wt of 2000) PEG-DSG: PEG-distyryl glycerol (C18-PEG, or PEG-C, 18) (PEG with avg mol wt of 2000) PEG-cDMA: PEG-carbamoyl-1,2-dimyristyloxypropylamine (PEG with avg mol wt of 2000) SNALP (1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA)) comprising formulations are described in International Publication No. WO2009/127060, filed Apr. 15, 2009, which is hereby incorporated by reference.

XTC comprising formulations are described, e.g., in PCT Publication No. WO 2010/088537, the entire contents of which are incorporated herein by reference.

MC3 comprising formulations are described, e.g., in U.S. Publication No. 2010/0324120, filed Jun. 10, 2010, the entire contents of which are incorporated herein by reference.

ALNY-100 comprising formulations are described, e.g., PCT Publication No. WO 2010/054406, the entire contents of which are incorporated herein by reference.

C12-200 comprising formulations are described in PCT Publication No. WO 2010/129709, the entire contents of which are incorporated herein by reference.

Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders can be desirable. In some embodiments, oral formulations are those in which dsRNAs featured in the invention are administered in conjunction with one or more penetration enhancer surfactants and chelators. Suitable surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Suitable bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucholic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Suitable fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g., sodium). In some embodiments, combinations of penetration enhancers are used, for example, fatty acids/salts in combination with bile acids/salts. One exemplary combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. DsRNAs featured in the invention can be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. DsRNA complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Suitable complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylaminomethylethylene P (TDAE), polyaminostyrene (e.g., p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcynaoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for dsRNAs and their preparation are described in detail in U.S. Pat. No. 6,887,906, US Publn. No. 20030027780, and U.S. Pat. No. 6,747,014, each of which is incorporated herein by reference.

Compositions and formulations for parenteral, intraparenchymal (into the brain), intrathecal, intraventricular or intrahepatic administration can include sterile aqueous solutions which can also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions can be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids. Particularly preferred are formulations that target the liver when treating hepatic disorders such as hepatic carcinoma.

The pharmaceutical formulations of the present invention, which can conveniently be presented in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention can be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention can also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions can further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension can also contain stabilizers.

C. Additional Formulations

i. Emulsions

The compositions of the present invention can be prepared and formulated as emulsions. Emulsions are typically heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 m in diameter (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 301). Emulsions are often biphasic systems comprising two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions can be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions can contain additional components in addition to the dispersed phases, and the active drug which can be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants can also be present in emulsions as needed. Pharmaceutical emulsions can also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous phase provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion can be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that can be incorporated into either phase of the emulsion. Emulsifiers can broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants can be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y. Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that can readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used can be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of ease of formulation, as well as efficacy from an absorption and bioavailability standpoint (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

ii. Microemulsions

In one embodiment of the present invention, the compositions of iRNAs and nucleic acids are formulated as microemulsions. A microemulsion can be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: Controlled Release of Drugs: Polymers and Aggregate Systems, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions can, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase can typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase can include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (see e.g., U.S. Pat. Nos. 6,191,105; 7,063,860; 7,070,802; 7,157,099; Constantinides et al., Pharmaceutical Research, 1994, 11, 1385-1390; Ritschel, Meth. Find. Exp. Clin. Pharmacol., 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (see e.g., U.S. Pat. Nos. 6,191,105; 7,063,860; 7,070,802; 7,157,099; Constantinides et al., Pharmaceutical Research, 1994, 11, 1385; Ho et al., J. Pharm. Sci., 1996, 85, 138-143). Often microemulsions can form spontaneously when their components are brought together at ambient temperature. This can be particularly advantageous when formulating thermolabile drugs, peptides or iRNAs. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of iRNAs and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of iRNAs and nucleic acids.

Microemulsions of the present invention can also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the iRNAs and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention can be classified as belonging to one of five broad categories—surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of these classes has been discussed above.

iii. Microparticles

An iRNA agent of the invention may be incorporated into a particle, e.g., a microparticle. Microparticles can be produced by spray-drying, but may also be produced by other methods including lyophilization, evaporation, fluid bed drying, vacuum drying, or a combination of these techniques.

iv. Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly iRNAs, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs can cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers can be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (see e.g., Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, N.Y., 2002; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants (or “surface-active agents”) are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of iRNAs through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (see e.g., Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, N.Y., 2002; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., J. Pharm. Pharmacol., 1988, 40, 252).

Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C1-20 alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (see e.g., Touitou, E., et al. Enhancement in Drug Delivery, CRC Press, Danvers, Mass., 2006; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; El Hariri et al., J. Pharm. Pharmacol., 1992, 44, 651-654).

The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (see e.g., Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, N.Y., 2002; Brunton, Chapter 38 in: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term “bile salts” includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. Suitable bile salts include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucholic acid (sodium glucholate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (see e.g., Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, N.Y., 2002; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Swinyard, Chapter 39 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Yamamoto et al., J. Pharm. Exp. Ther., 1992, 263, 25; Yamashita et al., J. Pharm. Sci., 1990, 79, 579-583).

Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of iRNAs through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, J. Chromatogr., 1993, 618, 315-339). Suitable chelating agents include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines)(see e.g., Katdare, A. et al., Excipient development for pharmaceutical, biotechnology, and drug delivery, CRC Press, Danvers, Mass., 2006; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Buur et al., J. Control Rel., 1990, 14, 43-51).

As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of iRNAs through the alimentary mucosa (see e.g., Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33). This class of penetration enhancers includes, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., J. Pharm. Pharmacol., 1987, 39, 621-626).

Agents that enhance uptake of iRNAs at the cellular level can also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of dsRNAs. Examples of commercially available transfection reagents include, for example Lipofectamine™ (Invitrogen; Carlsbad, Calif.), Lipofectamine 2000™ (Invitrogen; Carlsbad, Calif.), 293Fectin™ (Invitrogen; Carlsbad, Calif.), Cellfectin™ (Invitrogen; Carlsbad, Calif.), DMRIE-C™ (Invitrogen; Carlsbad, Calif.), FreeStyle™ MAX (Invitrogen; Carlsbad, Calif.), Lipofectamine™ 2000 CD (Invitrogen; Carlsbad, Calif.), Lipofectamine™ (Invitrogen; Carlsbad, Calif.), iRNAMAX (Invitrogen; Carlsbad, Calif.), Oligofectamine™ (Invitrogen; Carlsbad, Calif.), Optifect™ (Invitrogen; Carlsbad, Calif.), X-tremeGENE Q2 Transfection Reagent (Roche; Grenzacherstrasse, Switzerland), DOTAP Liposomal Transfection Reagent (Grenzacherstrasse, Switzerland), DOSPER Liposomal Transfection Reagent (Grenzacherstrasse, Switzerland), or Fugene (Grenzacherstrasse, Switzerland), Transfectam® Reagent (Promega; Madison, Wis.), TransFast™ Transfection Reagent (Promega; Madison, Wis.), Tfx™-20 Reagent (Promega; Madison, Wis.), Tfx™-50 Reagent (Promega; Madison, Wis.), DreamFect™ (OZ Biosciences; Marseille, France), EcoTransfect (OZ Biosciences; Marseille, France), TransPassa D1 Transfection Reagent (New England Biolabs; Ipswich, Mass., USA), LyoVec™/LipoGen™ (Invitrogen; San Diego, Calif., USA), PerFectin Transfection Reagent (Genlantis; San Diego, Calif., USA), NeuroPORTER Transfection Reagent (Genlantis; San Diego, Calif., USA), GenePORTER Transfection reagent (Genlantis; San Diego, Calif., USA), GenePORTER 2 Transfection reagent (Genlantis; San Diego, Calif., USA), Cytofectin Transfection Reagent (Genlantis; San Diego, Calif., USA), BaculoPORTER Transfection Reagent (Genlantis; San Diego, Calif., USA), TroganPORTER™ transfection Reagent (Genlantis; San Diego, Calif., USA), RiboFect (Bioline; Taunton, Mass., USA), PlasFect (Bioline; Taunton, Mass., USA), UniFECTOR (B-Bridge International; Mountain View, Calif., USA), SureFECTOR (B-Bridge International; Mountain View, Calif., USA), or HiFect™ (B-Bridge International, Mountain View, Calif., USA), among others.

Other agents can be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

v. Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, “carrier compound” or “carrier” can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate dsRNA in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4′isothiocyano-stilbene-2,2′-disulfonic acid (Miyao et al., DsRNA Res. Dev., 1995, 5, 115-121; Takakura et al., DsRNA & Nucl. Acid Drug Dev., 1996, 6, 177-183.

vi. Excipients

In contrast to a carrier compound, a “pharmaceutical carrier” or “excipient” is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient can be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc).

Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids can include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions can also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

vii. Other Components

The compositions of the present invention can additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions can contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or can contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions can contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension can also contain stabilizers.

In some embodiments, pharmaceutical compositions featured in the invention include (a) one or more iRNA compounds and (b) one or more agents which function by a non-iRNA mechanism and which are useful in treating an HBV infection. Examples of such agents include, but are not limited to antiviral agents aimed at suppressing or destroying HBV by interfering with viral replication; and immune modulators aimed at helping the human immune system mount a defense against the virus. In contrast, immune modulators, such as corticosteroids, which induce an enhanced expression of virus and viral antigens, and a suppression of T-lymphocyte function, or adenine arabinoside, acyclovir, or dideoxyinosine, are not beneficial for the treatment of chronic hepatitis B. Suitable agents are discussed in more detail below.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds that exhibit high therapeutic indices are preferred.

The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of compositions featured herein in the invention lies generally within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods featured in the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range of the compound or, when appropriate, of the polypeptide product of a target sequence (e.g., achieving a decreased concentration of the polypeptide) that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

In addition to their administration, as discussed above, the iRNAs featured in the invention can be administered in combination with other known agents effective in treatment of pathological processes mediated by HBV expression. In any event, the administering physician can adjust the amount and timing of iRNA administration on the basis of results observed using standard measures of efficacy known in the art or described herein.

VII. Methods of the Invention

The present invention provides therapeutic and prophylactic methods which include administering to a subject having an HBV infection and/or HBV-associated disease, disorder, and/or condition, or prone to developing, an HBV-associated disease, disorder, and/or condition (e.g., CHB), compositions comprising an iRNA agent, or pharmaceutical compositions comprising an iRNA agent, or vectors comprising an iRNA of the invention.

The methods of the invention are useful for treating a subject having an HBV infection, e.g., a subject that would benefit from reduction in HBV gene expression and/or HBV replication. In one aspect, the present invention provides methods of reducing the level of Hepatis B virus ccc DNA in a subject infected with HBV. In another aspect, the present invention provides methods of reducing the level of HBV antigen, e.g., HBsAg and/or HBeAg, in a subject infected with HBV. In another aspect, the present invention provides methods of reducing the viral load of HBV in a subject infected with HBV. The present invention also provides methods of reducing the level of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) in a subject infected with HBV. In one aspect, the present invention provides methods for increasing the level of anti-HBV antibodies in a subject infected with HBV. In another aspect, the present invention provides methods of treating a subject having an HBV infection. In one aspect, the present invention provides methods of treating a subject having an HBV-associated disease, e.g., hepatitis D virus infection, delta hepatitis, acute hepatitis B; acute fulminant hepatitis B; chronic hepatitis B; liver fibrosis; end-stage liver disease; hepatocellular carcinoma. Furthermore, as HDV infection depends on obligatory helper functions provided by HBV for transmission, and subjects having an HBV infection may also have an HDV infection, the methods for treatment described herein are also useful for treating a subject having an HDV infection and/or an HDV-associated disorder, such as hepatitis B virus infection, chronic hepatitis B infection (CHB), chronic Hepatitis B infection (CHB), cirrhosis, liver failure, and hepatocellular carcinoma (HCC). The treatment methods (and uses) of the invention include administering to the subject, e.g., a human, a therapeutically effective amount of an iRNA agent of the invention targeting an HBV gene or a pharmaceutical composition comprising an iRNA agent of the invention targeting an HBV gene or a vector of the invention comprising an iRNA agent targeting an HBV gene.

In one aspect, the invention provides methods of preventing at least one symptom in a subject having an HBV infection, e.g., the presence of serum and/or liver HBV ccc DNA, the presence of serum HBV DNA the presence of serum and/or liver HBV antigen, e.g., HBsAg and/or HBeAg, elevated ALT, elevated AST, the absence or low level of anti-HBV antibodies, a liver injury; cirrhosis; hepatitis D virus infection, delta hepatitis, acute hepatitis B; acute fulminant hepatitis B; chronic hepatitis B; liver fibrosis; end-stage liver disease; hepatocellular carcinoma; serum sickness-like syndrome; anorexia; nausea; vomiting, low-grade fever; myalgia; fatigability; disordered gustatory acuity and smell sensations (aversion to food and cigarettes); and/or right upper quadrant and epigastric pain (intermittent, mild to moderate); hepatic encephalopathy; somnolence; disturbances in sleep pattern; mental confusion; coma; ascites; gastrointestinal bleeding; coagulopathy; jaundice; hepatomegaly (mildly enlarged, soft liver); splenomegaly; palmar erythema; spider nevi; muscle wasting; spider angiomas; vasculitis; variceal bleeding; peripheral edema; gynecomastia; testicular atrophy; abdominal collateral veins (caput medusa); high levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), within a range of 1000-2000 IU/mL, although values 100 times above the upper limit of normal (ULN) can be also be identified; ALT levels higher than AST levels; elevated gamma-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP) levels (e.g., not more than 3 times the ULN); slightly low albumin levels; elevated serum iron levels; leukopenia (i.e., granulocytopenia); lymphocytosis; increased erythrocyte sedimentation rate (ESR); shortened red blood cell survival; hemolysis; thrombocytopenia; a prolongation of the international normalized ratio (INR); the presence of serum and/or liverHBsAg, HBeAg, Hepatitis B core antibody (anti-HBc) immunoglobulin M (IgM); hepatitis B surface antibody (anti-HBs), hepatitis B e antibody (anti-HBe), and/or HBV DNA; elevation of the aminotransferases (<5 times the ULN); ALT levels higher than the AST levels; increased bilirubin levels, prolonged prothrombin time (PT); hyperglobulinemia; the presence of tissue-nonspecific antibodies, such as anti-smooth muscle antibodies (ASMAs) or antinuclear antibodies (ANAs) (10-20%); the presence of tissue-specific antibodies, such as antibodies against the thyroid gland (10-20%); elevated levels of rheumatoid factor (RF); hyperbilirubinemia, prolonged PT, low platelet and white blood cell counts, AST levels higher than ALT levels; elevated alkaline phosphatase (ALP) and GGT levels; lobular, with degenerative and regenerative hepatocellular changes, and accompanying inflammation; predominantly centrilobular necrosis. The methods include administering to the subject a therapeutically effective amount of the iRNA agent, e.g., dsRNA, pharmaceutical compositions, or vectors of the invention, thereby preventing at least one symptom in the subject having a disorder that would benefit from reduction in HBV gene expression, such as a subject having an HBV infection or a subject having both an HBV and an HDV infection.

In another aspect, the present invention provides uses of a therapeutically effective amount of an iRNA agent of the invention for treating a subject, e.g., a subject that would benefit from a reduction and/or inhibition of HBV gene expression, such as a subject having an HBV infection or a subject having both an HBV and an HDV infection.

In a further aspect, the present invention provides uses of an iRNA agent, e.g., a dsRNA, of the invention targeting an HBV gene or pharmaceutical composition comprising an iRNA agent targeting an HBV gene in the manufacture of a medicament for treating a subject, e.g., a subject that would benefit from a reduction and/or inhibition of HBV gene expression and/or HBV replication, such as a subject having an HBV infection or a subject having both an HBV and an HDV infection, and a subject having a disorder that would benefit from reduction in HBV gene expression, e.g., a HBV-associated disease.

In another aspect, the invention provides uses of an iRNA, e.g., a dsRNA, of the invention for preventing at least one symptom in a subject suffering from a disorder that would benefit from a reduction and/or inhibition of HBV gene expression and/or HBV replication.

In a further aspect, the present invention provides uses of an iRNA agent of the invention in the manufacture of a medicament for preventing at least one symptom in a subject suffering from a disorder that would benefit from a reduction and/or inhibition of HBV gene expression and/or HBV replication, such as a HBV-associated disease.

In one embodiment, an iRNA agent targeting HBV is administered to a subject having an HBV infection or both and HBV and an HDV infection, and/or an HBV-associated disease such that the expression of one or more HBV genes, HBV ccc DNA levels, HBV antigen levels, HBV viral load levels, ALT, and/or AST, e.g., in a cell, tissue, blood or other tissue or fluid of the subject are reduced by at least about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 62%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% or more when the dsRNA agent is administered to the subject.

In one embodiment, an iRNA agent targeting HBV is administered to a subject having an HBV infection or both and HBV and an HDV infection, and/or an HBV-associated disease such that the level of anti-HBV antibodies, e.g., in a cell, tissue, blood or other tissue or fluid of the subject are increased by at least about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 62%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% or more when the dsRNA agent is administered to the subject.

The methods and uses of the invention include administering a composition described herein such that expression of the target HBV gene is decreased, such as for about 1, 2, 3, 4 5, 6, 7, 8, 12, 16, 18, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, or about 80 hours. In one embodiment, expression of the target HBV gene is decreased for an extended duration, e.g., at least about two, three, four, five, six, seven days or more, e.g., about one week, two weeks, three weeks, or about four weeks or longer.

Administration of the dsRNA according to the methods and uses of the invention may result in a reduction of the severity, signs, symptoms, and/or markers of such diseases or disorders in a patient with an HBV infection or both and HBV and an HDV infection, and/or HBV-associated disease. By “reduction” in this context is meant a statistically significant decrease in such level. The reduction can be, for example, at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or about 100%.

Efficacy of treatment or prevention of disease can be assessed, for example by measuring disease progression, disease remission, symptom severity, reduction in pain, quality of life, dose of a medication required to sustain a treatment effect, level of a disease marker or any other measurable parameter appropriate for a given disease being treated or targeted for prevention. It is well within the ability of one skilled in the art to monitor efficacy of treatment or prevention by measuring any one of such parameters, or any combination of parameters. For example, efficacy of treatment of CHB may be assessed, for example, by periodic monitoring of viral load and transaminase levels. Comparison of the later readings with the initial readings provide a physician an indication of whether the treatment is effective. It is well within the ability of one skilled in the art to monitor efficacy of treatment or prevention by measuring any one of such parameters, or any combination of parameters. In connection with the administration of an iRNA targeting HBV or pharmaceutical composition thereof, “effective against” an HBV-associated disease indicates that administration in a clinically appropriate manner results in a beneficial effect for at least a statistically significant fraction of patients, such as improvement of symptoms, a cure, a reduction in disease, extension of life, improvement in quality of life, or other effect generally recognized as positive by medical doctors familiar with treating HBV infection and/or an HBV-associated disease and the related causes.

A treatment or preventive effect is evident when there is a statistically significant improvement in one or more parameters of disease status, or by a failure to worsen or to develop symptoms where they would otherwise be anticipated. As an example, a favorable change of at least 10% in a measurable parameter of disease, and preferably at least 20%, 30%, 40%, 50% or more can be indicative of effective treatment. Efficacy for a given iRNA drug or formulation of that drug can also be judged using an experimental animal model for the given disease as known in the art. When using an experimental animal model, efficacy of treatment is evidenced when a statistically significant reduction in a marker or symptom is observed.

Subjects can be administered a therapeutic amount of iRNA, such as about 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.15 mg/kg, 0.2 mg/kg, 0.25 mg/kg, 0.3 mg/kg, 0.35 mg/kg, 0.4 mg/kg, 0.45 mg/kg, 0.5 mg/kg, 0.55 mg/kg, 0.6 mg/kg, 0.65 mg/kg, 0.7 mg/kg, 0.75 mg/kg, 0.8 mg/kg, 0.85 mg/kg, 0.9 mg/kg, 0.95 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg, 1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg, 1.9 mg/kg, 2.0 mg/kg, 2.1 mg/kg, 2.2 mg/kg, 2.3 mg/kg, 2.4 mg/kg, 2.5 mg/kg dsRNA, 2.6 mg/kg dsRNA, 2.7 mg/kg dsRNA, 2.8 mg/kg dsRNA, 2.9 mg/kg dsRNA, 3.0 mg/kg dsRNA, 3.1 mg/kg dsRNA, 3.2 mg/kg dsRNA, 3.3 mg/kg dsRNA, 3.4 mg/kg dsRNA, 3.5 mg/kg dsRNA, 3.6 mg/kg dsRNA, 3.7 mg/kg dsRNA, 3.8 mg/kg dsRNA, 3.9 mg/kg dsRNA, 4.0 mg/kg dsRNA, 4.1 mg/kg dsRNA, 4.2 mg/kg dsRNA, 4.3 mg/kg dsRNA, 4.4 mg/kg dsRNA, 4.5 mg/kg dsRNA, 4.6 mg/kg dsRNA, 4.7 mg/kg dsRNA, 4.8 mg/kg dsRNA, 4.9 mg/kg dsRNA, 5.0 mg/kg dsRNA, 5.1 mg/kg dsRNA, 5.2 mg/kg dsRNA, 5.3 mg/kg dsRNA, 5.4 mg/kg dsRNA, 5.5 mg/kg dsRNA, 5.6 mg/kg dsRNA, 5.7 mg/kg dsRNA, 5.8 mg/kg dsRNA, 5.9 mg/kg dsRNA, 6.0 mg/kg dsRNA, 6.1 mg/kg dsRNA, 6.2 mg/kg dsRNA, 6.3 mg/kg dsRNA, 6.4 mg/kg dsRNA, 6.5 mg/kg dsRNA, 6.6 mg/kg dsRNA, 6.7 mg/kg dsRNA, 6.8 mg/kg dsRNA, 6.9 mg/kg dsRNA, 7.0 mg/kg dsRNA, 7.1 mg/kg dsRNA, 7.2 mg/kg dsRNA, 7.3 mg/kg dsRNA, 7.4 mg/kg dsRNA, 7.5 mg/kg dsRNA, 7.6 mg/kg dsRNA, 7.7 mg/kg dsRNA, 7.8 mg/kg dsRNA, 7.9 mg/kg dsRNA, 8.0 mg/kg dsRNA, 8.1 mg/kg dsRNA, 8.2 mg/kg dsRNA, 8.3 mg/kg dsRNA, 8.4 mg/kg dsRNA, 8.5 mg/kg dsRNA, 8.6 mg/kg dsRNA, 8.7 mg/kg dsRNA, 8.8 mg/kg dsRNA, 8.9 mg/kg dsRNA, 9.0 mg/kg dsRNA, 9.1 mg/kg dsRNA, 9.2 mg/kg dsRNA, 9.3 mg/kg dsRNA, 9.4 mg/kg dsRNA, 9.5 mg/kg dsRNA, 9.6 mg/kg dsRNA, 9.7 mg/kg dsRNA, 9.8 mg/kg dsRNA, 9.9 mg/kg dsRNA, 9.0 mg/kg dsRNA, 10 mg/kg dsRNA, 15 mg/kg dsRNA, 20 mg/kg dsRNA, 25 mg/kg dsRNA, 30 mg/kg dsRNA, 35 mg/kg dsRNA, 40 mg/kg dsRNA, 45 mg/kg dsRNA, or about 50 mg/kg dsRNA. Values and ranges intermediate to the recited values are also intended to be part of this invention.

In certain embodiments, for example, when a composition of the invention comprises a dsRNA as described herein and a lipid, subjects can be administered a therapeutic amount of iRNA, such as about 0.01 mg/kg to about 5 mg/kg, about 0.01 mg/kg to about 10 mg/kg, about 0.05 mg/kg to about 5 mg/kg, about 0.05 mg/kg to about 10 mg/kg, about 0.1 mg/kg to about 5 mg/kg, about 0.1 mg/kg to about 10 mg/kg, about 0.2 mg/kg to about 5 mg/kg, about 0.2 mg/kg to about 10 mg/kg, about 0.3 mg/kg to about 5 mg/kg, about 0.3 mg/kg to about 10 mg/kg, about 0.4 mg/kg to about 5 mg/kg, about 0.4 mg/kg to about 10 mg/kg, about 0.5 mg/kg to about 5 mg/kg, about 0.5 mg/kg to about 10 mg/kg, about 1 mg/kg to about 5 mg/kg, about 1 mg/kg to about 10 mg/kg, about 1.5 mg/kg to about 5 mg/kg, about 1.5 mg/kg to about 10 mg/kg, about 2 mg/kg to about 2.5 mg/kg, about 2 mg/kg to about 10 mg/kg, about 3 mg/kg to about 5 mg/kg, about 3 mg/kg to about 10 mg/kg, about 3.5 mg/kg to about 5 mg/kg, about 4 mg/kg to about 5 mg/kg, about 4.5 mg/kg to about 5 mg/kg, about 4 mg/kg to about 10 mg/kg, about 4.5 mg/kg to about 10 mg/kg, about 5 mg/kg to about 10 mg/kg, about 5.5 mg/kg to about 10 mg/kg, about 6 mg/kg to about 10 mg/kg, about 6.5 mg/kg to about 10 mg/kg, about 7 mg/kg to about 10 mg/kg, about 7.5 mg/kg to about 10 mg/kg, about 8 mg/kg to about 10 mg/kg, about 8.5 mg/kg to about 10 mg/kg, about 9 mg/kg to about 10 mg/kg, or about 9.5 mg/kg to about 10 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.

For example, the dsRNA may be administered at a dose of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or about 10 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.

In other embodiments, for example, when a composition of the invention comprises a dsRNA as described herein and an N-acetylgalactosamine, subjects can be administered a therapeutic amount of iRNA, such as a dose of about 0.1 to about 50 mg/kg, about 0.25 to about 50 mg/kg, about 0.5 to about 50 mg/kg, about 0.75 to about 50 mg/kg, about 1 to about 50 mg/kg, about 1.5 to about 50 mg/kg, about 2 to about 50 mg/kg, about 2.5 to about 50 mg/kg, about 3 to about 50 mg/kg, about 3.5 to about 50 mg/kg, about 4 to about 50 mg/kg, about 4.5 to about 50 mg/kg, about 5 to about 50 mg/kg, about 7.5 to about 50 mg/kg, about 10 to about 50 mg/kg, about 15 to about 50 mg/kg, about 20 to about 50 mg/kg, about 20 to about 50 mg/kg, about 25 to about 50 mg/kg, about 25 to about 50 mg/kg, about 30 to about 50 mg/kg, about 35 to about 50 mg/kg, about 40 to about 50 mg/kg, about 45 to about 50 mg/kg, about 0.1 to about 45 mg/kg, about 0.25 to about 45 mg/kg, about 0.5 to about 45 mg/kg, about 0.75 to about 45 mg/kg, about 1 to about 45 mg/kg, about 1.5 to about 45 mg/kg, about 2 to about 45 mg/kg, about 2.5 to about 45 mg/kg, about 3 to about 45 mg/kg, about 3.5 to about 45 mg/kg, about 4 to about 45 mg/kg, about 4.5 to about 45 mg/kg, about 5 to about 45 mg/kg, about 7.5 to about 45 mg/kg, about 10 to about 45 mg/kg, about 15 to about 45 mg/kg, about 20 to about 45 mg/kg, about 20 to about 45 mg/kg, about 25 to about 45 mg/kg, about 25 to about 45 mg/kg, about 30 to about 45 mg/kg, about 35 to about 45 mg/kg, about 40 to about 45 mg/kg, about 0.1 to about 40 mg/kg, about 0.25 to about 40 mg/kg, about 0.5 to about 40 mg/kg, about 0.75 to about 40 mg/kg, about 1 to about 40 mg/kg, about 1.5 to about 40 mg/kg, about 2 to about 40 mg/kg, about 2.5 to about 40 mg/kg, about 3 to about 40 mg/kg, about 3.5 to about 40 mg/kg, about 4 to about 40 mg/kg, about 4.5 to about 40 mg/kg, about 5 to about 40 mg/kg, about 7.5 to about 40 mg/kg, about 10 to about 40 mg/kg, about 15 to about 40 mg/kg, about 20 to about 40 mg/kg, about 20 to about 40 mg/kg, about 25 to about 40 mg/kg, about 25 to about 40 mg/kg, about 30 to about 40 mg/kg, about 35 to about 40 mg/kg, about 0.1 to about 30 mg/kg, about 0.25 to about 30 mg/kg, about 0.5 to about 30 mg/kg, about 0.75 to about 30 mg/kg, about 1 to about 30 mg/kg, about 1.5 to about 30 mg/kg, about 2 to about 30 mg/kg, about 2.5 to about 30 mg/kg, about 3 to about 30 mg/kg, about 3.5 to about 30 mg/kg, about 4 to about 30 mg/kg, about 4.5 to about 30 mg/kg, about 5 to about 30 mg/kg, about 7.5 to about 30 mg/kg, about 10 to about 30 mg/kg, about 15 to about 30 mg/kg, about 20 to about 30 mg/kg, about 20 to about 30 mg/kg, about 25 to about 30 mg/kg, about 0.1 to about 20 mg/kg, about 0.25 to about 20 mg/kg, about 0.5 to about 20 mg/kg, about 0.75 to about 20 mg/kg, about 1 to about 20 mg/kg, about 1.5 to about 20 mg/kg, about 2 to about 20 mg/kg, about 2.5 to about 20 mg/kg, about 3 to about 20 mg/kg, about 3.5 to about 20 mg/kg, about 4 to about 20 mg/kg, about 4.5 to about 20 mg/kg, about 5 to about 20 mg/kg, about 7.5 to about 20 mg/kg, about 10 to about 20 mg/kg, or about 15 to about 20 mg/kg. In one embodiment, when a composition of the invention comprises a dsRNA as described herein and an N-acetylgalactosamine, subjects can be administered a therapeutic amount of about 10 to about 30 mg/kg of dsRNA. Values and ranges intermediate to the recited values are also intended to be part of this invention.

For example, subjects can be administered a therapeutic amount of iRNA, such as about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, 30, 31, 32, 33, 34, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or about 50 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.

In certain embodiments of the invention, for example, when a double-stranded RNAi agent includes a modification (e.g., one or more motifs of three identical modifications on three consecutive nucleotides), including one such motif at or near the cleavage site of the agent, six phosphorothioate linkages, and a ligand, such an agent is administered at a dose of about 0.01 to about 0.5 mg/kg, about 0.01 to about 0.4 mg/kg, about 0.01 to about 0.3 mg/kg, about 0.01 to about 0.2 mg/kg, about 0.01 to about 0.1 mg/kg, about 0.01 mg/kg to about 0.09 mg/kg, about 0.01 mg/kg to about 0.08 mg/kg, about 0.01 mg/kg to about 0.07 mg/kg, about 0.01 mg/kg to about 0.06 mg/kg, about 0.01 mg/kg to about 0.05 mg/kg, about 0.02 to about 0.5 mg/kg, about 0.02 to about 0.4 mg/kg, about 0.02 to about 0.3 mg/kg, about 0.02 to about 0.2 mg/kg, about 0.02 to about 0.1 mg/kg, about 0.02 mg/kg to about 0.09 mg/kg, about 0.02 mg/kg to about 0.08 mg/kg, about 0.02 mg/kg to about 0.07 mg/kg, about 0.02 mg/kg to about 0.06 mg/kg, about 0.02 mg/kg to about 0.05 mg/kg, about 0.03 to about 0.5 mg/kg, about 0.03 to about 0.4 mg/kg, about 0.03 to about 0.3 mg/kg, about 0.03 to about 0.2 mg/kg, about 0.03 to about 0.1 mg/kg, about 0.03 mg/kg to about 0.09 mg/kg, about 0.03 mg/kg to about 0.08 mg/kg, about 0.03 mg/kg to about 0.07 mg/kg, about 0.03 mg/kg to about 0.06 mg/kg, about 0.03 mg/kg to about 0.05 mg/kg, about 0.04 to about 0.5 mg/kg, about 0.04 to about 0.4 mg/kg, about 0.04 to about 0.3 mg/kg, about 0.04 to about 0.2 mg/kg, about 0.04 to about 0.1 mg/kg, about 0.04 mg/kg to about 0.09 mg/kg, about 0.04 mg/kg to about 0.08 mg/kg, about 0.04 mg/kg to about 0.07 mg/kg, about 0.04 mg/kg to about 0.06 mg/kg, about 0.05 to about 0.5 mg/kg, about 0.05 to about 0.4 mg/kg, about 0.05 to about 0.3 mg/kg, about 0.05 to about 0.2 mg/kg, about 0.05 to about 0.1 mg/kg, about 0.05 mg/kg to about 0.09 mg/kg, about 0.05 mg/kg to about 0.08 mg/kg, or about 0.05 mg/kg to about 0.07 mg/kg. Values and ranges intermediate to the foregoing recited values are also intended to be part of this invention, e.g., the RNAi agent may be administered to the subject at a dose of about 0.015 mg/kg to about 0.45 mg/kg.

For example, the RNAi agent, e.g., RNAi agent in a pharmaceutical composition, may be administered at a dose of about 0.01 mg/kg, 0.0125 mg/kg, 0.015 mg/kg, 0.0175 mg/kg, 0.02 mg/kg, 0.0225 mg/kg, 0.025 mg/kg, 0.0275 mg/kg, 0.03 mg/kg, 0.0325 mg/kg, 0.035 mg/kg, 0.0375 mg/kg, 0.04 mg/kg, 0.0425 mg/kg, 0.045 mg/kg, 0.0475 mg/kg, 0.05 mg/kg, 0.0525 mg/kg, 0.055 mg/kg, 0.0575 mg/kg, 0.06 mg/kg, 0.0625 mg/kg, 0.065 mg/kg, 0.0675 mg/kg, 0.07 mg/kg, 0.0725 mg/kg, 0.075 mg/kg, 0.0775 mg/kg, 0.08 mg/kg, 0.0825 mg/kg, 0.085 mg/kg, 0.0875 mg/kg, 0.09 mg/kg, 0.0925 mg/kg, 0.095 mg/kg, 0.0975 mg/kg, 0.1 mg/kg, 0.125 mg/kg, 0.15 mg/kg, 0.175 mg/kg, 0.2 mg/kg, 0.225 mg/kg, 0.25 mg/kg, 0.275 mg/kg, 0.3 mg/kg, 0.325 mg/kg, 0.35 mg/kg, 0.375 mg/kg, 0.4 mg/kg, 0.425 mg/kg, 0.45 mg/kg, 0.475 mg/kg, or about 0.5 mg/kg. Values intermediate to the foregoing recited values are also intended to be part of this invention.

In some embodiments, the RNAi agent is administered as a fixed dose of between about 100 mg to about 900 mg, e.g., between about 100 mg to about 850 mg, between about 100 mg to about 800 mg, between about 100 mg to about 750 mg, between about 100 mg to about 700 mg, between about 100 mg to about 650 mg, between about 100 mg to about 600 mg, between about 100 mg to about 550 mg, between about 100 mg to about 500 mg, between about 200 mg to about 850 mg, between about 200 mg to about 800 mg, between about 200 mg to about 750 mg, between about 200 mg to about 700 mg, between about 200 mg to about 650 mg, between about 200 mg to about 600 mg, between about 200 mg to about 550 mg, between about 200 mg to about 500 mg, between about 300 mg to about 850 mg, between about 300 mg to about 800 mg, between about 300 mg to about 750 mg, between about 300 mg to about 700 mg, between about 300 mg to about 650 mg, between about 300 mg to about 600 mg, between about 300 mg to about 550 mg, between about 300 mg to about 500 mg, between about 400 mg to about 850 mg, between about 400 mg to about 800 mg, between about 400 mg to about 750 mg, between about 400 mg to about 700 mg, between about 400 mg to about 650 mg, between about 400 mg to about 600 mg, between about 400 mg to about 550 mg, or between about 400 mg to about 500 mg.

In some embodiments, the RNAi agent is administered as a fixed dose of about 100 mg, about 125 mg, about 150 mg, about 175 mg, 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, or about 900 mg.

The iRNA can be administered by intravenous infusion over a period of time, such as over a 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or about a 25 minute period. The administration may be repeated, for example, on a regular basis, such as weekly, biweekly (i.e., every two weeks) for one month, two months, three months, four months or longer. After an initial treatment regimen, the treatments can be administered on a less frequent basis. For example, after administration weekly or biweekly for three months, administration can be repeated once per month, for six months or a year or longer.

Administration of the iRNA can reduce the presence of serum and/or liver HBV ccc DNA, the presence of serum and/or liver HBV antigen, e.g., HBsAg and/or HBeAg, ALT levels, and/or AST levels, e.g., in a cell, tissue, blood, urine or other compartment of the patient by at least about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% or more, e.g., to below the level of detection of the assay.

Administration of the iRNA can increase the presence of serum and/or liver anti-HBV antibodies, e.g., in a cell, tissue, blood, urine or other compartment of the patient by at least about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% or more.

Before administration of a full dose of the iRNA, patients can be administered a smaller dose, such as a 5% infusion, and monitored for adverse effects, such as an allergic reaction. In another example, the patient can be monitored for unwanted immunostimulatory effects, such as increased cytokine (e.g., TNF-alpha or INF-alpha) levels.

Owing to the inhibitory effects on HBV expression, a composition according to the invention or a pharmaceutical composition prepared therefrom can enhance the quality of life.

An iRNA of the invention may be administered in “naked” form, where the modified or unmodified iRNA agent is directly suspended in aqueous or suitable buffer solvent, as a “free iRNA.” A free iRNA is administered in the absence of a pharmaceutical composition.

The free iRNA may be in a suitable buffer solution. The buffer solution may comprise acetate, citrate, prolamine, carbonate, or phosphate, or any combination thereof. In one embodiment, the buffer solution is phosphate buffered saline (PBS). The pH and osmolarity of the buffer solution containing the iRNA can be adjusted such that it is suitable for administering to a subject.

Alternatively, an iRNA of the invention may be administered as a pharmaceutical composition, such as a dsRNA liposomal formulation.

Subjects that would benefit from a reduction and/or inhibition of HBV gene expression are those having an HBV infection and/or an HBV-associated disease or disorder as described herein.

Treatment of a subject that would benefit from a reduction and/or inhibition of HBV gene expression includes therapeutic and prophylactic treatment.

The invention further provides methods and uses of an iRNA agent or a pharmaceutical composition thereof for treating a subject that would benefit from reduction and/or inhibition of HBV gene expression, e.g., a subject having a HBV-associated disease, in combination with other pharmaceuticals and/or other therapeutic methods, e.g., with known pharmaceuticals and/or known therapeutic methods, such as, for example, those which are currently employed for treating these disorders.

For example, in certain embodiments, an iRNA targeting one or more HBV genes is administered in combination with, e.g., an agent useful in treating an HBV-associated disease as described elsewhere herein. For example, additional therapeutics and therapeutic methods suitable for treating a subject that would benefit from reduction in HBV expression, e.g., a subject having a HBV-associated disease, include an iRNA agent targeting a different portion of the HBV genome, an antiviral agent, a reverse transcriptase inhibitor (e.g., Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide, Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, and AGX-1009), an immune stimulator (e.g., pegylated interferon alfa 2a (PEG-IFN-α2a), Interferon alfa-2b, a recombinant human interleukin-7, and aToll-like receptor 7 (TLR7) agonist), a therapeutic vaccine (e.g., GS-4774, DV-601, and TG1050), a viral entry inhibitor (e.g., Myrcludex), an oligonucleotide that inhibits the secretion or release of HbsAg (e.g., REP 9AC), a capsid inhibitor (e.g., Bay41-4109 and NVR-1221), a cccDNA inhibitor (e.g., IHVR-25), or other therapeutic agents and/or procedures, e.g., liver transplant, chemotherapy, for treating a HBV-associated disease, a combination of any of the foregoing.

In certain embodiments, a first iRNA agent targeting one or more HBV genes is administered in combination with a second iRNA agent targeting a different portion of the HBV genome. For example, a first iRNA agent targeting one or more structural genes may be administered in combination with a second RNAi agent targeting the X gene. For example, the first RNAi agent comprises a first sense strand and a first antisense strand forming a double-stranded region, wherein substantially all of the nucleotides of said first sense strand and substantially all of the nucleotides of the first antisense strand are modified nucleotides, wherein said first sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; and the second RNAi agent comprises a second sense strand and a second antisense strand forming a double-stranded region, wherein substantially all of the nucleotides of the second sense strand and substantially all of the nucleotides of the second antisense strand are modified nucleotides, wherein the second sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; wherein the first sense strand comprises a sequences selected from the group consisting of 5′-UCGUGGUGGACUUCUCUCA-3′ (SEQ ID NO:5), 5′-GUGCACUUCGCUUCACCUCUA-3′ (SEQ ID NO:7), 5′-CGUGGUGGACUUCUCUCAAUU-3′ (SEQ ID NO:9), 5′-CGUGGUGGUCUUCUCUAAAUU-3′ (SEQ ID NO:37), 5′-GGUGGACUUCUCUCAAUUUUA-3′ (SEQ ID NO:11), and 5′-GUGUGCACUUCGCUUCACA-3′ (SEQ ID NO:39) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to any of the foregoing nucleotide sequences), and wherein the first and second antisense strands each independently comprise a sequence selected from the group consisting of 5′-UGAGAGAAGUCCACCACGAUU-3′ (SEQ ID NO:6); 5′-UAGAGGUGAAGCGAAGUGCACUU-3′ (SEQ ID NO:8); 5′-AAUUGAGAGAAGUCCACCAGCAG-3′ (SEQ ID NO: 10); 5′-AAUUGAGAGAAGUCCACCAGCUU-3′ (SEQ ID NO:38), 5′-UAAAAUUGAGAGAAGUCCACCAC-3′ (SEQ ID NO:12), and 5′-UGUGAAGCGAAGUGCACACUU-3′ (SEQ ID NO:40) (or a nucleotide sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to any of the foregoing nucleotide sequences), thereby treating the subject.

In one embodiment, all of the nucleotides of the first and second sense strand and/or all of the nucleotides of the first and second antisense strand comprise a modification.

In one embodiment, the at least one of the modified nucleotides is selected from the group consisting of a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.

In certain embodiments, a first iRNA agent targeting one or more HBV genes is administered in combination with a second iRNA agent targeting a gene that is different from one or more HBV genes. For example, the iRNA agent targeting one or more HBV genes may be administered in combination with an iRNA agent targeting a CD274/PD-L1 gene. Examples of iRNA agents targeting a CD274/PD-L1 gene are described in WO 2011/127180, the entire contents of which are incorporated herein by reference. The first iRNA agent targeting one or more HBV genes and the second iRNA agent targeting a gene different from one or more HBV genes, e.g., a CD274/PD-L1 gene and/or an HDV gene, may be administered as parts of the same pharmaceutical composition. Alternatively, the first iRNA agent targeting one or more HBV genes and the second iRNA agent targeting a gene different from one or more HBV genes, e.g., a CD274/PD-L1 gene and/or an HDV gene, may be administered as parts of different pharmaceutical compositions.

CD274 or PD-L1 is a 290 amino acid type I transmembrane protein encoded by the CD274 gene on mouse chromosome 19 and human chromosome 9. CD274/PD-L1 expression is implicated in evasion of immune responses involved in chronic infection, e.g., by viruses (including, for example, HIV, HBV, HCV and HTLV, among others), by bacteria (including, for example, Helicobacter pylori, among others) and by parasites (including, for example, Schistosoma mansoni).

PD-L1 can influence immune responses by engaging PD-1 or B7-1 (CD80) and modifying TCR or BCR signaling, but can also deliver signals into PD-L1 expressing cells, i.e., reverse signaling through PD-L1. Surface plasmon resonance studies demonstrate specific and unique interaction between both PD-L1 and B7-1, with an affinity of 1.7 PM, and an affinity of 0.5 μM for the interaction between PD-L1 and PD-1. Chemical cross-linking studies indicate that PD-L1 and B7-1, like PD-L1 and PD-1, can also interact through their IgV-like domains. The PD-L1:B7-1 interface overlaps at least partially with the putative PD-L1:PD-1 interface. B7-1:PD-L1 interactions can induce an inhibitory signal into T cells. Ligation of PD-L1 on CD4 T cells by B7-1, or ligation of B7-1 on CD4 T cells by PD-L1, delivers a functionally significant, inhibitory signal. Because both PD-L1 and B7-1 are expressed on T cells, B cells, DCs, and macrophages, there is the potential for bidirectional interactions between B7-1 and PD-L1 on these cell types. In addition, PD-L1 on nonhematopoietic cells may interact with B7-1 as well as PD-1 on T cells to regulate cells (Keir M E et al., 2008. Annu Rev Immunol. 26:677-704).

In chronic viral infections in humans, several groups have shown that PD-1 expression is high on HIV-specific (Petrovas C et al., 2006, J. Exp. Med. 203:2281-92; Day C L et al., 2006, Nature 443:350-54; Trautmann L et al., 2006, Nat. Med. 12: 1198-202), HBV-specific (Boettler T et al., 2006, J. Virol. 80:3532-40; Boni C et al. 2007, J. Virol. 81:4215-25), and HCV-specific T cells (Urbani S et al., 2006, J. Virol. 80: 11398-403). PD-L1 is also upregulated on peripheral blood CD14+monocytes and myeloid DCs in patients with chronic HBV infection (Chen L et al., 2007, J. Immunol. 178:6634-41; Ceng L et al., 2006, J. Viral Hepat. 13:725-33), and on CD 14+cells and T cells in HIV patients (Trabattoni D et al., 2003. Blood 101:2514-20). Blocking PD-LPD-L interactions in vitro reverses the exhaustion of HIV-specific, HBV-specific (Boni C et al. 2007, J. Virol. 81:4215-25), HCV-specific, and SIV-specific (Velu V et al., 2007, J. Virol. 81:5819-28) CD8 and CD4 T cells and restores proliferation and cytokine production (Petrovas C et al., 2006, J. Exp. Med. 203:2281-92; Day C L et al., 2006, Nature 443:350-54; Trautmann L et al., 2006, Nat. Med. 12: 1198-202; Urbani S et al., 2006, J. Virol. 80: 11398-403). Recent work shows that the HCV core, a nucleocapsid protein, can upregulate PD-1 and PD-L1 expression on healthy donor T cells and that upregulation of PD-1 is mediated by interaction of the HCV core with the complement receptor C1QBP (Yao Z Q et al., 2007, Viral Immunol. 20:276-87).

A subject administered a first RNAi agent or a first and second RNAi agent of the invention may further be administered with one or more other therapeutics which function by a non-iRNA mechanism and which are useful in treating an HBV infection. Exemplary therapeutics that may be used in a combination therapy of the invention include immune modulators which stimulate the immune system by, for example, enhancing T-cell helper activity, maturation of B lymphocytes, inhibiting T-cell suppressors, and enhancing HLA type I expression. Suitable immune modulators include interferons which have a variety of properties that include antiviral, immunomodulatory, and antiproliferative effects.

For example, the current treatment for chronic hepatitis B is interferon therapy, which is administered to subjects who have a documented HBV infection for at least six months, elevated liver enzymes (AST and ALT) and an actively dividing virus in their blood (HBeAg, and/or HBV DNA positive tests). Interferon-α therapy produces a long-term, sustained remission of the disease in about 35% of those with chronic hepatitis B, with normalization of liver enzymes and loss of the three markers for an active infection (HBeAg, HBV DNA, and HBsAg). Subjects with an acute HBV infection, end stage cirrhosis or other major medical problems are typically not treated with interferon.

In addition, interferon therapy for patients with HBV-related cirrhosis decreases significantly the hepatocellular carcinoma (HCC) rate, particularly in patients with a larger amount of serum HBV DNA. In patients with HBeAg-positive compensated cirrhosis, virological and biochemical remission following interferon therapy is associated with improved survival. In patients with chronic HBV infection, the clearance of HBeAg after treatment with interferon-α is associated with improved clinical outcomes.

The standard duration of therapy is considered 16 weeks. Patients who exhibit a low level of viral replication at the end of the standard regimen benefit most from prolonged treatment.

Other exemplary therapeutic agents which can be used in a combination therapy of the invention include, for example, an antiviral agent, a nucleotide analog, a nucleoside analog, a reverse transcriptase inhibitor (e.g., Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide, Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, and ganciclovir), an immune stimulator (e.g., pegylated interferon alfa 2a (PEG-IFN-α2a), Interferon alfa-2b, a recombinant human interleukin-7, and aToll-like receptor 7 (TLR7) agonist), a therapeutic vaccine (e.g., GS-4774, DV-601, and TG1050), a viral entry inhibitor (e.g., Myrcludex), an oligonucleotide that inhibits the secretion or release of HbsAg (e.g., REP 9AC), a capsid inhibitor (e.g., Bay41-4109 and NVR-1221), a cccDNA inhibitor (e.g., IHVR-25), or other therapeutic agents and/or procedures, e.g., liver transplant, chemotherapy, for treating a HBV-associated disease, a combination of any of the foregoing.

In one embodiment, the methods of the invention include administering to a subject having an HBV infection and/or HBV-associate disease a reverse transcriptase inhibitor. In another embodiment, the methods of the invention include administering to a subject having an HBV infection and/or HBV-associate disease a reverse transcriptase inhibitor and an immune stimulator.

The iRNA agent(s) and an additional therapeutic agent and/or treatment may be administered at the same time and/or in the same combination, e.g., parenterally, or the additional therapeutic agent can be administered as part of a separate composition or at separate times and/or by another method known in the art or described herein.

The present invention also provides methods of using an iRNA agent of the invention and/or a composition containing an iRNA agent of the invention to reduce and/or inhibit HBV expression in a cell. In other aspects, the present invention provides an iRNA of the invention and/or a composition comprising an iRNA of the invention for use in reducing and/or inhibiting HBV gene expression in a cell. In yet other aspects, use of an iRNA of the invention and/or a composition comprising an iRNA of the invention for the manufacture of a medicament for reducing and/or inhibiting HBV gene expression in a cell are provided. In still other aspect, the the present invention provides an iRNA of the invention and/or a composition comprising an iRNA of the invention for use in reducing and/or inhibiting HBV replication in a cell. In yet other aspects, use of an iRNA of the invention and/or a composition comprising an iRNA of the invention for the manufacture of a medicament for reducing and/or inhibiting HBV replication in a cell are provided. The methods and uses include contacting the cell with an iRNA, e.g., a dsRNA, of the invention and maintaining the cell for a time sufficient to obtain degradation of the mRNA transcript of an HBV gene, thereby inhibiting expression of the HBV gene or inhibiting HBV replication in the cell.

Reduction in gene expression can be assessed by any methods known in the art. For example, a reduction in the expression of HBV may be determined by determining the mRNA expression level of HBV using methods routine to one of ordinary skill in the art, e.g., northern blotting, qRT-PCR, by determining the protein level of HBV using methods routine to one of ordinary skill in the art, such as western blotting, immunological techniques, flow cytometry methods, ELISA, and/or by determining a biological activity of HBV.

In the methods and uses of the invention the cell may be contacted in vitro or in vivo, i.e., the cell may be within a subject.

A cell suitable for treatment using the methods of the invention may be any cell that expresses an HBV gene, e.g., a cell infected with HBV or a cell comprising an expression vector comprising an HBV genome or portion of an HBV gene. A cell suitable for use in the methods and uses of the invention may be a mammalian cell, e.g., a primate cell (such as a human cell or a non-human primate cell, e.g., a monkey cell or a chimpanzee cell), a non-primate cell (such as a cow cell, a pig cell, a camel cell, a llama cell, a horse cell, a goat cell, a rabbit cell, a sheep cell, a hamster, a guinea pig cell, a cat cell, a dog cell, a rat cell, a mouse cell, a lion cell, a tiger cell, a bear cell, or a buffalo cell), a bird cell (e.g., a duck cell or a goose cell), or a whale cell. In one embodiment, the cell is a human cell, e.g., a human liver cell.

HBV gene expression may be inhibited in the cell by at least about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100%, i.e., to below the level of detection of the assay.

HBV replication may be inhibited in the cell by at least about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100%, i.e., to below the level of detection of the assay.

The in vivo methods and uses of the invention may include administering to a subject a composition containing an iRNA, where the iRNA includes a nucleotide sequence that is complementary to at least a part of an RNA transcript of the HBV gene of the mammal to be treated. When the organism to be treated is a human, the composition can be administered by any means known in the art including, but not limited to subcutaneous, intravenous, oral, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal and intrathecal), intramuscular, transdermal, airway (aerosol), nasal, rectal, and topical (including buccal and sublingual) administration. In certain embodiments, the compositions are administered by subcutaneous injection. In some embodiments, the compositions are administered by intravenous infusion or injection. In other embodiments, the compositions are administered by intramuscular injection.

In some embodiments, the administration is via a depot injection. A depot injection may release the iRNA in a consistent way over a prolonged time period. Thus, a depot injection may reduce the frequency of dosing needed to obtain a desired effect, e.g., a desired inhibition of HBV, or a therapeutic or prophylactic effect. A depot injection may also provide more consistent serum concentrations. Depot injections may include subcutaneous injections or intramuscular injections. In preferred embodiments, the depot injection is a subcutaneous injection.

In some embodiments, the administration is via a pump. The pump may be an external pump or a surgically implanted pump. In certain embodiments, the pump is a subcutaneously implanted osmotic pump. In other embodiments, the pump is an infusion pump. An infusion pump may be used for intravenous, subcutaneous, arterial, or epidural infusions. In preferred embodiments, the infusion pump is a subcutaneous infusion pump. In other embodiments, the pump is a surgically implanted pump that delivers the iRNA to the liver.

The mode of administration may be chosen based upon whether local or systemic treatment is desired and based upon the area to be treated. The route and site of administration may be chosen to enhance targeting.

In one aspect, the present invention also provides methods for inhibiting the expression of an HBV gene in a mammal, e.g., a human. The present invention also provides a composition comprising an iRNA, e.g., a dsRNA, that targets an HBV gene in a cell of a mammal for use in inhibiting expression of the HBV gene in the mammal. In another aspect, the present invention provides use of an iRNA, e.g., a dsRNA, that targets an HBV gene in a cell of a mammal in the manufacture of a medicament for inhibiting expression of the HBV gene in the mammal.

The methods and uses include administering to the mammal, e.g., a human, a composition comprising an iRNA, e.g., a dsRNA, that targets an HBV gene in a cell of the mammal and maintaining the mammal for a time sufficient to obtain degradation of the mRNA transcript of the HBV gene, thereby inhibiting expression of the HBV gene in the mammal.

Reduction in gene expression can be assessed in peripheral blood sample of the iRNA-administered subject by any methods known it the art, e.g. qRT-PCR, described herein. Reduction in protein production can be assessed by any methods known it the art and by methods, e.g., ELISA or western blotting, described herein. In one embodiment, a puncture liver biopsy sample serves as the tissue material for monitoring the reduction in HBV gene and/or protein expression. In another embodiment, a blood sample serves as the tissue material for monitoring the reduction in HBV gene and/or protein expression.

In one embodiment, verification of RISC medicated cleavage of target in vivo following administration of iRNA agent is done by performing 5′-RACE or modifications of the protocol as known in the art (Lasham A et al., (2010) Nucleic AcidRes., 38 (3) p-e19) (Zimmermann et al. (2006) Nature 441: 111-4).

This invention is further illustrated by the following examples which should not be construed as limiting. The entire contents of all references, patents and published patent applications cited throughout this application, as well as the Figures and the Sequence Listing, are hereby incorporated herein by reference.

EXAMPLES Example 1. iRNA Synthesis Source of Reagents

Where the source of a reagent is not specifically given herein, such reagent can be obtained from any supplier of reagents for molecular biology at a quality/purity standard for application in molecular biology.

Transcripts

siRNA Design

The selection of siRNA designs targeting HBV was driven by two primary factors: a) potency and b), the desire to employ siRNA with near-perfect matches with greater than 90% fractional coverage of the large number of public HBV sequences of all known serotypes (A through H). The coordinates for the siRNA selection were determined relative to the NCBI HBV reference genome sequence NC_003977.1 (GenBank Accession No. GI:21326584 (SEQ ID NO: 1). A first set of siRNAs containing structure-activity modifications, including various 2′-O-methyl and 2′-fluoro substitution patterns, centered on two adjacent regions of the HBV genome coding for surface antigen (HbSAg) and the HBV polymerase, were designed, synthesized and screened in-vitro. A second set of siRNAs were designed, synthesized and screened targeting additional target regions with particular attention to positions 1581-1599 of SEQ ID NO: 1 that code, in addition to the HbSAg and polymerase, the X gene.

A detailed list of the unmodified HBV sense and antisense strand sequences is shown in Table 3.

A detailed list of the modified HBV sense and antisense strand sequences is shown in Table 4.

siRNA Synthesis

HBV siRNA sequences were synthesized at 1 μmol scale on Mermade 192 synthesizer (BioAutomation) using the solid support mediated phosphoramidite chemistry. The solid support was controlled pore glass (500 A) loaded with custom GalNAc ligand or universal solid support (AM biochemical). Ancillary synthesis reagents, 2′-F and 2′-O-Methyl RNA and deoxy phosphoramidites were obtained from Thermo-Fisher (Milwaukee, Wis.) and Hongene (China). 2′F 2′-O-Methyl, GNA (glycol nucleic acids), 5′phosphate and abasic modifications were introduced employing the corresponding phosphoramidites. Synthesis of 3′ GalNAc conjugated single strands was performed on a GalNAc modified CPG support. Custom CPG universal solid support was used for the synthesis of antisense single strands. Coupling time for all phosphoramidites (100 mM in acetonitrile) was 5 min employing 5-Ethylthio-1H-tetrazole (ETT) as activator (0.6 M in acetonitrile). Phosphorothioate linkages were generated using a 50 mM solution of 3-((Dimethylamino-methylidene) amino)-3H-1,2,4-dithiazole-3-thione (DDTT, obtained from Chemgenes (Wilmington, Mass., USA)) in anhydrous acetonitrile/pyridine (1:1 v/v). Oxidation time was 3 minutes. All sequences were synthesized with final removal of the DMT group (“DMT off”).

Upon completion of the solid phase synthesis, oligoribonucleotides were cleaved from the solid support and deprotected in sealed 96 deep well plates using 200 μL Aqueous Methylamine reagents at 60° C. for 20 minutes. At the end of cleavage and deprotection step, the synthesis plate was allowed to come to room temperature and was precipitated by addition of 1 mL of acetontile: ethanol mixture (9:1). The plates were cooled at −80 C for 2 hrs, superanatant decanted carefully with the aid of a multi channel pipette. The oligonucleotide pellet was re-suspended in 20 mM NaOAc buffer and were desalted using a 5 mL HiTrap size exclusion column (GE Healthcare) on an AKTA Purifier System equipped with an A905 autosampler and a Frac 950 fraction collector. Desalted samples were collected in 96-well plates. Samples from each sequence were analyzed by LC-MS to confirm the identity, UV (260 nm) for quantification and a selected set of samples by IEX chromatography to determine purity.

Annealing of HBV single strands was performed on a Tecan liquid handling robot. Equimolar mixture of sense and antisense single strands were combined and annealed in 96 well plates. After combining the complementary single strands, the 96-well plate was sealed tightly and heated in an oven at 100° C. for 10 minutes and allowed to come slowly to room temperature over a period 2-3 hours. The concentration of each duplex was normalized to 10 μM in 1×PBS.

Example 2. In Vitro Screening of siRNA Duplexes Cell Culture and Transfections

Cos7 cells (ATCC, Manassas, Va.) were grown to near confluence at 37° C. in an atmosphere of 5% CO2 in DMEM (ATCC) supplemented with 10% FBS, before being released from the plate by trypsinization. Dual-Glo® Luciferase constructs generated in the psiCHECK2 plasmid containing approximately 1.1 kb of HBV genomic sequences were transfected into approximately 15×10⁴ cells using Lipofectamine 2000 (Invitrogen, Carlsbad Calif. cat #11668-019). For each well of a 96 well plate, 0.2 μl of Lipofectamine was added to 10 ng of plasmid vector in 14.8 μl of Opti-MEM and allowed to complex at room temperature for 15 minutes. The mixture was then added to the cells which were resuspended in 80 μl of fresh complete media. After approximately 24 hours, the media were removed and the cells re-transfected with siRNA. Each siRNA was transfected into cells that had previously been transfected with the psiCHECK2-HBV vector that had a perfect match for the siRNA. siRNA transfection was carried out by adding 14.8 μl of Opti-MEM plus 0.2 μl of Lipofectamine RNAiMax per well (Invitrogen, Carlsbad Calif. cat #13778-150) to 5 μl of siRNA duplexes per well into a 96-well plate and incubated at room temperature for 15 minutes. The mixture was then added to the cells previously transfected with the psiCHECK2-HBV plasmid that had a perfect match to the siRNA sequence. Cells were incubated for 24 hours before luciferase was measured.

Single dose experiments were performed at 10 nM and 0.01 nM final duplex concentration.

Dual-Glo® Luciferase Assay

Twenty-four hours after the siRNAs were transfected, Firefly (transfection control) and Rinella (fused to HBV target sequence) luciferase were measured. First, media was removed from cells. Then Firefly luciferase activity was measured by adding 75 μl of Dual-Glo® Luciferase Reagent equal to the culture medium volume to each well and mix. The mixture was incubated at room temperature for 30 minutes before lunimescense (500 nm) was measured on a Spectramax (Molecular Devices) to detect the Firefly luciferase signal. Renilla luciferase activity was measured by adding 75 μl of room temperature of Dual-Glo® Stop & Glo® Reagent was added to each well and the plates were incubated for 10-15 minutes before luminescence was again measured to determine the Renilla luciferase signal. The Dual-Glo® Stop & Glo® Reagent, quench the firefly luciferase signal and sustain luminescence for the Renilla luciferase reaction. siRNA activity was determined by normalizing the Renilla (HBV) signal to the Firefly (control) signal within each well. The magnitude of siRNA activity was then assessed relative to cells that were transfected with the same vector but were not treated with siRNA or were treated with a non-targeting siRNA. All transfections were done at n=2 or greater.

Table 5 shows the results of a single dose screen in Cos7 cells transfected with the indicated HBV iRNAs. Data are expressed as percent of mRNA remaining relative to negative control.

TABLE 2 Abbreviations of nucleotide monomers used in nucleic acid sequence representation. It will be understood that, unless otherwise indicated, these monomers, when present in an oligonucleotide are mutually linked by 5′-3′-phosphodiester bodnds. Abbreviation Nucleotide(s) A Adenosine-3′-phosphate Af 2′-fluoroadenosine-3′-phosphate Afs 2′-fluoroadenosine-3′-phosphorothioate As adenosine-3′-phosphorothioate C cytidine-3′-phosphate Cf 2′-fluorocytidine-3′-phosphate Cfs 2′-fluorocytidine-3′-phosphorothioate Cs cytidine-3′-phosphorothioate G guanosine-3′-phosphate Gf 2′-fluoroguanosine-3′-phosphate Gfs 2′-fluoroguanosine-3′-phosphorothioate Gs guanosine-3′-phosphorothioate T 5′-methyluridine-3′-phosphate Tf 2′-fluoro-5-methyluridine-3′-phosphate Tfs 2′-fluoro-5-methyluridine-3′-phosphorothioate Ts 5-methyluridine-3′-phosphorothioate U Uridine-3′-phosphate Uf 2′-fluorouridine-3′-phosphate Ufs 2′-fluorouridine-3′-phosphorothioate Us uridine-3′-phosphorothioate N any nucleotide (G, A, C, T or U) a 2′-O-methyladenosine-3′-phosphate as 2′-O-methyladenosine-3′-phosphorothioate c 2′-O-methylcytidine-3′-phosphate cs 2′-O-methylcytidine-3′-phosphorothioate g 2′-O-methylguanosine-3′-phosphate gs 2′-O-methylguanosine-3′-phosphorothioate t 2′-O-methyl-5-methylthymine-3′-phosphate ts 2′-O-methyl-5-methylthymine-3′-phosphorothioate u 2′-O-methyluridine-3′-phosphate us 2′-O-methyluridine-3′-phosphorothioate s phosphorothioate linkage L96 N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol Hyp-(GalNAc-alkyl)3 (dT) 2′-deoxythymidine-3′-phosphate Y34 2-hydroxymethyl-tetrahydrofurane-4-methoxy-3-phosphate (abasic 2′- OMe furanose) Y44 2-hydroxymethyl-tetrahydrofurane-5-phosphate (Agn) Adenosine-glycol nucleic acid (GNA) (Tgn) Thymididne-glycol nucleic acid (GNA) S-Isomer (Cgn) Cytidine-glycol nucleic acid (GNA) P Phosphate VP Vinyl-phosphate

TABLE 3 Unmodified Sense and Antisense Strand Sequences of HBV dsRNAs Sense SEQ Antisense SEQ Position Duple Oligo Sense Sequence ID Oligo Antisense Sequence ID in Name Name (5′ to 3′) NO Name (5′ to 3′) NO: NC_003977.1 AD-61522.2 A-123463.2 AGUUAUAUGGAUGAUGUGGUA  47 A-123464.2 UACCACAUCAUCCAUAUAACUGA 263  731_753 AD-61547.2 A-123487.2 GGAUGUGUCUGCGGCGUUUUA  48 A-123488.2 UAAAACGCCGCAGACACAUCCAG 264  373_395 AD-63938.2 A-127896.1 ACUCGUGGUGGACUUCUCUCA  49 A-127897.1 UGAGAGAAGUCCACCACGAGUCU 265  250_272 AD-63939.2 A-127909.1 ACUCGUGGUGGACUUCUCUCA  50 A-127906.3 UGAGAGAAGUCCACCACGAGUCU 266  250_272 AD-63940.2 A-127917.1 ACUCGUGGUGGACUUCTCUCA  51 A-127906.11 UGAGAGAAGUCCACCACGAGUCU 267  250_272 AD-63941.2 A-127905.8 ACUCGUGGUGGACUUCUCUCA  52 A-127925.1 UGAGAGAAGUCCACCACGAGUCU 268  250_272 AD-63942.2 A-127933.1 UCGUGGUGGACUUCUCUCA  53 A-127934.1 UGAGAGAAGUCCACCACGAGU 269  252_274 AD-63943.2 A-127944.2 ACUCGUGGUGGACUUCUCUCA  54 A-127942.2 UGAGAGAAGUCCACCACGAGUCU 270  250_272 AD-63945.2 A-127910.1 ACUCGUGGUGGACUUCUCUCA  55 A-127906.4 UGAGAGAAGUCCACCACGAGUCU 271  250_272 AD-63946.2 A-127918.1 ACUCGUGGUGGACUUCUCUCA  56 A-127906.12 UGAGAGAAGUCCACCACGAGUCU 272  250_272 AD-63947.2 A-127905.9 ACUCGUGGUGGACUUCUCUCA  57 A-127926.1 UGAGAGAAGUCCACCACGAGUCU 273  250_272 AD-63948.2 A-127935.1 GUGGUGGACUUCUCUCA  58 A-127936.1 UGAGAGAAGUCCACCACGA 274  254_276 AD-63949.2 A-127944.3 ACUCGUGGUGGACUUCUCUCA  59 A-127906.14 UGAGAGAAGUCCACCACGAGUCU 275  250_272 AD-63950.2 A-127900.1 UCGUGGUGGACUUCUCUCAUU  60 A-127901.1 UGAGAGAAGUCCACCACGAUU 276  252_274 AD-63951.2 A-127911.1 ACUCGUGGUGGACUUCUCUCA  61 A-127906.5 UGAGAGAAGUCCACCACGAGUCU 277  250_272 AD-63952.2 A-127905.2 ACUCGUGGUGGACUUCUCUCA  62 A-127919.1 UGAGAGAAGUCCACCACGAGUCU 278  250_272 AD-63953.2 A-127905.10 ACUCGUGGUGGACUUCUCUCA  63 A-127927.1 UGAGAGAAGUCCACCACGAGUCU 279  250_272 AD-63955.2 A-127945.1 ACUCGUGGUGGACUUCUCUCA  64 A-127940.3 UGAGAGAAGUCCACCACGAGUCU 280  250_272 AD-63956.2 A-127902.1 UCGUGGUGGACUUCUCUCA  65 A-127903.1 UGAGAGAAGUCCACCACGAUU 281  252_274 AD-63957.2 A-127912.1 ACUCGUGGUGGACUUCUCUCA  66 A-127906.6 UGAGAGAAGUCCACCACGAGUCU 282  250_272 AD-63958.2 A-127905.3 ACUCGUGGUGGACUUCUCUCA  67 A-127920.1 UGAGAGAAGUCCACCACGAGUCU 283  250_272 AD-63959.2 A-127905.11 ACUCGUGGUGGACUUCUCUCA  68 A-127928.1 UGAGAGAAGUCCACCACGAGUCU 284  250_272 AD-63960.2 A-126619.2 UAUUUCCUAGGGUACAA  69 A-127938.1 UGAGAGAAGUCCACCACGA 285  254_276 AD-63961.2 A-127945.2 ACUCGUGGUGGACUUCUCUCA  70 A-127942.3 UGAGAGAAGUCCACCACGAGUCU 286  250_272 AD-63962.2 A-127902.2 UCGUGGUGGACUUCUCUCA  71 A-127904.1 UGAGAGAAGUCCACCACGAUU 287  252_274 AD-63963.2 A-127913.1 ACUCGUGGUGGACUUCUCUCA  72 A-127906.7 UGAGAGAAGUCCACCACGAGUCU 288  250_272 AD-63964.2 A-127905.4 ACUCGUGGUGGACUUCUCUCA  73 A-127921.1 UGAGAGAAGUCCACCACGAGUCU 289  250_272 AD-63965.2 A-127905.12 ACUCGUGGUGGACUUCUCUCA  74 A-127929.1 UGAGAGAAGUCCACCACGAGUCU 290  250_272 AD-63966.2 A-127939.1 ACUCGUGGUGGACUUCUCUCA  75 A-127940.1 UGAGAGAAGUCCACCACGAGUCU 291  250_272 AD-63967.2 A-127945.3 ACUCGUGGUGGACUUCUCUCA  76 A-127906.15 UGAGAGAAGUCCACCACGAGUCU 292  250_272 AD-63968.2 A-127905.1 ACUCGUGGUGGACUUCUCUCA  77 A-127906.1 UGAGAGAAGUCCACCACGAGUCU 293  250_272 AD-63968.4 A-127905.15 ACUCGUGGUGGACUUCUCUCA  78 A-127906.17 UGAGAGAAGUCCACCACGAGUCU 294  250_272 AD-63968.5 A-127905.17 ACUCGUGGUGGACUUCUCUCA  79 A-127906.18 UGAGAGAAGUCCACCACGAGUCU 295  250_272 AD-63969.2 A-127914.1 ACUCGUGGUGGACUUCUCUCA  80 A-127906.8 UGAGAGAAGUCCACCACGAGUCU 296  250_272 AD-63970.2 A-127905.5 ACUCGUGGUGGACUUCUCUCA  81 A-127922.1 UGAGAGAAGUCCACCACGAGUCU 297  250_272 AD-63971.2 A-127905.13 ACUCGUGGUGGACUUCUCUCA  82 A-127930.1 UGAGAGAAGUCCACCACGAGUCU 298  250_272 AD-63972.2 A-127941.1 ACUCGUGGUGGACUUCUCUCA  83 A-127942.1 UGAGAGAAGUCCACCACGAGUCU 299  250_272 AD-63973.2 A-127946.1 ACUCGUGGUGGACUUCUCUCA  84 A-127947.1 UGAGAGAAGTCCACCACGAGUCU 300  250_272 AD-63975.2 A-127915.1 ACUCGUGGUGGACUUCTCUCA  85 A-127906.9 UGAGAGAAGUCCACCACGAGUCU 301  250_272 AD-63976.2 A-127905.6 ACUCGUGGUGGACUUCUCUCA  86 A-127923.1 UGAGAGAAGUCCACCACGAGUCU 302  250_272 AD-63977.2 A-127917.2 ACUCGUGGUGGACUUCTCUCA  87 A-127931.1 UGAGAGAAGUCCACCACGAGUCU 303  250_272 AD-63978.2 A-127943.1 ACUCGUGGUGGACUUCUCUCA  88 A-127906.13 UGAGAGAAGUCCACCACGAGUCU 304  250_272 AD-63979.2 A-127908.1 ACUCGUGGUGGACUUCUCUCA  89 A-127906.2 UGAGAGAAGUCCACCACGAGUCU 305  250_272 AD-63980.2 A-127916.1 ACUCGUGGUGGACUUCTCUCA  90 A-127906.10 UGAGAGAAGUCCACCACGAGUCU 306  250_272 AD-63981.2 A-127905.7 ACUCGUGGUGGACUUCUCUCA  91 A-127924.1 UGAGAGAAGUCCACCACGAGUCU 307  250_272 AD-63982.2 A-127917.3 ACUCGUGGUGGACUUCTCUCA  92 A-127932.1 UGAGAGAAGUCCACCACGAGUCU 308  250_272 AD-63983.2 A-127944.1 ACUCGUGGUGGACUUCUCUCA  93 A-127940.2 UGAGAGAAGUCCACCACGAGUCU 309  250_272 AD-63985.2 A-127961.1 GUGGUGGACUUCUCUCAAUUU  94 A-127956.4 AAAUUGAGAGAAGUCCACCACGA 310  254_276 AD-63986.2 A-127969.1 GUGGUGGACUUCUCUCAAUUU  95 A-127956.12 AAAUUGAGAGAAGUCCACCACGA 311  254_276 AD-63987.2 A-127955.9 GUGGUGGACUUCUCUCAAUUU  96 A-127977.1 AAAUUGAGAGAAGUCCACCACGA 312  254_276 AD-63988.2 A-127986.1 UGGACUUCUCUCAAUUU  97 A-127987.1 AAAUUGAGAGAAGUCCACC 313  258_280 AD-63989.2 A-127996.1 GUGGUGGACUUCUCUCAAUUU  98 A-127992.2 AAAUUGAGAGAAGUCCACCACGA 314  254_276 AD-63990.2 A-127950.1 GGUGGACUUCUCUCAAUUUUU  99 A-127951.1 AAAUUGAGAGAAGUCCACCUU 315  256_278 AD-63991.2 A-127962.1 GUGGUGGACUUCUCUCAAUUU 100 A-127956.5 AAAUUGAGAGAAGUCCACCACGA 316  254_276 AD-63992.2 A-127955.2 GUGGUGGACUUCUCUCAAUUU 101 A-127970.1 AAAUUGAGAGAAGUCCACCACGA 317  254_276 AD-63993.2 A-127955.10 GUGGUGGACUUCUCUCAAUUU 102 A-127978.1 AAAUUGAGAGAAGUCCACCACGA 318  254_276 AD-63994.2 A-127984.2 GGUGGACUUCUCUCAAUUU 103 A-127988.1 AAAUUGAGAGAAGUCCACCAC 319  256_278 AD-63995.2 A-127996.2 GUGGUGGACUUCUCUCAAUUU 104 A-127993.2 AAAUUGAGAGAAGUCCACCACGA 320  254_276 AD-63996.2 A-127952.1 GGUGGACUUCUCUCAAUUU 105 A-127953.1 AAAUUGAGAGAAGUCCACCUU 321  256_278 AD-63997.2 A-127963.1 GUGGUGGACUUCUCUCAAUUU 106 A-127956.6 AAAUUGAGAGAAGUCCACCACGA 322  254_276 AD-63999.2 A-127955.11 GUGGUGGACUUCUCUCAAUUU 107 A-127979.1 AAAUUGAGAGAAGUCCACCACGA 323  254_276 AD-64000.2 A-127986.2 UGGACUUCUCUCAAUUU 108 A-127989.1 AAAUUGAGAGAAGUCCACC 324  258_280 AD-64001.2 A-127996.3 GUGGUGGACUUCUCUCAAUUU 109 A-127994.2 AAAUUGAGAGAAGUCCACCACGA 325  254_276 AD-64002.2 A-127952.2 GGUGGACUUCUCUCAAUUU 110 A-127954.1 AAAUUGAGAGAAGUCCACCUU 326  256_278 AD-64003.2 A-127964.1 GUGGUGGACUUCUCUCAAUUU 111 A-127956.7 AAAUUGAGAGAAGUCCACCACGA 327  254_276 AD-64004.2 A-127955.4 GUGGUGGACUUCUCUCAAUUU 112 A-127972.1 AAAUUGAGAGAAGUCCACCACGA 328  254_276 AD-64005.2 A-127955.12 GUGGUGGACUUCUCUCAAUUU 113 A-127980.1 AAAUUGAGAGAAGUCCACCACGA 329  254_276 AD-64006.2 A-127990.1 GUGGUGGACUUCUCUCAAUUU 114 A-127991.1 AAAUUGAGAGAAGUCCACCACGA 330  254_276 AD-64007.2 A-127996.4 GUGGUGGACUUCUCUCAAUUU 115 A-127995.2 AAAUUGAGAGAAGUCCACCACGA 331  254_276 AD-64008.2 A-127955.1 GUGGUGGACUUCUCUCAAUUU 116 A-127956.1 AAAUUGAGAGAAGUCCACCACGA 332  254_276 AD-64008.4 A-127955.15 GUGGUGGACUUCUCUCAAUUU 117 A-127956.14 AAAUUGAGAGAAGUCCACCACGA 333  254_276 AD-64009.2 A-127965.1 GUGGUGGACUUCUCUCAAUUU 118 A-127956.8 AAAUUGAGAGAAGUCCACCACGA 334  254_276 AD-64010.2 A-127955.5 GUGGUGGACUUCUCUCAAUUU 119 A-127973.1 AAAUUGAGAGAAGUCCACCACGA 335  254_276 AD-64011.2 A-127955.13 GUGGUGGACUUCUCUCAAUUU 120 A-127981.1 AAAUUGAGAGAAGUCCACCACGA 336  254_276 AD-64012.2 A-127990.2 GUGGUGGACUUCUCUCAAUUU 121 A-127992.1 AAAUUGAGAGAAGUCCACCACGA 337  254_276 AD-64013.2 A-127997.1 GUGGUGGACTTCUCUCAAUUU 122 A-127998.1 AAAUUGAGAGAAGTCCACCACGA 338  254_276 AD-64014.2 A-127957.1 GUGGUGGACUUCUCUCAAUUU 123 A-127958.1 AAAUUGAGAGAAGUCCACCACGA 339  254_276 AD-64015.2 A-127966.1 GUGGUGGACUUCUCUCAAUUU 124 A-127956.9 AAAUUGAGAGAAGUCCACCACGA 340  254_276 AD-64016.2 A-127955.6 GUGGUGGACUUCUCUCAAUUU 125 A-127974.1 AAAUUGAGAGAAGUCCACCACGA 341  254_276 AD-64017.2 A-127968.2 GUGGUGGACUTCUCUCAAUUU 126 A-127982.1 AAAUUGAGAGAAGTCCACCACGA 342  254_276 AD-64018.2 A-127990.3 GUGGUGGACUUCUCUCAAUUU 127 A-127993.1 AAAUUGAGAGAAGUCCACCACGA 343  254_276 AD-64019.2 A-127959.1 GUGGUGGACUUCUCUCAAUUU 128 A-127956.2 AAAUUGAGAGAAGUCCACCACGA 344  254_276 AD-64020.2 A-127967.1 GUGGUGGACUUCUCUCAAUUU 129 A-127956.10 AAAUUGAGAGAAGUCCACCACGA 345  254_276 AD-64021.2 A-127955.7 GUGGUGGACUUCUCUCAAUUU 130 A-127975.1 AAAUUGAGAGAAGUCCACCACGA 346  254_276 AD-64022.2 A-127968.3 GUGGUGGACUTCUCUCAAUUU 131 A-127983.1 AAAUUGAGAGAAGTCCACCACGA 347  254_276 AD-64023.2 A-127990.4 GUGGUGGACUUCUCUCAAUUU 132 A-127994.1 AAAUUGAGAGAAGUCCACCACGA 348  254_276 AD-64024.2 A-127960.1 GUGGUGGACUUCUCUCAAUUU 133 A-127956.3 AAAUUGAGAGAAGUCCACCACGA 349  254_276 AD-64025.2 A-127968.1 GUGGUGGACUTCUCUCAAUUU 134 A-127956.11 AAAUUGAGAGAAGUCCACCACGA 350  254_276 AD-64026.2 A-127955.8 GUGGUGGACUUCUCUCAAUUU 135 A-127976.1 AAAUUGAGAGAAGUCCACCACGA 351  254_276 AD-64027.2 A-127984.1 GGUGGACUUCUCUCAAUUU 136 A-127985.1 AAAUUGAGAGAAGUCCACCAC 352  256_278 AD-64028.2 A-127990.5 GUGGUGGACUUCUCUCAAUUU 137 A-127995.1 AAAUUGAGAGAAGUCCACCACGA 353  254_276 AD-64272.2 A-128001.2 GUGCACUUCGCUUCACCUCUG 138 A-128002.2 CAGAGGUGAAGCGAAGUGCACAC 354 1577_1599 AD-64274.1 A-128363.1 GUUGACAAAAAUCCUCACAAU 139 A-128364.1 AUUGUGAGGAUUUUUGUCAACAA 355  215_237 AD-64275.1 A-128377.1 UGUUGACAAAAAUCCUCACAA 140 A-128378.1 UUGUGAGGAUUUUUGUCAACAAG 356  214_236 AD-64276.1 A-128393.1 GGUGGACUUCUCUCAAUUUUA 141 A-128394.1 UAAAAUUGAGAGAAGUCCACCAC 357  256_278 AD-64277.1 A-128407.1 UCUUUUGGAGUGUGGAUUCGA 142 A-128408.1 UCGAAUCCACACUCCAAAAGACA 358 2259_2281 AD-64277.1 A-128407.1 UCUUUUGGAGUGUGGAUUCGA 143 A-128408.1 UCGAAUCCACACUCCAAAAGACA 359 2259_2281 AD-64278.1 A-128423.1 ACUGUUCAAGCCUCCAAGCUA 144 A-128424.1 UAGCUUGGAGGCUUGAACAAGAC 360 1857_1879 AD-64279.1 A-128435.1 UCUGCCGAUCCAUACUGCGGA 145 A-128436.1 UCCGCAGUAUGGAUCGGCAGAGG 361 1255_1277 AD-64280.1 A-128379.1 AUGUGUCUGCGGCGUUUUAUA 146 A-128380.1 UAUAAAACGCCGCAGACACAUCC 362  375_397 AD-64281.1 A-128395.1 CCCCGUCUGUGCCUUCUCAUA 147 A-128396.1 UAUGAGAAGGCACAGACGGGGAG 363 1545_1567 AD-64282.1 A-128409.1 GCCUAAUCAUCUCUUGUUCAU 148 A-128410.1 AUGAACAAGAGAUGAUUAGCGAG 364 1831_1853 AD-64283.1 A-128425.1 UCUAGACUCGUGGUGGACUUC 149 A-128426.1 GAAGUCCACCACGAGUCUAGACU 365  245_267 AD-64284.1 A-128437.1 CUGCCGAUCCAUACUGCGGAA 150 A-128438.1 UUCCGCAGUAUGGAUCGGCAGAG 366 1256_1278 AD-64285.1 A-128365.1 UUUUUCUUGUUGACAAAAAUA 151 A-128366.1 UAUUUUUGUCAACAAGAAAAACC 367  207_229 AD-64286.1 A-128381.1 AUCUUCUUGUUGGUUCUUCUA 152 A-128382.1 UAGAAGAACCAACAAGAAGAUGA 368  426_448 AD-64289.1 A-128367.1 GUUUUUCUUGUUGACAAAAAU 153 A-128368.1 AUUUUUGUCAACAAGAAAAACCC 369  206_228 AD-64290.1 A-128383.1 CUGCCUAAUCAUCUCUUGUUA 154 A-128384.1 UAACAAGAGAUGAUUAGGCAGAG 370 1829_1851 AD-64291.1 A-128399.1 UCCUCACAAUACCACAGAGUA 155 A-128400.1 UACUCUGUGGUAUUGUGAGGAUU 371  226_248 AD-64292.1 A-128413.1 CUUGUUGACAAAAAUCCUCAA 156 A-128414.1 UUGAGGAUUUUUGUCAACAAGAA 372  212_234 AD-64293.1 A-128439.1 GCAACUUUUUCACCUCUGCCU 157 A-128440.1 AGGCAGAGGUGAAAAAGUUGCAU 373 1814_1836 AD-64294.1 A-128369.1 GGGAACAAGAGCUACAGCAUA 158 A-128370.1 UAUGCUGUAGCUCUUGUUCCCAA 374 2828_2850 AD-64295.1 A-128385.1 CGUGGUGGACUUCUCUCAAUU 159 A-128386.1 AAUUGAGAGAAGUCCACCAGCAG 375  253_275 AD-64297.1 A-128415.1 CUGCUGCUAUGCCUCAUCUUA 160 A-128416.1 UAAGAUGAGGCAUAGCAGCAGGA 376  411_433 AD-64298.1 A-128427.1 GUUGGAUGUGUCUGCGGCGUU 161 A-128428.1 AACGCCGCAGACACAUCCAACGA 377  370_392 AD-64299.1 A-128441.1 UUCAUCCUGCUGCUAUGCCUA 162 A-128442.1 UAGGCAUAGCAGCAGGAUGAAGA 378  405_427 AD-64300.1 A-128371.1 UUCUUGUUGACAAAAAUCCUA 163 A-128372.1 UAGGAUUUUUGUCAACAAGAAAA 379  210_232 AD-64302.1 A-128417.1 UAUAUGGAUGAUGUGGUAUUA 164 A-128418.1 UAAUACCACAUCAUCCAUAUAAC 380  734_756 AD-64303.1 A-128429.1 UUCAUCCUGCUGCUAUGCCUC 165 A-128430.1 GAGGCAUAGCAGCAGGAUGAAGA 381  405_427 AD-64304.1 A-128443.1 GUGCACUUCGCUUCACCUCUA 166 A-128444.1 UAGAGGUGAAGCGAAGUGCACAC 382 1577_1599 AD-64305.1 A-128373.1 UUGACAAAAAUCCUCACAAUA 167 A-128374.1 UAUUGUGAGGAUUUUUGUCAACA 383  216_238 AD-64307.1 A-128403.1 AAGCCUCCAAGCUGUGCCUUA 168 A-128404.1 UAAGGCACAGCUUGGAGGCUUGA 384 1864_1886 AD-64308.1 A-128419.1 CCUCUUCAUCCUGCUGCUAUA 169 A-128420.1 UAUAGCAGCAGGAUGAAGAGGAA 385  401_423 AD-64309.1 A-128431.1 CCUGCUGCUAUGCCUCAUCUU 170 A-128432.1 AAGAUGAGGCAUAGCAGCAGGAU 386  410_432 AD-64310.1 A-128375.1 CAUCUUCUUGUUGGUUCUUCU 171 A-128376.1 AGAAGAACCAACAAGAAGAUGAG 387  425_447 AD-64311.1 A-128391.1 CCGUCUGUGCCUUCUCAUCUA 172 A-128392.1 UAGAUGAGAAGGCACAGACGGGG 388 1547_1569 AD-64312.1 A-128405.1 CCUCAUCUUCUUGUUGGUUCU 173 A-128406.1 AGAACCAACAAGAAGAUGAGGCA 389  422_444 AD-64313.1 A-128421.1 CCACCAAAUGCCCCUAUCUUA 174 A-128422.1 UAAGAUAGGGGCAUUUGGUGGUC 390 2298_2320 AD-64314.1 A-128433.1 GCUCCUCUGCCGAUCCAUACU 175 A-128434.1 AGUAUGGAUCGGCAGAGGAGCCA 391 1250_1272 AD-64315.1 A-128363.2 GUUGACAAAAAUCCUCACAAU 176 A-128445.1 AUUGUGAGGAUUUUUGUCAACAA 392  215_237 AD-64316.1 A-128377.2 UGUUGACAAAAAUCCUCACAA 177 A-128453.1 UUGUGAGGAUUUUUGUCAACAAG 393  214_236 AD-64317.1 A-128393.2 GGUGGACUUCUCUCAAUUUUA 178 A-128461.1 UAAAAUUGAGAGAAGUCCACCAC 394  256_278 AD-64318.1 A-128407.2 UCUUUUGGAGUGUGGAUUCGA 179 A-128469.1 UCGAAUCCACACUCCAAAAGACA 395 2259_2281 AD-64318.1 A-128407.2 UCUUUUGGAGUGUGGAUUCGA 180 A-128469.1 UCGAAUCCACACUCCAAAAGACA 396 2259_2281 AD-64319.1 A-128423.2 ACUGUUCAAGCCUCCAAGCUA 181 A-128477.1 UAGCUUGGAGGCUUGAACAAGAC 397 1857_1879 AD-64320.1 A-128435.2 UCUGCCGAUCCAUACUGCGGA 182 A-128483.1 UCCGCAGUAUGGAUCGGCAGAGG 398 1255_1277 AD-64321.1 A-123463.3 AGUUAUAUGGAUGAUGUGGUA 183 A-128446.1 UACCACAUCAUCCAUAUAACUGA 399  731_753 AD-64322.1 A-128379.2 AUGUGUCUGCGGCGUUUUAUA 184 A-128454.1 UAUAAAACGCCGCAGACACAUCC 400  375_397 AD-64323.1 A-128395.2 CCCCGUCUGUGCCUUCUCAUA 185 A-128462.1 UAUGAGAAGGCACAGACGGGGAG 401 1545_1567 AD-64324.1 A-128409.2 GCCUAAUCAUCUCUUGUUCAU 186 A-128470.1 AUGAACAAGAGAUGAUUAGCGAG 402 1831_1853 AD-64325.1 A-128425.2 UCUAGACUCGUGGUGGACUUC 187 A-128478.1 GAAGUCCACCACGAGUCUAGACU 403  245_267 AD-64326.1 A-128437.2 CUGCCGAUCCAUACUGCGGAA 188 A-128484.1 UUCCGCAGUAUGGAUCGGCAGAG 404 1256_1278 AD-64328.1 A-128381.2 AUCUUCUUGUUGGUUCUUCUA 189 A-128455.1 UAGAAGAACCAACAAGAAGAUGA 405  426_448 AD-64330.1 A-128411.2 UUCUCUCAAUUUUCUAGGGGA 190 A-128471.1 UCCCCUAGAAAAUUGAGAGAAGU 406  263_285 AD-64331.1 A-127905.16 ACUCGUGGUGGACUUCUCUCA 191 A-127907.2 UGAGAGAAGUCCACCACGAGUCU 407  250_272 AD-64332.1 A-128001.3 GUGCACUUCGCUUCACCUCUG 192 A-128485.1 CAGAGGUGAAGCGAAGUGCACAC 408 1577_1599 AD-64333.1 A-128367.2 GUUUUUCUUGUUGACAAAAAU 193 A-128448.1 AUUUUUGUCAACAAGAAAAACCC 409  206_228 AD-64334.1 A-128383.2 CUGCCUAAUCAUCUCUUGUUA 194 A-128456.1 UAACAAGAGAUGAUUAGGCAGAG 410 1829_1851 AD-64335.1 A-128399.2 UCCUCACAAUACCACAGAGUA 195 A-128464.1 UACUCUGUGGUAUUGUGAGGAUU 411  226_248 AD-64336.1 A-128413.2 CUUGUUGACAAAAAUCCUCAA 196 A-128472.1 UUGAGGAUUUUUGUCAACAAGAA 412  212_234 AD-64337.1 A-127955.16 GUGGUGGACUUCUCUCAAUUU 197 A-127958.2 AAAUUGAGAGAAGUCCACCACGA 413  254_276 AD-64338.1 A-128439.2 GCAACUUUUUCACCUCUGCCU 198 A-128486.1 AGGCAGAGGUGAAAAAGUUGCAU 414 1814_1836 AD-64339.1 A-128369.2 GGGAACAAGAGCUACAGCAUA 199 A-128449.1 UAUGCUGUAGCUCUUGUUCCCAA 415 2828_2850 AD-64341.1 A-128401.2 UCAUCUUCUUGUUGGUUCUUA 200 A-128465.1 UAAGAACCAACAAGAAGAUGAGG 416  424_446 AD-64342.1 A-128415.2 CUGCUGCUAUGCCUCAUCUUA 201 A-128473.1 UAAGAUGAGGCAUAGCAGCAGGA 417  411_433 AD-64343.1 A-128427.2 GUUGGAUGUGUCUGCGGCGUU 202 A-128479.1 AACGCCGCAGACACAUCCAACGA 418  370_392 AD-64344.1 A-128441.2 UUCAUCCUGCUGCUAUGCCUA 203 A-128487.1 UAGGCAUAGCAGCAGGAUGAAGA 419  405_427 AD-64345.1 A-128371.2 UUCUUGUUGACAAAAAUCCUA 204 A-128450.1 UAGGAUUUUUGUCAACAAGAAAA 420  210_232 AD-64347.1 A-123487.3 GGAUGUGUCUGCGGCGUUUUA 205 A-128466.1 UAAAACGCCGCAGACACAUCCAG 421  373_395 AD-64348.1 A-128417.2 UAUAUGGAUGAUGUGGUAUUA 206 A-128474.1 UAAUACCACAUCAUCCAUAUAAC 422  734_756 AD-64349.1 A-128429.2 UUCAUCCUGCUGCUAUGCCUC 207 A-128480.1 GAGGCAUAGCAGCAGGAUGAAGA 423  405_427 AD-64350.1 A-128443.2 GUGCACUUCGCUUCACCUCUA 208 A-128488.1 UAGAGGUGAAGCGAAGUGCACAC 424 1577_1599 AD-64351.1 A-128373.2 UUGACAAAAAUCCUCACAAUA 209 A-128451.1 UAUUGUGAGGAUUUUUGUCAACA 425  216_238 AD-64352.1 A-128389.2 CCAAGUGUUUGCUGACGCAAA 210 A-128459.1 UUUGCGUCAGCAAACACUUGGCA 426 1174_1196 AD-64352.1 A-128389.2 CCAAGUGUUUGCUGACGCAAA 211 A-128459.1 UUUGCGUCAGCAAACACUUGGCA 427 1174_1196 AD-64353.1 A-128403.2 AAGCCUCCAAGCUGUGCCUUA 212 A-128467.1 UAAGGCACAGCUUGGAGGCUUGA 428 1864_1886 AD-64354.1 A-128419.2 CCUCUUCAUCCUGCUGCUAUA 213 A-128475.1 UAUAGCAGCAGGAUGAAGAGGAA 429  401_423 AD-64355.1 A-128431.2 CCUGCUGCUAUGCCUCAUCUU 214 A-128481.1 AAGAUGAGGCAUAGCAGCAGGAU 430  410_432 AD-64356.1 A-128375.2 CAUCUUCUUGUUGGUUCUUCU 215 A-128452.1 AGAAGAACCAACAAGAAGAUGAG 431  425_447 AD-64357.1 A-128391.2 CCGUCUGUGCCUUCUCAUCUA 216 A-128460.1 UAGAUGAGAAGGCACAGACGGGG 432 1547_1569 AD-64358.1 A-128405.2 CCUCAUCUUCUUGUUGGUUCU 217 A-128468.1 AGAACCAACAAGAAGAUGAGGCA 433  422_444 AD-64359.1 A-128421.2 CCACCAAAUGCCCCUAUCUUA 218 A-128476.1 UAAGAUAGGGGCAUUUGGUGGUC 434 2298_2320 AD-64360.1 A-128433.2 GCUCCUCUGCCGAUCCAUACU 219 A-128482.1 AGUAUGGAUCGGCAGAGGAGCCA 435 1250_1272 AD-64700.1 A-129379.1 ACUCGUGGUGTACUUCUCUCA 220 A-127906.26 UGAGAGAAGUCCACCACGAGUCU 436  250_272 AD-64701.1 A-127905.20 ACUCGUGGUGGACUUCUCUCA 221 A-129387.1 UGAGAGAAGTCCACCACGAGUCU 437  250_272 AD-64702.1 A-127905.28 ACUCGUGGUGGACUUCUCUCA 222 A-129395.1 UGAGAGAAGUCCACCACGAGUCU 438  250_272 AD-64703.1 A-129376.2 ACUCGUGGUGGACUUCACUCA 223 A-129385.5 UGAGAGAAGTCCACCACGAGUCU 439  250_272 AD-64704.1 A-129381.3 ACUCGUGGTGTACUUCACUCA 224 A-129389.6 UGAGAGAAGUCCACCACGAGUCU 440  250_272 AD-64705.1 A-129380.1 ACUCGUGGUGTACUUCACUCA 225 A-127906.27 UGAGAGAAGUCCACCACGAGUCU 441  250_272 AD-64706.1 A-127905.21 ACUCGUGGUGGACUUCUCUCA 226 A-129388.1 UGAGAGAAGUCCACCACGAGUCU 442  250_272 AD-64707.1 A-127905.29 ACUCGUGGUGGACUUCUCUCA 227 A-129396.1 UGAGAGAAGTCCACCACGAGUCU 443  250_272 AD-64708.1 A-129382.2 ACUCGUGGTGGACUUCTCUCA 228 A-129385.6 UGAGAGAAGTCCACCACGAGUCU 444  250_272 AD-64709.1 A-129373.4 ACUCGUGGUGGACUUCUCUCA 229 A-129391.2 UGAGAGAAGTCCACCACGAGUCU 445  250_272 AD-64710.1 A-129373.1 ACUCGUGGUGGACUUCUCUCA 230 A-127906.20 UGAGAGAAGUCCACCACGAGUCU 446  250_272 AD-64711.1 A-129381.1 ACUCGUGGTGTACUUCACUCA 231 A-127906.28 UGAGAGAAGUCCACCACGAGUCU 447  250_272 AD-64712.1 A-127905.22 ACUCGUGGUGGACUUCUCUCA 232 A-129389.1 UGAGAGAAGUCCACCACGAGUCU 448  250_272 AD-64713.1 A-127905.30 ACUCGUGGUGGACUUCUCUCA 233 A-129397.1 UGAGAGAAGTCCACCACGAGUCU 449  250_272 AD-64714.1 A-129384.2 ACUCGUGGTGGACUUCACUCA 234 A-129385.7 UGAGAGAAGTCCACCACGAGUCU 450  250_272 AD-64715.1 A-129376.4 ACUCGUGGUGGACUUCACUCA 235 A-129391.3 UGAGAGAAGTCCACCACGAGUCU 451  250_272 AD-64716.1 A-129374.1 ACUCGUGGUGGACUUCUCUCA 236 A-127906.21 UGAGAGAAGUCCACCACGAGUCU 452  250_272 AD-64717.1 A-129382.1 ACUCGUGGTGGACUUCTCUCA 237 A-127906.29 UGAGAGAAGUCCACCACGAGUCU 453  250_272 AD-64718.1 A-127905.23 ACUCGUGGUGGACUUCUCUCA 238 A-129390.1 UGAGAGAAGUCCACCACGAGUCU 454  250_272 AD-64719.1 A-127917.5 ACUCGUGGUGGACUUCTCUCA 239 A-129385.2 UGAGAGAAGTCCACCACGAGUCU 455  250_272 AD-64720.1 A-129381.2 ACUCGUGGTGTACUUCACUCA 240 A-129385.8 UGAGAGAAGTCCACCACGAGUCU 456  250_272 AD-64721.1 A-129382.4 ACUCGUGGTGGACUUCTCUCA 241 A-129391.4 UGAGAGAAGTCCACCACGAGUCU 457  250_272 AD-64722.1 A-129375.1 ACUCGUGGUGGACUUCCUCA 242 A-127906.22 UGAGAGAAGUCCACCACGAGUCU 458  250_272 AD-64723.1 A-129383.1 ACUCGUGGUGGACUUCTCUCA 243 A-127906.30 UGAGAGAAGUCCACCACGAGUCU 459  250_272 AD-64725.1 A-127917.6 ACUCGUGGUGGACUUCTCUCA 244 A-129398.1 UGAGAGAAGTCCACCACGAGUCU 460  250_272 AD-64726.1 A-129373.3 ACUCGUGGUGGACUUCUCUCA 245 A-129389.2 UGAGAGAAGUCCACCACGAGUCU 461  250_272 AD-64727.1 A-129384.4 ACUCGUGGTGGACUUCACUCA 246 A-129391.5 UGAGAGAAGTCCACCACGAGUCU 462  250_272 AD-64728.1 A-129376.1 ACUCGUGGUGGACUUCACUCA 247 A-127906.23 UGAGAGAAGUCCACCACGAGUCU 463  250_272 AD-64729.1 A-129384.1 ACUCGUGGTGGACUUCACUCA 248 A-127906.31 UGAGAGAAGUCCACCACGAGUCU 464  250_272 AD-64730.1 A-127905.25 ACUCGUGGUGGACUUCUCUCA 249 A-129392.1 UGAGAGAAGTCCACCACGAGUCU 465  250_272 AD-64731.1 A-129399.1 ACUCGUGGUGGACUUCTCUCA 250 A-129385.3 UGAGAGAAGTCCACCACGAGUCU 466  250_272 AD-64732.1 A-129376.3 ACUCGUGGUGGACUUCACUCA 251 A-129389.3 UGAGAGAAGUCCACCACGAGUCU 467  250_272 AD-64733.1 A-129381.4 ACUCGUGGTGTACUUCACUCA 252 A-129391.6 UGAGAGAAGTCCACCACGAGUCU 468  250_272 AD-64734.1 A-129377.1 ACUCGUGGUGGACUUCCCUCA 253 A-127906.24 UGAGAGAAGUCCACCACGAGUCU 469  250_272 AD-64735.1 A-127905.18 ACUCGUGGUGGACUUCUCUCA 254 A-129385.1 UGAGAGAAGTCCACCACGAGUCU 470  250_272 AD-64736.1 A-127905.26 ACUCGUGGUGGACUUCUCUCA 255 A-129393.1 UGAGAGAAGTCCACCACGAGUCU 471  250_272 AD-64737.1 A-129399.2 ACUCGUGGUGGACUUCTCUCA 256 A-129398.2 UGAGAGAAGTCCACCACGAGUCU 472  250_272 AD-64738.1 A-129382.3 ACUCGUGGTGGACUUCTCUCA 257 A-129389.4 UGAGAGAAGUCCACCACGAGUCU 473  250_272 AD-64739.1 A-129378.1 ACUCGUGGUGGACUUCGCUCA 258 A-127906.25 UGAGAGAAGUCCACCACGAGUCU 474  250_272 AD-64740.1 A-127905.19 ACUCGUGGUGGACUUCUCUCA 259 A-129386.1 UGAGAGAAGTCCACCACGAGUCU 475  250_272 AD-64741.1 A-127905.27 ACUCGUGGUGGACUUCUCUCA 260 A-129394.1 UGAGAGAAGTCCACCACGAGUCU 476  250_272 AD-64742.1 A-129373.2 ACUCGUGGUGGACUUCUCUCA 261 A-129385.4 UGAGAGAAGTCCACCACGAGUCU 477  250_272 AD-64743.1 A-129384.3 ACUCGUGGTGGACUUCACUCA 262 A-129389.5 UGAGAGAAGUCCACCACGAGUCU 478  250_272

TABLE 4 Modified Sense and Antisense Strand Sequences of HBV dsRNAs Sense SEQ Antisense SEQ Duplex Oligo Sense Sequence ID Oligo Antisense Sequence ID Name Name (5′ to 3′) NO: Name (5′ to 3′) NO: AD-61522.2 A-123463.2 AfsgsUfuAfuAfuGfGfAfu 479 A-123464.2 usAfscCfaCfaUfcAfuc 694 GfaUfgUfgGfuAfL96 cAfuAfuAfaCfusgsa AD-61547.2 A-123487.2 GfsgsAfuGfuGfuCfUfGfc 480 A-123488.2 usAfsaAfaCfgCfcGfca 695 GfgCfgUfuUfuAfL96 gAfcAfcAfuCfcsasg AD-63938.2 A-127896.1 Y44ACUCGUGGUGGACUUCUC 481 A-127897.1 UGAGAGAAGUCCACCACGA 696 UCA GUCU AD-63939.2 A-127909.1 ascsucGfuGfgUfGfGfaCf 482 A-127906.3 usGfsaGfaGfaAfgUfcc 697 uucUfcucaL96 aCfcAfcGfaGfuscsu AD-63940.2 A-127917.1 ascsucguggugdGacuuc 483 A-127906.11 usGfsaGfaGfaAfgUfcc 698 (Tgn)cucaL96 aCfcAfcGfaGfuscsu AD-63941.2 A-127905.8 AfscsUfcGfuGfgUfGfGfa 484 A-127925.1 usGfsaGfagaAfguccaC 699 CfuUfcUfcUfcAfL96 fcAfcgaGfuscsu AD-63942.2 A-127933.1 uscsGfuGfgUfGfGfaCfuU 485 A-127934.1 usGfsaGfaGfaAfgUfcc 700 fcUfcUfcAfL96 aCfcAfcGfasgsu AD-63943.2 A-127944.2 ascsucGfuGfguGfGfaCfu 486 A-127942.2 usGfsAfgaGfaAfgUfcc 701 ucucucaL96 aCfcAfcGfaguscsu AD-63945.2 A-127910.1 ascsucguGfgUfGfGfaCfu 487 A-127906.4 usGfsaGfaGfaAfgUfcc 702 ucUfcucaL96 aCfcAfcGfaGfuscsu AD-63946.2 A-127918.1 ascsucguGfgUfGfGfacuu 488 A-127906.12 usGfsaGfaGfaAfgUfcc 703 CfucucaL96 aCfcAfcGfaGfuscsu AD-63947.2 A-127905.9 AfscsUfcGfuGfgUfGfGfa 489 A-127926.1 usGfsaGfagaagUfccaC 704 CfuUfcUfcUfcAfL96 fcAfcgaGfuscsu AD-63948.2 A-127935.1 gsusGfgUfGfGfaCfuUfcU 490 A-127936.1 usGfsaGfaGfaAfgUfcc 705 fcUfcAfL96 aCfcAfcsgsa AD-63949.2 A-127944.3 ascsucGfuGfguGfGfaCfu 491 A-127906.14 usGfsaGfaGfaAfgUfcc 706 ucucucaL96 aCfcAfcGfaGfuscsu AD-63950.2 A-127900.1 Y44UfcGfuGfgUfgGfaCfu 492 A-127901.1 usGfsasGfaGfaAfgUfc 707 UfcUfcUfcAfusuY44 CfaCfcAfcGfausu AD-63951.2 A-127911.1 ascsucguGfgUfGfGfaCfu 493 A-127906.5 usGfsaGfaGfaAfgUfcc 708 ucucucaL96 aCfcAfcGfaGfuscsu AD-63952.2 A-127905.2 AfscsUfcGfuGfgUfGfGfa 494 A-127919.1 usGfsaGfaGfaagUfcca 709 CfuUfcUfcUfcAfL96 CfcAfcGfaGfuscsu AD-63953.2 A-127905.10 AfscsUfcGfuGfgUfGfGfa 495 A-127927.1 usGfsagagaAfgUfccaC 710 CfuUfcUfcUfcAfL96 fcAfcgaguscsu AD-63955.2 A-127945.1 ascsucgugguGfGfacuucu 496 A-127940.3 usGfsAfgAfgAfaGfucc 711 cucaL96 aCfCfaCfgAfguscsu AD-63956.2 A-127902.1 Y44uscsGfuGfgUfgGfaCf 497 A-127903.1 usGfsaGfaGfaAfgUfcC 712 uUfcUfcUfcAfY44 faCfcAfcGfasusu AD-63957.2 A-127912.1 ascsucguGfgUfGfGfacuu 498 A-127906.6 usGfsaGfaGfaAfgUfcc 713 cucucaL96 aCfcAfcGfaGfuscsu AD-63958.2 A-127905.3 AfscsUfcGfuGfgUfGfGfa 499 A-127920.1 usGfsagaGfaAfgUfcca 714 CfuUfcUfcUfcAfL96 CfcAfcgaGfuscsu AD-63959.2 A-127905.11 AfscsUfcGfuGfgUfGfGfa 500 A-127928.1 usGfsaGfagaAfguccaC 715 CfuUfcUfcUfcAfL96 fcAfcgaguscsu AD-63960.2 A-126619.2 usasUfuUfCfCfuAfgGfgU 501 A-127938.1 PusGfsaGfaGfaAfgUfc 716 faCfaAfL96 caCfcAfcsgsa AD-63961.2 A-127945.2 ascsucgugguGfGfacuucu 502 A-127942.3 usGfsAfgaGfaAfgUfcc 717 cucaL96 aCfcAfcGfaguscsu AD-63962.2 A-127902.2 Y44uscsGfuGfgUfgGfaCf 503 A-127904.1 PusGfsaGfaGfaAfgUfc 718 uUfcUfcUfcAfY44 CfaCfcAfcGfasusu AD-63963.2 A-127913.1 ascsucguggUfgGfacuucu 504 A-127906.7 usGfsaGfaGfaAfgUfcc 719 cucaL96 aCfcAfcGfaGfuscsu AD-63964.2 A-127905.4 AfscsUfcGfuGfgUfGfGfa 505 A-127921.1 usGfsaGfaGfaAfgUfcc 720 CfuUfcUfcUfcAfL96 aCfcAfcgaguscsu AD-63965.2 A-127905.12 AfscsUfcGfuGfgUfGfGfa 506 A-127929.1 usGfsagaGfaaGfuccaC 721 CfuUfcUfcUfcAfL96 fcAfcgaguscsu AD-63966.2 A-127939.1 ascsUfcGfugguGfGfaCfu 507 A-127940.1 usGfsAfgAfgAfaGfucc 722 uCfuCfucaL96 aCfCfaCfgAfguscsu AD-63967.2 A-127945.3 ascsucgugguGfGfacuucu 508 A-127906.15 usGfsaGfaGfaAfgUfcc 723 cucaL96 aCfcAfcGfaGfuscsu AD-63968.2 A-127905.1 AfscsUfcGfuGfgUfGfGfa 509 A-127906.1 usGfsaGfaGfaAfgUfcc 724 CfuUfcUfcUfcAfL96 aCfcAfcGfaGfuscsu AD-63968.4 A-127905.15 AfscsUfcGfuGfgUfGfGfa 510 A-127906.17 usGfsaGfaGfaAfgUfcc 725 CfuUfcUfcUfcAfL96 aCfcAfcGfaGfuscsu AD-63968.5 A-127905.17 AfscsUfcGfuGfgUfGfGfa 511 A-127906.18 usGfsaGfaGfaAfgUfcc 726 CfuUfcUfcUfcAfL96 aCfcAfcGfaGfuscsu AD-63969.2 A-127914.1 ascsucguggugGfacuucuc 512 A-127906.8 usGfsaGfaGfaAfgUfcc 727 ucaL96 aCfcAfcGfaGfuscsu AD-63970.2 A-127905.5 AfscsUfcGfuGfgUfGfGfa 513 A-127922.1 usGfsagaGfaagUfccaC 728 CfuUfcUfcUfcAfL96 fcAfcgaGfuscsu AD-63971.2 A-127905.13 AfscsUfcGfuGfgUfGfGfa 514 A-127930.1 usGfsagaGfaaguccaCf 729 CfuUfcUfcUfcAfL96 cAfcgaguscsu AD-63972.2 A-127941.1 ascsUfcGfuGfguGfGfaCf 515 A-127942.1 usGfsAfgaGfaAfgUfcc 730 uuCfuCfucaL96 aCfcAfcGfaguscsu AD-63973.2 A-127946.1 ascsucguggudGdGacuucu 516 A-127947.1 usdGsaGfaGfaAfgdTcc 731 cucaL96 adCcAfcGfaguscsu AD-63975.2 A-127915.1 ascsucguggUfgGfacuuc 517 A-127906.9 usGfsaGfaGfaAfgUfcc 732 (Tgn)cucaL96 aCfcAfcGfaGfuscsu AD-63976.2 A-127905.6 AfscsUfcGfuGfgUfGfGfa 518 A-127923.1 usGfsagaGfaAfgUfcca 733 CfuUfcUfcUfcAfL96 CfcAfcgaguscsu AD-63977.2 A-127917.2 ascsucguggugdGacuuc 519 A-127931.1 usdGsagagaaguccadCc 734 (Tgn)cucaL96 acgaguscsu AD-63978.2 A-127943.1 ascsUfcGfuGfguGfGfaCf 520 A-127906.13 usGfsaGfaGfaAfgUfcc 735 uUfcUfcUfcaL96 aCfcAfcGfaGfuscsu AD-63979.2 A-127908.1 ascsucGfuGfgUfGfGfaCf 521 A-127906.2 usGfsaGfaGfaAfgUfcc 736 uucUfcucAfL96 aCfcAfcGfaGfuscsu AD-63980.2 A-127916.1 ascsucguggugGfacuuc 522 A-127906.10 usGfsaGfaGfaAfgUfcc 737 (Tgn)cucaL96 aCfcAfcGfaGfuscsu AD-63981.2 A-127905.7 AfscsUfcGfuGfgUfGfGfa 523 A-127924.1 usGfsaGfagaAfgUfcca 738 CfuUfcUfcUfcAfL96 CfcAfcgaGfuscsu AD-63982.2 A-127917.3 ascsucguggugdGacuuc 524 A-127932.1 PusdGsagagaaguccadC 739 (Tgn)cucaL96 cacgaguscsu AD-63983.2 A-127944.1 ascsucGfuGfguGfGfaCfu 525 A-127940.2 usGfsAfgAfgAfaGfucc 740 ucucucaL96 aCfCfaCfgAfguscsu AD-63985.2 A-127961.1 gsusggugGfaCfUfUfcUfc 526 A-127956.4 asAfsaUfuGfaGfaGfaa 741 ucAfauuuL96 gUfcCfaCfcAfcsgsa AD-63986.2 A-127969.1 gsusggugGfaCfUfUfcucu 527 A-127956.12 asAfsaUfuGfaGfaGfaa 742 CfaauuuL96 gUfcCfaCfcAfcsgsa AD-63987.2 A-127955.9 GfsusGfgUfgGfaCfUfUfc 528 A-127977.1 asAfsaUfugagaGfaagU 743 UfcUfcAfaUfuUfL96 fcCfaccAfcsgsa AD-63988.2 A-127986.1 usgsGfaCfUfUfcUfcUfcA 529 A-127987.1 asAfsaUfuGfaGfaGfaa 744 faUfuUfL96 gUfcCfascsc AD-63989.2 A-127996.1 gsusgguggacUfUfcucuca 530 A-127992.2 asAfsAfUfuGfaGfaGfa 745 auuuL96 agUfcCfaCfcacsgsa AD-63990.2 A-127950.1 Y44GfgUfgGfaCfuUfcUfc 531 A-127951.1 asAfsasUfuGfaGfaGfa 746 UfcAfaUfuUfusuY44 AfgUfcCfaCfcusu AD-63991.2 A-127962.1 gsusggugGfaCfUfUfcUfc 532 A-127956.5 asAfsaUfuGfaGfaGfaa 747 ucaauuuL96 gUfcCfaCfcAfcsgsa AD-63992.2 A-127955.2 GfsusGfgUfgGfaCfUfUfc 533 A-127970.1 asAfsaUfuGfagaGfaag 748 UfcUfcAfaUfuUfL96 UfcCfaCfcAfcsgsa AD-63993.2 A-127955.10 GfsusGfgUfgGfaCfUfUfc 534 A-127978.1 asAfsauugaGfaGfaagU 749 UfcUfcAfaUfuUfL96 fcCfaccacsgsa AD-63994.2 A-127984.2 gsgUfgGfaCfUfUfcUfcUf 535 A-127988.1 PasAfsaUfuGfaGfaGfa 750 cAfaUfuUfL96 agUfcCfaCfcsasc AD-63995.2 A-127996.2 gsusgguggacUfUfcucuca 536 A-127993.2 asAfsAfuuGfaGfaGfaa 751 auuuL96 gUfCfcaCfcacsgsa AD-63996.2 A-127952.1 Y44gsgsUfgGfaCfuUfcUf 537 A-127953.1 asAfsaUfuGfaGfaGfaA 752 cUfcAfaUfuUfY44 fgUfcCfaCfcsusu AD-63997.2 A-127963.1 gsusggugGfaCfUfUfcucu 538 A-127956.6 asAfsaUfuGfaGfaGfaa 753 caauuuL96 gUfcCfaCfcAfcsgsa AD-63999.2 A-127955.11 GfsusGfgUfgGfaCfUfUfc 539 A-127979.1 asAfsaUfugaGfagaagU 754 UfcUfcAfaUfuUfL96 fcCfaccacsgsa AD-64000.2 A-127986.2 usgsGfaCfUfUfcUfcUfcA 540 A-127989.1 PasAfsaUfuGfaGfaGfa 755 faUfuUfL96 agUfcCfascsc AD-64001.2 A-127996.3 gsusgguggacUfUfcucuca 541 A-127994.2 asAfsAfUfuGfaGfaGfa 756 auuuL96 agUfCfcaCfcacsgsa AD-64002.2 A-127952.2 Y44gsgsUfgGfaCfuUfcUf 542 A-127954.1 PasAfsaUfuGfaGfaGfa 757 cUfcAfaUfuUfY44 AfgUfcCfaCfcsusu AD-64003.2 A-127964.1 gsusgguggaCfuUfcucuca 543 A-127956.7 asAfsaUfuGfaGfaGfaa 758 auuuL96 gUfcCfaCfcAfcsgsa AD-64004.2 A-127955.4 GfsusGfgUfgGfaCfUfUfc 544 A-127972.1 asAfsaUfuGfaGfaGfaa 759 UfcUfcAfaUfuUfL96 gUfcCfaccacsgsa AD-64005.2 A-127955.12 GfsusGfgUfgGfaCfUfUfc 545 A-127980.1 asAfsauuGfagAfgaagU 760 UfcUfcAfaUfuUfL96 fcCfaccacsgsa AD-64006.2 A-127990.1 gsusGfgugGfaCfUfUfcUf 546 A-127991.1 asAfsaUfuGfaGfaGfaa 761 cUfcAfaUfuuL96 gUfcCfaCfcacsgsa AD-64007.2 A-127996.4 gsusgguggacUfUfcucuca 547 A-127995.2 asAfsAfUfugaGfaGfaa 762 auuuL96 gUfCfcaCfcacsgsa AD-64008.2 A-127955.1 GfsusGfgUfgGfaCfUfUfc 548 A-127956.1 asAfsaUfuGfaGfaGfaa 763 UfcUfcAfaUfuUfL96 gUfcCfaCfcAfcsgsa AD-64008.4 A-127955.15 GfsusGfgUfgGfaCfUfUfc 549 A-127956.14 asAfsaUfuGfaGfaGfaa 764 UfcUfcAfaUfuUfL96 gUfcCfaCfcAfcsgsa AD-64009.2 A-127965.1 gsusgguggacuUfcucucaa 550 A-127956.8 asAfsaUfuGfaGfaGfaa 765 uuuL96 gUfcCfaCfcAfcsgsa AD-64010.2 A-127955.5 GfsusGfgUfgGfaCfUfUfc 551 A-127973.1 asAfsauuGfagaGfaagU 766 UfcUfcAfaUfuUfL96 fcCfaccAfcsgsa AD-64011.2 A-127955.13 GfsusGfgUfgGfaCfUfUfc 552 A-127981.1 asAfsauuGfagagaagUf 767 UfcUfcAfaUfuUfL96 cCfaccacsgsa AD-64012.2 A-127990.2 gsusGfgugGfaCfUfUfcUf 553 A-127992.1 asAfsAfUfuGfaGfaGfa 768 cUfcAfaUfuuL96 agUfcCfaCfcacsgsa AD-64013.2 A-127997.1 gsusgguggacdTdTcucuca 554 A-127998.1 asdAsAfuugaGfaGfaag 769 auuuL96 dTdCcaCfcacsgsa AD-64014.2 A-127957.1 Y44GfsusGfgUfgGfaCfUf 555 A-127958.1 PasAfsaUfuGfaGfaGfa 770 UfcUfcUfcAfaUfuUfL96 agUfcCfaCfcAfcsgsa AD-64015.2 A-127966.1 gsusgguggaCfuUfcucuc 556 A-127956.9 asAfsaUfuGfaGfaGfaa 771 (Agn)auuuL96 gUfcCfaCfcAfcsgsa AD-64016.2 A-127955.6 GfsusGfgUfgGfaCfUfUfc 557 A-127974.1 asAfsauuGfaGfaGfaag 772 UfcUfcAfaUfuUfL96 UfcCfaccacsgsa AD-64017.2 A-127968.2 gsusgguggacudTcucuc 558 A-127982.1 asdAsauugagagaagdTc 773 (Agn)auuuL96 caccacsgsa AD-64018.2 A-127990.3 gsusGfgugGfaCfUfUfcUf 559 A-127993.1 asAfsAfuuGfaGfaGfaa 774 cUfcAfaUfuuL96 gUfCfcaCfcacsgsa AD-64019.2 A-127959.1 gsusggUfgGfaCfUfUfcUf 560 A-127956.2 asAfsaUfuGfaGfaGfaa 775 cucAfauuUfL96 gUfcCfaCfcAfcsgsa AD-64020.2 A-127967.1 gsusgguggacuUfcucuc 561 A-127956.10 asAfsaUfuGfaGfaGfaa 776 (Agn)auuuL96 gUfcCfaCfcAfcsgsa AD-64021.2 A-127955.7 GfsusGfgUfgGfaCfUfUfc 562 A-127975.1 asAfsaUfugaGfaGfaag 777 UfcUfcAfaUfuUfL96 UfcCfaccAfcsgsa AD-64022.2 A-127968.3 gsusgguggacudTcucuc 563 A-127983.1 PasdAsauugagagaagdT 778 (Agn)auuuL96 ccaccacsgsa AD-64023.2 A-127990.4 gsusGfgugGfaCfUfUfcUf 564 A-127994.1 asAfsAfUfuGfaGfaGfa 779 cUfcAfaUfuuL96 agUfCfcaCfcacsgsa AD-64024.2 A-127960.1 gsusggUfgGfaCfUfUfcUf 565 A-127956.3 asAfsaUfuGfaGfaGfaa 780 cucAfauuuL96 gUfcCfaCfcAfcsgsa AD-64025.2 A-127968.1 gsusgguggacudTcucuc 566 A-127956.11 asAfsaUfuGfaGfaGfaa 781 (Agn)auuuL96 gUfcCfaCfcAfcsgsa AD-64026.2 A-127955.8 GfsusGfgUfgGfaCfUfUfc 567 A-127976.1 asAfsaUfugaGfagaagU 782 UfcUfcAfaUfuUfL96 fcCfaccAfcsgsa AD-64027.2 A-127984.1 gsgUfgGfaCfUfUfcUfcUf 568 A-127985.1 asAfsaUfuGfaGfaGfaa 783 cAfaUfuUfL96 gUfcCfaCfcsasc AD-64028.2 A-127990.5 gsusGfgugGfaCfUfUfcUf 569 A-127995.1 asAfsAfUfugaGfaGfaa 784 cUfcAfaUfuuL96 gUfCfcaCfcacsgsa AD-64272.2 A-128001.2 GfsusGfcAfcUfuCfGfCfu 570 A-128002.2 csAfsgAfgGfuGfaAfgc 785 UfcAfcCfuCfuGfL96 gAfaGfuGfcAfcsasc AD-64274.1 A-128363.1 GfsusUfgAfcAfaAfAfAfu 571 A-128364.1 asUfsuGfuGfaGfgAfuu 786 CfcUfcAfcAfaUfL96 uUfuGfuCfaAfcsasa AD-64275.1 A-128377.1 UfsgsUfuGfaCfaAfAfAfa 572 A-128378.1 usUfsgUfgAfgGfaUfuu 787 UfcCfuCfaCfaAfL96 uUfgUfcAfaCfasasg AD-64276.1 A-128393.1 GfsgsUfgGfaCfuUfCfUfc 573 A-128394.1 usAfsaAfaUfuGfaGfag 788 UfcAfaUfuUfuAfL96 aAfgUfcCfaCfcsasc AD-64277.1 A-128407.1 UfscsUfuUfuGfgAfGfUfg 574 A-128408.1 usCfsgAfaUfcCfaCfac 789 UfgGfaUfuCfgAfL96 uCfcAfaAfaGfascsa AD-64277.1 A-128407.1 UfscsUfuUfuGfgAfGfUfg 575 A-128408.1 usCfsgAfaUfcCfaCfac 790 UfgGfaUfuCfgAfL96 uCfcAfaAfaGfascsa AD-64278.1 A-128423.1 AfscsUfgUfuCfaAfGfCfc 576 A-128424.1 usAfsgCfuUfgGfaGfgc 791 UfcCfaAfgCfuAfL96 uUfgAfaCfaAfgsasc AD-64279.1 A-128435.1 UfscsUfgCfcGfaUfCfCfa 577 A-128436.1 usCfscGfcAfgUfaUfgg 792 UfaCfuGfcGfgAfL96 aUfcGfgCfaGfasgsg AD-64280.1 A-128379.1 AfsusGfuGfuCfuGfCfGfg 578 A-128380.1 usAfsuAfaAfaCfgCfcg 793 CfgUfuUfuAfuAfL96 cAfgAfcAfcAfuscsc AD-64281.1 A-128395.1 CfscsCfcGfuCfuGfUfGfc 579 A-128396.1 usAfsuGfaGfaAfgGfca 794 CfuUfcUfcAfuAfL96 cAfgAfcGfgGfgsasg AD-64282.1 A-128409.1 GfscsCfuAfaUfcAfUfCfu 580 A-128410.1 asUfsgAfaCfaAfgAfga 795 CfuUfgUfuCfaUfL96 uGfaUfuAfgCfgsasg AD-64283.1 A-128425.1 UfscsUfaGfaCfuCfGfUfg 581 A-128426.1 gsAfsaGfuCfcAfcCfac 796 GfuGfgAfcUfuCfL96 gAfgUfcUfaGfascsu AD-64284.1 A-128437.1 CfsusGfcCfgAfuCfCfAfu 582 A-128438.1 usUfscCfgCfaGfuAfug 797 AfcUfgCfgGfaAfL96 gAfuCfgGfcAfgsasg AD-64285.1 A-128365.1 UfsusUfuUfcUfuGfUfUfg 583 A-128366.1 usAfsuUfuUfuGfuCfaa 798 AfcAfaAfaAfuAfL96 cAfaGfaAfaAfascsc AD-64286.1 A-128381.1 AfsusCfuUfcUfuGfUfUfg 584 A-128382.1 usAfsgAfaGfaAfcCfaa 799 GfuUfcUfuCfuAfL96 cAfaGfaAfgAfusgsa AD-64289.1 A-128367.1 GfsusUfuUfuCfuUfGfUfu 585 A-128368.1 asUfsuUfuUfgUfcAfac 800 GfaCfaAfaAfaUfL96 aAfgAfaAfaAfcscsc AD-64290.1 A-128383.1 CfsusGfcCfuAfaUfCfAfu 586 A-128384.1 usAfsaCfaAfgAfgAfug 801 CfuCfuUfgUfuAfL96 aUfuAfgGfcAfgsasg AD-64291.1 A-128399.1 UfscsCfuCfaCfaAfUfAfc 587 A-128400.1 usAfscUfcUfgUfgGfua 802 CfaCfaGfaGfuAfL96 uUfgUfgAfgGfasusu AD-64292.1 A-128413.1 CfsusUfgUfuGfaCfAfAfa 588 A-128414.1 usUfsgAfgGfaUfuUfuu 803 AfaUfcCfuCfaAfL96 gUfcAfaCfaAfgsasa AD-64293.1 A-128439.1 GfscsAfaCfuUfuUfUfCfa 589 A-128440.1 asGfsgCfaGfaGfgUfga 804 CfcUfcUfgCfcUfL96 aAfaAfgUfuGfcsasu AD-64294.1 A-128369.1 GfsgsGfaAfcAfaGfAfGfc 590 A-128370.1 usAfsuGfcUfgUfaGfcu 805 UfaCfaGfcAfuAfL96 cUfuGfuUfcCfcsasa AD-64295.1 A-128385.1 CfsgsUfgGfuGfgAfCfUfu 591 A-128386.1 asAfsuUfgAfgAfgAfag 806 CfuCfuCfaAfuUfL96 uCfcAfcCfaGfcsasg AD-64297.1 A-128415.1 CfsusGfcUfgCfuAfUfGfc 592 A-128416.1 usAfsaGfaUfgAfgGfca 807 CfuCfaUfcUfuAfL96 uAfgCfaGfcAfgsgsa AD-64298.1 A-128427.1 GfsusUfgGfaUfgUfGfUfc 593 A-128428.1 asAfscGfcCfgCfaGfac 808 UfgCfgGfcGfuUfL96 aCfaUfcCfaAfcsgsa AD-64299.1 A-128441.1 UfsusCfaUfcCfuGfCfUfg 594 A-128442.1 usAfsgGfcAfuAfgCfag 809 CfuAfuGfcCfuAfL96 cAfgGfaUfgAfasgsa AD-64300.1 A-128371.1 UfsusCfuUfgUfuGfAfCfa 595 A-128372.1 usAfsgGfaUfuUfuUfgu 810 AfaAfaUfcCfuAfL96 cAfaCfaAfgAfasasa AD-64302.1 A-128417.1 UfsasUfaUfgGfaUfGfAfu 596 A-128418.1 usAfsaUfaCfcAfcAfuc 811 GfuGfgUfaUfuAfL96 aUfcCfaUfaUfasasc AD-64303.1 A-128429.1 UfsusCfaUfcCfuGfCfUfg 597 A-128430.1 gsAfsgGfcAfuAfgCfag 812 CfuAfuGfcCfuCfL96 cAfgGfaUfgAfasgsa AD-64304.1 A-128443.1 GfsusGfcAfcUfuCfGfCfu 598 A-128444.1 usAfsgAfgGfuGfaAfgc 813 UfcAfcCfuCfuAfL96 gAfaGfuGfcAfcsasc AD-64305.1 A-128373.1 UfsusGfaCfaAfaAfAfUfc 599 A-128374.1 usAfsuUfgUfgAfgGfau 814 CfuCfaCfaAfuAfL96 uUfuUfgUfcAfascsa AD-64307.1 A-128403.1 AfsasGfcCfuCfcAfAfGfc 600 A-128404.1 usAfsaGfgCfaCfaGfcu 815 UfgUfgCfcUTuAfL96 uGfgAfgGfcUfusgsa AD-64308.1 A-128419.1 CfscsUfcUfuCfaUfCfCfu 601 A-128420.1 usAfsuAfgCfaGfcAfgg 816 GfcUfgCfuAfuAfL96 aUfgAfaGfaGfgsasa AD-64309.1 A-128431.1 CfscsUfgCfuGfcUfAfUfg 602 A-128432.1 asAfsgAfuGfaGfgCfau 817 CfcUfcAfuCfuUfL96 aGfcAfgCfaGfgsasu AD-64310.1 A-128375.1 CfsasUfcUfuCfuUfGfUfu 603 A-128376.1 asGfsaAfgAfaCfcAfac 818 GfgUfuCfuUfcUfL96 aAfgAfaGfaUfgsasg AD-64311.1 A-128391.1 CfscsGfuCfuGfuGfCfCfu 604 A-128392.1 usAfsgAfuGfaGfaAfgg 819 UfcUfcAfuCfuAfL96 cAfcAfgAfcGfgsgsg AD-64312.1 A-128405.1 CfscsUfcAfuCfuUfCfUfu 605 A-128406.1 asGfsaAfcCfaAfcAfag 820 GfuUfgGfuUfcUfL96 aAfgAfuGfaGfgscsa AD-64313.1 A-128421.1 CfscsAfcCfaAfaUfGfCfc 606 A-128422.1 usAfsaGfaUfaGfgGfgc 821 CfcUfaUfcUfuAfL96 aUfuUfgGfuGfgsusc AD-64314.1 A-128433.1 GfscsUfcCfuCfuGfCfCfg 607 A-128434.1 asGfsuAfuGfgAfuCfgg 822 AfuCfcAfuAfcUfL96 cAfgAfgGfaGfcscsa AD-64315.1 A-128363.2 GfsusUfgAfcAfaAfAfAfu 608 A-128445.1 PasUfsuGfuGfaGfgAfu 823 CfcUfcAfcAfaUfL96 uuUfuGfuCfaAfcsasa AD-64316.1 A-128377.2 UfsgsUfuGfaCfaAfAfAfa 609 A-128453.1 PusUfsgUfgAfgGfaUfu 824 UfcCfuCfaCfaAfL96 uuUfgUfcAfaCfasasg AD-64317.1 A-128393.2 GfsgsUfgGfaCfuUfCfUfc 610 A-128461.1 PusAfsaAfaUfuGfaGfa 825 UfcAfaUfuUfuAfL96 gaAfgUfcCfaCfcsasc AD-64318.1 A-128407.2 UfscsUfuUfuGfgAfGfUfg 611 A-128469.1 PusCfsgAfaUfcCfaCfa 826 UfgGfaUfuCfgAfL96 cuCfcAfaAfaGfascsa AD-64319.1 A-128423.2 AfscsUfgUfuCfaAfGfCfc 612 A-128477.1 PusAfsgCfuUfgGfaGfg 827 UfcCfaAfgCfuAfL96 cuUfgAfaCfaAfgsasc AD-64320.1 A-128435.2 UfscsUfgCfcGfaUfCfCfa 613 A-128483.1 PusCfscGfcAfgUfaUfg 828 UfaCfuGfcGfgAfL96 gaUfcGfgCfaGfasgsg AD-64321.1 A-123463.3 AfsgsUfuAfuAfuGfGfAfu 614 A-128446.1 PusAfscCfaCfaUfcAfu 829 GfaUfgUfgGfuAfL96 ccAfuAfuAfaCfusgsa AD-64322.1 A-128379.2 AfsusGfuGfuCfuGfCfGfg 615 A-128454.1 PusAfsuAfaAfaCfgCfc 830 CfgUfuUfuAfuAfL96 gcAfgAfcAfcAfuscsc AD-64323.1 A-128395.2 CfscsCfcGfuCfuGfUfGfc 616 A-128462.1 PusAfsuGfaGfaAfgGfc 831 CfuUfcUfcAfuAfL96 acAfgAfcGfgGfgsasg AD-64324.1 A-128409.2 GfscsCfuAfaUfcAfUfCfu 617 A-128470.1 PasUfsgAfaCfaAfgAfg 832 CfuUfgUfuCfaUfL96 auGfaUfuAfgCfgsasg AD-64325.1 A-128425.2 UfscsUfaGfaCfuCfGfUfg 618 A-128478.1 PgsAfsaGfuCfcAfcCfa 833 GfuGfgAfcUfuCfL96 cgAfgUfcUfaGfascsu AD-64326.1 A-128437.2 CfsusGfcCfgAfuCfCfAfu 619 A-128484.1 PusUfscCfgCfaGfuAfu 834 AfcUfgCfgGfaAfL96 ggAfuCfgGfcAfgsasg AD-64328.1 A-128381.2 AfsusCfuUfcUfuGfUfUfg 620 A-128455.1 PusAfsgAfaGfaAfcCfa 835 GfuUfcUfuCfuAfL96 acAfaGfaAfgAfusgsa AD-64330.1 A-128411.2 UfsusCfuCfuCfaAfUfUfu 621 A-128471.1 PusCfscCfcUfaGfaAfa 836 UfcUfaGfgGfgAfL96 auUfgAfgAfgAfasgsu AD-64331.1 A-127905.16 AfscsUfcGfuGfgUfGfGfa 622 A-127907.2 PusGfsaGfaGfaAfgUfc 837 CfuUfcUfcUfcAfL96 caCfcAfcGfaGfuscsu AD-64332.1 A-128001.3 GfsusGfcAfcUfuCfGfCfu 623 A-128485.1 PcsAfsgAfgGfuGfaAfg 838 UfcAfcCfuCfuGfL96 cgAfaGfuGfcAfcsasc AD-64333.1 A-128367.2 GfsusUfuUfuCfuUfGfUfu 624 A-128448.1 PasUfsuUfuUfgUfcAfa 839 GfaCfaAfaAfaUfL96 caAfgAfaAfaAfcscsc AD-64334.1 A-128383.2 CfsusGfcCfuAfaUfCfAfu 625 A-128456.1 PusAfsaCfaAfgAfgAfu 840 CfuCfuUfgUfuAfL96 gaUfuAfgGfcAfgsasg AD-64335.1 A-128399.2 UfscsCfuCfaCfaAfUfAfc 626 A-128464.1 PusAfscUfcUfgUfgGfu 841 CfaCfaGfaGfuAfL96 auUfgUfgAfgGfasusu AD-64336.1 A-128413.2 CfsusUfgUfuGfaCfAfAfa 627 A-128472.1 PusUfsgAfgGfaUfuUfu 842 AfaUfcCfuCfaAfL96 ugUfcAfaCfaAfgsasa AD-64337.1 A-127955.16 GfsusGfgUfgGfaCfUfUfc 628 A-127958.2 PasAfsaUfuGfaGfaGfa 843 UfcUfcAfaUfuUfL96 agUfcCfaCfcAfcsgsa AD-64338.1 A-128439.2 GfscsAfaCfuUfuUfUfCfa 629 A-128486.1 PasGfsgCfaGfaGfgUfg 844 CfcUfcUfgCfcUfL96 aaAfaAfgUfuGfcsasu AD-64339.1 A-128369.2 GfsgsGfaAfcAfaGfAfGfc 630 A-128449.1 PusAfsuGfcUfgUfaGfc 845 UfaCfaGfcAfuAfL96 ucUfuGfuUfcCfcsasa AD-64341.1 A-128401.2 UfscsAfuCfuUfcUfUfGfu 631 A-128465.1 PusAfsaGfaAfcCfaAfc 846 UfgGfuUfcUfuAfL96 aaGfaAfgAfuGfasgsg AD-64342.1 A-128415.2 CfsusGfcUfgCfuAfUfGfc 632 A-128473.1 PusAfsaGfaUfgAfgGfc 847 CfuCfaUfcUfuAfL96 auAfgCfaGfcAfgsgsa AD-64343.1 A-128427.2 GfsusUfgGfaUfgUfGfUfc 633 A-128479.1 PasAfscGfcCfgCfaGfa 848 UfgCfgGfcGfuUfL96 caCfaUfcCfaAfcsgsa AD-64344.1 A-128441.2 UfsusCfaUfcCfuGfCfUfg 634 A-128487.1 PusAfsgGfcAfuAfgCfa 849 CfuAfuGfcCfuAfL96 gcAfgGfaUfgAfasgsa AD-64345.1 A-128371.2 UfsusCfuUfgUfuGfAfCfa 635 A-128450.1 PusAfsgGfaUfuUfuUfg 850 AfaAfaUfcCfuAfL96 ucAfaCfaAfgAfasasa AD-64347.1 A-123487.3 GfsgsAfuGfuGfuCfUfGfc 636 A-128466.1 PusAfsaAfaCfgCfcGfc 851 GfgCfgUfuUfuAfL96 agAfcAfcAfuCfcsasg AD-64348.1 A-128417.2 UfsasUfaUfgGfaUfGfAfu 637 A-128474.1 PusAfsaUfaCfcAfcAfu 852 GfuGfgUfaUfuAfL96 caUfcCfaUfaUfasasc AD-64349.1 A-128429.2 UfsusCfaUfcCfuGfCfUfg 638 A-128480.1 PgsAfsgGfcAfuAfgCfa 853 CfuAfuGfcCfuCfL96 gcAfgGfaUfgAfasgsa AD-64350.1 A-128443.2 GfsusGfcAfcUfuCfGfCfu 639 A-128488.1 PusAfsgAfgGfuGfaAfg 854 UfcAfcCfuCfuAfL96 cgAfaGfuGfcAfcsasc AD-64351.1 A-128373.2 UfsusGfaCfaAfaAfAfUfc 640 A-128451.1 PusAfsuUfgUfgAfgGfa 855 CfuCfaCfaAfuAfL96 uuUfuUfgUfcAfascsa AD-64352.1 A-128389.2 CfscsAfaGfuGfuUfUfGfc 641 A-128459.1 PusUfsuGfcGfuCfaGfc 856 UfgAfcGfcAfaAfL96 aaAfcAfcUfuGfgscsa AD-64352.1 A-128389.2 CfscsAfaGfuGfuUfUfGfc 642 A-128459.1 PusUfsuGfcGfuCfaGfc 857 UfgAfcGfcAfaAfL96 aaAfcAfcUfuGfgscsa AD-64353.1 A-128403.2 AfsasGfcCfuCfcAfAfGfc 643 A-128467.1 PusAfsaGfgCfaCfaGfc 858 UfgUfgCfcUfuAfL96 uuGfgAfgGfcUfusgsa AD-64354.1 A-128419.2 CfscsUfcUfuCfaUfCfCfu 644 A-128475.1 PusAfsuAfgCfaGfcAfg 859 GfcUfgCfuAfuAfL96 gaUfgAfaGfaGfgsasa AD-64355.1 A-128431.2 CfscsUfgCfuGfcUfAfUfg 645 A-128481.1 PasAfsgAfuGfaGfgCfa 860 CfcUfcAfuCfuUfL96 uaGfcAfgCfaGfgsasu AD-64356.1 A-128375.2 CfsasUfcUfuCfuUfGfUfu 646 A-128452.1 PasGfsaAfgAfaCfcAfa 861 GfgUfuCfnUfcUfL96 caAfgAfaGfaUfgsasg AD-64357.1 A-128391.2 CfscsGfuCfuGfuGfCfCfn 647 A-128460.1 PusAfsgAfuGfaGfaAfg 862 UfcUfcAfuCfuAfL96 gcAfcAfgAfcGfgsgsg AD-64358.1 A-128405.2 CfscsUfcAfuCfnUfCfUfu 648 A-128468.1 PasGfsaAfcCfaAfcAfa 863 GfuUfgGfnUfcUfL96 gaAfgAfuGfaGfgscsa AD-64359.1 A-128421.2 CfscsAfcCfaAfaUfGfCfc 649 A-128476.1 PusAfsaGfaUfaGfgGfg 864 CfcUfaUfcUfuAfL96 caUfuUfgGfuGfgsusc AD-64360.1 A-128433.2 GfscsUfcCfuCfuGfCfCfg 650 A-128482.1 PasGfsuAfuGfgAfuCfg 865 AfuCfcAfuAfcUfL96 gcAfgAfgGfaGfcscsa AD-64700.1 A-129379.1 ascsucguggugdTacuu 651 A-127906.26 usGfsaGfaGfaAfgUfcc 866 (Cgn)ucucaL96 aCfcAfcGfaGfuscsu AD-64701.1 A-127905.20 AfscsUfcGfuGfgUfGfGfa 652 A-129387.1 PusgsagagaagdTccadC 867 CfuUfcUfcUfcAfL96 cacgaguscsu AD-64702.1 A-127905.28 AfscsUfcGfuGfgUfGfGfa 653 A-129395.1 usGsagadGaaguccaCca 868 CfuUfcUfcUfcAfL96 cgaguscsu AD-64703.1 A-129376.2 ascsucguggugdGacuucdA 654 A-129385.5 usdGsagagaagdTccadC 869 cucaL96 cacgaguscsu AD-64704.1 A-129381.3 ascsucguggdTgdTacuucd 655 A-129389.6 usdGsagadGaaguccadC 870 AcucaL96 cacgaguscsu AD-64705.1 A-129380.1 ascsucguggugdTacuucdA 656 A-127906.27 usGfsaGfaGfaAfgUfcc 871 cucaL96 aCfcAfcGfaGfuscsu AD-64706.1 A-127905.21 AfscsUfcGfuGfgUfGfGfa 657 A-129388.1 usdGsadGagaaguccadC 872 CfuUfcUfcUfcAfL96 cacgaguscsu AD-64707.1 A-127905.29 AfscsUfcGfuGfgUfGfGfa 658 A-129396.1 usgsagadGaagdTccadC 873 CfuUfcUfcUfcAfL96 cacgaguscsu AD-64708.1 A-129382.2 ascsucguggdTgdGacuuc 659 A-129385.6 usdGsagagaagdTccadC 874 (Tgn)cucaL96 cacgaguscsu AD-64709.1 A-129373.4 ascsucguggugdGacuu 660 A-129391.2 usdGsagadGaagdTccad 875 (Cgn)ucucaL96 Ccacgaguscsu AD-64710.1 A-129373.1 ascsucguggugdGacuu 661 A-127906.20 usGfsaGfaGfaAfgUfcc 876 (Cgn)ucucaL96 aCfcAfcGfaGfuscsu AD-64711.1 A-129381.1 ascsucguggdTgdTacuucd 662 A-127906.28 usGfsaGfaGfaAfgUfcc 877 AcucaL96 aCfcAfcGfaGfuscsu AD-64712.1 A-127905.22 AfscsUfcGfuGfgUfGfGfa 663 A-129389.1 usdGsagadGaaguccadC 878 CfuUfcUfcUfcAfL96 cacgaguscsu AD-64713.1 A-127905.30 AfscsUfcGfuGfgUfGfGfa 664 A-129397.1 PusgsagadGaagdTccad 879 CfuUfcUfcUfcAfL96 Ccacgaguscsu AD-64714.1 A-129384.2 ascsucguggdTgdGacuucd 665 A-129385.7 usdGsagagaagdTccadC 880 AcucaL96 cacgaguscsu AD-64715.1 A-129376.4 ascsucguggugdGacuucdA 666 A-129391.3 usdGsagadGaagdTccad 881 cucaL96 Ccacgaguscsu AD-64716.1 A-129374.1 ascsucguggugdGacuucu 667 A-127906.21 usGfsaGfaGfaAfgUfcc 882 (Cgn)ucaL96 aCfcAfcGfaGfuscsu AD-64717.1 A-129382.1 ascsucguggdTgdGacuuc 668 A-127906.29 usGfsaGfaGfaAfgUfcc 883 (Tgn)cucaL96 aCfcAfcGfaGfuscsu AD-64718.1 A-127905.23 AfscsUfcGfuGfgUfGfGfa 669 A-129390.1 usdGsagagadAguccadC 884 CfuUfcUfcUfcAfL96 cacgaguscsu AD-64719.1 A-127917.5 ascsucguggugdGacuuc 670 A-129385.2 usdGsagagaagdTccadC 885 (Tgn)cucaL96 cacgaguscsu AD-64720.1 A-129381.2 ascsucguggdTgdTacuucd 671 A-129385.8 usdGsagagaagdTccadC 886 AcucaL96 cacgaguscsu AD-64721.1 A-129382.4 ascsucguggdTgdGacuuc 672 A-129391.4 usdGsagadGaagdTccad 887 (Tgn)cucaL96 Ccacgaguscsu AD-64722.1 A-129375.1 ascsucguggugdGacuuc 673 A-127906.22 usGfsaGfaGfaAfgUfcc 888 Y34cucaL96 aCfcAfcGfaGfuscsu AD-64723.1 A-129383.1 ascsucguggugdGdAcuuc 674 A-127906.30 usGfsaGfaGfaAfgUfcc 889 (Tgn)cucaL96 aCfcAfcGfaGfuscsu AD-64725.1 A-127917.6 ascsucguggugdGacuuc 675 A-129398.1 PusdGsagagaagdTccad 890 (Tgn)cucaL96 Ccacgaguscsu AD-64726.1 A-129373.3 ascsucguggugdGacuu 676 A-129389.2 usdGsagadGaaguccadC 891 (Cgn)ucucaL96 cacgaguscsu AD-64727.1 A-129384.4 ascsucguggdTgdGacuucd 677 A-129391.5 usdGsagadGaagdTccad 892 AcucaL96 Ccacgaguscsu AD-64728.1 A-129376.1 ascsucguggugdGacuucdA 678 A-127906.23 usGfsaGfaGfaAfgUfcc 893 cucaL96 aCfcAfcGfaGfuscsu AD-64729.1 A-129384.1 ascsucguggdTgdGacuucd 679 A-127906.31 usGfsaGfaGfaAfgUfcc 894 AcucaL96 aCfcAfcGfaGfuscsu AD-64730.1 A-127905.25 AfscsUfcGfuGfgUfGfGfa 680 A-129392.1 usGsagagaagdTccadCc 895 CfuUfcUfcUfcAfL96 acgaguscsu AD-64731.1 A-129399.1 Y34ascsucguggugdGacuu 681 A-129385.3 usdGsagagaagdTccadC 896 c(Tgn)cucaL96 cacgaguscsu AD-64732.1 A-129376.3 ascsucguggugdGacuucdA 682 A-129389.3 usdGsagadGaaguccadC 897 cucaL96 cacgaguscsu AD-64733.1 A-129381.4 ascsucguggdTgdTacuucd 683 A-129391.6 usdGsagadGaagdTccad 898 AcucaL96 Ccacgaguscsu AD-64734.1 A-129377.1 ascsucguggugdGacuucdC 684 A-127906.24 usGfsaGfaGfaAfgUfcc 899 cucaL96 aCfcAfcGfaGfuscsu AD-64735.1 A-127905.18 AfscsUfcGfuGfgUfGfGfa 685 A-129385.1 usdGsagagaagdTccadC 900 CfnUfcUfcUfcAfL96 cacgaguscsu AD-64736.1 A-127905.26 AfscsUfcGfuGfgUfGfGfa 686 A-129393.1 usdGsagagaagdTccaCc 901 CfnUfcUfcUfcAfL96 acgaguscsu AD-64737.1 A-129399.2 Y34ascsucguggugdGacuu 687 A-129398.2 PusdGsagagaagdTccad 902 c(Tgn)cucaL96 Ccacgaguscsu AD-64738.1 A-129382.3 ascsucguggdTgdGacuuc 688 A-129389.4 usdGsagadGaaguccadC 903 (Tgn)cucaL96 cacgaguscsu AD-64739.1 A-129378.1 ascsucguggugdGacuucdG 689 A-127906.25 usGfsaGfaGfaAfgUfcc 904 cucaL96 aCfcAfcGfaGfuscsu AD-64740.1 A-127905.19 AfscsUfcGfuGfgUfGfGfa 690 A-129386.1 usgsagagaagdTccadCc 905 CfnUfcUfcUfcAfL96 acgaguscsu AD-64741.1 A-127905.27 AfscsUfcGfuGfgUfGfGfa 691 A-129394.1 usGsagagaagdTccaCca 906 CfnUfcUfcUfcAfL96 cgaguscsu AD-64742.1 A-129373.2 ascsucguggugdGacuu 692 A-129385.4 usdGsagagaagdTccadC 907 (Cgn)ucucaL96 cacgaguscsu AD-64743.1 A-129384.3 ascsucguggdTgdGacuucd 693 A-129389.5 usdGsagadGaaguccadC 908 AcucaL96 cacgaguscsu

TABLE 5 HBV single dose screen using Dual-Glo Luciferase ® Assay 10 nM 0.1 nM 10 nM Duplex ID Avg Avg SD 0.1 nM_SD AD-63938.2 0.12 ND 0.01 ND AD-63950.2 0.38 ND 0.04 ND AD-63956.2 0.31 ND 0.02 ND AD-63962.2 0.16 ND 0.03 ND AD-63968.2 0.56 ND 0.10 ND AD-63968.2 0.79 ND 0.09 ND AD-63979.2 0.54 ND 0.02 ND AD-63939.2 0.51 ND 0.01 ND AD-63945.2 0.54 ND 0.08 ND AD-63951.2 0.60 ND 0.03 ND AD-63957.2 0.57 ND 0.02 ND AD-63963.2 0.91 ND 0.06 ND AD-63969.2 0.92 ND 0.02 ND AD-63975.2 0.83 ND 0.01 ND AD-63980.2 0.77 ND 0.01 ND AD-63940.2 0.77 ND 0.06 ND AD-63946.2 0.60 ND 0.10 ND AD-63952.2 0.48 ND 0.04 ND AD-63958.2 0.51 ND 0.01 ND AD-63964.2 0.58 ND 0.04 ND AD-63970.2 0.69 ND 0.07 ND AD-63976.2 0.63 ND 0.04 ND AD-63981.2 0.60 ND 0.04 ND AD-63941.2 0.56 ND 0.09 ND AD-63947.2 0.55 ND 0.08 ND AD-63953.2 0.56 ND 0.06 ND AD-63959.2 0.51 ND 0.03 ND AD-63965.2 0.55 ND 0.03 ND AD-63971.2 0.65 ND 0.02 ND AD-63977.2 0.88 ND 0.01 ND AD-63982.2 0.73 ND 0.07 ND AD-63942.2 0.32 ND 0.09 ND AD-63948.2 0.57 ND 0.09 ND AD-63960.2 0.92 ND 0.05 ND AD-63966.2 0.85 ND 0.06 ND AD-63972.2 0.82 ND 0.06 ND AD-63978.2 0.83 ND 0.02 ND AD-63983.2 0.89 ND 0.02 ND AD-63943.2 0.86 ND 0.04 ND AD-63949.2 0.76 ND 0.02 ND AD-63955.2 0.82 ND 0.02 ND AD-63961.2 0.83 ND 0.07 ND AD-63967.2 0.86 ND 0.03 ND AD-63973.2 0.86 ND 0.03 ND AD-63990.2 0.27 ND 0.07 ND AD-63996.2 0.29 ND 0.06 ND AD-64002.2 0.30 ND 0.11 ND AD-64008.2 0.28 ND 0.05 ND AD-64008.2 0.34 ND 0.07 ND AD-64014.2 0.30 ND 0.03 ND AD-64019.2 0.36 ND 0.04 ND AD-64024.2 0.27 ND 0.03 ND AD-63985.2 0.28 ND 0.06 ND AD-63991.2 0.33 ND 0.02 ND AD-63997.2 0.47 ND 0.07 ND AD-64003.2 0.69 ND 0.06 ND AD-64009.2 0.91 ND 0.03 ND AD-64015.2 0.69 ND 0.09 ND AD-64020.2 0.81 ND 0.06 ND AD-64025.2 0.77 ND 0.06 ND AD-63986.2 0.28 ND 0.05 ND AD-63992.2 0.44 ND 0.04 ND AD-64004.2 0.45 ND 0.04 ND AD-64010.2 0.37 ND 0.05 ND AD-64016.2 0.48 ND 0.05 ND AD-64021.2 0.39 ND 0.03 ND AD-64026.2 0.30 ND 0.02 ND AD-63987.2 0.20 ND 0.02 ND AD-63993.2 0.33 ND 0.02 ND AD-63999.2 0.36 ND 0.05 ND AD-64005.2 0.45 ND 0.11 ND AD-64011.2 0.39 ND 0.08 ND AD-64017.2 0.84 ND 0.06 ND AD-64022.2 0.81 ND 0.03 ND AD-64027.2 0.38 ND 0.05 ND AD-63988.2 0.37 ND 0.04 ND AD-63994.2 0.23 ND 0.01 ND AD-64000.2 0.29 ND 0.00 ND AD-64006.2 0.40 ND 0.04 ND AD-64012.2 0.45 ND 0.17 ND AD-64018.2 0.65 ND 0.07 ND AD-64023.2 0.53 ND 0.07 ND AD-64028.2 0.52 ND 0.07 ND AD-63989.2 0.47 ND 0.04 ND AD-63995.2 0.81 ND 0.03 ND AD-64001.2 0.83 ND 0.04 ND AD-64007.2 0.87 ND 0.04 ND AD-64013.2 0.88 ND 0.03 ND AD-64289.1 0.276 ND 0.009 ND AD-64333.1 0.208 ND 0.015 ND AD-64285.1 0.324 ND 0.034 ND AD-64300.1 0.225 ND 0.005 ND AD-64345.1 0.102 ND 0.090 ND AD-64292.1 0.288 ND 0.232 ND AD-64336.1 0.199 ND 0.056 ND AD-64275.1 0.287 ND 0.185 ND AD-64316.1 0.297 ND 0.024 ND AD-64274.1 0.209 ND 0.033 ND AD-64315.1 0.199 ND 0.002 ND AD-64305.1 0.360 ND 0.035 ND AD-64351.1 0.281 ND 0.014 ND AD-64291.1 0.725 ND 0.005 ND AD-64335.1 0.478 ND 0.020 ND AD-64283.1 0.917 ND 0.018 ND AD-64304.1 0.937 ND 0.050 ND AD-64325.1 0.446 ND 0.223 ND AD-64350.1 0.934 ND 0.055 ND AD-63968.4 0.748 ND 0.008 ND AD-64331.1 0.294 ND 0.038 ND AD-64008.4 0.416 ND 0.028 ND AD-64337.1 0.318 ND 0.049 ND AD-64295.1 0.415 ND 0.034 ND AD-64276.1 0.453 ND 0.073 ND AD-64317.1 0.203 ND 0.040 ND AD-64330.1 0.313 ND 0.030 ND AD-64298.1 0.797 ND 0.007 ND AD-64343.1 0.667 ND 0.020 ND AD-61547.2 0.637 ND 0.019 ND AD-64347.1 0.418 ND 0.066 ND AD-64280.1 0.754 ND 0.092 ND AD-64322.1 0.407 ND 0.013 ND AD-64308.1 0.720 ND 0.055 ND AD-64354.1 0.315 ND 0.034 ND AD-64303.1 0.815 ND 0.150 ND AD-64349.1 0.447 ND 0.030 ND AD-64299.1 0.831 ND 0.007 ND AD-64344.1 0.404 ND 0.009 ND AD-64309.1 0.856 ND 0.005 ND AD-64355.1 0.498 ND 0.040 ND AD-64297.1 0.895 ND 0.024 ND AD-64342.1 0.508 ND 0.006 ND AD-64312.1 0.590 ND 0.034 ND AD-64358.1 0.425 ND 0.044 ND AD-64341.1 0.223 ND 0.119 ND AD-64310.1 0.301 ND 0.064 ND AD-64356.1 0.336 ND 0.024 ND AD-64286.1 0.611 ND 0.012 ND AD-64328.1 0.317 ND 0.043 ND AD-61522.2 0.447 ND 0.008 ND AD-64321.1 0.237 ND 0.009 ND AD-64302.1 0.523 ND 0.020 ND AD-64348.1 0.208 ND 0.003 ND AD-64352.1 0.343 ND 0.224 ND AD-64352.1 0.567 ND 0.015 ND AD-64314.1 0.920 ND 0.044 ND AD-64360.1 0.778 ND 0.029 ND AD-64279.1 0.882 ND 0.034 ND AD-64320.1 0.589 ND 0.017 ND AD-64284.1 0.696 ND 0.119 ND AD-64326.1 0.552 ND 0.009 ND AD-64281.1 0.921 ND 0.019 ND AD-64323.1 0.715 ND 0.097 ND AD-64311.1 0.815 ND 0.030 ND AD-64357.1 0.549 ND 0.001 ND AD-64272.2 0.965 ND 0.024 ND AD-64332.1 0.548 ND 0.013 ND AD-64293.1 0.837 ND 0.013 ND AD-64338.1 0.597 ND 0.031 ND AD-64290.1 0.489 ND 0.026 ND AD-64334.1 0.368 ND 0.003 ND AD-64282.1 0.767 ND 0.009 ND AD-64324.1 0.726 ND 0.077 ND AD-64278.1 0.951 ND 0.077 ND AD-64319.1 0.895 ND 0.029 ND AD-64307.1 0.890 ND 0.065 ND AD-64353.1 0.567 ND 0.500 ND AD-64277.1 0.416 ND 0.019 ND AD-64277.1 0.839 ND 0.058 ND AD-64318.1 0.613 ND 0.042 ND AD-64318.1 0.768 ND 0.042 ND AD-64313.1 0.698 ND 0.062 ND AD-64359.1 0.441 ND 0.081 ND AD-64294.1 0.563 ND 0.066 ND AD-64339.1 0.486 ND 0.044 ND AD-63968.5 0.57 0.72 0.07 0.03 AD-63940.3 0.81 0.83 0.11 0.03 AD-64710.1 0.79 0.85 0.12 0.04 AD-64716.1 0.73 0.85 0.08 0.01 AD-64722.1 0.67 0.80 0.06 0.02 AD-64728.1 0.74 0.87 0.06 0.05 AD-64734.1 0.78 0.83 0.08 0.05 AD-64739.1 0.73 0.85 0.07 0.02 AD-64700.1 0.54 0.75 0.13 0.02 AD-64705.1 0.67 0.79 0.15 0.04 AD-64711.1 0.57 0.83 0.13 0.04 AD-64717.1 0.72 0.83 0.13 0.02 AD-64723.1 0.83 0.87 0.12 0.01 AD-64729.1 0.74 0.87 0.08 0.07 AD-64735.1 0.73 0.89 0.05 0.04 AD-64740.1 0.89 0.88 0.05 0.07 AD-64701.1 0.88 0.84 0.07 0.05 AD-64706.1 0.71 0.88 0.12 0.05 AD-64712.1 0.81 0.86 0.13 0.07 AD-64718.1 0.84 0.89 0.16 0.01 AD-64730.1 0.88 0.89 0.02 0.04 AD-64736.1 0.80 0.88 0.10 0.05 AD-64741.1 0.85 0.83 0.06 0.05 AD-64702.1 0.87 0.93 0.02 0.06 AD-64707.1 0.95 0.88 0.05 0.08 AD-64713.1 0.90 0.85 0.08 0.03 AD-64719.1 0.80 0.89 0.09 0.09 AD-64725.1 0.70 0.84 0.09 0.03 AD-64731.1 0.82 0.87 0.04 0.08 AD-64737.1 0.76 0.84 0.09 0.08 AD-64742.1 0.76 0.85 0.09 0.03 AD-64703.1 0.79 0.88 0.05 0.02 AD-64708.1 0.83 0.82 0.08 0.06 AD-64714.1 0.75 0.85 0.12 0.03 AD-64720.1 0.61 0.81 0.17 0.04 AD-64726.1 0.75 0.83 0.07 0.02 AD-64732.1 0.86 0.84 0.14 0.10 AD-64738.1 0.80 0.90 0.04 0.02 AD-64743.1 0.75 0.85 0.12 0.04 AD-64704.1 0.67 0.78 0.16 0.02 AD-64709.1 0.83 0.86 0.16 0.03 AD-64715.1 0.87 0.88 0.09 0.04 AD-64721.1 0.77 0.82 0.12 0.06 AD-64727.1 0.75 0.85 0.14 0.02 AD-64733.1 0.67 0.81 0.14 0.03

Example 3. Synthesis and In Vitro Screening of Additional siRNA Duplexes

Additional iRNA molecules targeting the HBV genome were synthesized as described above. A detailed list of the additional unmodified HBV sense and antisense strand sequences is shown in Table 6 and a detailed list of the modified HBV sense and antisense strand sequences is shown in Table 7.

TABLE 6 Unmodified Sense and Antisense Strand Sequences of HBV dsRNAs SEQ SEQ Duplex Sense Sequence ID Antisense Sequence ID ID (5′ to 3′) NO: (5′ to 3′) NO: AD-65369.1 UCGUGGUGGACUUCUCUCA 909 UGAGAGAAGUCCACCACGAUU 938 AD-65381.1 UCGUGGUGGACUUCUCUCA 910 UGAGAGAAGUCCACCACGAUU 939 AD-63962.1 UCGUGGUGGACUUCUCUCA 911 UGAGAGAAGUCCACCACGAUU 940 AD-63938.1 ACUCGUGGUGGACUUCUCUCA 912 UGAGAGAAGUCCACCACGAGUCU 941 AD-65561.1 UCGUGGUGGACUUCUCUCA 913 UGAGAGAAGUCCACCACGAUU 942 AD-65566.1 UCGUGGUGGACUUCUCUCA 914 UGAGAGAAGUCCACCACGAUU 943 AD-63944.1 UCGUGGUGGACUUCUCUCAUU 915 UGAGAGAAGUCCACCACGAUU 944 AD-63968.1 ACUCGUGGUGGACUUCUCUCA 916 UGAGAGAAGUCCACCACGAGUCU 945 AD-65406.1 UCGUGGUGGACUUCUCUCA 917 UGAGAGAAGUCCACCACGAUU 946 AD-65396.1 ACUCGUGGUGGACUUCUCUCA 918 UGAGAGAAGUCCACCACGAGUUU 947 AD-65427.1 GUGCACUUCGCUUCACCUCUA 919 UAGAGGUGAAGCGAAGUGCACUU 948 AD-65573.1 GUGCACUUCGCUUCACCUCUA 920 UAGAGGUGAAGCGAAGUGCACAC 949 AD-65432.1 GCACUUCGCUUCACCUCUA 921 UAGAGGUGAAGCGAAGUGCAC 950 AD-64332.1 GUGCACUUCGCUUCACCUCUG 922 CAGAGGUGAAGCGAAGUGCACAC 951 AD-64322.1 AUGUGUCUGCGGCGUUUUAUA 923 UAUAAAACGCCGCAGACACAUCC 952 AD-64272.1 GUGCACUUCGCUUCACCUCUG 924 CAGAGGUGAAGCGAAGUGCACAC 953 AD-65583.1 GCACUUCGCUUCACCUCUA 925 UAGAGGUGAAGCGAAGUGCUU 954 AD-63994.1 GGUGGACUUCUCUCAAUUU 926 AAAUUGAGAGAAGUCCACCAC 955 AD-65370.1 CGUGGUGGACUUCUCUCAAUU 927 AAUUGAGAGAAGUCCACCAGCAG 956 AD-65265.1 GUGGUGGACUUCUCUCAAUUU 928 AAAUUGAGAGAAGUCCACCACGA 957 AD-65407.1 CGUGGUGGACUUCUCUCAAUU 929 AAUUGAGAGAAGUCCACCAGCAG 958 AD-64027.1 GGUGGACUUCUCUCAAUUU 930 AAAUUGAGAGAAGUCCACCAC 959 AD-65266.1 GUGGUGGACUUCUCUCAAUUU 931 AAAUUGAGAGAAGUCCACCACGA 960 AD-65389.1 UGGUGGUCTUCUCUAAAUU 932 AAUUGAGAGAAGUCCACCAUU 961 AD-64008.1 GUGGUGGACUUCUCUCAAUUU 933 AAAUUGAGAGAAGUCCACCACGA 962 AD-65377.1 CGUGGUGGUCTUCUCUAAAUU 934 AAUUGAGAGAAGUCCACCAGCUU 963 AD-65409.2 GGUGGACUUCUCUCAAUUUUA 935 UAAAAUUGAGAGAAGUCCACCAC 964 AD-65403.1 GGUGGACUUCUCUCAAUUUUA 936 UAAAAUUGAGAGAAGUCCACCAC 965 AD-65385.1 UGGACUACTCUCAAAUUUA 937 UAAAAUUGAGAGAAGUCCAUU 966

TABLE 7 Modified Sense and Antisense Strand Sequences of HBV dsRNAs SEQ SEQ Sense Sequence ID Antisense Sequence ID DuplexID (5′ to 3′) NO: (5′ to 3′) NO: AD-65369 uscsguGfgUfGfGfacuuCfUfcucaL96 967 PusGfsagaGfaAfGfuccaCfcAfcgasusu  996 AD-65381 uscsguGfgUfGfGfacuucucucaL96 968 PusGfsagaGfaAfGfuccaCfcAfcgasusu  997 AD-63962 Y44uscsGfuGfgUfgGfaCfuUfcUfcUfcAfY44 969 PusGfsaGfaGfaAfgUfcCfaCfcAfcGfasusu  998 AD-63938 Y44ACUCGUGGUGGACUUCUCUCA 970 UGAGAGAAGUCCACCACGAGUCU  999 AD-65561 uscsguGfgUfGfGfacuuCfUfcucaL96 971 UfsGfsagaGfaAfGfuccaCfcAfcgasusu 1000 AD-65566 uscsguGfgUfGfGfacuucucucaL96 972 UfsGfsagaGfaAfGfuccaCfcAfcgasusu 1001 AD-63944 Y44ucGuGGuGGAcuucucucAusuY44 973 UfGfagAfgAfAfGUfccaCfCAfcgAusu 1002 AD-63968 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 974 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 1003 AD-65406 uscsguGfgUfGfGfacuuCfUfcucaL96 975 usGfsagaGfaAfGfuccaCfcAfcgasusu 1004 AD-65396 ascsucguGfgUfGfGfacuucucucaL96 976 usGfsagaGfaaguccaCfcAfcgagususu 1005 AD-65427 gsusgcacUfuCfGfCfuucaccucuaL96 977 PusAfsgagGfugaagcgAfaGfugcacsusu 1006 AD-65573 gsusgcacUfuCfGfCfuucaCfCfucuaL96 978 UfsAfsgagGfuGfAfagcgAfaGfugcacsasc 1007 AD-65432 gscsacUfucGfCfuucacCfucuaL96 979 PusAfsgagGfuGfAfagcgAfaGfugcsasc 1008 AD-64332 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuGfL96 980 PcsAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 1009 AD-64322 AfsusGfuGfuCfuGfCfGfgCfgUfuUfuAfuAfL96 981 PusAfsuAfaAfaCfgCfcgcAfgAfcAfcAfuscsc 1010 AD-64272 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuGfL96 982 csAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 1011 AD-65583 gscsacuucgdCuucac(Cgn)ucuaL96 983 usdAsgagdGugaagcgdAagugcsusu 1012 AD-63994 gsgsUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 984 PasAfsaUfuGfaGfaGfaagUfcCfaCfcsasc 1013 AD-65370 csgsugguGfgAfCfUfucucUfCfaauuL96 985 asAfsuugAfgAfGfaaguCfcAfccagcsasg 1014 AD-65265 gsusggugGfaCfUfUfcUfcucaauuuL96 986 asAfsaUfugagaGfaagUfcCfaccAfcsgsa 1015 AD-65407 csgsugguGfgAfCfUfucucUfCfaauuL96 987 asAfsuugAfgAfgAfaguCfcAfccagcsasg 1016 AD-64027 gsgsUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 988 asAfsaUfuGfaGfaGfaagUfcCfaCfcsasc 1017 AD-65266 gsusggugGfaCfUfUfcucuCfaauuuL96 989 asAfsaUfugagaGfaagUfcCfaccAfcsgsa 1018 AD-65389 usgsgudGgucdTucucuaaauuL96 990 asdAsuugagagdAagudCcaccasusu 1019 AD-64008 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 991 asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa 1020 AD-65377 csgsuggudGgucdTucucuaaauuL96 992 asdAsuugagagdAagudCcaccagcsusu 1021 AD-65409 gsgsuggaCfuUfCfUfcucaAfUfuuuaL96 993 PusAfsaaaUfuGfAfgagaAfgUfccaccsasc 1022 AD-65403 gsgsuggaCfuUfCfUfcucaAfUfuuuaL96 994 usAfsaaaUfuGfAfgagaAfgUfccaccsasc 1023 AD-65385 usgsgacuacdTcucaaauuuaL96 995 usdAsaaauugadGagadAguccasusu 1024

A single dose screen of these duplexes was performed in duplicate by transfecting the duplexes into HepG2.215 and Hep3B cells and measuring HBV viral RNA using primer/probe pairs to detect HBV P open reading frame (ORF) RNA (PORF-1_A and PORF-1_B) and/or primer sets to detect HBV S ORF RNA (SORF-2_A and SORF-2_B). The results of the assays in HepG2.2.15 cells are shown in Table 8 and the results of the assays in Hep3B cells are provided in Table 9.

TABLE 8 HBV single dose screen In HepG2.2.15 cells PORF-1 SORF-2 PORF-1 Primer/ SORF-2 Primer/ Primer/ Probe Set Primer/ Probe Set Probe Set Duplicate Probe Set Duplicate Experi- Experi- Experi- Experi- DuplexID ment A ment B ment A ment B AD-65369 0.1875 0.042 0.0446 0.3018 AD-65381 0.086  0.249 0.1008 0.553 AD-63962 0.4838 0.3475 0.2237 0.5258 AD-63938 0.3587 2.1213 0.0501 1.1434 AD-65561 0.1076 0.3801 0.0718 0.6897 AD-65566 0.4127 0.3211 0.185 11.1161 AD-63944 0.9489 0.7098 0.393 0.2771 AD-63968 NoIC50 NoIC50 1.8788 NoIC50 AD-65406 3.3749 18.8396 3.8204 2.2662 AD-65396 NoIC50 6.8758 3.7382 4.2157 AD-65427 0.0089 0.0181 0.0066 0.015 AD-65573 0.0174 0.0332 0.0029 0.0227 AD-65432 0.0211 0.0593 0.0112 0.0366 AD-64332 0.0268 0.0329 0.0624 0.0217 AD-64322 0.0963 0.1077 0.0992 0.0963 AD-64272 0.0773 0.1199 0.0763 0.093 AD-65583 0.1624 0.2228 0.1568 0.1496 AD-63994 0.7019 0.1467 0.0832 0.0385 AD-65370 0.2404 0.7916 0.3952 0.1964 AD-65265 0.2255 0.5008 0.2893 0.318 AD-65407 0.9533 0.261 0.4254 0.1121 AD-64027 0.7692 0.5887 0.5208 0.5697 AD-65266 3.4109 0.5055 0.8532 0.3658 AD-65389 0.9172 0.6514 0.4915 0.2872 AD-64008 1.2738 0.7865 1.9519 0.808 AD-65377 0.6052 1.6 24.9403 0.6065 AD-65409 1.8304 1.6479 0.104 0.0557 AD-65403 12.1516  0.667 1.006 0.233 AD-65385 NoIC50 NoIC50 NoIC50 NoIC50

TABLE 9 HBV single dose screen In Hep3B cells PORF-1 Primer/ PORF-1 Primer/ Probe Set Probe Set DuplexID Experiment A Experiment B AD-65369 0.0982 0.0508 AD-65381 0.2392 0.1097 AD-63962 0.0769 0.0706 AD-63938 0.039  0.0111 AD-65561 0.6316 0.6931 AD-65566 0.2747 0.5331 AD-63944 0.1317 0.0566 AD-63968 0.4374 0.8811 AD-65406 1.4961 1.2573 AD-65396 1.9971 0.9952 AD-65427 0.0234 0.006  AD-65573 0.0346 0.0334 AD-65432 0.0352 0.2664 AD-64332 0.0221 0.4541 AD-64322 0.1743 0.1616 AD-64272 0.1885 0.6699 AD-65583 0.1241 8.1611 AD-63994 3.3623 5.2897 AD-65370 0.2281 NoIC50 AD-65265 NoIC50 7.3426 AD-65407 0.1404 1.3833 AD-64027 27.1417  1.1832 AD-65266 NoIC50 NoIC50 AD-65389 NoIC50 NoIC50 AD-64008 NoIC50 NoIC50 AD-65377 NoIC50 NoIC50 AD-65409 1.8065 3.436  AD-65403 0.5113 18.0359  AD-65385 NoIC50 NoIC50

A subset of these duplexes were also assayed for in vitro metabolic stability using two assays, a tritosome stability assay and a cytosol stability assay.

For the tritosome stability assays, rat liver tritosomes (Xenotech custom product PR14044) were thawed to room temperature and diluted to 0.5 units/mL Acid Phosphatase in 20 mM Sodium Citrate pH 5.0 Buffer. Twenty-four hour samples were prepared by mixing 100 μL of 0.5 units/mL Acid Phosphatase Tritosomes with 25 μL of 0.4 mg/mL siRNA sample in a microcentrifuge tube and incubating for twenty-four hours in an eppendorf Thermomixer set to 37° C. and 300 rpm. After twenty-four hours of incubation 300 μL of Phenomenex Lysis Loading Buffer (Cat. # ALO-8498) and 12.5 μL of a 0.4 mg/mL internal standard siRNA were added to each sample. Time 0 hour samples were prepared by by mixing 100 μL of 0.5 units/mL Acid Phosphatase Tritosomes with 25 μL of 0.4 mg/mL siRNA sample, 300 μL of Phenomenex Lysis Loading Buffer, and 12.5 μL of a 0.4 mg/mL internal standard siRNA. siRNA was extracted from twenty-four hour samples and 0 hour samples using a Phenomenex Clarity OTX Starter Kit (Cat. # KSO-8494). After the samples were extracted they were transferred to a microcentrifuge tube and dried down using a Labconco CentriVap Concentrator (Cat. #7810010). The samples were then resuspended with 500 μL of nuclease free water. Fifty μL of each sample was run on an Agilent Technologies 1260 Infinity Binary LC with Agilent Technologies 6130 Quadrupole LC/MS. The Quaternary pump method was run for 12.20 minutes at 0.400 mL/min with the following timetable:

Time Function Parameter 0.20 5% Buffer A(16 mM TEA 200 mM HFIP), 95% Buffer B (100% Methanol) 2.50 5% Buffer A(16 mM TEA 200 mM HFIP), 95% Buffer B (100% Methanol) 3.00 100% Buffer A(16 mM TEA 200 mM HFIP) The Binary Pump method was run for 12.20 min at 0.700 mL/min with the following timetable:

Time Function Parameter 0.00 100% Buffer A(16 mM TEA 200 mM HFIP) 0.40 100% Buffer A(16 mM TEA 200 mM HFIP) 10.00 60% Buffer A(16 mM TEA 200 mM HFIP), 40% Buffer B (100% ACN) 10.10 100% Buffer A(16 mM TEA 200 mM HFIP) 12.20 100% Buffer A(16 mM TEA 200 mM HFIP) Both the left and right column was set at 75.00° C. The UV signal was measured at 260 nm wavelength. The percent remaining of each strand was calculated using the following equation:

% Strand remaining=100*(Peak Area_(Strand24h)/Peak Area_(Strand 0h)*(Peak Area_(Standard 24h)/Peak Area_(Standard 0h))).

For the cytosol stability assay, female rat liver cytosol (Xenotech Cat. # R1500.C) were thawed to room temperature and diluted to 1 mg/mL in 50 mM Tris buffer: HCl pH 7.4, 5 mM MgCl2. 24 hour samples were prepared by mixing 100 uL of 1 mg/mL Cytosol with 25 uL of 0.4 mg/mL siRNA sample in a microcentrifuge tube and incubating for 24 hours in an eppendorf Thermomixer set to 37° C. and 300 rpm. After 24 hours of incubation 300 uL of Phenomenex Lysis Loading Buffer (Cat. # ALO-8498) and 12.5 uL of a 0.4 mg/mL internal standard siRNA were added to each sample. 0 hour samples were prepared by by mixing 100 uL of lmg/mL Cytosol with 25 uL of 0.4 mg/mL siRNA sample, 300 uL of Phenomenex Lysis Loading Buffer, and 12.5 uL of a 0.4 mg/mL internal standard siRNA. siRNA was extracted from 24 hour samples and 0 hour samples using a Phenomenex Clarity OTX Starter Kit (Cat. # KSO-8494). After the samples were extracted they were transferred to a microcentrifuge tube and dried down using a Labconco CentriVap Concentrator (Cat. #7810010). The samples were then resuspended with 500 uL of nuclease free water. 50 uL of each sample was run on an Agilent Technologies 1260 Infinity Binary LC with Agilent Technologies 6130 Quadrupole LC/MS. The Quaternary pump method was run for 12.20 minutes at 0.400 mL/min with the following timetable:

Time Function Parameter 0.20 5% Buffer A(16 mM TEA 200 mM HFIP), 95% Buffer B (100% Methanol) 2.50 5% Buffer A(16 mM TEA 200 mM HFIP), 95% Buffer B (100% Methanol) 3.00 100% Buffer A(16 mM TEA 200 mM HFIP) The Binary Pump method was run for 12.20 min at 0.700 mL/min with the following timetable:

Time FunctionParameter

Time Function Parameter 0.00 100% Buffer A(16 mM TEA 200 mM HFIP) 0.40 100% Buffer A(16 mM TEA 200 mM HFIP) 10.00 60% Buffer A(16 mM TEA 200 mM HFIP), 40% Buffer B (100% ACN) 10.10 100% Buffer A(16 mM TEA 200 mM HFIP) 12.20 100% Buffer A(16 mM TEA 200 mM HFIP)

Both the left and right column was set at 75.00° C. The UV signal was measured at 260 nm wavelength. The percent remaining of each strand was calculated using the following equation:

% Strand remaining=100*(Peak Area_(Strand24h)/Peak Area_(Strand 0h)*(Peak Area_(Standard 24h)/Peak Area_(Standard 0h))).

The results of the twenty-four hour tritosome stability assays are provided in Table 10 and the results of the twenty-four hour cytosol stability assays are provided in Table 11.

TABLE 10 Twenty-four hour tritosome stability assays. % Antisense % Sense Remaining Remaining DuplexID 87.59 72.43 AD-65381 67.59 82.48 AD-65566 30.52 34.98 AD-63968 115.17 79.61 AD-65427 43.00 76.84 AD-65573 129.69 128.59 AD-64272 100.30 119.85 AD-65407 94.06 110.90 AD-64008 98.63 127.48 AD-65377 105.06 119.88 AD-65409 117.55 104.30 AD-65403

TABLE 11 Twenty-four hour cytosol stability assays. % Antisense % Sense Remaining Remaining DuplexID 67.78 22.42 AD-65381 55.89 15.26 AD-65566 88.39 46.94 AD-63968 89.50 66.35 AD-65427 69.01 41.47 AD-65573 96.77 78.00 AD-64272 64.46 24.10 AD-65407 35.39 26.39 AD-64008 79.98 66.50 AD-65377 86.24 74.25 AD-65409 60.45 62.41 AD-65403

Example 4. Synthesis and Screening of Additional siRNA Duplexes

Additional iRNA molecules targeting the HBV genome were designed and synthesized as described above. A detailed list of the additional unmodified HBV sense and antisense strand sequences is shown in Table 12 and a detailed list of the modified HBV sense and antisense strand sequences is shown in Table 13.

TABLE 12 Unmodified Sense and Antisense Strand Sequences of HBV dsRNAs SEQ SEQ Duplex Sense Sequence ID Antisense Antisense Sequence ID ID Sense ID Unmodified (5′ to 3′) NO: ID Unmodified (5′ to 3′) NO: AD-65381 A-130366.9 UCGUGGUGGACUUCUCUCA 1025 A-131904.1 UGAGAGAAGUCCACCACGAUU 1036 AD-66019 A-130366.9 UCGUGGUGGACUUCUCUCA 1026 A-131904.1 UGAGAGAAGUCCACCACGAUU 1037 AD-65375 A-130366.9 UCGUGGUGGACUUCUCUCA 1027 A-130364.7 UGAGAGAAGUCCACCACGAUU 1038 AD-65427 A-130441.7 GUGCACUUCGCUUCACCUCUA 1028 A-131905.1 UAGAGGUGAAGCGAAGUGCACUU 1039 AD-66110 A-130441.7 GUGCACUUCGCUUCACCUCUA 1029 A-131905.1 UAGAGGUGAAGCGAAGUGCACUU 1040 AD-65421 A-130441.7 GUGCACUUCGCUUCACCUCUA 1030 A-130442.6 UAGAGGUGAAGCGAAGUGCACUU 1041 AD-65407 A-130371.12 CGUGGUGGACUUCUCUCAAUU 1031 A-130372.5 AAUUGAGAGAAGUCCACCAGCAG 1042 AD-65377 A-130384.4 CGUGGUGGUCTUCUCUAAAUU 1032 A-130748.3 AAUUGAGAGAAGUCCACCAGCUU 1043 AD-65409 A-130388.15 GGUGGACUUCUCUCAAUUUUA 1033 A-131906.1 UAAAAUUGAGAGAAGUCCACCAC 1044 AD-66111 A-130388.15 GGUGGACUUCUCUCAAUUUUA 1034 A-131906.1 UAAAAUUGAGAGAAGUCCACCAC 1045 AD-65403 A-130388.15 GGUGGACUUCUCUCAAUUUUA 1035 A-130389.4 UAAAAUUGAGAGAAGUCCACCAC 1046

TABLE 13 Modified Sense and Antisense Strand Sequences of HBV dsRNAs SEQ SEQ Duplex Sense Sequence ID Antisense Antisense Sequence ID ID Sense ID (5′ to 3′) NO: ID (5′ to 3′) NO: AD-65381 A-130366.9 uscsguGfgUfGfGfa 1047 A-131904.1 P usGfsagaGfaAfGfuc 1058 cuucucucaL96 caCfcAfcgasusu AD-66019 A-130366.9 uscsguGfgUfGfGfa 1048 A-131904.1 VP usGfsagaGfaAfGfu 1059 cuucucucaL96 ccaCfcAfcgasusu AD-65375 A-130366.9 uscsguGfgUfGfGfa 1049 A-130364.7 usGfsagaGfaAfGfucc 1060 cuucucucaL96 aCfcAfcgasusu AD-65427 A-130441.7 gsusgcacUfuCfGfC 1050 A-131905.1 P usAfsgagGfugaagcg 1061 fuucaccucuaL96 AfaGfugcacsusu AD-66110 A-130441.7 gsusgcacUfuCfGfC 1051 A-131905.1 VP usAfsgagGfugaagc 1062 fuucaccucuaL96 gAfaGfugcacsusu AD-65421 A-130441.7 gsusgcacUfuCfGfC 1052 A-130442.6 usAfsgagGfugaagcgA 1063 fuucaccucuaL96 faGfugcacsusu AD-65407 A-130371.12 csgsugguGfgAfCfU 1053 A-130372.5 asAfsuugAfgAfgAfag 1064 fucucUfCfaauuL96 uCfcAfccagcsasg AD-65377 A-130384.4 csgsuggudGgucdTu 1054 A-130748.3 asdAsuugagagdAagud 1065 cucuaaauuL96 Ccaccagcsusu AD-65409 A-130388.15 gsgsuggaCfuUfCfU 1055 A-131906.1 P usAfsaaaUfuGfAfga 1066 fcucaAfUfuuuaL96 gaAfgUfccaccsasc AD-66111 A-130388.15 gsgsuggaCfuUfCfU 1056 A-131906.1 VP usAfsaaaUfuGfAfg 1067 fcucaAfUfuuuaL96 agaAfgUfccaccsasc AD-65403 A-130388.15 gsgsuggaCfuUfCfU 1057 A-130389.4 usAfsaaaUfuGfAfgag 1068 fcucaAfUfuuuaL96 aAfgUfccaccsasc

A primary single dose screen of these iRNA duplexes was performed using the Dual-Glo® Luciferase assay, as described above. The results of this screen in Cos7 cells transfected with the indicated HBV iRNAs are shown in Table 14. Data are expressed as percent of mRNA remaining relative to negative control at 24 hours.

TABLE 14 HBV single dose primary screen In Cos7 cells using Dual-Glo Luciferase ® Assay Dual luciferase primary screen DRC % Message remaining at 24 hr ED50 Duplex ID at 50 nM STDEV at 1 nM STDEV (nM) AD-65381  9.3 0.24 15.6 0.77 0.019 AD-66019 ND ND ND ND ND AD-65375 24.2 0.36 71.4 0.69 No ED50 AD-65427 28.8 1.60 41.0 1.73 0.117 AD-66110 ND ND ND ND ND AD-65421 47.6 3.49 85.5 4.76 No ED50 AD-65407 14.3 0.52 25.3 2.11 0.038 AD-65377 21.8 0.31 37.9 1.12 0.130 AD-65409  9.5 0.41 13.2 0.71 0.013 AD-66111 ND ND ND ND ND AD-65403 12.6 0.50 37.2 2.31 0.069 ND—not done

These duplexes were also assayed for dose response for silencing viral RNA using the Dual-Glo® Luciferase assay, as described above. The doses of the duplexes used for these assays were 50 nM, 8.333333333 nM, 1.388888889 nM, 0.231481481 nM, 0.038580247 nM, 0.006430041 nM, 0.001071674 nM, 0.000178612 nM, 2.97687×10⁻⁵ nM, 4.96145×10⁻⁶ nM, 8.26909×10⁻⁷ nM, and 1.37818E×10⁻⁷ nM, which represent a 1 to 6 dilution of the duplexes starting at 50 nM over 12 doses. The results of this screen in Cos7 cells transfected with the indicated HBV iRNAs are shown in Table 15. Data are expressed as percent of mRNA remaining relative to negative control at 24 hours.

TABLE 15 Dose response screen In Cos7 cells using Dual-Glo Luciferase ® Assay Dual luciferase HBV reporter cells IC50 (nM) at 24 hr Duplex Assay Assay Assay Assay Assay Assay Assay Aver- ID 1 2 3 4 5 6 7 age¹ Stdev AD- 0.019 ND ND ND ND ND ND 0.019 65381 AD- ND 0.021 0.021 0.016 0.026 0.019 0.031 0.022 0.005 66019 AD- UD 0.215 0.149 0.081 0.246 0.138 0.276 0.184 0.074 65375 AD- 0.038 0.045 0.051 0.021 0.050 0.056 0.068 0.047 0.015 65407 AD- 0.130 0.029 0.046 0.087 0.096 0.146 0.090 0.089 0.042 65377 AD- 0.013 ND ND ND ND ND ND 0.013 65409 AD- ND 0.018 0.013 0.012 0.018 0.021 0.033 0.019 0.007 66111 AD- 0.069 0.044 0.033 0.039 0.042 0.046 0.062 0.048 0.013 65403 AD- 0.017 ND ND ND ND ND ND 0.117 65427 AD- ND 0.238 0.296 0.145 0.157 0.161 ND 0.199 0.065 66110 AD- UD 1.219 1.385 2.254 0.799 2.906 ND 1.713 0.852 65421 ¹Averages from 5-7 biological replicates run in triplicate ND - not done

The in vitro efficacy and potency of these duplexes were also assayed. In particular, the dose response of the duplexes for silencing viral RNA in transfected HepG2.2.15 and Hep3B cell lysates and for silencing HBsAg in HepG2.2.15 cell supernatants were determined. Cells were transfected with 12 separate doses of the duplexes ranging from 50 nM to 1×10⁻⁷ nM and at seventy-two hours after transfection, the level of viral RNA was determined using primer/probe pairs to detect the P ORF and/or the S ORF. The level of HBsAg was determined using an ELISA assay.

The results of the P ORF viral RNA silencing in HepG2.2.15 cells using the indicated duplexes are provided in Table 16. The results of the S ORF viral RNA silencing in HepG2.2.15 cells using the indicated duplexes are provided in Table 17. The results of HBsAg silencing in HepG2.2.15 cells are provided in Table 18.

The results of the P ORF viral RNA silencing in Hep3B cells using the indicated duplexes are provided in Table 19.

TABLE 16 Dose response screen In HepG2.2.15 cells Viral RNA silencing in HepG2.2.15 cells P-ORF primer/probe set IC50 (nM) at 72 hr Duplex Optimized Assay ID Assay Development Assay 1 Assay 2 Assay 3 AD-65381 0.079 0.208 ND ND ND ND ND AD-66019 ND ND 0.265 0.010 0.022 0.032 0.023 AD-65375 12.3 UD UD UD 0.172 0.257 0.672 AD-65407 0.247 1.0 0.365 0.109 0.069 0.103 0.095 AD-65377 1.3 UD 4.9 UD 0.842 0.838 0.615 AD-65409 0.436 1.0 ND ND ND ND ND AD-66111 ND ND 0.456 0.030 50 0.294 ND AD-65403 9.2 10.4 3.4 UD 0.114 0.384 1.0 AD-65427 0.007 0.018 ND ND ND ND ND AD-66110 ND ND 0.012 0.053 0.016 0.010 0.021 AD-65421 0.069 0.091 0.034 0.006 0.002 0.003 0.007 ND - not done

TABLE 17 Dose response screen In HepG2.2.15 cells Viral RNA silencing in HepG2.2.15 cells S-ORF primer/probe set IC50 (nM) at 72 hr Duplex Optimized Assay ID Assay Development Assay 1 Assay 2 Assay 3 AD-65381 0.252 0.215 ND ND ND ND ND AD-66019 ND ND 0.245 0.011 0.009 0.016 0.005 AD-65375 45 UD UD UD 0.124 0.048 0.056 AD-65407 0.232 0.645 0.577 0.015 0.021 0.023 0.016 AD-65377 1.4 8.6 UD UD 0.575 0.483 0.117 AD-65409 0.433 0.242 ND ND ND ND ND AD-66111 ND ND 2.1 0.455 ND 0.416 ND AD-65403 0.997 0.670 0.668 UD 0.074 0.270 1.1 AD-65427 0.008 0.018 ND ND ND ND ND AD-66110 ND ND 0.022 0.050 0.035 0.038 0.020 AD-65421 0.083 0.097 0.046 0.003 0.003 0.005 0.001 ND - not done

TABLE 18 Dose response screen In HepG2.2.15 cells HBsAg ELISA IC50 (nM) Duplex ID Assay 1 AD-65381 ND AD-66019 0.105 AD-65375 1.2  AD-65407 0.102 AD-65377 2.9  AD-65409 ND AD-66111 0.018 AD-65403 0.064 AD-65427 ND AD-66110 0.002 AD-65421 0.008 ND—not done

TABLE 19 Dose response screen In Hep3B cells Hep3B cells screen DRC ED50 P-ORF primer/probe set P-ORF P-ORF Duplex ID run 1 run 2 Combined AD-65381 0.239 0.110 0.194 AD-66019 ND ND ND AD-65375 ND ND ND AD-65427 0.023 0.006 0.018 AD-66110 ND ND ND AD-65421 ND ND ND AD-65407 0.140 1.383 0.527 AD-65377 No ED50 No ED50 No ED50 AD-65409 1.807 3.436 2.905 AD-66111 ND ND ND AD-65403 0.511 18.036  5.013 ND—not done

These duplexes were also assayed for in vitro stability using two assays, a tritosome stability assay and a cytosol stability assay, as described above. The results of these assays are provided in Table 20.

TABLE 20 Twenty-four hour tritosome and cytosol stability assays. In vitro metabolic stability % parent remaining at 24 hr incubation Endo-lysosome Cytosol Duplex ID % AS % SS % AS % SS AD-65381  88  72 68 22 AD-66019 ND ND ND ND AD-65375 ND ND ND ND AD-65407 100 120 64 24 AD-65377  99 127 80 67 AD-65409 105 120 86 74 AD-66111 ND ND ND ND AD-65403 ND ND ND ND AD-65427 115  80 89 66 AD-66110 ND ND ND ND AD-65421 ND ND ND ND

Dose response screens of various combinations of these duplexes were also performed in HepG2.215 cells. The doses of the duplexes used for these assays were 50 nM, 8.333333333 nM, 1.388888889 nM, 0.231481481 nM, 0.038580247 nM, 0.006430041 nM, 0.001071674 nM, 0.000178612 nM, 2.97687×10⁻⁵ nM, 4.96145×10⁻⁶ nM, 8.26909×10^(0.7) nM, and 1.37818E x 10⁻⁷ nM, which represent a 1 to 6 dilution of the duplexes starting at 50 nM over 12 doses. At seventy-two hours after transfection of these duplexes, the level of viral RNA (P ORF and S ORF) and the level of secreted HBsAg were determined, as described above. The results of these assays are provided in Table 21.

TABLE 21 Seventy-two hour HBV single dose screen In HepG2.2.15 cells S Ag S-ORF2 S-ORF2 S-ORF2 P-ORF1 P-ORF1 P-ORF1 ELISA IC50_A IC50_B IC50_Combine IC50_A IC50_B IC50_Combine ED50 DuplexID (nM) (nM) (nM) (nM) (nM) (nM) (nM) AD-66019/ 0.0091 0.0017 0.0038 0.0213 0.002 0.0076 0.007482 AD-66110 AD-66019/ 0.0438 0.2371 0.0131 0.0367 0.0106 0.0204 0.026398 AD-65421 AD-65375/ 0.0832 1.0896 0.193 0.0377 0.2348 0.2022 0.004174 AD-66110 AD-65375/ 0.084 0.0475 0.0708 0.0566 0.0388 0.0371 0.030822 AD-65421 AD-65407/ 0.0387 0.001 0.0083 0.0402 0.0018 0.0116 0.010172 AD-66110 AD-65407/ 0.0686 0.0062 0.0225 0.0711 0.0177 0.0396 0.066556 AD-65421 AD-65377/ 0.0634 0.8267 0.6269 0.0477 0.073 0.0618 0.01435 AD-66110 AD-65377/ 0.1461 0.0468 0.1372 0.1207 0.0088 0.0451 0.03419 AD-65421 AD-66111/ 0.0382 0.0094 0.0161 0.0292 0.0027 0.0088 0.013155 AD-66110 AD-66111/ 0.1628 0.0919 0.1579 0.1297 0.0396 0.0722 0.026889 AD-65421 AD-65403/ 0.0499 0.0094 0.0444 0.0383 0.0164 0.0348 0.003783 AD-66110 AD-65403/ 0.1011 0.0007 0.0208 0.1118 0.0031 0.0297 0.014569 AD-65421

Example 5. Synthesis and In Vitro Screening of Additional siRNA Duplexes

Additional iRNA molecules targeting the X ORF of the HBV genome were designed and synthesized as described above. A detailed list of the additional unmodified HBV sense and antisense strand sequences is shown in Table 22. A detailed list of the additional modified HBV sense and antisense strand sequences is shown in Table 23.

TABLE 22 Unmodified Sense and Antisense Strand Sequences of HBV dsRNAs Sense SEQ SEQ Oligo Sense Sequence ID Antisense Antisense Sequence ID DuplexID Name (5′ to 3′) NO: OligoName (5′ to 3′) NO: AD-65776 A-131859.1 UGUGCACUUCGCUUCACCUCU 1069 A-131860.1 AGAGGUGAAGCGAAGUGCACACG 1115 AD-65782 A-131877.1 UGCACUUCGCUUCACCUCUGA 1070 A-131878.1 UCAGAGGUGAAGCGAAGUGCACA 1116 AD-65792 A-131865.1 GUGUGCACUUCGCUUCACCUA 1071 A-131866.1 UAGGUGAAGCGAAGUGCACACGG 1117 AD-65781 A-131861.1 CGUGUGCACUUCGCUUCACCU 1072 A-131862.1 AGGUGAAGCGAAGUGCACACGGU 1118 AD-64304 A-128443.6 GUGCACUUCGCUUCACCUCUA 1073 A-128444.5 UAGAGGUGAAGCGAAGUGCACAC 1119 AD-65771 A-131857.1 CCGUGUGCACUUCGCUUCACA 1074 A-131858.1 UGUGAAGCGAAGUGCACACGGUC 1120 AD-65758 A-131867.1 CACUUCGCUUCACCUCUGCAA 1075 A-131868.1 UUGCAGAGGUGAAGCGAAGUGCA 1121 AD-65777 A-131875.1 ACUUCGCUUCACCUCUGCACA 1076 A-131876.1 UGUGCAGAGGUGAAGCGAAGUGC 1122 AD-61567 A-123525.2 GGCUGUAGGCAUAAAUUGGUA 1077 A-123526.2 UACCAAUUUAUGCCUACAGCCUC 1123 AD-65772 A-131873.1 UUCGCUUCACCUCUGCACGUA 1078 A-131874.1 UACGUGCAGAGGUGAAGCGAAGU 1124 AD-65767 A-131871.1 UCGCUUCACCUCUGCACGUCA 1079 A-131872.1 UGACGUGCAGAGGUGAAGCGAAG 1125 AD-65763 A-131869.1 CUUCGCUUCACCUCUGCACGU 1080 A-131870.1 ACGUGCAGAGGUGAAGCGAAGUG 1126 AD-64281 A-128395.3 CCCCGUCUGUGCCUUCUCAUA 1081 A-128396.2 UAUGAGAAGGCACAGACGGGGAG 1127 AD-64311 A-128391.3 CCGUCUGUGCCUUCUCAUCUA 1082 A-128392.2 UAGAUGAGAAGGCACAGACGGGG 1128 AD-65790 A-131837.1 CCAGCACCAUGCAACUUUUUA 1083 A-131838.1 UAAAAAGUUGCAUGGUGCUGGUG 1129 AD-65761 A-131841.1 CACCAGCACCAUGCAACUUUU 1084 A-131842.1 AAAAGUUGCAUGGUGCUGGUGCG 1130 AD-65786 A-131849.1 CACCAUGCAACUUUUUCACCU 1085 A-131850.1 AGGUGAAAAAGUUGCAUGGUGCU 1131 AD-65785 A-131835.1 CAAUGUCAACGACCGACCUUA 1086 A-131836.1 UAAGGUCGGUCGUUGACAUUGCA 1132 AD-65787 A-131863.1 CGCUUCACCUCUGCACGUCGA 1087 A-131864.1 UCGACGUGCAGAGGUGAAGCGAA 1133 AD-65770 A-131845.1 ACCUUGAGGCAUACUUCAAAG 1088 A-131846.1 CUUUGAAGUAUGCCUCAAGGUCG 1134 AD-65766 A-131843.1 CCGACCUUGAGGCAUACUUCA 1089 A-131844.1 UGAAGUAUGCCUCAAGGUCGGUC 1135 AD-61555 A-123521.2 GACCUUGAGGCAUACUUCAAA 1090 A-123522.2 UUUGAAGUAUGCCUCAAGGUCGG 1136 AD-65762 A-131855.1 ACCGACCUUGAGGCAUACUUA 1091 A-131856.1 UAAGUAUGCCUCAAGGUCGGUCG 1137 AD-65755 A-131827.1 UCGCAUGGAGACCACCGUGAA 1092 A-131828.1 UUCACGGUGGUCUCCAUGCGACG 1138 AD-65788 A-131811.1 UUACAUAAGAGGACUCUUGGA 1093 A-131812.1 UCCAAGAGUCCUCUUAUGUAAGA 1139 AD-65768 A-131803.1 UCUUACAUAAGAGGACUCUUA 1094 A-131804.1 UAAGAGUCCUCUUAUGUAAGACC 1140 AD-61561 A-123523.2 ACUUCAAAGACUGUUUGUUUA 1095 A-123524.2 UAAACAAACAGUCUUUGAAGUAU 1141 AD-65764 A-131801.1 UACUUCAAAGACUGUUUGUUU 1096 A-131802.1 AAACAAACAGUCUUUGAAGUAUG 1142 AD-65753 A-131799.1 AUACUUCAAAGACUGUUUGUU 1097 A-131800.1 AACAAACAGUCUUUGAAGUAUGC 1143 AD-65765 A-131817.1 UUGUUUAAAGACUGGGAGGAA 1098 A-131818.1 UUCCUCCCAGUCUUUAAACAAAC 1144 AD-65769 A-131819.1 GCAUACUUCAAAGACUGUUUA 1099 A-131820.1 UAAACAGUCUUUGAAGUAUGCCU 1145 AD-65759 A-131815.1 CAAAGACUGUUUGUUUAAAGA 1100 A-131816.1 UCUUUAAACAAACAGUCUUUGAA 1146 AD-65774 A-131831.1 AGACUGUUUGUUUAAAGACUA 1101 A-131832.1 UAGUCUUUAAACAAACAGUCUUU 1147 AD-65778 A-131807.1 GUUUGUUUAAAGACUGGGAGA 1102 A-131808.1 UCUCCCAGUCUUUAAACAAACAG 1148 AD-65773 A-131805.1 GGGGGAGGAGAUUAGAUUAAA 1103 A-131806.1 UUUAAUCUAAUCUCCUCCCCCAA 1149 AD-65789 A-131825.1 GGGGAGGAGAUUAGAUUAAAG 1104 A-131826.1 CUUUAAUCUAAUCUCCUCCCCCA 1150 AD-65783 A-131809.1 GUUGGGGGAGGAGAUUAGAUU 1105 A-131810.1 AAUCUAAUCUCCUCCCCCAACUC 1151 AD-65754 A-131813.1 UUGGGGGAGGAGAUUAGAUUA 1106 A-131814.1 UAAUCUAAUCUCCUCCCCCAACU 1152 AD-65779 A-131821.1 GGGAGGAGAUUAGAUUAAAGA 1107 A-131822.1 UCUUUAAUCUAAUCUCCUCCCCC 1153 AD-65791 A-131851.1 UUAGAUUAAAGGUCUUUGUAA 1108 A-131852.1 UUACAAAGACCUUUAAUCUAAUC 1154 AD-65760 A-131829.1 UAGAUUAAAGGUCUUUGUACU 1109 A-131830.1 AGUACAAAGACCUUUAAUCUAAU 1155 AD-65784 A-131823.1 AUUAGAUUAAAGGUCUUUGUA 1110 A-131824.1 UACAAAGACCUUUAAUCUAAUCU 1156 AD-65757 A-131853.1 GAGGAGAUUAGAUUAAAGGUA 1111 A-131854.1 UACCUUUAAUCUAAUCUCCUCCC 1157 AD-65775 A-131847.1 GGACUCUUGGACUCUCUGCAA 1112 A-131848.1 UUGCAGAGAGUCCAAGAGUCCUC 1158 AD-65780 A-131833.1 ACUCUUGGACUCUCUGCAAUA 1113 A-131834.1 UAUUGCAGAGAGUCCAAGAGUCC 1159 AD-65756 A-131839.1 AGAUUAAAGGUCUUUGUACUA 1114 A-131840.1 UAGUACAAAGACCUUUAAUCUAA 1160

TABLE 23 Unmodified Sense and Antisense Strand Sequences of HBV dsRNAs Sense SEQ Antisense SEQ Duplex Oligo Sense Sequence ID Oligo Antisense Sequence ID ID Name (5′ to 3′) NO: Name (5′ to 3′) NO: AD-65776 A-131859.1 UfsgsUfgCfaCfuUfCfG 1161 A-131860.1 asGfsaGfgUfgAfaGfc 1207 fcUfuCfaCfcUfcUfL96 gaAfgUfgCfaCfascsg AD-65782 A-131877.1 UfsgsCfaCfuUfcGfCfU 1162 A-131878.1 usCfsaGfaGfgUfgAfa 1208 fuCfaCfcUfcUfgAfL96 gcGfaAfgUfgCfascsa AD-65792 A-131865.1 GfsusGfuGfcAfcUfUfC 1163 A-131866.1 usAfsgGfuGfaAfgCfg 1209 fgCfuUfcAfcCfuAfL96 aaGfuGfcAfcAfcsgsg AD-65781 A-131861.1 CfsgsUfgUfgCfaCfUfU 1164 A-131862.1 asGfsgUfgAfaGfcGfa 1210 fcGfcUfuCfaCfcUfL96 agUfgCfaCfaCfgsgsu AD-64304 A-128443.6 GfsusGfcAfcUfuCfGfC 1165 A-128444.5 usAfsgAfgGfuGfaAfg 1211 fuUfcAfcCfuCfuAfL96 cgAfaGfuGfcAfcsasc AD-65771 A-131857.1 CfscsGfuGfuGfcAfCfU 1166 A-131858.1 usGfsuGfaAfgCfgAfa 1212 fuCfgCfuUfcAfcAfL96 guGfcAfcAfcGfgsusc AD-65758 A-131867.1 CfsasCfuUfcGfcUfUfC 1167 A-131868.1 usUfsgCfaGfaGfgUfg 1213 faCfcUfcUfgCfaAfL96 aaGfcGfaAfgUfgscsa AD-65777 A-131875.1 AfscsUfuCfgCfuUfCfA 1168 A-131876.1 usGfsuGfcAfgAfgGfu 1214 fcCfuCfuGfcAfcAfL96 gaAfgCfgAfaGfusgsc AD-61567 A-123525.2 GfsgsCfuGfuAfgGfCfA 1169 A-123526.2 usAfscCfaAfuUfuAfu 1215 fuAfaAfuUfgGfuAfL96 gcCfuAfcAfgCfcsusc AD-65772 A-131873.1 UfsusCfgCfuUfcAfCfC 1170 A-131874.1 usAfscGfuGfcAfgAfg 1216 fuCfuGfcAfcGfuAfL96 guGfaAfgCfgAfasgsu AD-65767 A-131871.1 UfscsGfcUfuCfaCfCfU 1171 A-131872.1 usGfsaCfgUfgCfaGfa 1217 fcUfgCfaCfgUfcAfL96 ggUfgAfaGfcGfasasg AD-65763 A-131869.1 CfsusUfcGfcUfuCfAfC 1172 A-131870.1 asCfsgUfgCfaGfaGfg 1218 fcUfcUfgCfaCfgUfL96 ugAfaGfcGfaAfgsusg AD-64281 A-128395.3 CfscsCfcGfuCfuGfUfG 1173 A-128396.2 usAfsuGfaGfaAfgGfc 1219 fcCfuUfcUfcAfuAfL96 acAfgAfcGfgGfgsasg AD-64311 A-128391.3 CfscsGfuCfuGfuGfCfC 1174 A-128392.2 usAfsgAfuGfaGfaAfg 1220 fuUfcUfcAfuCfuAfL96 gcAfcAfgAfcGfgsgsg AD-65790 A-131837.1 CfscsAfgCfaCfcAfUfG 1175 A-131838.1 usAfsaAfaAfgUfuGfc 1221 fcAfaCfuUfuUfuAfL96 auGfgUfgCfuGfgsusg AD-65761 A-131841.1 CfsasCfcAfgCfaCfCfA 1176 A-131842.1 asAfsaAfgUfuGfcAfu 1222 fuGfcAfaCfuUfuUfL96 ggUfgCfuGfgUfgscsg AD-65786 A-131849.1 CfsasCfcAfuGfcAfAfC 1177 A-131850.1 asGfsgUfgAfaAfaAfg 1223 fuUfuUfuCfaCfcUfL96 uuGfcAfuGfgUfgscsu AD-65785 A-131835.1 CfsasAfuGfuCfaAfCfG 1178 A-131836.1 usAfsaGfgUfcGfgUfc 1224 faCfcGfaCfcUfuAfL96 guUfgAfcAfuUfgscsa AD-65787 A-131863.1 CfsgsCfuUfcAfcCfUfC 1179 A-131864.1 usCfsgAfcGfuGfcAfg 1225 fuGfcAfcGfuCfgAfL96 agGfuGfaAfgCfgsasa AD-65770 A-131845.1 AfscsCfuUfgAfgGfCfA 1180 A-131846.1 csUfsuUfgAfaGfuAfu 1226 fuAfcUfuCfaAfaGfL96 gcCfuCfaAfgGfuscsg AD-65766 A-131843.1 CfscsGfaCfcUfuGfAfG 1181 A-131844.1 usGfsaAfgUfaUfgCfc 1227 fgCfaUfaCfuUfcAfL96 ucAfaGfgUfcGfgsusc AD-61555 A-123521.2 GfsasCfcUfuGfaGfGfC 1182 A-123522.2 usUfsuGfaAfgUfaUfg 1228 faUfaCfuUfcAfaAfL96 ccUfcAfaGfgUfcsgsg AD-65762 A-131855.1 AfscsCfgAfcCfuUfGfA 1183 A-131856.1 usAfsaGfuAfuGfcCfu 1229 fgGfcAfuAfcUfuAfL96 caAfgGfuCfgGfuscsg AD-65755 A-131827.1 UfscsGfcAfuGfgAfGfA 1184 A-131828.1 usUfscAfcGfgUfgGfu 1230 fcCfaCfcGfuGfaAfL96 cuCfcAfuGfcGfascsg AD-65788 A-131811.1 UfsusAfcAfuAfaGfAfG 1185 A-131812.1 usCfscAfaGfaGfuCfc 1231 fgAfcUfcUfuGfgAfL96 ucUfuAfuGfuAfasgsa AD-65768 A-131803.1 UfscsUfuAfcAfuAfAfG 1186 A-131804.1 usAfsaGfaGfuCfcUfc 1232 faGfgAfcUfcUfuAfL96 uuAfuGfuAfaGfascsc AD-61561 A-123523.2 AfscsUfuCfaAfaGfAfC 1187 A-123524.2 usAfsaAfcAfaAfcAfg 1233 fuGfuUfuGfuUfuAfL96 ucUfuUfgAfaGfusasu AD-65764 A-131801.1 UfsasCfuUfcAfaAfGfA 1188 A-131802.1 asAfsaCfaAfaCfaGfu 1234 fcUfgUfuUfgUfuUfL96 cuUfuGfaAfgUfasusg AD-65753 A-131799.1 AfsusAfcUfuCfaAfAfG 1189 A-131800.1 asAfscAfaAfcAfgUfc 1235 faCfuGfuUfuGfuUfL96 uuUfgAfaGfuAfusgsc AD-65765 A-131817.1 UfsusGfuUfuAfaAfGfA 1190 A-131818.1 usUfscCfuCfcCfaGfu 1236 fcUfgGfgAfgGfaAfL96 cuUfuAfaAfcAfasasc AD-65769 A-131819.1 GfscsAfuAfcUfuCfAfA 1191 A-131820.1 usAfsaAfcAfgUfcUfu 1237 faGfaCfuGfuUfuAfL96 ugAfaGfuAfuGfcscsu AD-65759 A-131815.1 CfsasAfaGfaCfuGfUfU 1192 A-131816.1 usCfsuUfuAfaAfcAfa 1238 fuGfuUfuAfaAfgAfL96 acAfgUfcUfuUfgsasa AD-65774 A-131831.1 AfsgsAfcUfgUfuUfGfU 1193 A-131832.1 usAfsgUfcUfuUfaAfa 1239 fuUfaAfaGfaCfuAfL96 caAfaCfaGfuCfususu AD-65778 A-131807.1 GfsusUfuGfuUfuAfAfA 1194 A-131808.1 usCfsuCfcCfaGfuCfu 1240 fgAfcUfgGfgAfgAfL96 uuAfaAfcAfaAfcsasg AD-65773 A-131805.1 GfsgsGfgGfaGfgAfGfA 1195 A-131806.1 usUfsuAfaUfcUfaAfu 1241 fuUfaGfaUfuAfaAfL96 cuCfcUfcCfcCfcsasa AD-65789 A-131825.1 GfsgsGfgAfgGfaGfAfU 1196 A-131826.1 csUfsuUfaAfuCfuAfa 1242 fuAfgAfuUfaAfaGfL96 ucUfcCfuCfcCfcscsa AD-65783 A-131809.1 GfsusUfgGfgGfgAfGfG 1197 A-131810.1 asAfsuCfuAfaUfcUfc 1243 faGfaUfuAfgAfuUfL96 cuCfcCfcCfaAfcsusc AD-65754 A-131813.1 UfsusGfgGfgGfaGfGfA 1198 A-131814.1 usAfsaUfcUfaAfuCfu 1244 fgAfuUfaGfaUfuAfL96 ccUfcCfcCfcAfascsu AD-65779 A-131821.1 GfsgsGfaGfgAfgAfUfU 1199 A-131822.1 usCfsuUfuAfaUfcUfa 1245 faGfaUfuAfaAfgAfL96 auCfuCfcUfcCfcscsc AD-65791 A-131851.1 UfsusAfgAfuUfaAfAfG 1200 A-131852.1 usUfsaCfaAfaGfaCfc 1246 fgUfaffuUfgUfaAfL96 uuUfaAfuCfuAfasusc AD-65760 A-131829.1 UfsasGfaUfuAfaAfGfG 1201 A-131830.1 asGfsuAfcAfaAfgAfc 1247 fuCfuUfuGfuAfcUfL96 cuUfuAfaUfcUfasasu AD-65784 A-131823.1 AfsusUfaGfaUfuAfAfA 1202 A-131824.1 usAfscAfaAfgAfcCfu 1248 fgGfuCfuUfuGfuAfL96 uuAfaUfcUfaAfuscsu AD-65757 A-131853.1 GfsasGfgAfgAfuUfAfG 1203 A-131854.1 usAfscCfuUfuAfaUfc 1249 faUfuAfaAfgGfuAfL96 uaAfuCfuCfcUfcscsc AD-65775 A-131847.1 GfsgsAfcUfcUfuGfGfA 1204 A-131848.1 usUfsgCfaGfaGfaGfu 1250 fcUfcUfcUfgCfaAfL96 ccAfaGfaGfuCfcsusc AD-65780 A-131833.1 AfscsUfaffuGfgAfCfU 1205 A-131834.1 usAfsuUfgCfaGfaGfa 1251 fcUfcUfgCfaAfuAfL96 guCfcAfaGfaGfuscsc AD-65756 A-131839.1 AfsgsAfuUfaAfaGfGfU 1206 A-131840.1 usAfsgUfaCfaAfaGfa 1252 fcUfuUfgUfaCfuAfL96 ccUfuUfaAfuCfusasa

A single dose screen of these duplexes was performed in Cos7 cells at 1 nm and 50 nm using the Dual-Glo® Luciferase assay described above. The results of the assays are provided in Table 24.

TABLE 24 HBV single dose screen using Dual-Glo Luciferase ® Assay DuplexID 50 nM STDEV 1 nM STDEV AD-65776 20.11 4.21 40.79 1.89 AD-65782 26.31 3.10 61.07 9.16 AD-65792 43.31 5.24 61.09 6.02 AD-65781 25.77 3.66 39.63 2.87 AD-64304 18.87 1.26 29.72 3.37 AD-65771 17.16 1.78 37.55 2.20 AD-65758 31.74 8.26 65.77 11.05 AD-65777 59.76 11.15 77.63 5.14 AD-61567 17.69 5.29 26.45 5.66 AD-65772 58.07 9.67 75.66 4.92 AD-65767 29.65 1.60 39.64 4.36 AD-65763 25.10 5.77 47.78 9.99 AD-64281 39.07 6.80 51.46 4.19 AD-64311 20.51 1.96 37.80 3.53 AD-65790 50.41 7.00 70.30 1.95 AD-65761 13.30 4.38 21.14 3.49 AD-65786 12.45 3.51 22.62 0.33 AD-65785 36.87 6.04 51.49 4.18 AD-65787 27.97 5.73 48.18 7.65 AD-65770 22.67 5.39 41.48 8.52 AD-65766 31.44 3.35 50.25 0.45 AD-61555 18.43 10.83 22.61 0.57 AD-65762 18.87 4.86 34.94 4.81 AD-65755 47.03 9.38 83.19 9.68 AD-65788 35.85 10.13 58.07 4.78 AD-65768 24.02 2.49 28.55 2.53 AD-61561 8.11 1.29 14.26 2.27 AD-65764 16.89 3.99 29.10 1.03 AD-65753 19.10 2.87 29.79 5.26 AD-65765 55.40 10.72 76.93 8.79 AD-65769 19.24 4.47 23.18 2.54 AD-65759 48.86 4.81 87.31 13.75 AD-65774 102.27 12.33 100.79 3.24 AD-65778 64.39 2.60 80.67 2.59 AD-65773 72.64 7.87 80.80 4.83 AD-65789 73.59 4.35 94.72 3.32 AD-65783 54.41 7.15 84.46 4.32 AD-65754 62.51 4.12 102.63 21.42 AD-65779 47.40 7.51 76.20 2.05 AD-65791 12.09 0.70 19.19 3.46 AD-65760 13.50 4.84 25.37 2.09 AD-65784 19.84 1.27 31.04 3.49 AD-65757 22.66 3.97 24.50 5.81 AD-65775 47.78 3.30 58.81 3.05 AD-65780 29.10 2.87 42.85 2.73 AD-65756 10.49 1.62 19.95 2.58

Based on these assays, RNAi agents targeting five sites in the HBV X ORF (nucleotides 1551, 1577, 1580, 1806, and 1812 of GenBank Accession No. NC_003977.1 were selected for lead optimization and additional agents were designed and synthesized. These additional agents are evaluated in in vitro assays as described above. A detailed list of the additional unmodified sense and antisense strand sequences targeting the HBV X ORF is shown in Table 25. A detailed list of the additional modified sense and antisense strand sequences targeting the HBV X ORF is shown in Table 26.

These iRNA agents were also assessed for in vivo efficacy using an AAV-HBV mouse model (see, e.g., Yang, et al. (2014) Cell and Mol Immunol 11:71). This mouse model exhibits sustained HBV viremia after infection with a recombinant adeno-associated virus (AAV) carrying a replicable HBV genome. Liver expression of the HBV gene in these mice mimics HBV infection in humans and these mice exhibit significant liver inflammation and liver damage, manifested by increased ALT levels, fibrosis and steatosis.

These AAV-HBV mice were subcutaneously administered a single 3 mg/kg dose of AD-66808, AD-66809, AD-66810, AD-66811, AD-66812, AD-66813, AD-66814, AD-66815, AD-66816, and AD-66817 and the level of HBsAg was determined in the serum of the animals pre-dose, and at day 14/15 post-dose. The results of these experiments are provided in FIG. 2 and Table 27 and demonstrate that serum levels of HBsAg are decrease following a single administration of these agents. Table 27 also provides the results of a single dose screen in Cos7 cells transfected with the indicated HBV iRNAs using the Dual-Glo® Luciferase assay, as described above, for the same RNAi agents. Data are expressed as percent of mRNA remaining relative to negative control at 24 hours.

TABLE 25 Unmodified HBV X ORF Sense and Antisense Sequences. Sense Sequence SEQ ID Antisense Sequence SEQ ID DuplexID Unmodified (5′ to 3′) NO: Umodified (5′ to 3′) NO: AD-66808 GUCUGUGCCUUCUCAUCUA 1253 UAGAUGAGAAGGCACAGACUU 1263 AD-66809 GUCUGUGCCUUCUCAUCUA 1254 UAGAUGAGAAGGCACAGACUU 1264 AD-66810 GUGUGCACUUCGCUUCACA 1255 UGUGAAGCGAAGUGCACACUU 1265 AD-66811 GUGUGCACUUCGCUUCACA 1256 UGUGAAGCGAAGUGCACACUU 1266 AD-66812 UGUGCACUUCGCUUCACCUCU 1257 AGAGGUGAAGCGAAGUGCACAUU 1267 AD-66813 UGUGCACUUCGCUUCACCUCU 1258 AGAGGUGAAGCGAAGUGCACAUU 1268 AD-66814 CACCAGCACCAUGCAACUUUU 1259 AAAAGUUGCAUGGUGCUGGUGUU 1269 AD-66815 CACCAGCACCAUGCAACUUUU 1260 AAAAGUUGCAUGGUGCUGGUGUU 1270 AD-66816 CACCAUGCAACUUUUUCACCU 1261 AGGUGAAAAAGUUGCAUGGUGUU 1271 AD-66817 CACCAUGCAACUUUUUCACCU 1262 AGGUGAAAAAGUUGCAUGGUGUU 1272

TABLE 26 Modified HBV X ORF Sense and Antisense Sequences. Sense Sequence SEQ ID Antisense Sequence SEQ ID DuplexID Modified (5′ to 3′) NO: Modified (5′ to 3′) NO: AD-66808 gsuscuGfuGfCfCfuucucaucuaL96 1273 usAfsgauGfaGfAfaggcAfcAfgacsusu 1283 AD-66809 gsuscuGfuGfCfCfuucucaucuaL96 1274 UfsAfsgauGfaGfAfaggcAfcAfgacsusu 1284 AD-66810 gsusguGfcAfCfUfucgcuucacaL96 1275 usGfsugaAfgCfGfaaguGfcAfcacsusu 1285 AD-66811 gsusguGfcAfCfUfucgcuucacaL96 1276 UfsGfsugaAfgCfGfaaguGfcAfcacsusu 1286 AD-66812 usgsugcaCfuUfCfGfcuucaccucuL96 1277 asGfsaggUfgAfAfgcgaAfgUfgcacasusu 1287 AD-66813 usgsugcaCfuUfCfGfcuucaccucuL96 1278 AfsGfsaggUfgAfAfgcgaAfgUfgcacasusu 1288 AD-66814 csasccagCfaCfCfAfugcaacuuuuL96 1279 asAfsaagUfuGfCfauggUfgCfuggugsusu 1289 AD-66815 csasccagCfaCfCfAfugcaacuuuuL96 1280 AfsAfsaagUfuGfCfauggUfgCfuggugsusu 1290 AD-66816 csasccauGfcAfAfCfuuuuucaccuL96 1281 asGfsgugAfaAfAfaguuGfcAfuggugsusu 1291 AD-66817 csasccauGfcAfAfCfuuuuucaccuL96 1282 AfsGfsgugAfaAfAfaguuGfcAfuggugsusu 1292

TABLE 27 In vitro IC₅₀ Log₁₀ HBsAg KD Site (# vRNA¹) Duplex ID Luc HBV (nM) In Vivo @ 3 mg/kg 1551 AD-66808 0.187 2.4 (4) AD-66809 0.014 1.46 1577 AD-66810 0.290 1.7 (4) AD-66811 0.029 1.3 1580 AD-66812 0.795 2.19 (4) AD-66813 0.074 >>1.14 1806 AD-66814 0.0002 1.5 (4) AD-66815 0.0001 >>1.56 1812 AD-66816 0.047 1.61 (4) AD-66817 0.0001 1.60 ¹Number of viral RNAs silenced

Example 6. In Vivo Screening of siRNA Duplexes

A subset of lead iRNA agents was assessed for in vivo efficacy using the AAV-HBV mouse model described above. AAV-HBV mice were administered a single 3 mg/kg dose of AD-66019, AD-65375, AD-65047, AD-65377, AD-66111, AD-65421, or AD-66110 and the level of HBsAg was determined in the serum of the animals pre-dose, and at days 5 and 10 post-dose. As a control, AAV-HBV mice were administered a 3 mg/kg dose of a dsRNA targeting mouse/rat transtherytin (mrTTR). The results of these experiments are depicted in FIG. 3 and demonstrate that serum levels of HBsAg are decreased following a single administration of these agents.

FIG. 4 is a graph depicting the percent of pre-dose HBsAg remaining at days 5 and 10 in these animals following administration of a single 3 mg/kg dose was also determined. The results of these experiments are depicted in FIG. 4. FIG. 4 also depicts the percent of HBsAG remaining at day 10 post-dose relative to the percent of HBsAG remaining at day 10 post-dose in an animal administered 3 mg/kg of a control dsRNA targeting mouse/rat transtherytin (mrTTR).

Based, at least in part, on the results of the in vitro and in vivo assays described above, AD-65403, which silences 3 HBV RNAs, and AD-66810, which silences the X gene, were selected as drug candidates (DC) for use in a monotherapy or in a combination therapy.

FIG. 5 demonstrates that, in the AAV-HBV mouse model of HBV infection, a single 3 mg/kg dose of AD-65403 achieves potent and specific knockdown of HBsAg. In particular, a single 3 mg/kg subcutaneous dose of AD-65403 achieves up to a 3.9 log₁₀ reduction in HBsAg levels, with a mean HBsAg reduction of 1.8 log₁₀ 5-10 days after a single dose.

FIGS. 6A and 6B demonstrate that, in the AAV-HBV mouse model of HBV infection, a single 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 9 mg/kg subcutaneous dose of AD-66810 achieves potent and specific knockdown of HBsAg, especially at the higher doses of AD-66810. The percent decrease of HBsAg in serum is shown on a standard scale in FIG. 6A and on a log₁₀ scale in FIG. 6B. FIG. 7 demonstrates that, in the AAV-HBV mouse model of HBV infection, AD-66810 administered in three weekly subcutaneous 3 mg/kg doses, achieves potent and specific knockdown of HBsAg for a period of greater than 4 months.

Example 7. Treatment of HBV Infection with a Combination of Agents Targeting HBV

A subset of iRNA agents of the invention are assessed for in vivo efficacy using the AAV-HBV mouse model described above. AAV-HBV mice are administered one or more doses of AD-65403 and AD-66810, either alone or in combination with each other. Exemplary dosing regimens include a single 3 mg/kg total iRNA dose of AD-65403, AD-66810, or a combination of AD-65403 and AD-66810 (i.e., 1.5 mg/kg of each iRNA agent for a total of 3 mg/kg of iRNA administered as an admixture or as two separate doses); or a single dose of 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 9 mg/kg total iRNA agent dose of AD-65403, AD-66810, or a combination of AD-65403 and AD-66810. Exemplary multi-dose regimens include, for example, three weekly doses, one per week using any of the dosage levels provided in the exemplary single dose regimens. An appropriate control iRNA agent is also administered as a control as is routine in the art.

The level of HBsAg is determined in the serum of the animals pre-dose, and at predetermined intervals post-dose, e.g., every five days post-dose until the HBsAg level returns to baseline for all animals. Administration of AD-65403, AD-66810, or a combination of AD-65403 and AD-66810 results in sustained and specific knockdown of serum HBsAg.

Example 8. Treatment of HDV Infection with iRNA Agents Targeting Hepatitis B Virus

Hepatitis Delta virus (HDV) is a defective RNA virus which requires the help of HBV for its replication and assembly of new virions. Therefore, HDV is only infectious in the presence of active HBV infection. The HDV genome contains only one actively transcribed open reading frame which encodes two isoforms of hepatitis delta antigen. Post-translational modifications of small and large delta antigens (S-HDAg and L-HDAg) involving phosphorylation and isoprenylation respectively confer these antigens their specific properties. Effective treatment of HBV will also ameliorate HDV infection.

A chimpanzee model of HDV is known. A subset of iRNA agents of the invention are assessed for in vivo efficacy using the chimpanzee HDV model or other appropriate model of HDV. HDV infected chimpanzees are administered one or more doses of AD-65403 and AD-66810, either alone or in combination with each other. Exemplary dosing regimens include a single 3 mg/kg total iRNA agent dose of AD-65403, AD-66810, or a combination of AD-65403 and AD-66810 (i.e., 1.5 mg/kg of each iRNA agent for a total of 3 mg/kg of iRNA agent administered as an admixture or as two separate doses); or a single dose of 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 9 mg/kg total iRNA agent dose of AD-65403, AD-66810, or a combination of AD-65403 and AD-66810. Exemplary multi-dose regimens include, for example, three weekly doses, one per week using any of the dosage levels provided in the exemplary single dose regimens. An appropriate control iRNA is also administered as a control as is routine in the art.

The level of one or more of S-HDAg, L-HDAg, and HDV RNA, optionally in combination with HBsAg, is determined in the serum of the animals pre-dose and at predetermined intervals post-dose, e.g., every five days to monitor antigen or RNA levels. Administration of AD-65403, AD-66810, or a combination of AD-65403 and AD-66810 results in sustained and specific knockdown of serum HBsAg resulting in amelioration of HDV as demonstrated by, for example, a statistically significant decrease in one or more of S-HDAg, L-HDAg, and HDV RNA. These results demonstrate that administration of one or both of AD-65403 and AD-66810 is effective in the treatment of HDV.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed by the scope of the following claims. 

1.-220. (canceled)
 221. A double stranded RNAi agent for inhibiting expression of hepatitis B virus (HBV) in a cell, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand comprises 5′-GGUGGACUUCUCUCAAUUUUA-3′ (SEQ ID NO: 11), and the antisense strand comprises 5′-UAAAAUUGAGAGAAGUCCACCAC-3′ (SEQ ID NO: 12), wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives and it is attached to the 3′ terminus of said sense strand through a bivalent or trivalent branched linker.
 222. The double stranded RNAi agent of claim 221, wherein all of the nucleotides of said sense strand and all of the nucleotides of said antisense strand are modified nucleotides.
 223. The double stranded RNAi agent of claim 221, wherein at least one of said modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.
 224. The double stranded RNAi agent of claim 221, wherein at least one strand comprises a 3′ overhang of at least 1 nucleotide; or at least one strand comprises a 3′ overhang of at least 2 nucleotides.
 225. The double stranded RNAi agent of claim 221, wherein the double-stranded region is 21-30 base pairs in length.
 226. The double stranded RNAi agent of claim 221, wherein the ligand is


227. The double stranded RNAi agent of claim 221, wherein the ligand attached through a bivalent or trivalent branched linker is

wherein X is O or S.
 228. The double stranded RNAi agent of claim 221, wherein at least one of said modified nucleotides is a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, or a nucleotide comprising a phosphorothioate group.
 229. The double stranded RNAi agent of claim 221, wherein the sense strand comprises the nucleotide sequence of 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:25) and the antisense strand comprises the nucleotide sequence of 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:26), wherein a, g, c, and u are 2′-O-methyl (2′-OMe) A, 2′-OMe G, 2′-OMe C, and 2′-OMe U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, 2′-fluoro C, 2′-fluoro G, and 2′-fluoro U, respectively; and s is a phosphorothioate linkage.
 230. The double stranded RNAi agent of claim 229, wherein the ligand is


231. The double stranded RNAi agent of claim 229, wherein the ligand attached through a bivalent or trivalent branched linker is

wherein X is O or S.
 232. A pharmaceutical composition comprising the double stranded RNAi agent of claim 221 and a pharmaceutically acceptable carrier.
 233. A pharmaceutical composition comprising the double stranded RNAi agent of claim 229 and a pharmaceutically acceptable carrier.
 234. A pharmaceutical composition comprising the double stranded RNAi agent of claim 231 and a pharmaceutically acceptable carrier.
 235. A pharmaceutical composition for inhibiting expression of hepatitis B virus (HBV) in a cell, comprising: (a) the double stranded RNAi agent of claim 221; and (b) a second double-stranded RNAi agent comprising a second sense strand and a second antisense strand forming a second double-stranded region, wherein the second sense strand comprises 5′-GUGUGCACUUCGCUUCACA-3′ (SEQ ID NO:39), and the second antisense strand comprises 5′-UGUGAAGCGAAGUGCACACUU-3′ (SEQ ID NO:40), wherein substantially all of the nucleotides of the second sense strand and substantially all of the nucleotides of the second antisense strand are modified nucleotides, wherein the second sense strand is conjugated to a ligand attached at the 3′-terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; and (c) a pharmaceutically acceptable carrier.
 236. The pharmaceutical composition of claim 235, wherein (a) the first sense strand comprises 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:25) and the first antisense strand comprises 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:26); and (b) the second sense strand comprises 5′-gsusguGfcAfCfUfucgcuucaca-3′ (SEQ ID NO:41) and the second antisense strand comprises 5′-usGfsugaAfgCfGfaaguGfcAfcacsusu-3′ (SEQ ID NO:42); wherein a, g, c, and u are 2′-O-methyl (2′-OMe) A, 2′-OMe G, 2′-OMe C, and 2′-OMe U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, 2′-fluoro C, 2′-fluoro G, and 2′-fluoro U, respectively; and s is a phosphorothioate linkage.
 237. The pharmaceutical composition of claim 235, wherein (a) the first sense strand comprises 5′-gsgsuggaCfuUfCfUfcucaAfUfuuuaL96-3′ (SEQ ID NO:994) and the first antisense strand comprises 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:1023); and (b) the second sense strand comprises 5′-gsusguGfcAfCfUfucgcuucacaL96-3′ (SEQ ID NO: 1275) and the second antisense strand comprises 5′-usGfsugaAfgCfGfaaguGfcAfcacsusu-3′ (SEQ ID NO: 1285); wherein a, g, c, and u are 2′-O-methyl (2′-OMe) A, 2′-OMe G, 2′-OMe C, and 2′-OMe U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, 2′-fluoro C, 2′-fluoro G, and 2′-fluoro U, respectively; s is a phosphorothioate linkage; and L96 is N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol.
 238. A method of inhibiting Hepatitis B virus (HBV) gene expression and/or replication of HBV in a cell, the method comprising: (a) contacting the cell with the double stranded RNAi agent of claim 221; and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of an HBV gene, thereby inhibiting expression of the HBV gene and/or replication of the HBV in the cell.
 239. A method of inhibiting Hepatitis B virus (HBV) gene expression and/or replication of HBV in a cell, the method comprising: (a) contacting the cell with the double stranded RNAi agent of claim 229; and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of an HBV gene, thereby inhibiting expression of the HBV gene and/or replication of the HBV in the cell.
 240. A method of inhibiting Hepatitis B virus (HBV) gene expression and/or replication of HBV in a cell, the method comprising: (a) contacting the cell with the double stranded RNAi agent of claim 231; and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of an HBV gene, thereby inhibiting expression of the HBV gene and/or replication of the HBV in the cell.
 241. The method of claim 238, wherein the HBV gene expression is inhibited by at least about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, or about 100%.
 242. A method of reducing the viral load of Hepatitis B virus (HBV) in a subject infected with HBV, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of claim 221, thereby reducing the viral load of HBV in the subject.
 243. A method of reducing the viral load of Hepatitis B virus (HBV) in a subject infected with HBV, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of claim 229, thereby reducing the viral load of HBV in the subject.
 244. A method of reducing the viral load of Hepatitis B virus (HBV) in a subject infected with HBV, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of claim 231, thereby reducing the viral load of HBV in the subject
 245. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of claim 221, thereby treating said subject.
 246. The method of claim 245, wherein the double stranded RNAi agent is administered to the subject at a weight based dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 50 mg/kg; a weight based dose of about 10 mg/kg to about 30 mg/kg; a weight based dose of about 3 mg/kg; a weight based dose of about 10 mg/kg; or a fixed dose of about 50 mg to 200 mg.
 247. The method of claim 245, wherein the double stranded RNAi agent is administered subcutaneously; or intravenously.
 248. The method of claim 245, further comprising administering to the subject an additional therapeutic agent.
 249. The method of claim 248, wherein the additional therapeutic agent is selected from the group consisting of an antiviral agent, a reverse transcriptase inhibitor, an immune stimulator, a therapeutic vaccine, a viral entry inhibitor, an oligonucleotide that inhibits the secretion or release of HbsAg, a capsid inhibitor, a covalently closed circular (ccc) HBV DNA inhibitor, and a combination of any of the foregoing.
 250. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of claim 229, thereby treating said subject.
 251. The method of claim 250, wherein the double stranded RNAi agent is administered to the subject at a weight based dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 50 mg/kg; a weight based dose of about 10 mg/kg to about 30 mg/kg; a weight based dose of about 3 mg/kg; a weight based dose of about 10 mg/kg; or a fixed dose of about 50 mg to 200 mg.
 252. The method of claim 250, wherein the double stranded RNAi agent is administered subcutaneously; or intravenously.
 253. The method of claim 250, further comprising administering to the subject an additional therapeutic agent.
 254. The method of claim 253, wherein the additional therapeutic agent is selected from the group consisting of an antiviral agent, a reverse transcriptase inhibitor, an immune stimulator, a therapeutic vaccine, a viral entry inhibitor, an oligonucleotide that inhibits the secretion or release of HbsAg, a capsid inhibitor, a covalently closed circular (ccc) HBV DNA inhibitor, and a combination of any of the foregoing.
 255. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of claim 231, thereby treating said subject.
 256. The method of claim 255, wherein the double stranded RNAi agent is administered to the subject at a weight based dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 50 mg/kg; a weight based dose of about 10 mg/kg to about 30 mg/kg; a weight based dose of about 3 mg/kg; a weight based dose of about 10 mg/kg; or a fixed dose of about 50 mg to 200 mg.
 257. The method of claim 255, wherein the double stranded RNAi agent is administered subcutaneously; or intravenously.
 258. The method of claim 255, further comprising administering to the subject an additional therapeutic agent.
 259. The method of claim 258, wherein the additional therapeutic agent is selected from the group consisting of an antiviral agent, a reverse transcriptase inhibitor, an immune stimulator, a therapeutic vaccine, a viral entry inhibitor, an oligonucleotide that inhibits the secretion or release of HbsAg, a capsid inhibitor, a covalently closed circular (ccc) HBV DNA inhibitor, and a combination of any of the foregoing.
 260. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 232, thereby treating said subject.
 261. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 233, thereby treating said subject.
 262. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 234, thereby treating said subject.
 263. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 235, thereby treating said subject.
 264. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 236, thereby treating said subject.
 265. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 237, thereby treating said subject. 